{"3ae34e27bfd7842f895704aaa14b740374b54ae8": [["The year 2020 has not gone to plan in any shape or form; not for any sector of healthcare and certainly not for Neglected Tropical Diseases (NTDs).", [["Neglected Tropical Diseases", "DISEASE", 112, 139], ["NTDs", "DISEASE", 141, 145], ["Neglected Tropical Diseases", "PROBLEM", 112, 139]]], ["After recognition by the World Health Organization (WHO) and addition back into the collection of NTDs, snakebite envenoming was gaining recognition, funding and momentum.", [["NTDs", "DISEASE", 98, 102], ["snakebite envenoming", "DISEASE", 104, 124], ["NTDs", "PROBLEM", 98, 102], ["snakebite envenoming", "PROBLEM", 104, 124]]], ["The WHO released the blueprint of the roadmap to reduce death and disability in May 2019; impressive targets were set, and the foundations were made ready.", [["death", "DISEASE", 56, 61], ["disability", "DISEASE", 66, 76], ["death", "PROBLEM", 56, 61]]], ["Four strategic objectives were highlighted; empowering and engaging with communities, ensuring safe and effective treatments, strengthening health systems and increasing partnerships, coordination and resources (Williams et al, 2019) .", [["effective treatments", "TREATMENT", 104, 124]]]], "PMC7302273": [["We usually use the directed acyclic graph (DAG) [5] to model the data stream processing application (DSPA) in DSPSs.", [["DAG", "SIMPLE_CHEMICAL", 43, 46], ["the directed acyclic graph (DAG)", "TREATMENT", 15, 47]]], ["In the DAG, each vertex represents a kind of operations, named as the operator, and each edge represents a data stream between two operators.", [["DAG", "SIMPLE_CHEMICAL", 7, 10], ["vertex", "ANATOMY_MODIFIER", 17, 23], ["operations", "OBSERVATION", 45, 55]]], ["At the run time, the DSPS initiates a certain number of operator instances for each operator and deploy them on the run-time environment.IntroductionConsidering the constant fluctuating data stream, we adopt the elastic scaling in the DSPSs, which adjusts the number of the operators dynamically, to satisfy the QoS requirements.", [["DSPS", "DNA", 21, 25], ["the DSPS", "PROBLEM", 17, 25], ["the constant fluctuating data stream", "PROBLEM", 161, 197], ["the elastic scaling", "TREATMENT", 208, 227]]], ["There have been many researches on the elastic scaling.", [["the elastic scaling", "PROBLEM", 35, 54], ["many", "OBSERVATION_MODIFIER", 16, 20], ["researches", "OBSERVATION", 21, 31], ["elastic", "OBSERVATION_MODIFIER", 39, 46], ["scaling", "OBSERVATION_MODIFIER", 47, 54]]], ["Hidalgo et al. [7] evaluates the processing power of the operator through the benchmarking, and adjusts the number of the operator instances based on the threshold and the workload prediction.", [["the workload prediction", "TEST", 168, 191]]], ["Wei et al. [8] only adjusts the CPU frequency of the virtual machines as the workload fluctuates to reduce the energy cost.", [["the virtual machines", "TREATMENT", 49, 69], ["energy cost", "OBSERVATION", 111, 122]]], ["Marangozova-Martin et al. [9] presents the method to allocate three levels of resources to the operator instances including virtual machines, processes and threads.", [["virtual machines", "TREATMENT", 124, 140]]], ["The above methods allocate the same amount of resources to the instances of the same operator, but they ignore the correlation between the operator performance and resource provision.", [["The above methods", "TREATMENT", 0, 17]]], ["Actually, the unreasonable resources provision for the operator instance will cause some severe problems.", [["some severe problems", "PROBLEM", 84, 104], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["problems", "OBSERVATION", 96, 104]]], ["Besides, the under-provision means that the DSPSs will create a lot of instances to achieve high processing performance, which results in the huge overhead of the scheduling and the state transition.IntroductionIn this paper, we present a quantitative elastic scaling framework, named QEScalor, to allocate the resources for the operator instances quantitatively based on the actual performance requirements.", [["a quantitative elastic scaling framework", "TREATMENT", 237, 277]]], ["This framework firstly builds the operator performance and resource provision model (OPRPM), then it generates the low-cost elastic scaling plan based on the OPRPM.", [["the low-cost elastic scaling plan", "TREATMENT", 111, 144]]], ["It learns the correlation samples of the operator performance and resource provision based on the gradient strategy and re-sampling mechanism.", [["the operator performance", "TEST", 37, 61], ["resource provision", "TREATMENT", 66, 84], ["the gradient strategy", "TREATMENT", 94, 115]]], ["Besides, we use the random forest regression model (RFR) [10] to build the OPRPM to get the suitable resource provision options for the operator performance requirement.We present a quantitative and cost-based elastic scaling algorithm, QCESA.", [["the random forest regression model (RFR)", "TREATMENT", 16, 56], ["cost-based elastic scaling algorithm", "TREATMENT", 199, 235]]], ["It refers to the prediction of the workload [11] and the operator performance [12] to generate the low-cost scaling plan based on the OPRPM to achieve the resource-efficient elastic scaling to improve the performance.We implement the QEScalor as a key part of our DataDock [11].", [["the operator performance", "TEST", 53, 77], ["the low-cost scaling plan", "TREATMENT", 95, 120], ["the OPRPM", "TREATMENT", 130, 139], ["efficient elastic scaling", "TREATMENT", 164, 189]]]], "4408b82f2bbedf83a7118bc26d875e9fb647ceb2": [["IntroductionThe COVID-19 pandemic has caused unprecedented disruption to modern societies throughout the world.", [["The COVID", "TREATMENT", 12, 21], ["unprecedented disruption", "PROBLEM", 45, 69], ["unprecedented", "OBSERVATION_MODIFIER", 45, 58], ["disruption", "OBSERVATION", 59, 69]]], ["Since the emergence of the disease, it has become clear that the course of disease can vary considerably between individuals 1 , with some experiencing mild or non-existent symptoms and others experiencing severe outcomes, including hospitalization or even death.", [["death", "DISEASE", 257, 262], ["the disease", "PROBLEM", 23, 34], ["disease", "PROBLEM", 75, 82], ["some experiencing mild or non-existent symptoms", "PROBLEM", 134, 181], ["even death", "PROBLEM", 252, 262], ["disease", "OBSERVATION", 27, 34], ["clear", "OBSERVATION", 50, 55], ["disease", "OBSERVATION", 75, 82], ["mild", "OBSERVATION_MODIFIER", 152, 156]]], ["It has been well documented that a number of host factors are correlated with disease progression, with primary risk factors including sex, age, ethnicity, and the presence of underlying medical conditions 2 .IntroductionMuch less is known about the genetic basis of COVID-19 disease risk, both in terms of susceptibility to infection and severity of outcomes following infection.", [["infection", "DISEASE", 325, 334], ["infection", "DISEASE", 370, 379], ["disease progression", "PROBLEM", 78, 97], ["primary risk factors", "PROBLEM", 104, 124], ["underlying medical conditions", "PROBLEM", 176, 205], ["COVID-19 disease risk", "PROBLEM", 267, 288], ["susceptibility to infection", "PROBLEM", 307, 334], ["infection", "PROBLEM", 370, 379], ["infection", "OBSERVATION", 325, 334], ["infection", "OBSERVATION", 370, 379]]], ["It has been wellestablished that genetics plays a role in host susceptibility to infection and disease pathogenesis in humans 3 .", [["infection", "DISEASE", 81, 90], ["humans", "ORGANISM", 119, 125], ["humans", "SPECIES", 119, 125], ["humans", "SPECIES", 119, 125], ["infection", "PROBLEM", 81, 90], ["disease pathogenesis in humans", "PROBLEM", 95, 125], ["infection", "OBSERVATION", 81, 90]]], ["Notable examples include the protective effects of the CCR5\u039432 mutation on infection with the HIV-1 virus 4 and the sickle-cell mutation in the HBB gene offering protection against the malaria-causing Plasmodium falciparum 5 .", [["sickle-cell", "ANATOMY", 116, 127], ["infection", "DISEASE", 75, 84], ["malaria", "DISEASE", 185, 192], ["Plasmodium falciparum", "DISEASE", 201, 222], ["CCR5\u039432", "GENE_OR_GENE_PRODUCT", 55, 62], ["HIV-1 virus 4", "ORGANISM", 94, 107], ["sickle-cell", "CELL", 116, 127], ["HBB", "GENE_OR_GENE_PRODUCT", 144, 147], ["Plasmodium falciparum", "ORGANISM", 201, 222], ["5", "ORGANISM", 223, 224], ["CCR5\u039432", "PROTEIN", 55, 62], ["HBB gene", "DNA", 144, 152], ["HIV-1 virus", "SPECIES", 94, 105], ["Plasmodium falciparum", "SPECIES", 201, 222], ["HIV-1 virus", "SPECIES", 94, 105], ["Plasmodium falciparum", "SPECIES", 201, 222], ["the CCR5\u039432 mutation", "PROBLEM", 51, 71], ["infection", "PROBLEM", 75, 84], ["the HIV", "TEST", 90, 97], ["the sickle-cell mutation", "TREATMENT", 112, 136], ["the HBB gene", "TREATMENT", 140, 152], ["the malaria", "PROBLEM", 181, 192], ["Plasmodium falciparum", "PROBLEM", 201, 222], ["cell mutation", "OBSERVATION", 123, 136], ["malaria", "OBSERVATION", 185, 192], ["Plasmodium falciparum", "OBSERVATION", 201, 222]]], ["Over the past decade, genomewide association studies (GWAS) have proved to be a useful tool for uncovering novel infectious disease susceptibility loci, identifying loci associated with pathogen clearance or persistence, and providing supporting evidence for the role of certain host factors implicated in disease progression and severity 6, 7 .IntroductionGiven the rapid emergence of COVID-19, pre-existing genetic cohorts offer a path to rapid data collection that can address questions surrounding the relationship between host genetics and COVID-19 in a timely fashion.", [["infectious disease susceptibility loci", "DNA", 113, 151], ["genomewide association studies", "TEST", 22, 52], ["uncovering novel infectious disease susceptibility loci", "PROBLEM", 96, 151], ["pathogen clearance", "PROBLEM", 186, 204], ["severity", "TEST", 330, 338], ["COVID", "TEST", 386, 391], ["rapid data collection", "PROBLEM", 441, 462], ["COVID", "TEST", 545, 550], ["infectious", "OBSERVATION", 113, 123]]], ["Amongst the largest pre-existing genetic cohorts are those that have been developed via direct-to-consumer (DTC) genetic testing.", [["genetic testing", "TEST", 113, 128], ["largest", "OBSERVATION_MODIFIER", 12, 19]]], ["As part of the 23andMe service, customers are genotyped on SNP microarrays and offered the opportunity to participate in scientific research, and approximately 80% of customers consent to do so.", [["SNP", "CHEMICAL", 59, 62], ["SNP microarrays", "TREATMENT", 59, 74]]], ["In general, research participation is conducted via online surveys, which research participants can complete at any time.", [["participants", "SPECIES", 83, 95]]], ["Research participants are re-contactable and can be invited to participate in new surveys that are developed over time.IntroductionIn this paper, we describe the engagement of the 23andMe research cohort to address questions surrounding COVID-19 risk factors and host genetics.", [["COVID-19 risk factors", "PROTEIN", 237, 258], ["participants", "SPECIES", 9, 21]]], ["Having collected data from over one million research participants, we identified 15,434 individuals who reported a positive COVID-19 test, of whom 1,131 reported hospitalization with COVID-19 symptoms.", [["participants", "SPECIES", 53, 65], ["COVID", "TEST", 183, 188], ["symptoms", "PROBLEM", 192, 200]]], ["We first investigated non-genetic risk factors associated with COVID-19 severity and found that lower socio-economic status, African American ancestry, obesity, and pre-existing conditions associated with a higher risk of hospitalization.", [["obesity", "DISEASE", 152, 159], ["non-genetic risk factors", "PROBLEM", 22, 46], ["COVID", "TEST", 63, 68], ["obesity", "PROBLEM", 152, 159], ["pre-existing conditions", "PROBLEM", 165, 188], ["obesity", "OBSERVATION", 152, 159]]], ["We subsequently conducted a GWAS of phenotypes related to both COVID-19 diagnosis and severity.", [["a GWAS of phenotypes", "PROBLEM", 26, 46], ["COVID", "TEST", 63, 68], ["severity", "PROBLEM", 86, 94]]], ["We performed GWAS separately in samples of European, Latino, and African American ancestries and used the resulting data to perform a trans-ethnic meta-analysis.", [["GWAS", "TEST", 13, 17], ["a trans-ethnic meta-analysis", "TREATMENT", 132, 160]]], ["We identified a strong association with the ABO gene, which appears to be connected with COVID-19 diagnosis, and another strong association within a gene-rich locus at chr3p21.31, which appears to be connected with COVID-19 severity.MethodsOverview of study recruitment and data collection Participants in this study were recruited from the customer base of 23andMe, Inc., a personal genetics company.", [["ABO", "GENE_OR_GENE_PRODUCT", 44, 47], ["chr3p21.31", "GENE_OR_GENE_PRODUCT", 168, 178], ["ABO gene", "DNA", 44, 52], ["COVID-19", "DNA", 89, 97], ["chr3p21.31", "DNA", 168, 178], ["COVID", "TEST", 215, 220], ["study recruitment", "TEST", 252, 269], ["data collection", "TEST", 274, 289], ["this study", "TEST", 306, 316], ["strong", "OBSERVATION_MODIFIER", 16, 22]]], ["All individuals included in the analyses provided informed consent and answered surveys online according to our human subjects research protocol, which was reviewed and approved by Ethical and Independent Review Services, a private institutional review board (http://www.eandireview.com).MethodsPrimary recruitment was carried out by email to approximately 6.7 million 23andMe research participants over 18 years of age and living in the United States or the United Kingdom.", [["human", "ORGANISM", 112, 117], ["human", "SPECIES", 112, 117], ["participants", "SPECIES", 386, 398], ["human", "SPECIES", 112, 117]]], ["Additionally, pre-existing customers were invited to participate in the study through promotional materials on the 23andMe website, the 23andMe mobile application, and via social media.MethodsStudy participation consisted solely of web-based surveys, including an initial baseline survey, and three follow-up surveys fielded 1-month following completion of the baseline survey.", [["the study", "TEST", 68, 77], ["the baseline survey", "TEST", 357, 376]]], ["Because enrollment is ongoing, not all participants would have received, or completed all of the follow-up surveys.", [["participants", "SPECIES", 39, 51]]], ["All (4) surveys included questions about symptoms of cold or flu-like illnesses from February of 2020 onward, COVID-19 diagnosis and testing, hospitalization, severity of illness, COVID-19 diagnosis of first and second degree family members, and potential sources of exposure to COVID-19.", [["flu-like illnesses", "DISEASE", 61, 79], ["illness", "DISEASE", 171, 178], ["COVID-19", "CHEMICAL", 279, 287], ["COVID-19", "CHEMICAL", 279, 287], ["symptoms", "PROBLEM", 41, 49], ["cold", "PROBLEM", 53, 57], ["flu", "PROBLEM", 61, 64], ["testing", "TEST", 133, 140], ["illness", "PROBLEM", 171, 178], ["COVID", "TEST", 180, 185], ["COVID", "TEST", 279, 284]]], ["Other respondent characteristics, such as age, sex, pre-existing conditions, educational attainment, zip code, and smoking status had been collected via previously deployed surveys for the majority of participants, but were also queried in the COVID-19 baseline survey if the data were missing.MethodsDue to the geographically localized nature of the COVID-19 outbreak during the study period, we geo-targeted the email recruitment campaign to follow the outbreak as it moved through the United States ( Figure 1 ).", [["participants", "SPECIES", 201, 213], ["the data", "TEST", 272, 280], ["the study", "TEST", 376, 385]]], ["Emails to each state/country were batched into tranches on the basis of the anticipated timing of the hospitalization demand peak within each region, as assessed from the Institute for Health Metrics and Evaluation (IHME) prediction model 8 .", [["Evaluation", "TEST", 204, 214]]], ["Each tranche was recruited via email a minimum of two weeks after estimated peak hospitalization demand, as determined by the IHME predictive models.", [["tranche", "CANCER", 5, 12], ["estimated peak hospitalization demand", "PROBLEM", 66, 103]]], ["IHME predictions varied over the course of the study, and the order in which regions were targeted was adjusted accordingly.", [["the study", "TEST", 43, 52]]], ["To visualize the estimated prevalence of test positive COVID-19 study participants across the United States, we calculated the proportion of test positive cases among participants for each county with greater than 10 responses.", [["participants", "SPECIES", 70, 82], ["participants", "SPECIES", 167, 179]]], ["To highlight how the smoothed 4 version represents the raw data, we also generated a version without smoothing, with a random 10% of study participants removed in order to eliminate the possibility of reidentification in the dataset.MethodsSocial, demographic, and pre-existing conditions evaluated as risk factors for COVID-19 hospitalization To explore non-genetic factors associated with hospitalization for COVID-19, age, sex, ancestry, median household income of the residential zip code, educational attainment, body mass index, and pre-existing conditions were evaluated as risk factors in bivariate and multivariate logistic regression models.", [["body", "ANATOMY", 518, 522], ["COVID", "DISEASE", 319, 324], ["body", "ORGANISM_SUBDIVISION", 518, 522], ["participants", "SPECIES", 139, 151], ["reidentification in the dataset", "PROBLEM", 201, 232], ["COVID", "TEST", 319, 324], ["non-genetic factors", "PROBLEM", 355, 374], ["body mass index", "PROBLEM", 518, 533], ["pre-existing conditions", "PROBLEM", 539, 562]]], ["As social and demographic factors are strongly associated with COVID-19 hospitalization and many of the pre-existing conditions, final models estimating the relationship between the preexisting condition and COVID-19 hospitalization were adjusted for age (10-year increments), sex, ancestry, high school or below education, and median household income of the residential zip code (in $10,000 increments).", [["the pre-existing conditions", "PROBLEM", 100, 127]]], ["Finally, a multivariate logistic regression model was specified to quantify the risk of the top conditions after adjusting for each other, and for sociodemographic characteristics related to risk of hospitalization for COVID-19.MethodsThe relationship between age and COVID-19 and hospitalization was determined by categorizing cases by 10-year age increments between 30 and 80, and then calculating the percentage of cases in each age group and the percentage of cases which reported hospitalization.", [["a multivariate logistic regression model", "PROBLEM", 9, 49], ["COVID", "TEST", 219, 224], ["COVID", "TEST", 268, 273]]], ["While our data also included respondents of other ancestries, such as East Asian and South Asian, the sample sizes for these populations were too small for robust inferences to be performed.", [["these populations", "PROBLEM", 119, 136]]], ["All analyses were conducted in R statistical software, version 3.3.Phenotype definitions for GWASUsing the information derived from the surveys, we defined a set of phenotypes that aimed to capture aspects of COVID-19 diagnosis and severity.", [["All analyses", "TEST", 0, 12], ["Phenotype definitions", "PROBLEM", 67, 88], ["COVID", "TEST", 209, 214], ["severity", "PROBLEM", 232, 240]]], ["Following preliminary analysis, we selected one 'diagnosis' phenotype that contrasts positive and negative outcomes from a COVID-19 test, and four phenotypes that capture aspects of COVID-19 disease 'severity', including pneumonia, hospitalization, or the need for respiratory support (Supplementary Table 2 ).", [["respiratory", "ANATOMY", 265, 276], ["pneumonia", "DISEASE", 221, 230], ["preliminary analysis", "TEST", 10, 30], ["a COVID-19 test", "TEST", 121, 136], ["COVID", "TEST", 182, 187], ["19 disease 'severity'", "PROBLEM", 188, 209], ["pneumonia", "PROBLEM", 221, 230], ["respiratory support", "TREATMENT", 265, 284], ["pneumonia", "OBSERVATION", 221, 230]]], ["For the severity phenotypes, we explored different choices of how to define controls, and found that using controls who had not reported a COVID-19 diagnosis (were neither diagnosed with nor tested positive for COVID-19) provided a large-scale control set that appeared to maximize power in the GWAS.Phenotype definitions for GWAS.", [["the severity phenotypes", "PROBLEM", 4, 27], ["COVID", "TEST", 211, 216], ["a large-scale control", "TREATMENT", 230, 251], ["Phenotype definitions", "PROBLEM", 300, 321], ["GWAS", "PROBLEM", 326, 330]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Phenotype definitions for GWASThe copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint Genotyping and SNP imputation DNA extraction and genotyping were performed on saliva samples by CLIA-certified and CAPaccredited clinical laboratories of Laboratory Corporation of America.", [["samples", "ANATOMY", 463, 470], ["CC", "CHEMICAL", 0, 2], ["SNP", "CHEMICAL", 393, 396], ["DNA", "CELLULAR_COMPONENT", 408, 411], ["saliva samples", "ORGANISM_SUBSTANCE", 456, 470], ["ND", "PROBLEM", 9, 11], ["Phenotype definitions", "PROBLEM", 202, 223], ["medRxiv preprint Genotyping", "TREATMENT", 361, 388], ["SNP imputation DNA extraction", "TREATMENT", 393, 422], ["genotyping", "TEST", 427, 437], ["saliva samples", "TEST", 456, 470], ["med", "ANATOMY", 105, 108]]], ["Samples were genotyped on one of five genotyping platforms.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["five genotyping platforms", "TEST", 33, 58]]], ["The V1 and V2 platforms were variants of the Illumina HumanHap550 + BeadChip and contained a total of about 560,000 SNPs, including about 25,000 custom SNPs selected by 23andMe.", [["V1 and V2 platforms", "DNA", 4, 23], ["Illumina HumanHap550", "DNA", 45, 65], ["23andMe", "DNA", 169, 176], ["BeadChip", "TEST", 68, 76], ["total", "OBSERVATION_MODIFIER", 93, 98]]], ["The V3 platform was based on the Illumina OmniExpress + BeadChip and contained a total of about 950,000 SNPs and custom content to improve the overlap with our V2 array.", [["Illumina OmniExpress", "DNA", 33, 53], ["V2 array", "DNA", 160, 168]]], ["The V4 platform was a fully custom array of about 950,000 SNPs and included a lower redundancy subset of V2 and V3 SNPs with additional coverage of lower-frequency coding variation.", [["V4", "DNA", 4, 6], ["950,000 SNPs", "DNA", 50, 62], ["V2 and V3 SNPs", "DNA", 105, 119], ["a lower redundancy subset of V2 and V3 SNPs", "PROBLEM", 76, 119], ["additional coverage", "TREATMENT", 125, 144], ["lower", "OBSERVATION_MODIFIER", 78, 83], ["redundancy", "OBSERVATION", 84, 94]]], ["The V5 platform was based on the Illumina GSA array, consisting of approximately 654,000 pre-selected SNPs and approximately 50,000 custom content variants.", [["V5", "DNA", 4, 6], ["Illumina GSA array", "DNA", 33, 51], ["the Illumina GSA array", "TEST", 29, 51], ["custom content variants", "OBSERVATION", 132, 155]]], ["Samples that failed to reach 98.5% call rate were re-analyzed.", [["Samples", "TEST", 0, 7]]], ["Individuals whose analyses failed repeatedly were re-contacted by 23andMe customer service to provide additional samples, as is done for all 23andMe customers.Phenotype definitions for GWASParticipant genotype data were imputed using the Haplotype Reference Consortium (HRC) panel 11 , augmented by the Phase 3 1000 Genomes Project panel 12 for variants not present in HRC.", [["HRC", "CANCER", 369, 372], ["HRC", "PROTEIN", 369, 372], ["Phenotype definitions", "PROBLEM", 159, 180], ["GWASParticipant genotype data", "PROBLEM", 185, 214], ["HRC) panel", "TEST", 270, 280], ["Genomes Project panel", "TEST", 316, 337], ["variants", "PROBLEM", 345, 353]]], ["For the nonpseudoautosomal region of the X chromosome, males and females were phased together in segments, treating the males as already phased; the pseudoautosomal regions were phased separately.", [["X chromosome", "ANATOMY", 41, 53], ["X chromosome", "CELLULAR_COMPONENT", 41, 53], ["nonpseudoautosomal region", "DNA", 8, 33], ["X chromosome", "DNA", 41, 53], ["pseudoautosomal regions", "DNA", 149, 172], ["X chromosome", "OBSERVATION_MODIFIER", 41, 53], ["males", "OBSERVATION", 120, 125]]], ["We then imputed males and females together, treating males as homozygous pseudo-diploids for the non-pseudoautosomal region.Genome-wide association study (GWAS)Genotyped participants were included in GWAS analyses on the basis of ancestry as determined by a genetic ancestry classification algorithm 10 .", [["non-pseudoautosomal region", "DNA", 97, 123], ["participants", "SPECIES", 170, 182], ["homozygous pseudo-diploids", "PROBLEM", 62, 88], ["the non-pseudoautosomal region", "PROBLEM", 93, 123], ["GWAS analyses", "TEST", 200, 213]]], ["For each phenotype, we selected a set of unrelated individuals so that no two individuals shared more than 700cM of DNA identical by descent (IBD).", [["DNA", "CELLULAR_COMPONENT", 116, 119], ["DNA", "PROBLEM", 116, 119]]], ["For case-control phenotypes, if a case and a control were identified as having at least 700cM of DNA IBD, we preferentially discarded the control from the sample.Genome-wide association study (GWAS)For case-control comparisons, we tested for association using logistic regression, assuming additive allelic effects.", [["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNA IBD", "PROBLEM", 97, 104], ["additive allelic effects", "PROBLEM", 290, 314]]], ["For tests using imputed data, we use the imputed dosages rather than best-guess genotypes.", [["tests", "TEST", 4, 9], ["the imputed dosages", "TREATMENT", 37, 56]]], ["We included covariates for age, age squared, sex, a sex:age interaction, the top ten principal components to account for residual population structure, and dummy variables to account for genotyping platform.", [["residual population structure", "PROBLEM", 121, 150], ["dummy variables", "PROBLEM", 156, 171], ["genotyping platform", "TEST", 187, 206]]], ["The association test p-value was computed using a likelihood ratio test, which in our experience is better behaved than a Wald test on the regression coefficient.", [["The association test p-value", "TEST", 0, 28], ["a likelihood ratio test", "TEST", 48, 71], ["a Wald test", "TEST", 120, 131]]], ["Results for the X chromosome were computed similarly, with men coded as if they were homozygous diploid for the observed allele.Genome-wide association study (GWAS)We ran GWAS for each phenotype separately, and combined both genotyped and imputed data.", [["X chromosome", "ANATOMY", 16, 28], ["X chromosome", "CELLULAR_COMPONENT", 16, 28], ["men", "ORGANISM", 59, 62], ["X chromosome", "DNA", 16, 28], ["allele", "DNA", 121, 127], ["men", "SPECIES", 59, 62], ["the X chromosome", "TEST", 12, 28], ["homozygous diploid", "PROBLEM", 85, 103]]], ["When choosing between imputed and genotyped GWAS results, we favored the imputed result, unless the imputed variant was unavailable or failed quality control (QC).", [["the imputed variant", "PROBLEM", 96, 115]]], ["For imputed variants, we removed variants with low imputation quality (r 2 < 0.5 averaged across batches, or .", [["imputed variants", "PROBLEM", 4, 20]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint a minimum r 2 < 0.3) or with evidence of batch effects (ANOVA F-test across batches, p-value < 10 -50 ).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 330, 337], ["batch effects", "PROBLEM", 388, 401], ["ANOVA F-test across batches", "TEST", 403, 430], ["p-value", "TEST", 432, 439], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["For genotyped variants, we removed variants only present on our V1 or V2 arrays (due to small sample size) that failed a Mendelian transmission test in trios (p-value < 10 -20 ), that failed a Hardy-Weinberg test in Europeans (p-value < 10 -20 ), failed a batch effect test (ANOVA p-value < 10 -50 ), or had a call rate < 90%.(which was not certified by peer review)We repeated the GWAS analysis separately in each population cohort for which we had sufficient data (European, Latino, African American), and then performed trans-ethnic metaanalysis using a fixed effects model (inverse variance method 13 ), restricting to variants of at least 1% minor allele frequency.(which was not certified by peer review)Within each GWAS, we identified regions with genome-wide significant (GWS) associations.", [["V1", "DNA", 64, 66], ["genotyped variants", "PROBLEM", 4, 22], ["small sample size", "PROBLEM", 88, 105], ["a Mendelian transmission test", "TEST", 119, 148], ["p-value", "TEST", 159, 166], ["p-value", "TEST", 227, 234], ["a batch effect test", "TEST", 254, 273], ["ANOVA p-value", "TEST", 275, 288], ["a call rate", "TEST", 308, 319], ["the GWAS analysis", "TEST", 378, 395], ["trans-ethnic metaanalysis", "TREATMENT", 523, 548], ["a fixed effects model (inverse variance method", "TREATMENT", 555, 601], ["wide", "OBSERVATION_MODIFIER", 762, 766], ["significant", "OBSERVATION_MODIFIER", 767, 778]]], ["We define the region boundaries by identifying all SNPs with p-value < 10 \u22125 within the vicinity of a GWS association, and then grouping these regions into intervals so that no two regions are separated by less than 250 kb.", [["GWS", "DNA", 102, 105], ["p-value", "TEST", 61, 68]]], ["We consider the SNP with the smallest p-value within each interval to be the index SNP.", [["SNP", "CHEMICAL", 16, 19], ["SNP", "CHEMICAL", 83, 86], ["the SNP", "TREATMENT", 12, 19], ["the index SNP", "TREATMENT", 73, 86]]], ["We also annotated our findings based on linkage disequilibrium (LD) with results from published GWAS, coding variation, and expression quantitative trait loci (eQTL), specifically by finding annotations with r 2 > 0.5 and within 500kb of the index SNP.Blood group analysesWe classified haplotypes into blood groups on the basis of genotypes at three SNPs: rs8176747, rs41302905, and rs8176719 14, 15 .", [["Blood", "ANATOMY", 252, 257], ["blood", "ANATOMY", 302, 307], ["SNP", "CHEMICAL", 248, 251], ["Blood", "ORGANISM_SUBSTANCE", 252, 257], ["blood", "ORGANISM_SUBSTANCE", 302, 307], ["expression quantitative trait loci", "DNA", 124, 158], ["eQTL", "DNA", 160, 164], ["published GWAS", "TEST", 86, 100], ["coding variation", "TEST", 102, 118], ["expression quantitative trait loci", "PROBLEM", 124, 158], ["the index SNP", "TREATMENT", 238, 251], ["Blood group analyses", "TEST", 252, 272], ["index SNP", "OBSERVATION", 242, 251]]], ["A deletion at rs8176719 confers a type O haplotype, as does a T allele at rs41302905.", [["T", "GENE_OR_GENE_PRODUCT", 62, 63], ["rs8176719", "DNA", 14, 23], ["T allele", "DNA", 62, 70], ["A deletion", "PROBLEM", 0, 10]]], ["If neither rs8176719 nor rs41302905 confers type O, then rs8176747 distinguishes between types A and B. This assignment paradigm is described in Supplementary Table 3 .Blood group analysesGiven haplotype assignments, individuals were assigned a blood type on the basis of their diploid combination of haplotypes, with type O being recessive, so that individuals with two O haplotypes were assigned type O, individuals with one O and one A haplotype were assigned type A, and so on.Blood group analysesWe note that the blood group assignment methodology described above is incomplete, and there are other rare variants that can influence blood group 14 .", [["Blood", "ANATOMY", 168, 173], ["blood", "ANATOMY", 245, 250], ["Blood", "ANATOMY", 481, 486], ["blood", "ANATOMY", 518, 523], ["blood", "ANATOMY", 637, 642], ["rs8176719", "GENE_OR_GENE_PRODUCT", 11, 20], ["Blood", "ORGANISM_SUBSTANCE", 168, 173], ["blood", "ORGANISM_SUBSTANCE", 245, 250], ["Blood", "ORGANISM_SUBSTANCE", 481, 486], ["blood", "ORGANISM_SUBSTANCE", 518, 523], ["blood", "ORGANISM_SUBSTANCE", 637, 642], ["Blood group analyses", "TEST", 168, 188], ["a blood type", "TEST", 243, 255], ["Blood group analyses", "TEST", 481, 501], ["the blood group assignment methodology", "TEST", 514, 552], ["other rare variants", "PROBLEM", 598, 617]]], ["In order to understand the accuracy of the genetic blood group assignments, we compared to self-reported blood groups from over 1.47 million research participants.", [["blood", "ANATOMY", 51, 56], ["blood", "ANATOMY", 105, 110], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["participants", "SPECIES", 150, 162]]], ["We found that the genetic assignments achieved 90-94% precision and 72-96% recall compared to the self-reported data, depending on blood group (Supplementary Table 4 ).Blood group analysesWe tested for association between ABO blood group and COVID-19 phenotypes in each population using logistic regression, testing blood group pairs separately (e.g. individuals with blood group O vs individuals with blood group A) and only testing unrelated individuals.", [["blood", "ANATOMY", 131, 136], ["Blood", "ANATOMY", 168, 173], ["blood", "ANATOMY", 226, 231], ["blood", "ANATOMY", 316, 321], ["blood", "ANATOMY", 368, 373], ["blood", "ANATOMY", 402, 407], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["Blood", "ORGANISM_SUBSTANCE", 168, 173], ["ABO", "GENE_OR_GENE_PRODUCT", 222, 225], ["blood", "ORGANISM_SUBSTANCE", 226, 231], ["blood", "ORGANISM_SUBSTANCE", 316, 321], ["blood", "ORGANISM_SUBSTANCE", 368, 373], ["blood", "ORGANISM_SUBSTANCE", 402, 407], ["COVID", "PROTEIN", 242, 247], ["Blood group analysesWe", "TEST", 168, 190], ["ABO blood group", "TEST", 222, 237], ["COVID", "TEST", 242, 247], ["logistic regression", "TEST", 287, 306], ["testing blood group pairs", "TEST", 308, 333]]], ["We meta-analysed across populations using a fixed effects model.", [["a fixed effects model", "TREATMENT", 42, 63]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint these analyses using self-reported blood group assignments in place of genetically determined assignments and found the results to be qualitatively similar (data not shown).(which was not certified by peer review)We performed a similar analysis between ABO blood groups and experience of influenza by considering research participants who answered the question \"Have you had influenza (flu) in the past 12-months?", [["blood", "ANATOMY", 382, 387], ["blood", "ANATOMY", 604, 609], ["CC", "CHEMICAL", 0, 2], ["influenza", "DISEASE", 635, 644], ["influenza", "DISEASE", 722, 731], ["blood", "ORGANISM_SUBSTANCE", 382, 387], ["blood", "ORGANISM_SUBSTANCE", 604, 609], ["participants", "SPECIES", 669, 681], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["blood group assignments", "TEST", 382, 405], ["a similar analysis", "TEST", 573, 591], ["ABO blood groups", "TREATMENT", 600, 616], ["influenza", "PROBLEM", 635, 644], ["influenza", "PROBLEM", 722, 731], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Common symptoms of flu are fever over 100 o F (38 o C), muscle aches, chills and sweats, headache, dry cough, fatigue, nasal congestion and sore throat.", [["muscle", "ANATOMY", 56, 62], ["nasal", "ANATOMY", 119, 124], ["flu", "DISEASE", 19, 22], ["fever", "DISEASE", 27, 32], ["muscle aches", "DISEASE", 56, 68], ["chills", "DISEASE", 70, 76], ["sweats", "DISEASE", 81, 87], ["headache", "DISEASE", 89, 97], ["dry cough", "DISEASE", 99, 108], ["fatigue", "DISEASE", 110, 117], ["nasal congestion", "DISEASE", 119, 135], ["sore throat", "DISEASE", 140, 151], ["muscle", "ORGAN", 56, 62], ["nasal", "ORGANISM_SUBDIVISION", 119, 124], ["Common symptoms", "PROBLEM", 0, 15], ["flu", "PROBLEM", 19, 22], ["fever", "PROBLEM", 27, 32], ["muscle aches", "PROBLEM", 56, 68], ["chills", "PROBLEM", 70, 76], ["sweats", "PROBLEM", 81, 87], ["headache", "PROBLEM", 89, 97], ["dry cough", "PROBLEM", 99, 108], ["fatigue", "PROBLEM", 110, 117], ["nasal congestion", "PROBLEM", 119, 135], ["sore throat", "PROBLEM", 140, 151], ["flu", "OBSERVATION", 19, 22], ["muscle", "ANATOMY", 56, 62], ["aches", "ANATOMY", 63, 68], ["chills", "OBSERVATION", 70, 76], ["dry", "ANATOMY", 99, 102], ["cough", "OBSERVATION", 103, 108], ["nasal", "ANATOMY", 119, 124], ["congestion", "OBSERVATION", 125, 135], ["sore throat", "ANATOMY", 140, 151]]], ["As compared to the common cold, symptom onset for influenza is faster, more severe, and can last 1-2 weeks.\"", [["influenza", "DISEASE", 50, 59], ["influenza", "PROBLEM", 50, 59], ["more severe", "OBSERVATION_MODIFIER", 71, 82]]], ["In order to avoid overlap with individuals reporting experiences with COVID-19, we tested for association between influenza and the ABO blood groups using a sample of To test for differences between rhesus positive and negative blood groups, we use the structural variant esv3585521 to obtain rhesus type.", [["blood", "ANATOMY", 136, 141], ["blood", "ANATOMY", 228, 233], ["influenza", "DISEASE", 114, 123], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["rhesus", "ORGANISM", 199, 205], ["blood", "ORGANISM_SUBSTANCE", 228, 233], ["COVID", "TEST", 70, 75], ["influenza", "PROBLEM", 114, 123], ["the ABO blood groups", "TEST", 128, 148], ["a sample", "TEST", 155, 163]]], ["This variant, located within the RHD gene, has a 39.4% frequency in European populations and associates very strongly with self-reported rhesus type in 23andMe data (OR = 22.1, p-value = 1.8e-298).", [["rhesus", "ORGANISM", 137, 143], ["RHD gene", "DNA", 33, 41], ["p-value", "TEST", 177, 184], ["RHD", "OBSERVATION", 33, 36]]], ["We take individuals imputed as homozygous for the deletion as being rhesus negative.", [["the deletion", "PROBLEM", 46, 58]]], ["Within each blood group, we tested for association between rhesus type and COVID-19 phenotypes in the European-ancestry population using logistic regression.", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["rhesus", "ORGANISM", 59, 65], ["rhesus type", "TEST", 59, 70], ["COVID", "TEST", 75, 80]]], ["We included covariates for age, age squared, sex, a sex:age interaction, and the top ten principal components.Respondent characteristicsAs of July 25th 2020, just over 1.05 million research participants took the COVID-19 baseline survey.", [["participants", "SPECIES", 190, 202]]], ["Respondents were included in this analysis if they had consented to research and had a non-missing response to the question, \"Have you been tested for COVID-19?\".", [["this analysis", "TEST", 29, 42]]], ["The majority of respondents were of European ancestry (80.3%), although the study also included substantial representation from Latino (11.3%, n = 118, 787), and African American or Black (2.7%, n = 28,592; hereafter referred to as African American) ancestries.", [["the study", "TEST", 72, 81], ["Latino", "TEST", 128, 134], ["Black", "TEST", 182, 187], ["Black", "OBSERVATION_MODIFIER", 182, 187]]], ["Study participants were 63% female with a median age of 51 years.Respondent characteristicsThose reporting a positive test were more likely to be male (OR = 1.22, 95% CI 1.18-1.26, pvalue < 2.2e-16), younger on average (43.0 vs. 51.0, p-value <0.001), and less likely to be of European ancestry (70.3% COVID-19 positive test were European vs. 80.3% of all study participants, p-value <0.001), compared to other survey respondents.", [["participants", "SPECIES", 6, 18], ["participants", "SPECIES", 362, 374], ["a positive test", "TEST", 107, 122], ["CI", "TEST", 167, 169], ["pvalue", "TEST", 181, 187], ["p-value", "TEST", 235, 242], ["European ancestry", "TEST", 277, 294], ["COVID", "TEST", 302, 307], ["positive test", "TEST", 311, 324], ["European", "TEST", 330, 338], ["all study", "TEST", 352, 361], ["p-value", "TEST", 376, 383], ["less likely to be", "UNCERTAINTY", 256, 273]]], ["Comparing those who tested positive to all other study participants, living in an urban environment (90.5% of respondents vs. 95% of those with a COVID-19 positive test, p-value <0.001) and employment .", [["participants", "SPECIES", 55, 67], ["a COVID", "TEST", 144, 151], ["p-value", "TEST", 170, 177]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint as a healthcare professional (9.2% of respondents but 21.7% of COVID-19 positive tests, pvalue <0.001) were associated with a higher likelihood of reporting a positive test.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["COVID", "TEST", 410, 415], ["positive tests", "TEST", 419, 433], ["pvalue", "TEST", 435, 441], ["a positive test", "PROBLEM", 504, 519], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Pre-existing conditions were negatively associated with reporting a COVID-19 positive test, as was current smoking status (Table 1) . .", [["Pre-existing conditions", "PROBLEM", 0, 23], ["a COVID", "TEST", 66, 73]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In models taking into account age, sex, education, ancestry, education level, and median household income in the residential zip code, among those with a COVID-19 positive test, several cardiometabolic and respiratory conditions were associated with an elevated risk of hospitalization.", [["cardiometabolic and respiratory conditions", "DISEASE", 186, 228], ["a COVID", "TEST", 152, 159], ["several cardiometabolic and respiratory conditions", "PROBLEM", 178, 228], ["an elevated risk of hospitalization", "PROBLEM", 250, 285]]], ["However, the strongest association was with obesity, which conferred a 2.5 fold increased risk of hospitalization (aOR = 2.45, 95% CI: 1.99-3.02).", [["obesity", "DISEASE", 44, 51], ["obesity", "PROBLEM", 44, 51], ["aOR", "TEST", 115, 118], ["CI", "TEST", 131, 133], ["obesity", "OBSERVATION", 44, 51]]], ["Type 2 diabetes, .", [["Type 2 diabetes", "DISEASE", 0, 15], ["Type 2 diabetes", "PROBLEM", 0, 15], ["diabetes", "OBSERVATION", 7, 15]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint cardiovascular disease, hypertension, respiratory conditions including asthma, fatty liver disease, and gastro-esophageal reflux disease (GERD) were all positively associated with COVID-19 hospitalization, in models adjusting for BMI (Table 2) .", [["cardiovascular", "ANATOMY", 347, 361], ["respiratory", "ANATOMY", 385, 396], ["fatty liver", "ANATOMY", 426, 437], ["gastro-esophageal", "ANATOMY", 451, 468], ["CC", "CHEMICAL", 0, 2], ["cardiovascular disease", "DISEASE", 347, 369], ["hypertension", "DISEASE", 371, 383], ["respiratory conditions", "DISEASE", 385, 407], ["asthma", "DISEASE", 418, 424], ["fatty liver disease", "DISEASE", 426, 445], ["gastro-esophageal reflux disease", "DISEASE", 451, 483], ["GERD", "DISEASE", 485, 489], ["liver", "ORGAN", 432, 437], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint cardiovascular disease", "PROBLEM", 330, 369], ["hypertension", "PROBLEM", 371, 383], ["respiratory conditions", "PROBLEM", 385, 407], ["asthma", "PROBLEM", 418, 424], ["fatty liver disease", "PROBLEM", 426, 445], ["gastro-esophageal reflux disease", "PROBLEM", 451, 483], ["GERD", "PROBLEM", 485, 489], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["cardiovascular disease", "OBSERVATION", 347, 369], ["hypertension", "OBSERVATION", 371, 383], ["respiratory conditions", "OBSERVATION", 385, 407], ["asthma", "OBSERVATION", 418, 424], ["fatty liver disease", "OBSERVATION", 426, 445], ["gastro-esophageal", "ANATOMY", 451, 468], ["reflux disease", "OBSERVATION", 469, 483]]], ["All models were adjusted for sex, age (10 yr increments), education level, BMI (categorical), genetic ancestry (categorical), and income ($10,000 increments), * p-value <0.05, ** p-value <0.01, *** p-value <0.0001.", [["p-value", "TEST", 161, 168], ["p-value", "TEST", 179, 186], ["p-value", "TEST", 198, 205]]], ["Note that the model evaluating BMI as a primary risk factor did not also adjust for BMI as a covariate.(which was not certified by peer review).", [["BMI", "PROBLEM", 84, 87]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint(which was not certified by peer review)Combining the most common risk factors into a single logistic regression model (obesity, type 2 diabetes, fatty liver disease, and high blood pressure), the most significant risk factor for hospitalization remained obesity (defined as BMI >30), which accounted for a doubling in the risk of hospitalization (aOR = 2.07, 95% CI = 1.66 -2.58) after adjusting for age, sex, ancestry, education, and household income and the other conditions (Table 3 ).", [["fatty liver", "ANATOMY", 492, 503], ["blood", "ANATOMY", 522, 527], ["CC", "CHEMICAL", 0, 2], ["obesity", "DISEASE", 466, 473], ["type 2 diabetes", "DISEASE", 475, 490], ["fatty liver disease", "DISEASE", 492, 511], ["obesity", "DISEASE", 601, 608], ["liver", "ORGAN", 498, 503], ["blood", "ORGANISM_SUBSTANCE", 522, 527], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["a single logistic regression model (obesity", "PROBLEM", 430, 473], ["type 2 diabetes", "PROBLEM", 475, 490], ["fatty liver disease", "PROBLEM", 492, 511], ["high blood pressure)", "PROBLEM", 517, 537], ["obesity", "PROBLEM", 601, 608], ["BMI", "TEST", 621, 624], ["aOR", "TEST", 694, 697], ["CI", "TEST", 710, 712], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["fatty", "OBSERVATION", 492, 497], ["liver", "ANATOMY", 498, 503], ["obesity", "OBSERVATION", 601, 608]]], ["In this model, African Americans were 83% more likely to be hospitalized for COVID-19 (aOR = 1.83, 95% CI 1.33 -2.52).", [["COVID", "DISEASE", 77, 82], ["COVID", "TEST", 77, 82], ["aOR", "TEST", 87, 90], ["CI", "TEST", 103, 105]]], ["Socio-economic status was inversely associated with hospitalization risk, with a 4% decrease in hospitalization per $10,000 increase in median income in the zip code of residence.", [["increase", "OBSERVATION_MODIFIER", 124, 132]]], ["High school or less education conferred a 38% increased risk in hospitalization (aOR=1.39, 95% CI 1.10 -1.74). .", [["aOR", "TEST", 81, 84], ["CI", "TEST", 95, 97]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprintGeographic distribution of casesThe prevalence of infection, estimated as the number of reported test positives in a state relative to the number of study participants in the state, varied across geographic regions.", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 396, 405], ["participants", "SPECIES", 501, 513], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 330, 337], ["infection", "PROBLEM", 396, 405], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["cases", "OBSERVATION", 373, 378], ["infection", "OBSERVATION", 396, 405]]], ["The highest proportions of positive COVID-19 tests were reported in New York (4.4%) and New Jersey (3.3%), and the lowest proportions were reported in Maine (0.4%) and West Virginia (0.4%).", [["positive COVID", "TEST", 27, 41]]], ["Nonetheless, the selfreported prevalence of positive COVID-19 tests at the US state level was reasonably well correlated with the number of positive tests reported per capita 16 as of July (Figure 3b ; Pearson r = 0.85).", [["COVID", "PROTEIN", 53, 58], ["positive COVID", "PROBLEM", 44, 58], ["the US state level", "TEST", 71, 89], ["positive tests", "TEST", 140, 154], ["Figure", "TEST", 190, 196], ["Pearson r", "TEST", 202, 211]]], ["However, the prevalence of self-reported COVID-19 test positive status was higher in the 23andMe database than per-capita estimates, likely reflecting differences in the composition of the 23andMe database and the general population, and potential selection bias arising from individuals with a positive test potentially being more likely to choose to participate in the study.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 41, 49], ["COVID", "TEST", 41, 46], ["a positive test", "PROBLEM", 293, 308], ["the study", "TEST", 367, 376], ["likely reflecting", "UNCERTAINTY", 133, 150]]], ["Table 5 ).Geographic distribution of cases.", [["cases", "OBSERVATION", 37, 42]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprintFigure 4: Manhattan and QQ plots for 'COVID-19 test +ve vs COVID-19 test -ve' a) and 'COVID-19 severe respiratory symptoms' b) from trans-ethnic meta-analysis.", [["respiratory", "ANATOMY", 448, 459], ["CC", "CHEMICAL", 0, 2], ["respiratory symptoms", "DISEASE", 448, 468], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["'COVID", "TEST", 383, 389], ["test", "TEST", 393, 397], ["ve", "TEST", 399, 401], ["COVID", "TEST", 405, 410], ["test", "TEST", 414, 418], ["'COVID", "TEST", 431, 437], ["severe respiratory symptoms", "PROBLEM", 441, 468], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The nearest gene to the index SNP is indicated above each association peak.ABO: In our phenotype contrasting COVID-19 test positive individuals to test negative individuals, we identified an association at chr9q34.2, with index SNP rs9411378 (p-value = 5.3e-20, C allele OR = 0.857; Figure 5 ).", [["SNP", "CHEMICAL", 30, 33], ["SNP", "CHEMICAL", 228, 231], ["COVID-19", "GENE_OR_GENE_PRODUCT", 109, 117], ["chr9q34.2", "GENE_OR_GENE_PRODUCT", 206, 215], ["COVID-19", "DNA", 109, 117], ["chr9q34.2", "DNA", 206, 215], ["the index SNP", "TEST", 20, 33], ["COVID", "TEST", 109, 114], ["test", "TEST", 147, 151], ["index SNP rs", "TEST", 222, 234], ["p-value", "TEST", 243, 250], ["C allele", "TEST", 262, 270]]], ["This index SNP is in LD with a functional variant in the ABO gene, specifically rs8176719 (r 2 = 0.57 in the European population), which is a well-known single-nucleotide deletion that usually confers a type O blood group when present in the homozygous form.", [["blood", "ANATOMY", 210, 215], ["SNP", "CHEMICAL", 11, 14], ["ABO", "GENE_OR_GENE_PRODUCT", 57, 60], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["ABO gene", "DNA", 57, 65], ["This index SNP", "TEST", 0, 14], ["nucleotide deletion", "PROBLEM", 160, 179], ["functional variant", "OBSERVATION", 31, 49]]], ["While multiple rare variants elsewhere within the ABO gene can contribute to blood group determination, individuals heterozygous for the deletion are most likely to have blood groups A or B, whereas individuals without any copies of the deletion are most likely to have blood groups A, B, or AB.Figure 4: Manhattan and QQ plots for 'COVID-19 test +ve vs COVID-19 test -ve' a) and 'COVID-19 severe respiratory symptoms' b) from trans-ethnic meta-analysis.", [["blood", "ANATOMY", 77, 82], ["blood", "ANATOMY", 170, 175], ["blood", "ANATOMY", 270, 275], ["respiratory", "ANATOMY", 397, 408], ["respiratory symptoms", "DISEASE", 397, 417], ["ABO", "GENE_OR_GENE_PRODUCT", 50, 53], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["A", "GENE_OR_GENE_PRODUCT", 183, 184], ["B", "GENE_OR_GENE_PRODUCT", 188, 189], ["blood", "ORGANISM_SUBSTANCE", 270, 275], ["B", "GENE_OR_GENE_PRODUCT", 286, 287], ["ABO gene", "DNA", 50, 58], ["multiple rare variants", "PROBLEM", 6, 28], ["blood group determination", "TEST", 77, 102], ["individuals heterozygous", "PROBLEM", 104, 128], ["the deletion", "PROBLEM", 133, 145], ["the deletion", "PROBLEM", 233, 245], ["'COVID", "TEST", 332, 338], ["test", "TEST", 342, 346], ["ve", "TEST", 348, 350], ["COVID", "TEST", 354, 359], ["test", "TEST", 363, 367], ["'COVID", "TEST", 380, 386], ["severe respiratory symptoms", "PROBLEM", 390, 417], ["rare", "OBSERVATION_MODIFIER", 15, 19], ["variants", "OBSERVATION", 20, 28], ["most likely", "UNCERTAINTY", 150, 161], ["most likely", "UNCERTAINTY", 250, 261]]], ["The nearest gene to the index SNP is indicated above each association peak..", [["SNP", "CHEMICAL", 30, 33], ["the index SNP", "TEST", 20, 33]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprintFigure 5: a) Regional plot around the ABO locus for phenotype 'COVID-19 test positive vs COVID-19 test negative' from trans-ethnic meta-analysis.", [["CC", "CHEMICAL", 0, 2], ["ABO locus", "DNA", 384, 393], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 330, 337], ["Regional plot", "TEST", 359, 372], ["the ABO locus", "TEST", 380, 393], ["phenotype 'COVID", "TEST", 398, 414], ["test", "TEST", 418, 422], ["COVID", "TEST", 435, 440], ["test", "TEST", 444, 448], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Imputed variants are indicated with '+' symbols or 'x' symbols for coding variants.", [["coding variants", "PROBLEM", 67, 82]]], ["Where imputed variants weren't available, genotyped variants are indicated by 'o' symbols or diamond symbols for coding variants. b) Odds ratios and 95% confidence intervals for each population.To further understand the relationship between COVID-19 test positive status and ABO blood group, we used genetically determined blood group assignments (see Methods) and estimated the contribution to risk by comparing each blood group against each of the others.", [["blood", "ANATOMY", 279, 284], ["blood", "ANATOMY", 323, 328], ["blood", "ANATOMY", 418, 423], ["COVID-19", "GENE_OR_GENE_PRODUCT", 241, 249], ["ABO", "GENE_OR_GENE_PRODUCT", 275, 278], ["blood", "ORGANISM_SUBSTANCE", 279, 284], ["blood", "ORGANISM_SUBSTANCE", 323, 328], ["blood", "ORGANISM_SUBSTANCE", 418, 423], ["diamond symbols", "DNA", 93, 108], ["COVID", "PROTEIN", 241, 246], ["coding variants", "PROBLEM", 113, 128], ["Odds ratios", "TEST", 133, 144], ["COVID", "TEST", 241, 246], ["ABO blood group", "TEST", 275, 290]]], ["For all COVID-19 phenotypes, we found that the O blood group was protective when compared to other blood groups, whereas blood groups A, B, and AB did not differ from each other ( Table 6 ).", [["blood", "ANATOMY", 49, 54], ["blood", "ANATOMY", 99, 104], ["blood", "ANATOMY", 121, 126], ["O", "SIMPLE_CHEMICAL", 47, 48], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["B", "GENE_OR_GENE_PRODUCT", 137, 138]]], ["We see a similar size of effect in both the diagnosis and severity phenotypes, albeit with the severity phenotypes not achieving statistical significance, possibly due to smaller sample size.", [["severity phenotypes", "PROBLEM", 58, 77], ["the severity phenotypes", "PROBLEM", 91, 114], ["smaller sample size", "PROBLEM", 171, 190], ["size", "OBSERVATION_MODIFIER", 17, 21], ["possibly due to", "UNCERTAINTY", 155, 170], ["smaller", "OBSERVATION_MODIFIER", 171, 178], ["sample", "OBSERVATION_MODIFIER", 179, 185], ["size", "OBSERVATION_MODIFIER", 186, 190]]], ["We also note that the association with COVID-19 diagnosis is in contrast to the ABO results obtained when considering individuals that reported influenza symptoms in the years before the COVID19 pandemic, where blood group O appears to be a risk factor (see Discussion).Figure 5: a) Regional plot around the ABO locus for phenotype 'COVID-19 test positive vs COVID-19 test negative' from trans-ethnic meta-analysis.", [["blood", "ANATOMY", 211, 216], ["influenza symptoms", "DISEASE", 144, 162], ["blood", "ORGANISM_SUBSTANCE", 211, 216], ["ABO locus", "DNA", 308, 317], ["influenza symptoms", "PROBLEM", 144, 162], ["Regional plot", "TEST", 283, 296], ["the ABO locus", "TEST", 304, 317], ["phenotype 'COVID", "TEST", 322, 338], ["test", "TEST", 342, 346], ["COVID", "TEST", 359, 364], ["test", "TEST", 368, 372]]], ["Imputed variants are indicated with '+' symbols or 'x' symbols for coding variants.", [["coding variants", "PROBLEM", 67, 82]]], ["Where imputed variants weren't available, genotyped variants are indicated by 'o' symbols or diamond symbols for coding variants. b) Odds ratios and 95% confidence intervals for each population.There have been preliminary reports suggesting that the rhesus factor (Rh) can also contribute to differences in susceptibility and severity 17 .", [["rhesus", "ORGANISM", 250, 256], ["Rh", "GENE_OR_GENE_PRODUCT", 265, 267], ["diamond symbols", "DNA", 93, 108], ["rhesus factor", "PROTEIN", 250, 263], ["coding variants", "PROBLEM", 113, 128], ["Odds ratios", "TEST", 133, 144], ["severity", "TEST", 326, 334]]], ["We do not detect a genetic association at the RHD locus, which suggests that Rh is not a major risk factor by itself independent of ABO blood group.", [["blood", "ANATOMY", 136, 141], ["Rh", "GENE_OR_GENE_PRODUCT", 77, 79], ["ABO", "GENE_OR_GENE_PRODUCT", 132, 135], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["RHD locus", "DNA", 46, 55], ["ABO blood group", "PROBLEM", 132, 147]]], ["In order to further investigate, we also compared positive and negative forms of each ABO blood group, and detected no significant difference in any comparison (Supplementary Table 7 ).Figure 5: a) Regional plot around the ABO locus for phenotype 'COVID-19 test positive vs COVID-19 test negative' from trans-ethnic meta-analysis.", [["blood", "ANATOMY", 90, 95], ["ABO", "ORGANISM", 86, 89], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["ABO locus", "DNA", 223, 232], ["each ABO blood group", "TEST", 81, 101], ["Regional plot", "TEST", 198, 211], ["the ABO locus", "TEST", 219, 232], ["phenotype 'COVID", "TEST", 237, 253], ["test", "TEST", 257, 261], ["COVID", "TEST", 274, 279], ["test", "TEST", 283, 287], ["no", "UNCERTAINTY", 116, 118], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["difference", "OBSERVATION_MODIFIER", 131, 141]]], ["Imputed variants are indicated with '+' symbols or 'x' symbols for coding variants.", [["coding variants", "PROBLEM", 67, 82]]], ["Where imputed variants weren't available, genotyped variants are indicated by 'o' symbols or diamond symbols for coding variants. b) Odds ratios and 95% confidence intervals for each population..", [["diamond symbols", "DNA", 93, 108], ["coding variants", "PROBLEM", 113, 128], ["Odds ratios", "TEST", 133, 144]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprintchr3p21.31:We identified an association at chr3p21.31, which was shared across all phenotypes (Figure 7a; Supplementary Figure 7) .", [["CC", "CHEMICAL", 0, 2], ["chr3p21.31", "GENE_OR_GENE_PRODUCT", 389, 399], ["chr3p21.31", "DNA", 389, 399], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["The association appeared strongest in our phenotypes related to respiratory symptoms, with the lowest p-value observed in the severe respiratory symptoms phenotype (index SNP rs13078854, alleles A/G, p-value = 1.6e-18), and with a relatively large estimated effect size (G allele OR = 0.592, 95% CI 0.527 -0.665).", [["respiratory", "ANATOMY", 64, 75], ["respiratory", "ANATOMY", 133, 144], ["respiratory symptoms", "DISEASE", 64, 84], ["respiratory symptoms", "DISEASE", 133, 153], ["our phenotypes", "PROBLEM", 38, 52], ["respiratory symptoms", "PROBLEM", 64, 84], ["the lowest p-value", "PROBLEM", 91, 109], ["the severe respiratory symptoms phenotype", "PROBLEM", 122, 163], ["SNP rs", "TEST", 171, 177], ["alleles A/G", "TEST", 187, 198], ["p-value", "TEST", 200, 207], ["a relatively large estimated effect size", "PROBLEM", 229, 269], ["G allele", "TEST", 271, 279], ["CI", "TEST", 296, 298], ["strongest", "OBSERVATION_MODIFIER", 25, 34], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["respiratory", "ANATOMY", 133, 144], ["large", "OBSERVATION_MODIFIER", 242, 247], ["effect", "OBSERVATION_MODIFIER", 258, 264], ["size", "OBSERVATION_MODIFIER", 265, 269]]], ["The majority of support for this association comes from the European population (Figure 7b) , likely reflecting the larger sample size for this cohort.", [["likely reflecting", "UNCERTAINTY", 94, 111], ["larger", "OBSERVATION_MODIFIER", 116, 122], ["sample", "OBSERVATION_MODIFIER", 123, 129], ["size", "OBSERVATION_MODIFIER", 130, 134]]], ["However, the risk allele is also more common in the European population, with the rs13078854 A allele having frequency 7.8%, 5.8%, and 2.7% in the European, Latino, and African American populations, respectively.chr3p21.31:The credible set for this locus overlaps the LZTFL1 gene, although none of the variants in the credible set alter the resulting protein.", [["locus", "CELLULAR_COMPONENT", 249, 254], ["LZTFL1", "GENE_OR_GENE_PRODUCT", 268, 274], ["LZTFL1 gene", "DNA", 268, 279], ["A allele", "TEST", 93, 101], ["frequency", "TEST", 109, 118]]], ["The locus also contains other nearby genes that could plausibly be driving the association, including SLC6A20, CCR9, FYCO1, CXCR6, and XCR1.", [["locus", "CELLULAR_COMPONENT", 4, 9], ["SLC6A20", "GENE_OR_GENE_PRODUCT", 102, 109], ["CCR9", "GENE_OR_GENE_PRODUCT", 111, 115], ["FYCO1", "GENE_OR_GENE_PRODUCT", 117, 122], ["CXCR6", "GENE_OR_GENE_PRODUCT", 124, 129], ["XCR1", "GENE_OR_GENE_PRODUCT", 135, 139], ["SLC6A20", "PROTEIN", 102, 109], ["CCR9", "PROTEIN", 111, 115], ["FYCO1", "PROTEIN", 117, 122], ["CXCR6", "PROTEIN", 124, 129], ["XCR1", "PROTEIN", 135, 139], ["SLC6A20", "TEST", 102, 109], ["CCR9", "TEST", 111, 115], ["CXCR6", "TEST", 124, 129], ["nearby genes", "OBSERVATION", 30, 42], ["CCR9", "ANATOMY", 111, 115], ["CXCR6", "ANATOMY", 124, 129]]], ["In our data, the index SNP is in high LD (r 2 >= 0.85) with eQTLs for SLC6A20, as detected in GTEx within breast epithelium and esophagus muscularis mucosa 17 , suggesting increased expression of SLC6A20 correlates with increased risk of severe outcomes.chr3p21.31:.", [["breast epithelium", "ANATOMY", 106, 123], ["esophagus muscularis mucosa", "ANATOMY", 128, 155], ["SNP", "CHEMICAL", 23, 26], ["SLC6A20", "GENE_OR_GENE_PRODUCT", 70, 77], ["breast epithelium", "TISSUE", 106, 123], ["esophagus muscularis mucosa 17", "CANCER", 128, 158], ["SLC6A20", "GENE_OR_GENE_PRODUCT", 196, 203], ["SLC6A20", "PROTEIN", 70, 77], ["SLC6A20", "PROTEIN", 196, 203], ["the index SNP", "TEST", 13, 26], ["eQTLs", "TEST", 60, 65], ["SLC6A20", "TEST", 70, 77], ["increased expression of SLC6A20", "PROBLEM", 172, 203], ["severe outcomes.chr3p21.31", "PROBLEM", 238, 264], ["breast", "ANATOMY", 106, 112], ["epithelium", "ANATOMY_MODIFIER", 113, 123], ["esophagus muscularis", "ANATOMY", 128, 148], ["increased", "OBSERVATION_MODIFIER", 172, 181], ["severe", "OBSERVATION_MODIFIER", 238, 244]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint Figure 7 : a) Regional plot around the chr3 locus for the COVID-19 severe respiratory symptoms phenotype.", [["respiratory", "ANATOMY", 421, 432], ["CC", "CHEMICAL", 0, 2], ["respiratory symptoms", "DISEASE", 421, 441], ["chr3", "GENE_OR_GENE_PRODUCT", 386, 390], ["chr3 locus", "DNA", 386, 396], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Regional plot", "TEST", 361, 374], ["the COVID", "TEST", 401, 410], ["severe respiratory symptoms phenotype", "PROBLEM", 414, 451], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["severe", "OBSERVATION_MODIFIER", 414, 420], ["respiratory symptoms", "OBSERVATION", 421, 441]]], ["Imputed variants are indicated with '+' symbols or 'x' symbols for coding variants.", [["coding variants", "PROBLEM", 67, 82]]], ["Where imputed variants weren't available, genotyped variants are indicated by 'o' symbols or diamond symbols for coding variants. b) Odds ratio estimate and 95% confidence interval for each population.(which was not certified by peer review)Given the reported differences in outcome severity between males and females, we tested for a difference in effect at the chr3p21.31 locus.", [["diamond symbols", "DNA", 93, 108], ["chr3p21.31 locus", "DNA", 363, 379], ["coding variants", "PROBLEM", 113, 128]]], ["Testing rs13078854 separately in males and females for the severe respiratory symptoms phenotype gave an OR = 0.49 (95% CI: 0.41 -0.59) in males and OR = 0.69 (95% CI: 0.58 -0.82) in females, with the difference being moderately significant (p-value = 0.003; z-test).", [["respiratory", "ANATOMY", 66, 77], ["respiratory symptoms", "DISEASE", 66, 86], ["rs13078854", "GENE_OR_GENE_PRODUCT", 8, 18], ["Testing", "TEST", 0, 7], ["the severe respiratory symptoms", "PROBLEM", 55, 86], ["CI", "TEST", 120, 122], ["CI", "TEST", 164, 166], ["p-value", "TEST", 242, 249], ["z-test", "TEST", 259, 265], ["moderately", "OBSERVATION_MODIFIER", 218, 228], ["significant", "OBSERVATION_MODIFIER", 229, 240]]], ["On the basis of the association between ABO and COVID-19, we further hypothesized that the chr3p21.31 locus may show a difference in effect size depending on ABO blood type.", [["blood", "ANATOMY", 162, 167], ["ABO", "GENE_OR_GENE_PRODUCT", 40, 43], ["COVID-19", "GENE_OR_GENE_PRODUCT", 48, 56], ["chr3p21.31", "GENE_OR_GENE_PRODUCT", 91, 101], ["ABO", "GENE_OR_GENE_PRODUCT", 158, 161], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["ABO and COVID-19", "DNA", 40, 56], ["chr3p21.31 locus", "DNA", 91, 107], ["ABO", "TEST", 40, 43], ["COVID", "TEST", 48, 53], ["effect size", "PROBLEM", 133, 144], ["ABO blood type", "TEST", 158, 172], ["size", "OBSERVATION_MODIFIER", 140, 144]]], ["Conditioning on blood type O, we estimated the OR of rs13078854 to be 0.63 (95% CI: 0.52 -0.77), whereas conditioning on any other blood type gave an OR of 0.57 (95% CI: 0.49 -0.66).", [["blood", "ANATOMY", 16, 21], ["blood", "ANATOMY", 131, 136], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["CI", "TEST", 80, 82], ["any other blood type", "TEST", 121, 141], ["CI", "TEST", 166, 168]]], ["We therefore conclude that ABO blood type does not modulate the effect at the chr3p21.31 locus (p-value = 0.80; z-test).(which was not certified by peer review)Other associations: In addition to the two main associations, we observed 5 weaker associations which, while achieving genome-wide significance, typically only include a small number of low-frequency variants within the association peak, and may represent false-positive associations (Supplementary Table 5 ).DiscussionThe COVID-19 pandemic represents a unique emergency in recent human history, and has dramatically accelerated the pace of scientific investigation into the effects of the virus on .", [["blood", "ANATOMY", 31, 36], ["ABO", "GENE_OR_GENE_PRODUCT", 27, 30], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["human", "ORGANISM", 541, 546], ["chr3p21.31 locus", "DNA", 78, 94], ["human", "SPECIES", 541, 546], ["human", "SPECIES", 541, 546], ["ABO blood type", "TEST", 27, 41], ["p-value", "TEST", 96, 103], ["z-test", "TEST", 112, 118], ["5 weaker associations", "PROBLEM", 234, 255], ["a small number of low-frequency variants", "PROBLEM", 328, 368], ["false-positive associations", "PROBLEM", 416, 443], ["the virus", "PROBLEM", 646, 655], ["small", "OBSERVATION_MODIFIER", 330, 335], ["number", "OBSERVATION_MODIFIER", 336, 342], ["low-frequency variants", "OBSERVATION_MODIFIER", 346, 368], ["may represent", "UNCERTAINTY", 402, 415], ["false", "OBSERVATION", 416, 421], ["-positive", "OBSERVATION_MODIFIER", 421, 430], ["virus", "OBSERVATION", 650, 655]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint human health.", [["CC", "CHEMICAL", 0, 2], ["human", "ORGANISM", 347, 352], ["human", "SPECIES", 347, 352], ["human", "SPECIES", 347, 352], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In this paper, we have utilized a direct-to-consumer research platform to collect data regarding experiences of COVID-19 at large scale and over a compressed timeline.(which was not certified by peer review)Both Latino and African American groups reported a higher rate of COVID-19 infection and, as reported elsewhere 2, 18, 19 , our data show an elevated risk of hospitalization in these populations.", [["infection", "DISEASE", 282, 291], ["COVID-19", "SPECIES", 273, 281], ["COVID", "TEST", 112, 117], ["COVID-19 infection", "PROBLEM", 273, 291], ["our data", "TEST", 331, 339], ["infection", "OBSERVATION", 282, 291], ["elevated", "OBSERVATION", 348, 356]]], ["For Latino respondents, the higher rate of hospitalization was broadly consistent with the higher rate of infection.", [["infection", "DISEASE", 106, 115], ["infection", "PROBLEM", 106, 115], ["infection", "OBSERVATION", 106, 115]]], ["However, for African American respondents, the risk of hospitalization was disproportionately high, and remained so after adjusting for socio-demographic characteristics, age, sex, obesity, type 2 diabetes, hypertension, and fatty liver disease.(which was not certified by peer review)Our data also strengthens the evidence for a role for ABO in COVID-19 host genetics.", [["fatty liver", "ANATOMY", 225, 236], ["obesity", "DISEASE", 181, 188], ["type 2 diabetes", "DISEASE", 190, 205], ["hypertension", "DISEASE", 207, 219], ["fatty liver disease", "DISEASE", 225, 244], ["liver", "ORGAN", 231, 236], ["ABO", "GENE_OR_GENE_PRODUCT", 339, 342], ["ABO", "PROTEIN", 339, 342], ["obesity", "PROBLEM", 181, 188], ["type 2 diabetes", "PROBLEM", 190, 205], ["hypertension", "PROBLEM", 207, 219], ["fatty liver disease", "PROBLEM", 225, 244], ["obesity", "OBSERVATION", 181, 188], ["diabetes", "OBSERVATION", 197, 205], ["hypertension", "OBSERVATION", 207, 219], ["fatty liver disease", "OBSERVATION", 225, 244]]], ["ABO blood group has been reported as a risk factor for both COVID-19 susceptibility 20 and severity 15 , and is notable given the reported links between COVID-19 and blood clotting complications 21, 22 .", [["blood", "ANATOMY", 4, 9], ["blood", "ANATOMY", 166, 171], ["blood clotting", "DISEASE", 166, 180], ["ABO", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["ABO blood group", "TEST", 0, 15], ["both COVID", "TEST", 55, 65], ["severity", "TEST", 91, 99], ["COVID", "TEST", 153, 158], ["blood clotting complications", "PROBLEM", 166, 194]]], ["Our data supports a role in susceptibility to infection, suggesting that blood group O is protective in contrast to non-O blood groups.", [["blood", "ANATOMY", 73, 78], ["blood", "ANATOMY", 122, 127], ["infection", "DISEASE", 46, 55], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["Our data", "TEST", 0, 8], ["infection", "PROBLEM", 46, 55], ["blood group O", "PROBLEM", 73, 86], ["infection", "OBSERVATION", 46, 55]]], ["Whereas previous reports suggested protection was limited to the rhesus positive group 23 , our data does not support that conclusion.(which was not certified by peer review)The mechanism by which ABO is associated with COVID-19 is unclear, but ABO blood groups can play a direct role in pathogen infection by serving as receptors and/or coreceptors 24 .", [["blood", "ANATOMY", 249, 254], ["infection", "DISEASE", 297, 306], ["COVID-19", "CHEMICAL", 220, 228], ["ABO", "GENE_OR_GENE_PRODUCT", 197, 200], ["COVID-19", "GENE_OR_GENE_PRODUCT", 220, 228], ["ABO", "GENE_OR_GENE_PRODUCT", 245, 248], ["blood", "ORGANISM_SUBSTANCE", 249, 254], ["coreceptors 24", "PROTEIN", 338, 352], ["our data", "TEST", 92, 100], ["COVID", "TEST", 220, 225], ["ABO blood groups", "PROBLEM", 245, 261], ["pathogen infection", "PROBLEM", 288, 306], ["infection", "OBSERVATION", 297, 306]]], ["SARS-CoV-2 is an enveloped virus that carries ABO antigens on the viral spike (S) glycoprotein and host envelope glycolipids.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["ABO antigens", "GENE_OR_GENE_PRODUCT", 46, 58], ["spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 72, 94], ["ABO antigens", "PROTEIN", 46, 58], ["viral spike (S) glycoprotein", "PROTEIN", 66, 94], ["SARS-CoV-2", "SPECIES", 0, 10], ["an enveloped virus", "PROBLEM", 14, 32], ["ABO antigens", "PROBLEM", 46, 58], ["the viral spike (S) glycoprotein", "TREATMENT", 62, 94], ["host envelope glycolipids", "TREATMENT", 99, 124], ["virus", "OBSERVATION", 27, 32]]], ["Recent work has shown the SARS-CoV-2 S protein interacts with multiple host C-type lectin receptors in a glycosylation-dependent manner 25, 26 , similar to previous work on the SARS-CoV virus from the earlier SARS outbreak 27, 28 .", [["SARS-CoV virus", "DISEASE", 177, 191], ["SARS", "DISEASE", 209, 213], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 76, 99], ["SARS-CoV virus", "ORGANISM", 177, 191], ["SARS-CoV-2 S protein", "PROTEIN", 26, 46], ["C-type lectin receptors", "PROTEIN", 76, 99], ["SARS-CoV virus", "SPECIES", 177, 191], ["the SARS", "TEST", 22, 30], ["CoV", "TEST", 31, 34], ["the SARS", "PROBLEM", 173, 181], ["CoV virus", "PROBLEM", 182, 191]]], ["Differential glycosylation of the spike protein or the envelope glycolipids from expression of different ABO glycosyltransferases may then impact the binding and internalization of SARS-CoV-2 viral particles.", [["ABO glycosyltransferases", "GENE_OR_GENE_PRODUCT", 105, 129], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 181, 191], ["spike protein", "PROTEIN", 34, 47], ["ABO glycosyltransferases", "PROTEIN", 105, 129], ["the spike protein", "PROBLEM", 30, 47], ["the envelope glycolipids", "PROBLEM", 51, 75], ["different ABO glycosyltransferases", "TREATMENT", 95, 129], ["the binding", "PROBLEM", 146, 157], ["SARS", "TEST", 181, 185], ["CoV", "TEST", 186, 189]]], ["Others have speculated that the lower susceptibility of blood group O could be linked to anti-A blood antibodies inhibiting the adhesion of coronavirus to ACE2-expressing cells, thereby providing protection 29 .(which was not certified by peer review)The ABO locus is also highly pleiotropic 30 and exhibits complex population structure 31 .", [["blood", "ANATOMY", 56, 61], ["blood", "ANATOMY", 96, 101], ["cells", "ANATOMY", 171, 176], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["anti-A blood antibodies", "GENE_OR_GENE_PRODUCT", 89, 112], ["coronavirus", "ORGANISM", 140, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 155, 159], ["cells", "CELL", 171, 176], ["ABO", "GENE_OR_GENE_PRODUCT", 255, 258], ["anti-A blood antibodies", "PROTEIN", 89, 112], ["ACE2", "PROTEIN", 155, 159], ["expressing cells", "CELL_TYPE", 160, 176], ["ABO locus", "DNA", 255, 264], ["the lower susceptibility of blood group O", "PROBLEM", 28, 69], ["anti", "TEST", 89, 93], ["A blood antibodies", "TEST", 94, 112], ["coronavirus", "PROBLEM", 140, 151], ["ACE2", "TEST", 155, 159], ["The ABO locus", "TEST", 251, 264], ["lower", "OBSERVATION_MODIFIER", 32, 37], ["ABO locus", "OBSERVATION", 255, 264], ["highly", "OBSERVATION_MODIFIER", 273, 279], ["pleiotropic", "OBSERVATION_MODIFIER", 280, 291], ["complex", "OBSERVATION_MODIFIER", 308, 315], ["population", "OBSERVATION", 316, 326]]], ["Interestingly, while old literature regarding the association between ABO and influenza is inconsistent 32 , our own data suggests that blood type O is actually a risk factor for seasonal flu.", [["blood", "ANATOMY", 136, 141], ["influenza", "DISEASE", 78, 87], ["flu", "DISEASE", 188, 191], ["ABO", "GENE_OR_GENE_PRODUCT", 70, 73], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["ABO", "TEST", 70, 73], ["influenza", "PROBLEM", 78, 87], ["a risk factor", "PROBLEM", 161, 174], ["seasonal flu", "PROBLEM", 179, 191]]], ["This is notable because COVID-19 testing in the United States was largely restricted to individuals with flu-like symptoms at the time we were collecting the majority of our data.", [["flu-like symptoms", "DISEASE", 105, 122], ["COVID", "TEST", 24, 29], ["flu-like symptoms", "PROBLEM", 105, 122]]], ["As such, it is possible that the population of individuals receiving COVID-19 tests was enriched for influenza cases, and the apparent protective nature of ABO for COVID-19 could arise from a subtle form of collider bias.", [["influenza", "DISEASE", 101, 110], ["COVID-19", "CHEMICAL", 164, 172], ["COVID", "TEST", 69, 74], ["tests", "TEST", 78, 83], ["influenza cases", "PROBLEM", 101, 116], ["COVID", "TEST", 164, 169], ["collider bias", "OBSERVATION", 207, 220]]], ["However, our data also shows that blood type O is protective in the severe-outcome population, which wouldn't be expected under the collider bias hypothesis.(which was not certified by peer review)Likewise, our data strengthens the evidence of association at the chr3p21.31 gene cluster, first identified by Ellinghaus et al. 15 .", [["blood", "ANATOMY", 34, 39], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["chr3p21.31", "GENE_OR_GENE_PRODUCT", 263, 273], ["chr3p21.31 gene cluster", "DNA", 263, 286], ["our data", "TEST", 9, 17], ["the severe-outcome population", "PROBLEM", 64, 93], ["severe", "OBSERVATION_MODIFIER", 68, 74]]], ["The locus contains multiple genes (SLC6A20, LZFTL1, CCR9, CXCR6, XCR1, FYCO1) that could be functionally implicated in COVID-19 pathology.", [["locus", "CELLULAR_COMPONENT", 4, 9], ["SLC6A20", "GENE_OR_GENE_PRODUCT", 35, 42], ["LZFTL1", "GENE_OR_GENE_PRODUCT", 44, 50], ["CCR9", "GENE_OR_GENE_PRODUCT", 52, 56], ["CXCR6", "GENE_OR_GENE_PRODUCT", 58, 63], ["XCR1", "GENE_OR_GENE_PRODUCT", 65, 69], ["FYCO1", "GENE_OR_GENE_PRODUCT", 71, 76], ["multiple genes", "DNA", 19, 33], ["SLC6A20", "DNA", 35, 42], ["LZFTL1", "DNA", 44, 50], ["CCR9", "DNA", 52, 56], ["CXCR6", "DNA", 58, 63], ["XCR1", "DNA", 65, 69], ["FYCO1", "DNA", 71, 76], ["SLC6A20", "TEST", 35, 42], ["LZFTL1", "TEST", 44, 50], ["CCR9", "TEST", 52, 56], ["CXCR6", "TEST", 58, 63], ["COVID", "TEST", 119, 124], ["locus", "OBSERVATION_MODIFIER", 4, 9], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["genes", "OBSERVATION_MODIFIER", 28, 33], ["CCR9", "ANATOMY", 52, 56]]], ["In particular, SLC6A20 can be linked to the association via eQTLs in relevant tissue and has been noted 15 as potentially forming a complex with angiotensin converting enzyme 2 (ACE2), the cell .", [["tissue", "ANATOMY", 78, 84], ["cell", "ANATOMY", 189, 193], ["angiotensin", "CHEMICAL", 145, 156], ["SLC6A20", "GENE_OR_GENE_PRODUCT", 15, 22], ["tissue", "TISSUE", 78, 84], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 145, 176], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["cell", "CELL", 189, 193], ["SLC6A20", "PROTEIN", 15, 22], ["eQTLs", "DNA", 60, 65], ["angiotensin converting enzyme 2", "PROTEIN", 145, 176], ["ACE2", "PROTEIN", 178, 182], ["angiotensin converting enzyme", "TEST", 145, 174], ["cell", "ANATOMY", 189, 193]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint surface receptor for SARS-CoV-2 viral entry 33, 34 .", [["surface", "ANATOMY", 347, 354], ["CC", "CHEMICAL", 0, 2], ["doi: medRxiv preprint surface receptor", "PROTEIN", 325, 363], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint surface receptor", "TREATMENT", 330, 363], ["SARS", "PROBLEM", 368, 372], ["CoV", "TEST", 373, 376], ["viral entry", "TEST", 379, 390], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["It is possible that increased SLC6A20 expression leads to increased ACE2 protein levels and greater viral uptake.", [["SLC6A20", "GENE_OR_GENE_PRODUCT", 30, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["SLC6A20", "PROTEIN", 30, 37], ["ACE2", "PROTEIN", 68, 72], ["increased SLC6A20 expression", "PROBLEM", 20, 48], ["increased ACE2 protein levels", "PROBLEM", 58, 87], ["greater viral uptake", "PROBLEM", 92, 112], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["SLC6A20 expression", "OBSERVATION", 30, 48], ["greater", "OBSERVATION_MODIFIER", 92, 99], ["viral uptake", "OBSERVATION", 100, 112]]], ["LZFTL1 has been implicated in ciliogenesis and intracellular trafficking of ciliary proteins, which may impact airway epithelial cell function.", [["intracellular", "ANATOMY", 47, 60], ["ciliary", "ANATOMY", 76, 83], ["airway epithelial cell", "ANATOMY", 111, 133], ["LZFTL1", "CHEMICAL", 0, 6], ["LZFTL1", "GENE_OR_GENE_PRODUCT", 0, 6], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["ciliary proteins", "GENE_OR_GENE_PRODUCT", 76, 92], ["airway epithelial cell", "CELL", 111, 133], ["LZFTL1", "PROTEIN", 0, 6], ["ciliary proteins", "PROTEIN", 76, 92], ["LZFTL1", "TREATMENT", 0, 6], ["ciliogenesis", "PROBLEM", 30, 42], ["ciliary proteins", "PROBLEM", 76, 92], ["ciliogenesis", "OBSERVATION", 30, 42], ["intracellular trafficking", "OBSERVATION", 47, 72], ["ciliary proteins", "OBSERVATION", 76, 92], ["airway epithelial cell function", "OBSERVATION", 111, 142]]], ["As noted elsewhere 15 , CXCR6 promotes NKT cell and tissue resident memory CD8+ T cells residence in the lung 35 and plays a role in the trafficking of T lymphocytes to the bronchial epithelia during respiratory infection and inflammatory lung disease.", [["NKT cell", "ANATOMY", 39, 47], ["tissue", "ANATOMY", 52, 58], ["T cells", "ANATOMY", 80, 87], ["lung 35", "ANATOMY", 105, 112], ["T lymphocytes", "ANATOMY", 152, 165], ["bronchial epithelia", "ANATOMY", 173, 192], ["respiratory", "ANATOMY", 200, 211], ["lung", "ANATOMY", 239, 243], ["respiratory infection", "DISEASE", 200, 221], ["inflammatory lung disease", "DISEASE", 226, 251], ["CXCR6", "GENE_OR_GENE_PRODUCT", 24, 29], ["NKT cell", "CELL", 39, 47], ["tissue", "TISSUE", 52, 58], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["T cells", "CELL", 80, 87], ["lung", "ORGAN", 105, 109], ["T lymphocytes", "CELL", 152, 165], ["bronchial epithelia", "TISSUE", 173, 192], ["lung", "ORGAN", 239, 243], ["CXCR6", "PROTEIN", 24, 29], ["NKT cell", "CELL_TYPE", 39, 47], ["tissue resident memory CD8+", "CELL_TYPE", 52, 79], ["T cells", "CELL_TYPE", 80, 87], ["T lymphocytes", "CELL_TYPE", 152, 165], ["the bronchial epithelia", "PROBLEM", 169, 192], ["respiratory infection", "PROBLEM", 200, 221], ["inflammatory lung disease", "PROBLEM", 226, 251], ["NKT cell", "OBSERVATION", 39, 47], ["lung", "ANATOMY", 105, 109], ["bronchial", "ANATOMY", 173, 182], ["epithelia", "ANATOMY_MODIFIER", 183, 192], ["respiratory", "ANATOMY", 200, 211], ["infection", "OBSERVATION", 212, 221], ["inflammatory", "OBSERVATION_MODIFIER", 226, 238], ["lung", "ANATOMY", 239, 243], ["disease", "OBSERVATION", 244, 251]]], ["CCR9 predominantly regulates T cell homing to the gut, which may indirectly impact the response in the lung, however it has also been shown to regulate eosinophil recruitment to the lung 36 .", [["T cell", "ANATOMY", 29, 35], ["gut", "ANATOMY", 50, 53], ["lung", "ANATOMY", 103, 107], ["eosinophil", "ANATOMY", 152, 162], ["lung", "ANATOMY", 182, 186], ["CCR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["T cell", "CELL", 29, 35], ["gut", "ORGAN", 50, 53], ["lung", "ORGAN", 103, 107], ["eosinophil", "CELL", 152, 162], ["lung", "ORGAN", 182, 186], ["CCR9", "PROTEIN", 0, 4], ["CCR9", "TEST", 0, 4], ["eosinophil recruitment", "TREATMENT", 152, 174], ["T cell homing", "OBSERVATION", 29, 42], ["gut", "ANATOMY", 50, 53], ["response", "OBSERVATION_MODIFIER", 87, 95], ["lung", "ANATOMY", 103, 107], ["eosinophil recruitment", "OBSERVATION", 152, 174], ["lung", "ANATOMY", 182, 186]]], ["Recent studies have identified elevated chemokines and eosinophilia as a hallmark of severe disease [37] [38] [39] , but additional work will be required to define any functional contribution of these genes to the genetic association with COVID-19.(which was not certified by peer review)In phenotypes contrasting individuals with severe COVID-19 symptoms to controls without a COVID-19 diagnosis, the risk variants at the chr3p21.31 locus achieve odds ratios of approximately 2.0 in our data, which is relatively large in the context of GWAS studies.", [["eosinophilia", "DISEASE", 55, 67], ["chemokines", "PROTEIN", 40, 50], ["chr3p21.31 locus", "DNA", 423, 439], ["Recent studies", "TEST", 0, 14], ["elevated chemokines", "PROBLEM", 31, 50], ["eosinophilia", "PROBLEM", 55, 67], ["severe disease", "PROBLEM", 85, 99], ["severe COVID-19 symptoms", "PROBLEM", 331, 355], ["a COVID", "TEST", 376, 383], ["the risk variants", "PROBLEM", 398, 415], ["odds ratios", "TEST", 448, 459], ["GWAS studies", "TEST", 538, 550], ["elevated", "OBSERVATION_MODIFIER", 31, 39], ["chemokines", "OBSERVATION", 40, 50], ["eosinophilia", "OBSERVATION", 55, 67], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["disease", "OBSERVATION", 92, 99], ["severe", "OBSERVATION_MODIFIER", 331, 337], ["relatively", "OBSERVATION_MODIFIER", 503, 513], ["large", "OBSERVATION_MODIFIER", 514, 519]]], ["Given the risk alleles are also relatively common (~3 -8% frequency, depending on population), it is likely that this locus makes a meaningful contribution to determining why some individuals experience severe COVID-19 outcomes.", [["the risk alleles", "PROBLEM", 6, 22], ["severe COVID", "PROBLEM", 203, 215]]], ["However, while the population sample sizes in our study differ considerably, we found little evidence to suggest that allele frequency differences at this locus could account for the higher rate of severe outcomes from COVID-19 for non-European ancestry groups.", [["locus", "CELLULAR_COMPONENT", 155, 160], ["our study", "TEST", 46, 55], ["allele frequency differences", "PROBLEM", 118, 146], ["severe outcomes", "PROBLEM", 198, 213], ["COVID", "TEST", 219, 224], ["non-European ancestry groups", "TREATMENT", 232, 260], ["sizes", "OBSERVATION_MODIFIER", 37, 42], ["little evidence to suggest", "UNCERTAINTY", 86, 112], ["severe", "OBSERVATION_MODIFIER", 198, 204]]], ["In fact, the primary risk allele at the chr3p21.31 locus is most common in European populations, and less common in Latino, and African American populations.(which was not certified by peer review)This study is a testament to the power of the 23andMe research platform, which in less than four months enabled over one million research participants to contribute to the study of a novel disease.", [["chr3p21.31", "GENE_OR_GENE_PRODUCT", 40, 50], ["primary risk allele", "DNA", 13, 32], ["chr3p21.31 locus", "DNA", 40, 56], ["participants", "SPECIES", 335, 347], ["This study", "TEST", 197, 207], ["the study", "TEST", 365, 374], ["a novel disease", "PROBLEM", 378, 393], ["most common", "OBSERVATION_MODIFIER", 60, 71]]], ["However, there are notable caveats to relying on self-reported data for a disease with lethal outcomes.", [["a disease with lethal outcomes", "PROBLEM", 72, 102]]], ["Namely, the cases identified in this study were healthy enough to respond to the survey therefore are likely biased towards a healthier case population than otherwise exists.", [["this study", "TEST", 32, 42]]], ["In addition, 23andMe research participants are a self-selected group and may not reflect the general population.", [["participants", "SPECIES", 30, 42], ["may not reflect", "UNCERTAINTY", 73, 88]]], ["Furthermore, the scarcity of testing has likely further obscured the true picture of SARS-CoV-2 infections in the United States, leading to misclassification of true cases as controls in this study if they did not receive a positive test result.", [["SARS-CoV-2 infections", "DISEASE", 85, 106], ["SARS-CoV-2", "ORGANISM", 85, 95], ["SARS-CoV", "SPECIES", 85, 93], ["testing", "TEST", 29, 36], ["SARS", "PROBLEM", 85, 89], ["2 infections", "PROBLEM", 94, 106], ["this study", "TEST", 187, 197], ["a positive test result", "PROBLEM", 222, 244]]], ["The effect of these types of error would bias the reported effect estimates towards the null, meaning that the true impact of risk factors reported here may be expected to be larger if the sample were randomly drawn from the broader population and had perfect case and control classification.Data availabilityThe full set of de-identified summary statistics can be made available to qualified investigators who enter into an agreement with 23andMe that protects participant confidentiality.", [["larger", "OBSERVATION_MODIFIER", 175, 181]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Data availabilityThe copyright holder for this preprint this version posted September 7, 2020. .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 219, 239], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Data availabilityThe copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint Supplementary Table 5 : Genome-wide significant association index SNP from the trans-ethnic meta analysis. .", [["CC", "CHEMICAL", 0, 2], ["SNP", "CHEMICAL", 431, 434], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 219, 239], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)SupplementaryThe copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188318 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 344, 351], ["med", "ANATOMY", 105, 108]]]], "b44b7288e7b0e89de76c852a5174dc42f7a7ea7c": [["Emerging and re-emerging infectious diseases in humans and animals have been reported with increased frequency in recent years 1 .", [["infectious diseases", "DISEASE", 25, 44], ["humans", "ORGANISM", 48, 54], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["infectious", "OBSERVATION", 25, 35], ["increased", "OBSERVATION_MODIFIER", 91, 100]]], ["The growing demands on land use, intensified farming practices to feed a larger population and the increase in travel and transportation allow the emergence, re-emergence and rapid spread of infectious agents around the globe.", [["a larger population", "PROBLEM", 71, 90], ["infectious agents", "TREATMENT", 191, 208], ["growing", "OBSERVATION_MODIFIER", 4, 11], ["larger", "OBSERVATION_MODIFIER", 73, 79], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["rapid", "OBSERVATION_MODIFIER", 175, 180], ["spread", "OBSERVATION_MODIFIER", 181, 187], ["infectious", "OBSERVATION", 191, 201], ["globe", "ANATOMY", 220, 225]]], ["The emergence of high-pathogenicity avian influenza (HPAI) viruses in domestic poultry and the increasing number of cases of direct transmission of avian influenza viruses of different subtypes to humans are a significant threat to public health because of the potential for pandemic spread of these viruses.", [["avian influenza (HPAI) viruses", "DISEASE", 36, 66], ["avian influenza viruses", "DISEASE", 148, 171], ["high-pathogenicity", "ORGANISM", 17, 35], ["avian influenza", "ORGANISM", 36, 51], ["HPAI) viruses", "ORGANISM", 53, 66], ["avian influenza viruses", "ORGANISM", 148, 171], ["humans", "ORGANISM", 197, 203], ["avian influenza (HPAI", "SPECIES", 36, 57], ["avian influenza viruses", "SPECIES", 148, 171], ["humans", "SPECIES", 197, 203], ["HPAI", "SPECIES", 53, 57], ["humans", "SPECIES", 197, 203], ["high-pathogenicity avian influenza (HPAI) viruses", "PROBLEM", 17, 66], ["avian influenza viruses", "PROBLEM", 148, 171], ["pandemic spread of these viruses", "PROBLEM", 275, 307], ["increasing", "OBSERVATION_MODIFIER", 95, 105], ["number", "OBSERVATION_MODIFIER", 106, 112], ["viruses", "OBSERVATION", 300, 307]]], ["The ongoing outbreak of HPAI H5N1 viruses in the bird population and the nearly 50% case-fatality rate among people who become infected with H5N1 viruses underscore the need for control strategies to prevent a potential influenza pandemic.", [["HPAI H5N1 viruses", "DISEASE", 24, 41], ["H5N1 viruses", "DISEASE", 141, 153], ["influenza pandemic", "DISEASE", 220, 238], ["HPAI H5N1 viruses", "ORGANISM", 24, 41], ["people", "ORGANISM", 109, 115], ["H5N1 viruses", "ORGANISM", 141, 153], ["HPAI H5N1 viruses", "SPECIES", 24, 41], ["people", "SPECIES", 109, 115], ["HPAI H5N1 viruses", "SPECIES", 24, 41], ["HPAI H5N1 viruses", "PROBLEM", 24, 41], ["H5N1 viruses", "TREATMENT", 141, 153], ["control strategies", "TREATMENT", 178, 196], ["a potential influenza pandemic", "PROBLEM", 208, 238], ["HPAI", "OBSERVATION_MODIFIER", 24, 28], ["H5N1 viruses", "OBSERVATION", 29, 41], ["influenza", "OBSERVATION", 220, 229]]]], "PMC7537588": [["IntroductionCoronaviruses are a diverse group of viruses infecting many different animals, and they can cause mild to severe respiratory infections in humans.", [["respiratory", "ANATOMY", 125, 136], ["respiratory infections", "DISEASE", 125, 147], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["humans", "ORGANISM", 151, 157], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 151, 157], ["IntroductionCoronaviruses", "PROBLEM", 0, 25], ["mild to severe respiratory infections in humans", "PROBLEM", 110, 157], ["mild", "OBSERVATION_MODIFIER", 110, 114], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["respiratory", "OBSERVATION_MODIFIER", 125, 136], ["infections", "OBSERVATION", 137, 147]]], ["In 2002 and 2012, respectively, two highly pathogenic coronaviruses with zoonotic origin, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), emerged in humans and caused fatal respiratory illness, making emerging coronaviruses a new public health concern in the twenty-first century1.", [["respiratory", "ANATOMY", 243, 254], ["coronaviruses", "DISEASE", 54, 67], ["zoonotic origin", "DISEASE", 73, 88], ["acute respiratory syndrome coronavirus", "DISEASE", 97, 135], ["SARS-CoV)", "DISEASE", 137, 146], ["Middle East respiratory syndrome coronavirus", "DISEASE", 151, 195], ["respiratory illness", "DISEASE", 243, 262], ["coronaviruses", "DISEASE", 280, 293], ["coronaviruses", "ORGANISM", 54, 67], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 90, 135], ["SARS-CoV", "ORGANISM", 137, 145], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 151, 195], ["MERS-CoV", "ORGANISM", 197, 205], ["humans", "ORGANISM", 219, 225], ["coronaviruses", "ORGANISM", 280, 293], ["humans", "SPECIES", 219, 225], ["severe acute respiratory syndrome coronavirus", "SPECIES", 90, 135], ["SARS-CoV", "SPECIES", 137, 145], ["Middle East respiratory syndrome coronavirus", "SPECIES", 151, 195], ["MERS-CoV", "SPECIES", 197, 205], ["humans", "SPECIES", 219, 225], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 90, 135], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 151, 195], ["fatal respiratory illness", "PROBLEM", 237, 262], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome coronavirus", "OBSERVATION", 103, 135], ["Middle", "ANATOMY_MODIFIER", 151, 157], ["respiratory syndrome", "OBSERVATION", 163, 183], ["fatal", "OBSERVATION_MODIFIER", 237, 242], ["respiratory illness", "OBSERVATION", 243, 262]]], ["At the end of 2019, a novel coronavirus designated as SARS-CoV-2 emerged in the city of Wuhan, China, and caused an outbreak of unusual viral pneumonia.", [["coronavirus", "DISEASE", 28, 39], ["SARS", "DISEASE", 54, 58], ["viral pneumonia", "DISEASE", 136, 151], ["coronavirus", "ORGANISM", 28, 39], ["SARS-CoV-2", "ORGANISM", 54, 64], ["coronavirus", "SPECIES", 28, 39], ["SARS-CoV", "SPECIES", 54, 62], ["a novel coronavirus", "PROBLEM", 20, 39], ["SARS-CoV", "TEST", 54, 62], ["unusual viral pneumonia", "PROBLEM", 128, 151], ["viral", "OBSERVATION_MODIFIER", 136, 141], ["pneumonia", "OBSERVATION", 142, 151]]], ["Being highly transmissible, this novel coronavirus disease, also known as coronavirus disease 2019 (COVID-19), has spread fast all over the world2,3.", [["coronavirus disease", "DISEASE", 39, 58], ["coronavirus disease", "DISEASE", 74, 93], ["COVID-19", "CHEMICAL", 100, 108], ["coronavirus", "ORGANISM", 39, 50], ["coronavirus", "SPECIES", 39, 50], ["this novel coronavirus disease", "PROBLEM", 28, 58], ["coronavirus disease", "PROBLEM", 74, 93], ["COVID", "TEST", 100, 105], ["coronavirus disease", "OBSERVATION", 39, 58], ["coronavirus disease", "OBSERVATION", 74, 93]]], ["It has overwhelmingly surpassed SARS and MERS in terms of both the number of infected people and the spatial range of epidemic areas.", [["SARS", "DISEASE", 32, 36], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["SARS", "PROBLEM", 32, 36], ["surpassed", "OBSERVATION_MODIFIER", 22, 31], ["SARS", "OBSERVATION", 32, 36], ["number", "OBSERVATION_MODIFIER", 67, 73], ["infected", "OBSERVATION", 77, 85], ["spatial", "OBSERVATION_MODIFIER", 101, 108], ["range", "OBSERVATION_MODIFIER", 109, 114], ["epidemic", "OBSERVATION_MODIFIER", 118, 126]]], ["The ongoing outbreak of COVID-19 has posed an extraordinary threat to global public health4,5.", [["COVID-19", "CHEMICAL", 24, 32], ["COVID", "TEST", 24, 29]]], ["In this Review, we summarize the current understanding of the nature of SARS-CoV-2 and COVID-19.", [["SARS", "DISEASE", 72, 76], ["COVID-19", "GENE_OR_GENE_PRODUCT", 87, 95], ["COVID-19", "DNA", 87, 95], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["COVID", "TEST", 87, 92]]], ["On the basis of recently published findings, this comprehensive Review covers the basic biology of SARS-CoV-2, including the genetic characteristics, the potential zoonotic origin and its receptor binding.", [["SARS", "DISEASE", 99, 103], ["SARS-CoV-2", "ORGANISM", 99, 109], ["SARS-CoV", "SPECIES", 99, 107], ["SARS", "TEST", 99, 103], ["CoV", "TEST", 104, 107]]], ["Furthermore, we will discuss the clinical and epidemiological features, diagnosis of and countermeasures against COVID-19.Emergence and spreadIn late December 2019, several health facilities in Wuhan, in Hubei province in China, reported clusters of patients with pneumonia of unknown cause6.", [["pneumonia", "DISEASE", 264, 273], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 250, 258], ["COVID", "TEST", 113, 118], ["pneumonia", "PROBLEM", 264, 273], ["spread", "OBSERVATION_MODIFIER", 136, 142], ["pneumonia", "OBSERVATION", 264, 273]]], ["Similarly to patients with SARS and MERS, these patients showed symptoms of viral pneumonia, including fever, cough and chest discomfort, and in severe cases dyspnea and bilateral lung infiltration6,7.", [["chest", "ANATOMY", 120, 125], ["lung", "ANATOMY", 180, 184], ["SARS", "DISEASE", 27, 31], ["MERS", "DISEASE", 36, 40], ["viral pneumonia", "DISEASE", 76, 91], ["fever", "DISEASE", 103, 108], ["cough", "DISEASE", 110, 115], ["chest discomfort", "DISEASE", 120, 136], ["dyspnea", "DISEASE", 158, 165], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 48, 56], ["lung", "ORGAN", 180, 184], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 48, 56], ["SARS", "PROBLEM", 27, 31], ["MERS", "PROBLEM", 36, 40], ["symptoms", "PROBLEM", 64, 72], ["viral pneumonia", "PROBLEM", 76, 91], ["fever", "PROBLEM", 103, 108], ["cough", "PROBLEM", 110, 115], ["chest discomfort", "PROBLEM", 120, 136], ["severe cases dyspnea", "PROBLEM", 145, 165], ["bilateral lung infiltration", "PROBLEM", 170, 197], ["viral", "OBSERVATION_MODIFIER", 76, 81], ["pneumonia", "OBSERVATION", 82, 91], ["chest", "ANATOMY", 120, 125], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["bilateral", "ANATOMY_MODIFIER", 170, 179], ["lung", "ANATOMY", 180, 184], ["infiltration", "OBSERVATION", 185, 197]]], ["Among the first 27 documented hospitalized patients, most cases were epidemiologically linked to Huanan Seafood Wholesale Market, a wet market located in downtown Wuhan, which sells not only seafood but also live animals, including poultry and wildlife4,8.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51]]], ["According to a retrospective study, the onset of the first known case dates back to 8 December 2019 (ref.9).", [["a retrospective study", "TEST", 13, 34]]], ["On 31 December, Wuhan Municipal Health Commission notified the public of a pneumonia outbreak of unidentified cause and informed the World Health Organization (WHO)9 (Fig. 1).Emergence and spreadBy metagenomic RNA sequencing and virus isolation from bronchoalveolar lavage fluid samples from patients with severe pneumonia, independent teams of Chinese scientists identified that the causative agent of this emerging disease is a betacoronavirus that had never been seen before6,10,11.", [["bronchoalveolar lavage fluid samples", "ANATOMY", 250, 286], ["pneumonia", "DISEASE", 75, 84], ["pneumonia", "DISEASE", 313, 322], ["bronchoalveolar lavage fluid samples", "ORGANISM_SUBSTANCE", 250, 286], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["a pneumonia", "PROBLEM", 73, 84], ["Emergence and spreadBy metagenomic RNA sequencing", "PROBLEM", 175, 224], ["virus isolation", "TREATMENT", 229, 244], ["bronchoalveolar lavage fluid samples", "TEST", 250, 286], ["severe pneumonia", "PROBLEM", 306, 322], ["this emerging disease", "PROBLEM", 403, 424], ["pneumonia", "OBSERVATION", 75, 84], ["bronchoalveolar lavage", "OBSERVATION", 250, 272], ["severe", "OBSERVATION_MODIFIER", 306, 312], ["pneumonia", "OBSERVATION", 313, 322]]], ["The first genome sequence of the novel coronavirus was published on the Virological website on 10 January, and more nearly complete genome sequences determined by different research institutes were then released via the GISAID database on 12 January7.", [["coronavirus", "ORGANISM", 39, 50], ["genome sequences", "DNA", 132, 148], ["coronavirus", "SPECIES", 39, 50], ["the novel coronavirus", "PROBLEM", 29, 50], ["the GISAID database", "TEST", 216, 235]]], ["Later, more patients with no history of exposure to Huanan Seafood Wholesale Market were identified.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Several familial clusters of infection were reported, and nosocomial infection also occurred in health-care facilities.", [["infection", "DISEASE", 29, 38], ["nosocomial infection", "DISEASE", 58, 78], ["Several familial clusters of infection", "PROBLEM", 0, 38], ["nosocomial infection", "PROBLEM", 58, 78], ["familial", "OBSERVATION_MODIFIER", 8, 16], ["clusters", "OBSERVATION_MODIFIER", 17, 25], ["infection", "OBSERVATION", 29, 38], ["nosocomial", "OBSERVATION_MODIFIER", 58, 68], ["infection", "OBSERVATION", 69, 78]]], ["All these cases provided clear evidence for human-to-human transmission of the new virus4,12\u201314.", [["human", "ORGANISM", 44, 49], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 53, 58], ["the new virus", "PROBLEM", 75, 88]]], ["As the outbreak coincided with the approach of the lunar New Year, travel between cities before the festival facilitated virus transmission in China.", [["virus", "OBSERVATION", 121, 126]]], ["This novel coronavirus pneumonia soon spread to other cities in Hubei province and to other parts of China.", [["coronavirus pneumonia", "DISEASE", 11, 32], ["coronavirus", "ORGANISM", 11, 22], ["coronavirus", "SPECIES", 11, 22], ["This novel coronavirus pneumonia", "PROBLEM", 0, 32], ["coronavirus", "OBSERVATION_MODIFIER", 11, 22], ["pneumonia", "OBSERVATION", 23, 32]]], ["The number of confirmed cases suddenly increased, with thousands of new cases diagnosed daily during late January15.", [["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["On 30 January, the WHO declared the novel coronavirus outbreak a public health emergency of international concern16.", [["coronavirus", "DISEASE", 42, 53], ["coronavirus", "ORGANISM", 42, 53]]], ["On 11 February, the International Committee on Taxonomy of Viruses named the novel coronavirus \u2018SARS-CoV-2\u2019, and the WHO named the disease \u2018COVID-19\u2019 (ref.17).Emergence and spreadThe outbreak of COVID-19 in China reached an epidemic peak in February.", [["SARS", "DISEASE", 96, 100], ["COVID-19", "CHEMICAL", 195, 203], ["coronavirus", "ORGANISM", 83, 94], ["coronavirus", "SPECIES", 83, 94], ["Viruses", "TREATMENT", 59, 66], ["COVID", "TEST", 140, 145], ["COVID", "TEST", 195, 200], ["spread", "OBSERVATION_MODIFIER", 173, 179]]], ["Owing to these measures, the daily number of new cases in China started to decrease steadily19.Emergence and spreadHowever, despite the declining trend in China, the international spread of COVID-19 accelerated from late February.", [["COVID-19", "CHEMICAL", 190, 198], ["COVID", "TEST", 190, 195]]], ["Large clusters of infection have been reported from an increasing number of countries18.", [["infection", "DISEASE", 18, 27], ["Large clusters of infection", "PROBLEM", 0, 27], ["clusters", "OBSERVATION_MODIFIER", 6, 14], ["infection", "OBSERVATION", 18, 27], ["increasing", "OBSERVATION_MODIFIER", 55, 65], ["number", "OBSERVATION_MODIFIER", 66, 72]]], ["The high transmission efficiency of SARS-CoV-2 and the abundance of international travel enabled rapid worldwide spread of COVID-19.", [["SARS", "DISEASE", 36, 40], ["COVID-19", "CHEMICAL", 123, 131], ["COVID-19", "DNA", 123, 131], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["COVID", "TEST", 123, 128], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["Since March, while COVID-19 in China has become effectively controlled, the case numbers in Europe, the USA and other regions have jumped sharply.", [["COVID", "TEST", 19, 24]]], ["According to the COVID-19 dashboard of the Center for System Science and Engineering at Johns Hopkins University, as of 11 August 2020, 216 countries and regions from all six continents had reported more than 20 million cases of COVID-19, and more than 733,000 patients had died21.", [["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 261, 269], ["COVID", "TEST", 229, 234]]], ["High mortality occurred especially when health-care resources were overwhelmed.", [["High mortality", "PROBLEM", 0, 14]]], ["The USA is the country with the largest number of cases so far.Emergence and spreadAlthough genetic evidence suggests that SARS-CoV-2 is a natural virus that likely originated in animals, there is no conclusion yet about when and where the virus first entered humans.", [["SARS", "DISEASE", 123, 127], ["SARS-CoV-2", "ORGANISM", 123, 133], ["humans", "ORGANISM", 260, 266], ["humans", "SPECIES", 260, 266], ["SARS-CoV-2", "SPECIES", 123, 133], ["humans", "SPECIES", 260, 266], ["SARS", "PROBLEM", 123, 127], ["CoV", "PROBLEM", 128, 131], ["a natural virus", "PROBLEM", 137, 152], ["natural virus", "OBSERVATION", 139, 152], ["no", "UNCERTAINTY", 197, 199]]], ["As some of the first reported cases in Wuhan had no epidemiological link to the seafood market22, it has been suggested that the market may not be the initial source of human infection with SARS-CoV-2.", [["infection", "DISEASE", 175, 184], ["SARS", "DISEASE", 190, 194], ["human", "ORGANISM", 169, 174], ["SARS-CoV-2", "ORGANISM", 190, 200], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["SARS-CoV", "SPECIES", 190, 198], ["human infection", "PROBLEM", 169, 184], ["infection", "OBSERVATION", 175, 184]]], ["One study from France detected SARS-CoV-2 by PCR in a stored sample from a patient who had pneumonia at the end of 2019, suggesting SARS-CoV-2 might have spread there much earlier than the generally known starting time of the outbreak in France23.", [["sample", "ANATOMY", 61, 67], ["pneumonia", "DISEASE", 91, 100], ["SARS", "DISEASE", 132, 136], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["patient", "ORGANISM", 75, 82], ["SARS-CoV-2", "ORGANISM", 132, 142], ["patient", "SPECIES", 75, 82], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 132, 140], ["One study", "TEST", 0, 9], ["SARS", "TEST", 31, 35], ["CoV", "TEST", 36, 39], ["PCR", "TEST", 45, 48], ["pneumonia", "PROBLEM", 91, 100], ["SARS", "PROBLEM", 132, 136], ["pneumonia", "OBSERVATION", 91, 100]]], ["However, this individual early report cannot give a solid answer to the origin of SARS-CoV-2 and contamination, and thus a false positive result cannot be excluded.", [["SARS", "DISEASE", 82, 86], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["contamination", "PROBLEM", 97, 110], ["a false positive result", "PROBLEM", 121, 144], ["SARS", "OBSERVATION", 82, 86], ["cannot be excluded", "UNCERTAINTY", 145, 163]]], ["To address this highly controversial issue, further retrospective investigations involving a larger number of banked samples from patients, animals and environments need to be conducted worldwide with well-validated assays.Genomics, phylogeny and taxonomyAs a novel betacoronavirus, SARS-CoV-2 shares 79% genome sequence identity with SARS-CoV and 50% with MERS-CoV24.", [["samples", "ANATOMY", 117, 124], ["SARS", "DISEASE", 283, 287], ["SARS-CoV", "DISEASE", 335, 343], ["patients", "ORGANISM", 130, 138], ["SARS-CoV-2", "ORGANISM", 283, 293], ["SARS-CoV", "ORGANISM", 335, 343], ["MERS-CoV24", "GENE_OR_GENE_PRODUCT", 357, 367], ["SARS-CoV-2", "DNA", 283, 293], ["MERS-CoV24", "DNA", 357, 367], ["patients", "SPECIES", 130, 138], ["SARS-CoV", "SPECIES", 283, 291], ["SARS-CoV", "SPECIES", 335, 343], ["further retrospective investigations", "TEST", 44, 80], ["banked samples", "TEST", 110, 124], ["taxonomyAs", "TEST", 247, 257], ["SARS", "TEST", 283, 287], ["CoV", "TEST", 288, 291], ["SARS", "TEST", 335, 339], ["CoV", "TEST", 340, 343], ["larger", "OBSERVATION_MODIFIER", 93, 99]]], ["Its genome organization is shared with other betacoronaviruses.", [["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 45, 62], ["other betacoronaviruses", "PROBLEM", 39, 62], ["genome organization", "OBSERVATION", 4, 23]]], ["The six functional open reading frames (ORFs) are arranged in order from 5\u2032 to 3\u2032: replicase (ORF1a/ORF1b), spike (S), envelope (E), membrane (M) and nucleocapsid (N).", [["membrane", "ANATOMY", 133, 141], ["3", "GENE_OR_GENE_PRODUCT", 79, 80], ["\u2032", "GENE_OR_GENE_PRODUCT", 80, 81], ["ORF1a", "GENE_OR_GENE_PRODUCT", 94, 99], ["ORF1b", "GENE_OR_GENE_PRODUCT", 100, 105], ["spike (S)", "GENE_OR_GENE_PRODUCT", 108, 117], ["membrane", "CELLULAR_COMPONENT", 133, 141], ["open reading frames", "DNA", 19, 38], ["ORFs", "DNA", 40, 44], ["5\u2032 to 3\u2032: replicase", "DNA", 73, 92], ["ORF1a", "DNA", 94, 99], ["ORF1b", "DNA", 100, 105], ["S", "DNA", 115, 116], ["E", "DNA", 129, 130], ["spike", "PROBLEM", 108, 113]]], ["In addition, seven putative ORFs encoding accessory proteins are interspersed between the structural genes25.", [["ORFs", "DNA", 28, 32], ["accessory proteins", "PROTEIN", 42, 60], ["structural genes25", "DNA", 90, 108], ["seven putative ORFs encoding accessory proteins", "PROBLEM", 13, 60], ["accessory proteins", "OBSERVATION", 42, 60]]], ["Most of the proteins encoded by SARS-CoV-2 have a similar length to the corresponding proteins in SARS-CoV.", [["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV", "ORGANISM", 98, 106], ["SARS-CoV-2", "DNA", 32, 42], ["SARS-CoV", "SPECIES", 32, 40], ["SARS-CoV", "SPECIES", 98, 106], ["the proteins", "TEST", 8, 20], ["CoV", "TEST", 37, 40]]], ["Of the four structural genes, SARS-CoV-2 shares more than 90% amino acid identity with SARS-CoV except for the S gene, which diverges11,24.", [["amino acid", "CHEMICAL", 62, 72], ["amino acid", "CHEMICAL", 62, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["amino acid", "AMINO_ACID", 62, 72], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["SARS-CoV-2", "DNA", 30, 40], ["SARS-CoV", "DNA", 87, 95], ["S gene", "DNA", 111, 117], ["SARS-CoV", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "TEST", 30, 38], ["amino acid identity", "TEST", 62, 81], ["SARS", "PROBLEM", 87, 91]]], ["The replicase gene covers two thirds of the 5\u2032 genome, and encodes a large polyprotein (pp1ab),which is proteolytically cleaved into 16 non-structural proteins that are involved in transcription and virus replication.", [["pp1ab", "GENE_OR_GENE_PRODUCT", 88, 93], ["replicase gene", "DNA", 4, 18], ["5\u2032 genome", "DNA", 44, 53], ["pp1ab", "PROTEIN", 88, 93], ["structural proteins", "PROTEIN", 140, 159], ["The replicase gene", "TREATMENT", 0, 18], ["a large polyprotein (pp1ab)", "PROBLEM", 67, 94], ["virus replication", "TREATMENT", 199, 216], ["large", "OBSERVATION_MODIFIER", 69, 74], ["polyprotein", "OBSERVATION", 75, 86]]], ["Most of these SARS-CoV-2 non-structural proteins have greater than 85% amino acid sequence identity with SARS-CoV25.Genomics, phylogeny and taxonomyThe phylogenetic analysis for the whole genome shows that SARS-CoV-2 is clustered with SARS-CoV and SARS-related coronaviruses (SARSr-CoVs) found in bats, placing it in the subgenus Sarbecovirus of the genus Betacoronavirus.", [["SARS", "DISEASE", 14, 18], ["amino acid", "CHEMICAL", 71, 81], ["SARS", "DISEASE", 248, 252], ["amino acid", "CHEMICAL", 71, 81], ["SARS-CoV-2", "ORGANISM", 14, 24], ["amino acid", "AMINO_ACID", 71, 81], ["SARS-CoV25", "GENE_OR_GENE_PRODUCT", 105, 115], ["SARS-CoV-2", "ORGANISM", 206, 216], ["SARS-CoV", "ORGANISM", 235, 243], ["SARS-related coronaviruses", "ORGANISM", 248, 274], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 276, 286], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 356, 371], ["SARS-CoV-2 non-structural proteins", "PROTEIN", 14, 48], ["SARS-CoV-2", "DNA", 206, 216], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 206, 214], ["SARS-CoV", "SPECIES", 235, 243], ["these SARS", "TEST", 8, 18], ["CoV", "TEST", 19, 22], ["non-structural proteins", "TEST", 25, 48], ["amino acid sequence identity", "TEST", 71, 99], ["SARS", "TEST", 105, 109], ["The phylogenetic analysis", "TEST", 148, 173], ["the whole genome", "TEST", 178, 194], ["SARS", "TEST", 206, 210], ["CoV", "TEST", 211, 214], ["SARS", "PROBLEM", 235, 239], ["CoV", "PROBLEM", 240, 243], ["SARS", "PROBLEM", 248, 252], ["coronaviruses", "PROBLEM", 261, 274], ["subgenus Sarbecovirus", "OBSERVATION", 321, 342], ["genus Betacoronavirus", "OBSERVATION", 350, 371]]], ["Within this clade, SARS-CoV-2 is grouped in a distinct lineage together with four horseshoe bat coronavirus isolates (RaTG13, RmYN02, ZC45 and ZXC21) as well as novel coronaviruses recently identified in pangolins, which group parallel to SARS-CoV and other SARSr-CoVs (Fig. 2).", [["SARS", "DISEASE", 239, 243], ["SARS-CoV-2", "ORGANISM", 19, 29], ["horseshoe bat coronavirus", "ORGANISM", 82, 107], ["RmYN02", "GENE_OR_GENE_PRODUCT", 126, 132], ["ZC45", "GENE_OR_GENE_PRODUCT", 134, 138], ["ZXC21", "GENE_OR_GENE_PRODUCT", 143, 148], ["coronaviruses", "ORGANISM", 167, 180], ["pangolins", "GENE_OR_GENE_PRODUCT", 204, 213], ["SARS-CoV", "ORGANISM", 239, 247], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 258, 268], ["horseshoe bat coronavirus", "SPECIES", 82, 107], ["SARS-CoV", "SPECIES", 19, 27], ["horseshoe bat coronavirus", "SPECIES", 82, 107], ["SARS-CoV", "SPECIES", 239, 247], ["SARS-CoV", "TEST", 19, 27], ["four horseshoe bat coronavirus isolates", "PROBLEM", 77, 116], ["RaTG13", "TEST", 118, 124], ["RmYN02", "TEST", 126, 132], ["ZC45", "TEST", 134, 138], ["novel coronaviruses", "PROBLEM", 161, 180], ["SARS", "TEST", 239, 243], ["coronaviruses", "OBSERVATION", 167, 180], ["CoVs", "ANATOMY", 264, 268]]], ["Using sequences of five conserved replicative domains in pp1ab (3C-like protease (3CLpro), nidovirus RNA-dependent RNA polymerase (RdRp)-associated nucleotidyltransferase (NiRAN), RdRp, zinc-binding domain (ZBD) and HEL1), the Coronaviridae Study Group of the International Committee on Taxonomy of Viruses estimated the pairwise patristic distances between SARS-CoV-2 and known coronaviruses, and assigned SARS-CoV-2 to the existing species SARSr-CoV17.", [["pp1ab (3C-like protease", "GENE_OR_GENE_PRODUCT", 57, 80], ["3CLpro", "GENE_OR_GENE_PRODUCT", 82, 88], ["nidovirus RNA-dependent RNA polymerase (RdRp)-associated nucleotidyltransferase", "GENE_OR_GENE_PRODUCT", 91, 170], ["NiRAN", "GENE_OR_GENE_PRODUCT", 172, 177], ["zinc-binding domain", "GENE_OR_GENE_PRODUCT", 186, 205], ["CoV-2", "ORGANISM", 363, 368], ["coronaviruses", "ORGANISM", 379, 392], ["SARSr-CoV17", "SIMPLE_CHEMICAL", 442, 453], ["pp1ab (3C-like protease", "PROTEIN", 57, 80], ["3CLpro", "PROTEIN", 82, 88], ["nidovirus RNA-dependent RNA polymerase (RdRp)-associated nucleotidyltransferase", "PROTEIN", 91, 170], ["NiRAN", "PROTEIN", 172, 177], ["RdRp", "PROTEIN", 180, 184], ["zinc-binding domain", "PROTEIN", 186, 205], ["ZBD", "PROTEIN", 207, 210], ["HEL1", "PROTEIN", 216, 220], ["CoV17", "DNA", 448, 453], ["SARS-CoV", "SPECIES", 358, 366], ["SARS-CoV", "SPECIES", 407, 415], ["pp1ab", "TEST", 57, 62], ["3C", "TEST", 64, 66], ["protease (3CLpro)", "TREATMENT", 72, 89], ["nidovirus RNA", "TEST", 91, 104], ["RdRp", "TEST", 131, 135], ["associated nucleotidyltransferase (NiRAN)", "PROBLEM", 137, 178], ["RdRp", "PROBLEM", 180, 184], ["zinc-binding domain", "PROBLEM", 186, 205], ["Viruses", "PROBLEM", 299, 306], ["SARS", "TEST", 358, 362], ["CoV", "TEST", 363, 366], ["known coronaviruses", "PROBLEM", 373, 392], ["SARS", "TEST", 407, 411], ["CoV", "TEST", 412, 415], ["coronaviruses", "OBSERVATION", 379, 392]]], ["Although phylogenetically related, SARS-CoV-2 is distinct from all other coronaviruses from bats and pangolins in this species.Genomics, phylogeny and taxonomyThe SARS-CoV-2 S protein has a full size of 1,273 amino acids, longer than that of SARS-CoV (1,255 amino acids) and known bat SARSr-CoVs (1,245\u20131,269 amino acids).", [["SARS", "DISEASE", 35, 39], ["amino acids", "CHEMICAL", 209, 220], ["amino acids", "CHEMICAL", 258, 269], ["1,245\u20131,269 amino acids", "CHEMICAL", 297, 320], ["amino acids", "CHEMICAL", 209, 220], ["amino acids", "CHEMICAL", 258, 269], ["amino acids", "CHEMICAL", 309, 320], ["SARS-CoV-2", "ORGANISM", 35, 45], ["coronaviruses", "ORGANISM", 73, 86], ["pangolins", "GENE_OR_GENE_PRODUCT", 101, 110], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 163, 175], ["amino acids", "AMINO_ACID", 209, 220], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 242, 250], ["amino acids", "AMINO_ACID", 258, 269], ["SARSr-CoVs", "GENE_OR_GENE_PRODUCT", 285, 295], ["amino acids", "AMINO_ACID", 309, 320], ["SARS-CoV-2 S protein", "PROTEIN", 163, 183], ["SARS-CoV", "PROTEIN", 242, 250], ["SARSr", "PROTEIN", 285, 290], ["CoVs", "PROTEIN", 291, 295], ["1,245\u20131,269 amino acids", "PROTEIN", 297, 320], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 163, 171], ["SARS-CoV", "SPECIES", 242, 250], ["SARS", "PROBLEM", 35, 39], ["all other coronaviruses", "PROBLEM", 63, 86], ["The SARS", "TEST", 159, 167], ["CoV", "TEST", 168, 171], ["S protein", "TEST", 174, 183], ["amino acids", "TEST", 209, 220], ["SARS", "TEST", 242, 246], ["CoV", "TEST", 247, 250], ["amino acids", "TEST", 258, 269], ["bat SARSr", "TEST", 281, 290], ["amino acids", "TEST", 309, 320], ["coronaviruses", "OBSERVATION", 73, 86]]], ["It is distinct from the S proteins of most members in the subgenus Sarbecovirus, sharing amino acid sequence similarities of 76.7\u201377.0% with SARS-CoVs from civets and humans, 75\u201397.7% with bat coronaviruses in the same subgenus and 90.7\u201392.6% with pangolin coronaviruses11.", [["amino acid", "CHEMICAL", 89, 99], ["SARS", "DISEASE", 141, 145], ["amino acid", "CHEMICAL", 89, 99], ["Sarbecovirus", "GENE_OR_GENE_PRODUCT", 67, 79], ["amino acid", "AMINO_ACID", 89, 99], ["SARS-CoVs", "GENE_OR_GENE_PRODUCT", 141, 150], ["civets", "CANCER", 156, 162], ["humans", "ORGANISM", 167, 173], ["bat coronaviruses", "ORGANISM", 189, 206], ["pangolin coronaviruses", "ORGANISM", 248, 270], ["S proteins", "PROTEIN", 24, 34], ["humans", "SPECIES", 167, 173], ["humans", "SPECIES", 167, 173], ["bat coronaviruses", "SPECIES", 189, 206], ["pangolin coronaviruses", "SPECIES", 248, 270], ["sharing amino acid sequence similarities", "TEST", 81, 121], ["SARS", "TEST", 141, 145], ["civets", "TEST", 156, 162], ["humans", "TEST", 167, 173], ["bat coronaviruses", "TEST", 189, 206], ["pangolin coronaviruses", "PROBLEM", 248, 270], ["distinct", "OBSERVATION_MODIFIER", 6, 14], ["subgenus Sarbecovirus", "ANATOMY", 58, 79]]], ["In the receptor-binding domain (RBD) of S protein, the amino acid similarity between SARS-CoV-2 and SARS-CoV is only 73%.", [["amino acid", "CHEMICAL", 55, 65], ["SARS", "DISEASE", 100, 104], ["amino acid", "CHEMICAL", 55, 65], ["amino acid", "AMINO_ACID", 55, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["receptor-binding domain", "PROTEIN", 7, 30], ["RBD", "PROTEIN", 32, 35], ["S protein", "PROTEIN", 40, 49], ["SARS-CoV", "SPECIES", 100, 108], ["S protein", "TEST", 40, 49], ["the amino acid similarity", "TEST", 51, 76], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["SARS", "TEST", 100, 104], ["CoV", "TEST", 105, 108]]], ["Another specific genomic feature of SARS-CoV-2 is the insertion of four amino acid residues (PRRA) at the junction of subunits S1 and S2 of the S protein26 (Fig. 3a).", [["SARS", "DISEASE", 36, 40], ["amino acid", "CHEMICAL", 72, 82], ["amino acid", "CHEMICAL", 72, 82], ["SARS-CoV-2", "ORGANISM", 36, 46], ["amino acid", "AMINO_ACID", 72, 82], ["PRRA", "GENE_OR_GENE_PRODUCT", 93, 97], ["S1", "GENE_OR_GENE_PRODUCT", 127, 129], ["S2", "GENE_OR_GENE_PRODUCT", 134, 136], ["S protein26", "GENE_OR_GENE_PRODUCT", 144, 155], ["Fig. 3a", "GENE_OR_GENE_PRODUCT", 157, 164], ["amino acid residues", "PROTEIN", 72, 91], ["PRRA", "PROTEIN", 93, 97], ["S1", "PROTEIN", 127, 129], ["S2", "PROTEIN", 134, 136], ["S protein26", "PROTEIN", 144, 155], ["Fig. 3a", "PROTEIN", 157, 164], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["four amino acid residues", "TREATMENT", 67, 91], ["acid residues", "OBSERVATION", 78, 91], ["subunits S1", "ANATOMY", 118, 129], ["S2", "ANATOMY_MODIFIER", 134, 136]]], ["This insertion generates a polybasic cleavage site (RRAR), which enables effective cleavage by furin and other proteases27.", [["furin", "GENE_OR_GENE_PRODUCT", 95, 100], ["polybasic cleavage site", "PROTEIN", 27, 50], ["RRAR", "PROTEIN", 52, 56], ["furin", "PROTEIN", 95, 100], ["proteases27", "PROTEIN", 111, 122], ["This insertion", "TREATMENT", 0, 14], ["a polybasic cleavage site", "TREATMENT", 25, 50], ["polybasic cleavage", "OBSERVATION", 27, 45]]], ["Such an S1\u2013S2 cleavage site is not observed in all related viruses belonging to the subgenus Sarbecovirus, except for a similar three amino acid insertion (PAA) in RmYN02, a bat-derived coronavirus newly reported from Rhinolophus malayanus in China28 (Fig. 3a).", [["amino acid", "CHEMICAL", 134, 144], ["PAA", "CHEMICAL", 156, 159], ["amino acid", "CHEMICAL", 134, 144], ["PAA", "CHEMICAL", 156, 159], ["S2", "GENE_OR_GENE_PRODUCT", 11, 13], ["Sarbecovirus", "GENE_OR_GENE_PRODUCT", 93, 105], ["amino acid", "AMINO_ACID", 134, 144], ["RmYN02", "GENE_OR_GENE_PRODUCT", 164, 170], ["bat-derived coronavirus", "ORGANISM", 174, 197], ["Rhinolophus malayanus", "ORGANISM", 218, 239], ["S1\u2013S2 cleavage site", "DNA", 8, 27], ["RmYN02", "PROTEIN", 164, 170], ["Rhinolophus malayanus", "SPECIES", 218, 239], ["Rhinolophus malayanus", "SPECIES", 218, 239], ["an S1\u2013S2 cleavage site", "PROBLEM", 5, 27], ["a similar three amino acid insertion", "TREATMENT", 118, 154], ["a bat-derived coronavirus", "PROBLEM", 172, 197], ["acid insertion", "OBSERVATION", 140, 154], ["coronavirus", "OBSERVATION", 186, 197]]], ["Although the insertion in RmYN02 does not functionally represent a polybasic cleavage site, it provides support for the notion that this characteristic, initially considered unique to SARS-CoV-2, has been acquired naturally28.", [["SARS", "DISEASE", 184, 188], ["RmYN02", "GENE_OR_GENE_PRODUCT", 26, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 184, 194], ["RmYN02", "DNA", 26, 32], ["polybasic cleavage site", "PROTEIN", 67, 90], ["SARS-CoV", "SPECIES", 184, 192], ["the insertion in RmYN02", "TREATMENT", 9, 32], ["a polybasic cleavage site", "PROBLEM", 65, 90], ["CoV", "TEST", 189, 192], ["insertion", "OBSERVATION_MODIFIER", 13, 22], ["polybasic cleavage", "OBSERVATION", 67, 85]]], ["A structural study suggested that the furin-cleavage site can reduce the stability of SARS-CoV-2 S protein and facilitate the conformational adaption that is required for the binding of the RBD to its receptor29.", [["furin", "GENE_OR_GENE_PRODUCT", 38, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["receptor29", "GENE_OR_GENE_PRODUCT", 201, 211], ["furin", "PROTEIN", 38, 43], ["SARS-CoV-2 S protein", "PROTEIN", 86, 106], ["RBD", "PROTEIN", 190, 193], ["receptor29", "PROTEIN", 201, 211], ["A structural study", "TEST", 0, 18], ["the furin-cleavage site", "PROBLEM", 34, 57], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["the conformational adaption", "TREATMENT", 122, 149], ["stability", "OBSERVATION_MODIFIER", 73, 82]]], ["Whether the higher transmissibility of SARS-CoV-2 compared with SARS-CoV is a gain of function associated with acquisition of the furin-like cleavage site is yet to be demonstrated26.Genomics, phylogeny and taxonomyAn additional distinction is the accessory gene orf8 of SARS-CoV-2, which encodes a novel protein showing only 40% amino acid identity to ORF8 of SARS-CoV.", [["SARS", "DISEASE", 39, 43], ["SARS", "DISEASE", 64, 68], ["amino acid", "CHEMICAL", 330, 340], ["SARS", "DISEASE", 361, 365], ["amino acid", "CHEMICAL", 330, 340], ["SARS-CoV-2", "ORGANISM", 39, 49], ["SARS-CoV", "ORGANISM", 64, 72], ["furin", "GENE_OR_GENE_PRODUCT", 130, 135], ["orf8", "GENE_OR_GENE_PRODUCT", 263, 267], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 271, 281], ["amino acid", "AMINO_ACID", 330, 340], ["ORF8", "GENE_OR_GENE_PRODUCT", 353, 357], ["SARS-CoV", "ORGANISM", 361, 369], ["furin", "PROTEIN", 130, 135], ["accessory gene orf8", "DNA", 248, 267], ["SARS-CoV-2", "DNA", 271, 281], ["ORF8", "PROTEIN", 353, 357], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 271, 279], ["SARS-CoV", "SPECIES", 361, 369], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47], ["SARS", "PROBLEM", 64, 68], ["the furin", "PROBLEM", 126, 135], ["cleavage site", "PROBLEM", 141, 154], ["a novel protein", "TEST", 297, 312]]], ["Unlike in SARS-CoV, this new ORF8 protein does not contain a motif that triggers intracellular stress pathways25.", [["intracellular", "ANATOMY", 81, 94], ["SARS", "DISEASE", 10, 14], ["SARS-CoV", "ORGANISM", 10, 18], ["ORF8", "GENE_OR_GENE_PRODUCT", 29, 33], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["ORF8 protein", "PROTEIN", 29, 41], ["SARS-CoV", "SPECIES", 10, 18], ["CoV", "PROBLEM", 15, 18], ["intracellular stress pathways", "TEST", 81, 110], ["SARS", "OBSERVATION", 10, 14]]], ["Notably, a SARS-CoV-2 variant with a 382-nucleotide deletion covering the whole of ORF8 has been discovered in a number of patients in Singapore, which resembles the 29- or 415-nucleotide deletions in the ORF8 region observed in human SARS-CoV variants from the late phase of the 2002\u20132003 outbreak30.", [["SARS", "DISEASE", 235, 239], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 11, 21], ["ORF8", "GENE_OR_GENE_PRODUCT", 83, 87], ["patients", "ORGANISM", 123, 131], ["ORF8", "GENE_OR_GENE_PRODUCT", 205, 209], ["human", "ORGANISM", 229, 234], ["SARS-CoV", "ORGANISM", 235, 243], ["SARS-CoV-2 variant", "DNA", 11, 29], ["382-nucleotide deletion", "DNA", 37, 60], ["ORF8", "DNA", 83, 87], ["29- or 415-nucleotide deletions", "DNA", 166, 197], ["ORF8 region", "DNA", 205, 216], ["2002\u20132003 outbreak30", "DNA", 280, 300], ["patients", "SPECIES", 123, 131], ["human", "SPECIES", 229, 234], ["SARS-CoV", "SPECIES", 11, 19], ["human SARS-CoV", "SPECIES", 229, 243], ["a SARS", "TEST", 9, 15], ["nucleotide deletion", "PROBLEM", 41, 60], ["nucleotide deletions in the ORF8 region", "PROBLEM", 177, 216], ["human SARS", "PROBLEM", 229, 239], ["late phase", "OBSERVATION_MODIFIER", 262, 272]]], ["Such ORF8 deletion may be indicative of human adaptation after cross-species transmission from an animal host.Genomics, phylogeny and taxonomyTo assess the genetic variation of different SARS-CoV-2 strains, the 2019 Novel Coronavirus Resource of China National Center for Bioinformation aligned 77,801 genome sequences of SARS-CoV-2 detected globally and identified a total of 15,018 mutations, including 14,824 single-nucleotide polymorphisms (BIGD)31.", [["ORF8", "GENE_OR_GENE_PRODUCT", 5, 9], ["human", "ORGANISM", 40, 45], ["SARS-CoV-2", "ORGANISM", 187, 197], ["SARS-CoV-2", "ORGANISM", 322, 332], ["ORF8 deletion", "DNA", 5, 18], ["77,801 genome sequences", "DNA", 295, 318], ["14,824 single-nucleotide polymorphisms (BIGD)31", "DNA", 405, 452], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["SARS-CoV-2", "SPECIES", 187, 197], ["SARS-CoV-2", "SPECIES", 322, 332], ["Such ORF8 deletion", "PROBLEM", 0, 18], ["human adaptation", "PROBLEM", 40, 56], ["different SARS", "PROBLEM", 177, 191], ["genome sequences", "TEST", 302, 318], ["SARS", "TEST", 322, 326], ["CoV", "TEST", 327, 330], ["single-nucleotide polymorphisms (BIGD)", "TREATMENT", 412, 450], ["may be indicative", "UNCERTAINTY", 19, 36]]], ["In the S protein, four amino acid alterations, V483A, L455I, F456V and G476S, are located near the binding interface in the RBD, but their effects on binding to the host receptor are unknown.", [["amino acid", "CHEMICAL", 23, 33], ["amino acid", "CHEMICAL", 23, 33], ["amino acid", "AMINO_ACID", 23, 33], ["S protein", "PROTEIN", 7, 16], ["RBD", "PROTEIN", 124, 127], ["host receptor", "PROTEIN", 165, 178], ["the S protein", "TEST", 3, 16], ["four amino acid alterations", "TEST", 18, 45], ["L455I", "TEST", 54, 59], ["acid alterations", "OBSERVATION", 29, 45], ["binding interface", "OBSERVATION", 99, 116], ["RBD", "ANATOMY", 124, 127]]], ["The alteration D614G in the S1 subunit was found far more frequently than other S variant sites, and it is the marker of a major subclade of SARS-CoV-2 (clade G).", [["SARS", "DISEASE", 141, 145], ["D614G", "GENE_OR_GENE_PRODUCT", 15, 20], ["S1", "GENE_OR_GENE_PRODUCT", 28, 30], ["SARS-CoV-2", "ORGANISM", 141, 151], ["clade G", "GENE_OR_GENE_PRODUCT", 153, 160], ["D614G", "DNA", 15, 20], ["S1 subunit", "PROTEIN", 28, 38], ["S variant sites", "DNA", 80, 95], ["SARS-CoV", "SPECIES", 141, 149], ["The alteration D614G in the S1 subunit", "TREATMENT", 0, 38], ["CoV", "TEST", 146, 149]]], ["Since March 2020, SARS-CoV-2 variants with G614 in the S protein have replaced the original D614 variants and become the dominant form circulating globally.", [["SARS-CoV-2", "ORGANISM", 18, 28], ["G614", "GENE_OR_GENE_PRODUCT", 43, 47], ["SARS-CoV-2 variants", "DNA", 18, 37], ["G614", "DNA", 43, 47], ["S protein", "PROTEIN", 55, 64], ["D614 variants", "DNA", 92, 105], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["the original D614 variants", "TREATMENT", 79, 105], ["dominant", "OBSERVATION", 121, 129]]], ["Compared with the D614 variant, higher viral loads were found in patients infected with the G614 variant, but clinical data suggested no significant link between the D614G alteration and disease severity32.", [["D614", "GENE_OR_GENE_PRODUCT", 18, 22], ["patients", "ORGANISM", 65, 73], ["D614 variant", "PROTEIN", 18, 30], ["patients", "SPECIES", 65, 73], ["higher viral loads", "PROBLEM", 32, 50], ["clinical data", "TEST", 110, 123], ["the D614G alteration", "PROBLEM", 162, 182], ["disease severity32", "PROBLEM", 187, 205], ["viral loads", "OBSERVATION", 39, 50]]], ["Pseudotyped viruses carrying the S protein with G614 generated higher infectious titres than viruses carrying the S protein with D614, suggesting the alteration may have increased the infectivity of SARS-CoV-2 (ref.32).", [["SARS", "DISEASE", 199, 203], ["G614", "GENE_OR_GENE_PRODUCT", 48, 52], ["D614", "GENE_OR_GENE_PRODUCT", 129, 133], ["SARS-CoV-2", "ORGANISM", 199, 209], ["S protein", "PROTEIN", 33, 42], ["G614", "PROTEIN", 48, 52], ["S protein", "PROTEIN", 114, 123], ["D614", "PROTEIN", 129, 133], ["SARS-CoV", "SPECIES", 199, 207], ["Pseudotyped viruses", "PROBLEM", 0, 19], ["the S protein", "TEST", 29, 42], ["higher infectious titres", "PROBLEM", 63, 87], ["D614", "TREATMENT", 129, 133], ["the infectivity of SARS", "PROBLEM", 180, 203], ["CoV", "TEST", 204, 207], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["infectious", "OBSERVATION", 70, 80], ["infectivity", "OBSERVATION_MODIFIER", 184, 195]]], ["However, the results of in vitro experiments based on pseudovirus models may not exactly reflect natural infection.", [["infection", "DISEASE", 105, 114], ["pseudovirus", "ORGANISM", 54, 65], ["pseudovirus models", "PROBLEM", 54, 72], ["natural infection", "PROBLEM", 97, 114], ["may not exactly reflect", "UNCERTAINTY", 73, 96], ["natural", "OBSERVATION_MODIFIER", 97, 104], ["infection", "OBSERVATION", 105, 114]]], ["This preliminary finding should be validated by more studies using wild-type SARS-CoV-2 variants to infect different target cells and animal models.", [["cells", "ANATOMY", 124, 129], ["SARS-CoV-2", "ORGANISM", 77, 87], ["cells", "CELL", 124, 129], ["target cells", "CELL_TYPE", 117, 129], ["wild-type SARS", "PROBLEM", 67, 81], ["CoV", "TEST", 82, 85]]], ["Whether this amino acid change enhanced virus transmissibility is also to be determined.", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["this amino acid change enhanced virus transmissibility", "PROBLEM", 8, 62]]], ["Another marker mutation for SARS-CoV-2 evolution is the single-nucleotide polymorphism at nucleotide position 28,144, which results in amino acid substitution of Ser for Lys at residue 84 of the ORF8 protein.", [["SARS", "DISEASE", 28, 32], ["nucleotide", "CHEMICAL", 90, 100], ["amino acid", "CHEMICAL", 135, 145], ["Lys", "CHEMICAL", 170, 173], ["nucleotide", "CHEMICAL", 90, 100], ["amino acid", "CHEMICAL", 135, 145], ["Ser", "CHEMICAL", 162, 165], ["Lys", "CHEMICAL", 170, 173], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["amino acid", "AMINO_ACID", 135, 145], ["Ser", "AMINO_ACID", 162, 165], ["Lys", "AMINO_ACID", 170, 173], ["residue 84", "AMINO_ACID", 177, 187], ["ORF8", "GENE_OR_GENE_PRODUCT", 195, 199], ["ORF8 protein", "PROTEIN", 195, 207], ["SARS-CoV", "SPECIES", 28, 36], ["Another marker mutation", "TEST", 0, 23], ["SARS", "PROBLEM", 28, 32], ["CoV", "TEST", 33, 36], ["the single-nucleotide polymorphism at nucleotide position", "PROBLEM", 52, 109], ["amino acid substitution", "TREATMENT", 135, 158], ["Lys at residue", "PROBLEM", 170, 184], ["the ORF8 protein", "TEST", 191, 207]]], ["Those variants with this mutation make up a single subclade labelled as \u2018clade S\u201933,34.", [["this mutation", "PROBLEM", 20, 33]]], ["Currently, however, the available sequence data are not sufficient to interpret the early global transmission history of the virus, and travel patterns, founder effects and public health measures also strongly influence the spread of particular lineages, irrespective of potential biological differences between different virus variants.Animal host and spilloverBats are important natural hosts of alphacoronaviruses and betacoronaviruses.", [["spilloverBats", "GENE_OR_GENE_PRODUCT", 353, 366], ["alphacoronaviruses", "GENE_OR_GENE_PRODUCT", 398, 416], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 421, 438], ["the available sequence data", "TEST", 20, 47], ["the virus", "PROBLEM", 121, 130], ["public health measures", "TREATMENT", 173, 195], ["potential biological differences between different virus variants", "PROBLEM", 271, 336], ["alphacoronaviruses", "TREATMENT", 398, 416], ["betacoronaviruses", "TREATMENT", 421, 438], ["virus variants", "OBSERVATION", 322, 336]]], ["The closest relative to SARS-CoV-2 known to date is a bat coronavirus detected in Rhinolophus affinis from Yunnan province, China, named \u2018RaTG13\u2019, whose full-length genome sequence is 96.2% identical to that of SARS-CoV-2 (ref.11).", [["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 211, 215], ["SARS-CoV-2", "ORGANISM", 24, 34], ["bat coronavirus", "ORGANISM", 54, 69], ["Rhinolophus affinis", "ORGANISM", 82, 101], ["RaTG13", "GENE_OR_GENE_PRODUCT", 138, 144], ["SARS-CoV-2", "ORGANISM", 211, 221], ["full-length genome sequence", "DNA", 153, 180], ["bat coronavirus", "SPECIES", 54, 69], ["Rhinolophus affinis", "SPECIES", 82, 101], ["SARS-CoV", "SPECIES", 24, 32], ["bat coronavirus", "SPECIES", 54, 69], ["Rhinolophus affinis", "SPECIES", 82, 101], ["SARS-CoV", "SPECIES", 211, 219], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["a bat coronavirus", "PROBLEM", 52, 69], ["CoV", "TEST", 216, 219]]], ["This bat virus shares more than 90% sequence identity with SARS-CoV-2 in all ORFs throughout the genome, including the highly variable S and ORF8 (ref.11).", [["bat virus", "ORGANISM", 5, 14], ["SARS-CoV-2", "ORGANISM", 59, 69], ["ORF8", "GENE_OR_GENE_PRODUCT", 141, 145], ["SARS-CoV-2", "DNA", 59, 69], ["ORFs", "DNA", 77, 81], ["S", "DNA", 135, 136], ["ORF8", "DNA", 141, 145], ["ref.11", "DNA", 147, 153], ["bat virus", "SPECIES", 5, 14], ["SARS-CoV", "SPECIES", 59, 67], ["This bat virus", "TEST", 0, 14], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67]]], ["Phylogenetic analysis confirms that SARS-CoV-2 closely clusters with RaTG13 (Fig. 2).", [["SARS-CoV-2", "ORGANISM", 36, 46], ["RaTG13", "DNA", 69, 75], ["Phylogenetic analysis", "TEST", 0, 21], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44]]], ["The high genetic similarity between SARS-CoV-2 and RaTG13 supports the hypothesis that SARS-CoV-2 likely originated from bats35.", [["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "ORGANISM", 36, 46], ["RaTG13", "GENE_OR_GENE_PRODUCT", 51, 57], ["SARS-CoV-2", "ORGANISM", 87, 97], ["RaTG13", "DNA", 51, 57], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 87, 95], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["the hypothesis", "PROBLEM", 67, 81], ["CoV", "TEST", 92, 95]]], ["Another related coronavirus has been reported more recently in a Rhinolophus malayanus bat sampled in Yunnan.", [["coronavirus", "DISEASE", 16, 27], ["coronavirus", "ORGANISM", 16, 27], ["Rhinolophus malayanus bat", "ORGANISM", 65, 90], ["coronavirus", "SPECIES", 16, 27], ["Rhinolophus malayanus bat", "SPECIES", 65, 90], ["Rhinolophus malayanus bat", "SPECIES", 65, 90], ["Another related coronavirus", "PROBLEM", 0, 27], ["coronavirus", "OBSERVATION", 16, 27]]], ["This novel bat virus, denoted \u2018RmYN02\u2019, is 93.3% identical to SARS-CoV-2 across the genome.", [["SARS", "DISEASE", 62, 66], ["bat virus", "ORGANISM", 11, 20], ["RmYN02", "GENE_OR_GENE_PRODUCT", 31, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["SARS-CoV-2", "DNA", 62, 72], ["bat virus", "SPECIES", 11, 20], ["SARS-CoV", "SPECIES", 62, 70], ["This novel bat virus", "PROBLEM", 0, 20], ["SARS", "TEST", 62, 66], ["CoV", "TEST", 67, 70], ["genome", "ANATOMY", 84, 90]]], ["In the long 1ab gene, it exhibits 97.2% identity to SARS-CoV-2, which is even higher than for RaTG13 (ref.28).", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["long 1ab gene", "DNA", 7, 20], ["RaTG13", "DNA", 94, 100], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["higher", "OBSERVATION_MODIFIER", 78, 84]]], ["In addition to RaTG13 and RmYN02, phylogenetic analysis shows that bat coronaviruses ZC45 and ZXC21 previously detected in Rhinolophus pusillus bats from eastern China also fall into the SARS-CoV-2 lineage of the subgenus Sarbecovirus36 (Fig. 2).", [["SARS", "DISEASE", 187, 191], ["RaTG13", "GENE_OR_GENE_PRODUCT", 15, 21], ["RmYN02", "GENE_OR_GENE_PRODUCT", 26, 32], ["bat coronaviruses ZC45", "ORGANISM", 67, 89], ["ZXC21", "GENE_OR_GENE_PRODUCT", 94, 99], ["Rhinolophus pusillus bats", "ORGANISM", 123, 148], ["RaTG13", "DNA", 15, 21], ["RmYN02", "DNA", 26, 32], ["Rhinolophus pusillus", "SPECIES", 123, 143], ["bat coronaviruses", "SPECIES", 67, 84], ["Rhinolophus pusillus bats", "SPECIES", 123, 148], ["SARS-CoV", "SPECIES", 187, 195], ["RaTG13", "TEST", 15, 21], ["phylogenetic analysis", "TEST", 34, 55], ["bat coronaviruses ZC45", "PROBLEM", 67, 89], ["ZXC21", "TREATMENT", 94, 99], ["Rhinolophus pusillus bats", "PROBLEM", 123, 148], ["the SARS", "TEST", 183, 191], ["CoV", "TEST", 192, 195]]], ["The discovery of diverse bat coronaviruses closely related to SARS-CoV-2 suggests that bats are possible reservoirs of SARS-CoV-2 (ref.37).", [["SARS", "DISEASE", 62, 66], ["SARS", "DISEASE", 119, 123], ["bat coronaviruses", "ORGANISM", 25, 42], ["SARS-CoV-2", "ORGANISM", 62, 72], ["bats", "ORGANISM", 87, 91], ["SARS-CoV-2", "ORGANISM", 119, 129], ["bat coronaviruses", "SPECIES", 25, 42], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 119, 127], ["diverse bat coronaviruses", "PROBLEM", 17, 42], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 124, 127], ["diverse bat coronaviruses", "OBSERVATION", 17, 42]]], ["Nevertheless, on the basis of current findings, the divergence between SARS-CoV-2 and related bat coronaviruses likely represents more than 20 years of sequence evolution, suggesting that these bat coronaviruses can be regarded only as the likely evolutionary precursor of SARS-CoV-2 but not as the direct progenitor of SARS-CoV-2 (ref.38).Animal host and spilloverBeyond bats, pangolins are another wildlife host probably linked with SARS-CoV-2.", [["SARS", "DISEASE", 71, 75], ["SARS", "DISEASE", 273, 277], ["SARS-CoV-2", "ORGANISM", 71, 81], ["bat coronaviruses", "ORGANISM", 94, 111], ["bat coronaviruses", "ORGANISM", 194, 211], ["SARS-CoV-2", "ORGANISM", 273, 283], ["progenitor", "CELL", 306, 316], ["SARS-CoV-2", "ORGANISM", 320, 330], ["spilloverBeyond bats", "ORGANISM", 356, 376], ["pangolins", "GENE_OR_GENE_PRODUCT", 378, 387], ["SARS-CoV-2", "ORGANISM", 435, 445], ["SARS-CoV", "SPECIES", 71, 79], ["bat coronaviruses", "SPECIES", 94, 111], ["bat coronaviruses", "SPECIES", 194, 211], ["SARS-CoV", "SPECIES", 273, 281], ["SARS-CoV", "SPECIES", 320, 328], ["SARS-CoV", "SPECIES", 435, 443], ["SARS", "TEST", 71, 75], ["related bat coronaviruses", "PROBLEM", 86, 111], ["these bat coronaviruses", "PROBLEM", 188, 211], ["SARS", "PROBLEM", 273, 277], ["CoV", "TEST", 278, 281], ["CoV", "TEST", 325, 328], ["bat", "ANATOMY", 94, 97], ["coronaviruses", "OBSERVATION", 98, 111], ["spilloverBeyond bats", "OBSERVATION", 356, 376]]], ["Multiple SARS-CoV-2-related viruses have been identified in tissues of Malayan pangolins smuggled from Southeast Asia into southern China from 2017 to 2019.", [["tissues", "ANATOMY", 60, 67], ["SARS-CoV-2", "ORGANISM", 9, 19], ["tissues", "TISSUE", 60, 67], ["Malayan pangolins", "ORGANISM", 71, 88], ["Malayan pangolins", "SPECIES", 71, 88], ["Multiple SARS-CoV-2", "PROBLEM", 0, 19], ["related viruses", "PROBLEM", 20, 35], ["SARS", "OBSERVATION", 9, 13], ["viruses", "OBSERVATION", 28, 35]]], ["These viruses from pangolins independently seized by Guangxi and Guangdong provincial customs belong to two distinct sublineages39\u201341.", [["viruses", "OBSERVATION", 6, 13]]], ["The Guangdong strains, which were isolated or sequenced by different research groups from smuggled pangolins, have 99.8% sequence identity with each other41.", [["pangolins", "GENE_OR_GENE_PRODUCT", 99, 108], ["other41", "DNA", 149, 156], ["The Guangdong strains", "PROBLEM", 0, 21], ["Guangdong strains", "OBSERVATION", 4, 21]]], ["They are very closely related to SARS-CoV-2, exhibiting 92.4% sequence similarity.", [["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "ORGANISM", 33, 43], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "TEST", 33, 37], ["CoV", "TEST", 38, 41]]], ["Notably, the RBD of Guangdong pangolin coronaviruses is highly similar to that of SARS-CoV-2.", [["SARS", "DISEASE", 82, 86], ["Guangdong pangolin coronaviruses", "ORGANISM", 20, 52], ["SARS-CoV-2", "ORGANISM", 82, 92], ["RBD", "PROTEIN", 13, 16], ["Guangdong pangolin coronaviruses", "SPECIES", 20, 52], ["SARS-CoV", "SPECIES", 82, 90], ["Guangdong pangolin coronaviruses", "PROBLEM", 20, 52], ["CoV", "TEST", 87, 90], ["RBD", "OBSERVATION", 13, 16]]], ["The receptor-binding motif (RBM; which is part of the RBD) of these viruses has only one amino acid variation from SARS-CoV-2, and it is identical to that of SARS-CoV-2 in all five critical residues for receptor binding40 (Fig. 3b).", [["amino acid", "CHEMICAL", 89, 99], ["SARS", "DISEASE", 115, 119], ["SARS", "DISEASE", 158, 162], ["amino acid", "CHEMICAL", 89, 99], ["amino acid", "AMINO_ACID", 89, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 158, 168], ["receptor-binding motif", "PROTEIN", 4, 26], ["RBM", "PROTEIN", 28, 31], ["RBD", "PROTEIN", 54, 57], ["receptor binding40", "PROTEIN", 203, 221], ["Fig. 3b", "PROTEIN", 223, 230], ["SARS-CoV", "SPECIES", 158, 166], ["The receptor-binding motif (RBM", "TREATMENT", 0, 31], ["these viruses", "PROBLEM", 62, 75], ["one amino acid variation", "PROBLEM", 85, 109], ["CoV", "TEST", 120, 123], ["SARS", "PROBLEM", 158, 162], ["CoV", "TEST", 163, 166], ["viruses", "OBSERVATION", 68, 75]]], ["In comparison with the Guangdong strains, pangolin coronaviruses reported from Guangxi are less similar to SARS-CoV-2, with 85.5% genome sequence identity39.", [["SARS", "DISEASE", 107, 111], ["pangolin coronaviruses", "ORGANISM", 42, 64], ["SARS-CoV-2", "ORGANISM", 107, 117], ["85.5% genome sequence identity39", "DNA", 124, 156], ["pangolin coronaviruses", "SPECIES", 42, 64], ["SARS-CoV-2", "SPECIES", 107, 117], ["pangolin coronaviruses", "PROBLEM", 42, 64], ["SARS", "TEST", 107, 111], ["CoV", "TEST", 112, 115]]], ["The repeated occurrence of SARS-CoV-2-related coronavirus infections in pangolins from different smuggling events suggests that these animals are possible hosts of the viruses.", [["SARS", "DISEASE", 27, 31], ["coronavirus infections", "DISEASE", 46, 68], ["pangolins", "CHEMICAL", 72, 81], ["SARS-CoV-2-related coronavirus", "ORGANISM", 27, 57], ["pangolins", "GENE_OR_GENE_PRODUCT", 72, 81], ["coronavirus", "SPECIES", 46, 57], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["CoV-2", "PROBLEM", 32, 37], ["coronavirus infections in pangolins", "PROBLEM", 46, 81], ["different smuggling events", "PROBLEM", 87, 113], ["the viruses", "PROBLEM", 164, 175], ["SARS", "OBSERVATION", 27, 31], ["coronavirus", "OBSERVATION_MODIFIER", 46, 57], ["infections", "OBSERVATION", 58, 68], ["different smuggling", "OBSERVATION", 87, 106], ["viruses", "OBSERVATION", 168, 175]]], ["However, unlike bats, which carry coronaviruses healthily, the infected pangolins showed clinical signs and histopathological changes, including interstitial pneumonia and inflammatory cell infiltration in diverse organs40.", [["pangolins", "ANATOMY", 72, 81], ["interstitial", "ANATOMY", 145, 157], ["inflammatory cell", "ANATOMY", 172, 189], ["organs", "ANATOMY", 214, 220], ["interstitial pneumonia", "DISEASE", 145, 167], ["coronaviruses", "ORGANISM", 34, 47], ["pangolins", "CELL", 72, 81], ["inflammatory cell", "CELL", 172, 189], ["organs", "ORGAN", 214, 220], ["the infected pangolins", "PROBLEM", 59, 81], ["clinical signs", "PROBLEM", 89, 103], ["histopathological changes", "PROBLEM", 108, 133], ["interstitial pneumonia", "PROBLEM", 145, 167], ["inflammatory cell infiltration", "PROBLEM", 172, 202], ["bats", "OBSERVATION", 16, 20], ["interstitial", "ANATOMY_MODIFIER", 145, 157], ["pneumonia", "OBSERVATION", 158, 167], ["inflammatory cell infiltration", "OBSERVATION", 172, 202]]], ["These abnormalities suggest that pangolins are unlikely to be the reservoir of these coronaviruses but more likely acquired the viruses after spillover from the natural hosts.Animal host and spilloverAn intermediate host usually plays an important role in the outbreak of bat-derived emerging coronaviruses; for example, palm civets for SARS-CoV and dromedary camels for MERS-CoV.", [["pangolins", "CHEMICAL", 33, 42], ["coronaviruses", "DISEASE", 293, 306], ["SARS", "DISEASE", 337, 341], ["pangolins", "GENE_OR_GENE_PRODUCT", 33, 42], ["coronaviruses", "ORGANISM", 85, 98], ["coronaviruses", "ORGANISM", 293, 306], ["palm", "ORGANISM_SUBDIVISION", 321, 325], ["SARS-CoV", "ORGANISM", 337, 345], ["MERS-CoV", "ORGANISM", 371, 379], ["SARS-CoV", "SPECIES", 337, 345], ["MERS-CoV", "SPECIES", 371, 379], ["These abnormalities", "PROBLEM", 0, 19], ["pangolins", "PROBLEM", 33, 42], ["these coronaviruses", "PROBLEM", 79, 98], ["SARS", "PROBLEM", 337, 341], ["CoV and dromedary camels", "TREATMENT", 342, 366], ["coronaviruses", "OBSERVATION", 85, 98], ["viruses", "OBSERVATION", 128, 135], ["spillover", "OBSERVATION", 191, 200], ["intermediate host", "OBSERVATION", 203, 220]]], ["The virus strains carried by these two intermediate hosts were almost genetically identical to the corresponding viruses in humans (more than 99% genome sequence identity)1.", [["humans", "ORGANISM", 124, 130], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 124, 130], ["The virus strains", "PROBLEM", 0, 17], ["virus strains", "OBSERVATION", 4, 17], ["viruses", "OBSERVATION", 113, 120]]], ["Despise an RBD that is virtually identical to that of SARS-CoV-2, the pangolin coronaviruses known to date have no more than 92% genome identity with SARS-CoV-2 (ref.42).", [["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "ORGANISM", 54, 64], ["pangolin coronaviruses", "ORGANISM", 70, 92], ["SARS-CoV-2", "ORGANISM", 150, 160], ["RBD", "PROTEIN", 11, 14], ["SARS-CoV", "SPECIES", 54, 62], ["pangolin coronaviruses", "SPECIES", 70, 92], ["SARS-CoV", "SPECIES", 150, 158], ["an RBD", "PROBLEM", 8, 14], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["the pangolin coronaviruses", "PROBLEM", 66, 92], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["RBD", "OBSERVATION", 11, 14]]], ["The available data are insufficient to interpret pangolins as the intermediate host of SARS-CoV-2.", [["SARS", "DISEASE", 87, 91], ["pangolins", "GENE_OR_GENE_PRODUCT", 49, 58], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV", "SPECIES", 87, 95]]], ["So far, no evidence has shown that pangolins were directly involved in the emergence of SARS-CoV-2.Animal host and spilloverCurrently, our knowledge on the animal origin of SARS-CoV-2 remains incomplete to a large part.", [["pangolins", "CHEMICAL", 35, 44], ["SARS", "DISEASE", 88, 92], ["SARS", "DISEASE", 173, 177], ["pangolins", "CHEMICAL", 35, 44], ["pangolins", "GENE_OR_GENE_PRODUCT", 35, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["SARS-CoV-2", "ORGANISM", 173, 183], ["pangolins", "PROTEIN", 35, 44], ["SARS-CoV", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 173, 181], ["CoV", "TEST", 93, 96], ["SARS", "PROBLEM", 173, 177], ["CoV", "TEST", 178, 181], ["no evidence", "UNCERTAINTY", 8, 19]]], ["The reservoir hosts of the virus have not been clearly proven.", [["The reservoir hosts", "TREATMENT", 0, 19], ["the virus", "PROBLEM", 23, 32]]], ["It is unknown whether SARS-CoV-2 was transmitted to humans through an intermediate host and which animals may act as its intermediate host.", [["SARS-CoV-2", "ORGANISM", 22, 32], ["humans", "ORGANISM", 52, 58], ["humans", "SPECIES", 52, 58], ["humans", "SPECIES", 52, 58], ["SARS", "PROBLEM", 22, 26]]], ["Detection of RaTG13, RmYN02 and pangolin coronaviruses implies that diverse coronaviruses similar to SARS-CoV-2 are circulating in wildlife.", [["SARS", "DISEASE", 101, 105], ["RaTG13", "GENE_OR_GENE_PRODUCT", 13, 19], ["RmYN02", "GENE_OR_GENE_PRODUCT", 21, 27], ["pangolin coronaviruses", "ORGANISM", 32, 54], ["coronaviruses", "ORGANISM", 76, 89], ["SARS-CoV-2", "ORGANISM", 101, 111], ["RaTG13", "PROTEIN", 13, 19], ["RmYN02", "PROTEIN", 21, 27], ["CoV-2", "SPECIES", 106, 111], ["pangolin coronaviruses", "SPECIES", 32, 54], ["SARS-CoV", "SPECIES", 101, 109], ["Detection", "TEST", 0, 9], ["RaTG13", "TEST", 13, 19], ["RmYN02", "TREATMENT", 21, 27], ["pangolin coronaviruses", "PROBLEM", 32, 54], ["diverse coronaviruses", "PROBLEM", 68, 89], ["diverse", "OBSERVATION_MODIFIER", 68, 75], ["coronaviruses", "OBSERVATION", 76, 89]]], ["In addition, as previous studies showed recombination as the potential origin of some sarbecoviruses such as SARS-CoV, it cannot be excluded that viral RNA recombination among different related coronaviruses was involved in the evolution of SARS-CoV-2.", [["SARS", "DISEASE", 109, 113], ["SARS", "DISEASE", 241, 245], ["sarbecoviruses", "GENE_OR_GENE_PRODUCT", 86, 100], ["SARS-CoV", "ORGANISM", 109, 117], ["coronaviruses", "ORGANISM", 194, 207], ["SARS-CoV-2", "ORGANISM", 241, 251], ["SARS-CoV", "SPECIES", 109, 117], ["SARS-CoV", "SPECIES", 241, 249], ["previous studies", "TEST", 16, 32], ["some sarbecoviruses", "PROBLEM", 81, 100], ["SARS-CoV", "PROBLEM", 109, 117], ["viral RNA recombination", "PROBLEM", 146, 169], ["different related coronaviruses", "PROBLEM", 176, 207], ["SARS", "PROBLEM", 241, 245], ["CoV", "TEST", 246, 249]]], ["Extensive surveillance of SARS-CoV-2-related viruses in China, Southeast Asia and other regions targeting bats, wild and captured pangolins and other wildlife species will help us to better understand the zoonotic origin of SARS-CoV-2.Animal host and spilloverBesides wildlife, researchers investigated the susceptibility of domesticated and laboratory animals to SARS-CoV-2 infection.", [["SARS", "DISEASE", 26, 30], ["SARS", "DISEASE", 224, 228], ["SARS-CoV-2 infection", "DISEASE", 364, 384], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV-2", "ORGANISM", 224, 234], ["SARS-CoV-2", "ORGANISM", 364, 374], ["CoV-", "SPECIES", 31, 35], ["CoV-2", "SPECIES", 369, 374], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 224, 232], ["SARS-CoV-2", "SPECIES", 364, 374], ["SARS", "PROBLEM", 26, 30], ["CoV", "TEST", 31, 34], ["viruses", "PROBLEM", 45, 52], ["SARS", "PROBLEM", 364, 368], ["CoV-2 infection", "PROBLEM", 369, 384], ["SARS", "OBSERVATION", 26, 30], ["viruses", "OBSERVATION", 45, 52], ["infection", "OBSERVATION", 375, 384]]], ["The study demonstrated experimentally that SARS-CoV-2 replicates efficiently in cats and in the upper respiratory tract of ferrets, whereas dogs, pigs, chickens and ducks were not susceptible to SARS-CoV-2 (ref.43).", [["upper respiratory tract", "ANATOMY", 96, 119], ["SARS", "DISEASE", 195, 199], ["SARS-CoV-2", "ORGANISM", 43, 53], ["cats", "ORGANISM", 80, 84], ["upper respiratory", "ORGANISM_SUBDIVISION", 96, 113], ["tract", "ORGANISM_SUBDIVISION", 114, 119], ["ferrets", "ORGANISM", 123, 130], ["dogs", "ORGANISM", 140, 144], ["pigs", "ORGANISM", 146, 150], ["chickens", "ORGANISM", 152, 160], ["ducks", "ORGANISM", 165, 170], ["SARS-CoV-2", "ORGANISM", 195, 205], ["cats", "SPECIES", 80, 84], ["ferrets", "SPECIES", 123, 130], ["dogs", "SPECIES", 140, 144], ["pigs", "SPECIES", 146, 150], ["chickens", "SPECIES", 152, 160], ["ducks", "SPECIES", 165, 170], ["SARS-CoV", "SPECIES", 43, 51], ["ferrets", "SPECIES", 123, 130], ["pigs", "SPECIES", 146, 150], ["chickens", "SPECIES", 152, 160], ["ducks", "SPECIES", 165, 170], ["SARS-CoV", "SPECIES", 195, 203], ["The study", "TEST", 0, 9], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["CoV", "TEST", 200, 203], ["upper", "ANATOMY_MODIFIER", 96, 101], ["respiratory tract", "ANATOMY", 102, 119]]], ["The susceptibility of minks was documented by a report from the Netherlands on an outbreak of SARS-CoV-2 infection in farmed minks.", [["SARS-CoV-2 infection", "DISEASE", 94, 114], ["SARS-CoV-2", "ORGANISM", 94, 104], ["CoV-2", "SPECIES", 99, 104], ["SARS-CoV-2", "SPECIES", 94, 104], ["SARS", "PROBLEM", 94, 98], ["2 infection in farmed minks", "PROBLEM", 103, 130], ["infection", "OBSERVATION", 105, 114]]], ["Although the symptoms in most infected minks were mild, some developed severe respiratory distress and died of interstitial pneumonia44.", [["respiratory", "ANATOMY", 78, 89], ["interstitial", "ANATOMY", 111, 123], ["respiratory distress", "DISEASE", 78, 98], ["the symptoms", "PROBLEM", 9, 21], ["severe respiratory distress", "PROBLEM", 71, 98], ["interstitial pneumonia44", "PROBLEM", 111, 135], ["mild", "OBSERVATION_MODIFIER", 50, 54], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["respiratory distress", "OBSERVATION", 78, 98], ["interstitial", "ANATOMY_MODIFIER", 111, 123], ["pneumonia44", "OBSERVATION", 124, 135]]], ["Both virological and serological testing found evidence for natural SARS-CoV-2 infection in two dogs from households with human cases of COVID-19 in Hong Kong, but the dogs appeared asymptomatic45.", [["SARS-CoV-2 infection", "DISEASE", 68, 88], ["SARS-CoV-2", "ORGANISM", 68, 78], ["dogs", "ORGANISM", 96, 100], ["human", "ORGANISM", 122, 127], ["dogs", "ORGANISM", 168, 172], ["dogs", "SPECIES", 96, 100], ["human", "SPECIES", 122, 127], ["dogs", "SPECIES", 168, 172], ["SARS-CoV-2", "SPECIES", 68, 78], ["human", "SPECIES", 122, 127], ["Both virological", "TEST", 0, 16], ["serological testing", "TEST", 21, 40], ["natural SARS", "PROBLEM", 60, 72], ["CoV", "PROBLEM", 73, 76], ["2 infection", "PROBLEM", 77, 88], ["COVID", "TREATMENT", 137, 142], ["infection", "OBSERVATION", 79, 88]]], ["Another serological study detected SARS-CoV-2 neutralizing antibodies in cat serum samples collected in Wuhan after the COVID-19 outbreak, providing evidence for SARS-CoV-2 infection in cat populations in Wuhan, although the potential of SARS-CoV-2 transmission from cats to humans is currently uncertain46.Receptor use and pathogenesisSARS-CoV-2 uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2)11,47.", [["serum samples", "ANATOMY", 77, 90], ["SARS-CoV-2 infection", "DISEASE", 162, 182], ["SARS", "DISEASE", 238, 242], ["angiotensin", "CHEMICAL", 383, 394], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 35, 45], ["cat", "ORGANISM", 73, 76], ["serum samples", "ORGANISM_SUBSTANCE", 77, 90], ["SARS-CoV-2", "ORGANISM", 162, 172], ["cat", "ORGANISM", 186, 189], ["SARS-CoV-2", "ORGANISM", 238, 248], ["cats", "ORGANISM", 267, 271], ["humans", "ORGANISM", 275, 281], ["pathogenesisSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 324, 346], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 373, 381], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 383, 414], ["ACE2", "GENE_OR_GENE_PRODUCT", 416, 420], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 35, 69], ["SARS-CoV, angiotensin-converting enzyme 2 (ACE2)11,47", "PROTEIN", 373, 426], ["CoV-", "SPECIES", 243, 247], ["cats", "SPECIES", 267, 271], ["humans", "SPECIES", 275, 281], ["SARS-CoV", "SPECIES", 35, 43], ["cat", "SPECIES", 73, 76], ["SARS-CoV-2", "SPECIES", 162, 172], ["SARS-CoV-2", "SPECIES", 238, 248], ["humans", "SPECIES", 275, 281], ["SARS-CoV", "SPECIES", 373, 381], ["Another serological study", "TEST", 0, 25], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["neutralizing antibodies", "TEST", 46, 69], ["cat serum samples", "TEST", 73, 90], ["the COVID", "TEST", 116, 125], ["SARS", "PROBLEM", 162, 166], ["CoV", "PROBLEM", 167, 170], ["2 infection", "PROBLEM", 171, 182], ["SARS", "PROBLEM", 238, 242], ["CoV", "TEST", 243, 246], ["pathogenesisSARS", "TEST", 324, 340], ["CoV", "TEST", 341, 344], ["angiotensin", "TEST", 383, 394], ["converting enzyme", "TEST", 395, 412], ["infection", "OBSERVATION", 173, 182]]], ["Besides human ACE2 (hACE2), SARS-CoV-2 also recognizes ACE2 from pig, ferret, rhesus monkey, civet, cat, pangolin, rabbit and dog11,43,48,49.", [["human", "ORGANISM", 8, 13], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["hACE2", "GENE_OR_GENE_PRODUCT", 20, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["pig", "ORGANISM", 65, 68], ["ferret", "ORGANISM", 70, 76], ["rhesus monkey", "ORGANISM", 78, 91], ["civet", "ORGANISM", 93, 98], ["cat", "ORGANISM", 100, 103], ["pangolin", "GENE_OR_GENE_PRODUCT", 105, 113], ["rabbit", "ORGANISM", 115, 121], ["dog", "ORGANISM", 126, 129], ["human ACE2", "PROTEIN", 8, 18], ["hACE2", "PROTEIN", 20, 25], ["ACE2", "PROTEIN", 55, 59], ["human", "SPECIES", 8, 13], ["pig", "SPECIES", 65, 68], ["ferret", "SPECIES", 70, 76], ["rhesus monkey", "SPECIES", 78, 91], ["cat", "SPECIES", 100, 103], ["rabbit", "SPECIES", 115, 121], ["dog", "SPECIES", 126, 129], ["human", "SPECIES", 8, 13], ["pig", "SPECIES", 65, 68], ["rhesus monkey", "SPECIES", 78, 91], ["rabbit", "SPECIES", 115, 121], ["human ACE2 (hACE2)", "TREATMENT", 8, 26]]], ["The broad receptor usage of SARS-CoV-2 implies that it may have a wide host range, and the varied efficiency of ACE2 usage in different animals may indicate their different susceptibilities to SARS-CoV-2 infection.", [["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 193, 197], ["infection", "DISEASE", 204, 213], ["SARS-CoV-2", "ORGANISM", 28, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["SARS-CoV-2", "ORGANISM", 193, 203], ["ACE2", "PROTEIN", 112, 116], ["SARS-CoV", "SPECIES", 193, 201], ["SARS", "PROBLEM", 28, 32], ["ACE2 usage", "TREATMENT", 112, 122], ["SARS", "PROBLEM", 193, 197], ["CoV-2 infection", "PROBLEM", 198, 213], ["wide host", "OBSERVATION_MODIFIER", 66, 75], ["infection", "OBSERVATION", 204, 213]]], ["The S1 subunit of a coronavirus is further divided into two functional domains, an N-terminal domain and a C-terminal domain.", [["N", "CHEMICAL", 83, 84], ["C", "CHEMICAL", 107, 108], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["coronavirus", "ORGANISM", 20, 31], ["S1 subunit", "PROTEIN", 4, 14], ["N-terminal domain", "PROTEIN", 83, 100], ["C-terminal domain", "PROTEIN", 107, 124], ["a coronavirus", "PROBLEM", 18, 31], ["a C-terminal domain", "PROBLEM", 105, 124], ["coronavirus", "OBSERVATION", 20, 31]]], ["Structural and biochemical analyses identified a 211 amino acid region (amino acids 319\u2013529) at the S1 C-terminal domain of SARS-CoV-2 as the RBD, which has a key role in virus entry and is the target of neutralizing antibodies50,51 (Fig. 3a).", [["amino acid", "CHEMICAL", 53, 63], ["amino acids", "CHEMICAL", 72, 83], ["amino acid", "CHEMICAL", 53, 63], ["amino acids", "CHEMICAL", 72, 83], ["C", "CHEMICAL", 103, 104], ["amino acid", "AMINO_ACID", 53, 63], ["amino acids", "AMINO_ACID", 72, 83], ["319\u2013529", "AMINO_ACID", 84, 91], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 124, 134], ["RBD", "GENE_OR_GENE_PRODUCT", 142, 145], ["211 amino acid region", "PROTEIN", 49, 70], ["amino acids 319\u2013529", "PROTEIN", 72, 91], ["S1 C-terminal domain", "PROTEIN", 100, 120], ["SARS-CoV-2", "PROTEIN", 124, 134], ["RBD", "PROTEIN", 142, 145], ["Structural and biochemical analyses", "TEST", 0, 35], ["a 211 amino acid region", "PROBLEM", 47, 70], ["amino acids", "TEST", 72, 83], ["SARS", "PROBLEM", 124, 128], ["CoV", "TEST", 129, 132], ["the RBD", "PROBLEM", 138, 145], ["neutralizing antibodies", "TEST", 204, 227], ["SARS", "OBSERVATION", 124, 128], ["RBD", "ANATOMY", 142, 145], ["virus", "OBSERVATION", 171, 176]]], ["The RBM mediates contact with the ACE2 receptor (amino acids 437\u2013507 of SARS-CoV-2 S protein), and this region in SARS-CoV-2 differs from that in SARS-CoV in the five residues critical for ACE2 binding, namely Y455L, L486F, N493Q, D494S and T501N52 (Fig. 3b,c).", [["amino acids", "CHEMICAL", 49, 60], ["SARS", "DISEASE", 114, 118], ["SARS", "DISEASE", 146, 150], ["amino acids", "CHEMICAL", 49, 60], ["RBM", "GENE_OR_GENE_PRODUCT", 4, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["amino acids", "AMINO_ACID", 49, 60], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 72, 84], ["SARS-CoV-2", "ORGANISM", 114, 124], ["SARS-CoV", "ORGANISM", 146, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 189, 193], ["RBM", "PROTEIN", 4, 7], ["ACE2 receptor", "PROTEIN", 34, 47], ["amino acids 437\u2013507 of SARS-CoV-2 S protein", "PROTEIN", 49, 92], ["ACE2", "PROTEIN", 189, 193], ["Fig. 3b,c)", "PROTEIN", 250, 260], ["SARS-CoV", "SPECIES", 114, 122], ["SARS-CoV", "SPECIES", 146, 154], ["the ACE2 receptor", "TEST", 30, 47], ["amino acids", "TEST", 49, 60], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["this region in SARS", "PROBLEM", 99, 118], ["CoV", "TEST", 119, 122], ["SARS", "PROBLEM", 146, 150], ["ACE2 binding", "TEST", 189, 201], ["D494S", "TEST", 231, 236]]], ["Owing to these residue changes, interaction of SARS-CoV-2 with its receptor stabilizes the two virus-binding hotspots on the surface of hACE2 (ref.50) (Fig. 3d).", [["surface", "ANATOMY", 125, 132], ["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["surface", "CELLULAR_COMPONENT", 125, 132], ["hACE2", "GENE_OR_GENE_PRODUCT", 136, 141], ["hACE2", "PROTEIN", 136, 141], ["these residue changes", "PROBLEM", 9, 30], ["SARS", "PROBLEM", 47, 51], ["the two virus", "PROBLEM", 87, 100], ["residue", "OBSERVATION", 15, 22]]], ["Moreover, a four-residue motif in the RBM of SARS-CoV-2 (amino acids 482\u2013485: G-V-E-G) results in a more compact conformation of its hACE2-binding ridge than in SARS-CoV and enables better contact with the N-terminal helix of hACE2 (ref.50).", [["SARS", "DISEASE", 45, 49], ["amino acids 482\u2013485", "CHEMICAL", 57, 76], ["amino acids", "CHEMICAL", 57, 68], ["G-V-E-G", "CHEMICAL", 78, 85], ["N", "CHEMICAL", 206, 207], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["amino acids", "AMINO_ACID", 57, 68], ["hACE2", "GENE_OR_GENE_PRODUCT", 133, 138], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["hACE2", "GENE_OR_GENE_PRODUCT", 226, 231], ["RBM", "PROTEIN", 38, 41], ["SARS-CoV-2", "DNA", 45, 55], ["hACE2", "PROTEIN", 133, 138], ["N-terminal helix", "PROTEIN", 206, 222], ["hACE2", "PROTEIN", 226, 231], ["ref.50", "PROTEIN", 233, 239], ["SARS-CoV", "SPECIES", 161, 169], ["a four-residue motif", "TEST", 10, 30], ["the RBM of SARS", "TEST", 34, 49], ["CoV", "TEST", 50, 53], ["amino acids", "TEST", 57, 68], ["G-V", "TEST", 78, 81]]], ["Biochemical data confirmed that the structural features of the SARS-CoV-2 RBD has strengthened its hACE2 binding affinity compared with that of SARS-CoV50,52,53.Receptor use and pathogenesisSimilarly to other coronaviruses, SARS-CoV-2 needs proteolytic processing of the S protein to activate the endocytic route.", [["SARS", "DISEASE", 63, 67], ["SARS", "DISEASE", 224, 228], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["hACE2", "GENE_OR_GENE_PRODUCT", 99, 104], ["SARS-CoV-2", "ORGANISM", 224, 234], ["S protein", "GENE_OR_GENE_PRODUCT", 271, 280], ["SARS-CoV-2 RBD", "PROTEIN", 63, 77], ["hACE2", "PROTEIN", 99, 104], ["S protein", "PROTEIN", 271, 280], ["SARS-CoV", "SPECIES", 224, 232], ["Biochemical data", "TEST", 0, 16], ["the SARS", "TEST", 59, 67], ["CoV", "TEST", 68, 71], ["pathogenesisSimilarly to other coronaviruses", "PROBLEM", 178, 222], ["SARS", "PROBLEM", 224, 228], ["CoV", "TEST", 229, 232], ["proteolytic processing", "TREATMENT", 241, 263], ["the S protein", "TREATMENT", 267, 280]]], ["It has been shown that host proteases participate in the cleavage of the S protein and activate the entry of SARS-CoV-2, including transmembrane protease serine protease 2 (TMPRSS2), cathepsin L and furin47,54,55.", [["SARS", "DISEASE", 109, 113], ["serine", "CHEMICAL", 154, 160], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["transmembrane protease serine protease 2", "GENE_OR_GENE_PRODUCT", 131, 171], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 173, 180], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 183, 194], ["furin", "GENE_OR_GENE_PRODUCT", 199, 204], ["S protein", "PROTEIN", 73, 82], ["SARS-CoV-2", "PROTEIN", 109, 119], ["transmembrane protease serine protease 2", "PROTEIN", 131, 171], ["TMPRSS2", "PROTEIN", 173, 180], ["cathepsin L", "PROTEIN", 183, 194], ["furin47,54,55", "PROTEIN", 199, 212], ["SARS-CoV", "SPECIES", 109, 117], ["host proteases", "TREATMENT", 23, 37], ["the S protein", "TREATMENT", 69, 82], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["transmembrane protease serine protease", "TREATMENT", 131, 169], ["cathepsin L", "TREATMENT", 183, 194], ["furin", "TEST", 199, 204]]], ["Single-cell RNA sequencing data showed that TMPRSS2 is highly expressed in several tissues and body sites and is co-expressed with ACE2 in nasal epithelial cells, lungs and bronchial branches, which explains some of the tissue tropism of SARS-CoV-2 (refs56,57).", [["tissues", "ANATOMY", 83, 90], ["body sites", "ANATOMY", 95, 105], ["nasal epithelial cells", "ANATOMY", 139, 161], ["lungs", "ANATOMY", 163, 168], ["bronchial branches", "ANATOMY", 173, 191], ["tissue", "ANATOMY", 220, 226], ["SARS", "DISEASE", 238, 242], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 44, 51], ["tissues", "TISSUE", 83, 90], ["body sites", "MULTI-TISSUE_STRUCTURE", 95, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 131, 135], ["nasal epithelial cells", "CELL", 139, 161], ["lungs", "ORGAN", 163, 168], ["bronchial branches", "MULTI-TISSUE_STRUCTURE", 173, 191], ["tissue", "TISSUE", 220, 226], ["SARS-CoV-2", "ORGANISM", 238, 248], ["TMPRSS2", "PROTEIN", 44, 51], ["ACE2", "PROTEIN", 131, 135], ["nasal epithelial cells", "CELL_TYPE", 139, 161], ["SARS-CoV", "SPECIES", 238, 246], ["Single-cell RNA sequencing data", "TEST", 0, 31], ["TMPRSS2", "PROBLEM", 44, 51], ["ACE2 in nasal epithelial cells", "PROBLEM", 131, 161], ["the tissue tropism of SARS", "PROBLEM", 216, 242], ["CoV", "TEST", 243, 246], ["TMPRSS2", "OBSERVATION", 44, 51], ["several tissues", "OBSERVATION_MODIFIER", 75, 90], ["nasal", "ANATOMY", 139, 144], ["epithelial cells", "OBSERVATION", 145, 161], ["lungs", "ANATOMY", 163, 168], ["bronchial", "ANATOMY", 173, 182], ["branches", "ANATOMY_MODIFIER", 183, 191], ["tissue tropism", "OBSERVATION", 220, 234]]], ["SARS-CoV-2 pseudovirus entry assays revealed that TMPRSS2 and cathepsin L have cumulative effects with furin on activating virus entry55.", [["SARS-CoV-2", "ORGANISM", 0, 10], ["pseudovirus", "ORGANISM", 11, 22], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 50, 57], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 62, 73], ["furin", "GENE_OR_GENE_PRODUCT", 103, 108], ["TMPRSS2", "PROTEIN", 50, 57], ["cathepsin L", "PROTEIN", 62, 73], ["furin", "PROTEIN", 103, 108], ["SARS", "TEST", 0, 4], ["CoV-2 pseudovirus entry assays", "TEST", 5, 35], ["TMPRSS2", "PROBLEM", 50, 57], ["cathepsin", "TREATMENT", 62, 71], ["cumulative effects", "PROBLEM", 79, 97], ["furin", "TREATMENT", 103, 108], ["activating virus entry55", "TREATMENT", 112, 136]]], ["Analysis of the cryo-electron microscopy structure of SARS-CoV-2 S protein revealed that its RBD is mostly in the lying-down state, whereas the SARS-CoV S protein assumes equally standing-up and lying-down conformational states50,51,58,59.", [["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 54, 66], ["RBD", "GENE_OR_GENE_PRODUCT", 93, 96], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["SARS-CoV-2 S protein", "PROTEIN", 54, 74], ["RBD", "PROTEIN", 93, 96], ["lying-down state", "PROTEIN", 114, 130], ["SARS-CoV S protein", "PROTEIN", 144, 162], ["SARS-CoV", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 144, 152], ["the cryo-electron microscopy", "TEST", 12, 40], ["SARS", "TEST", 54, 58], ["CoV-2 S protein", "TEST", 59, 74], ["its RBD", "PROBLEM", 89, 96], ["the SARS", "TEST", 140, 148], ["CoV S protein", "TEST", 149, 162], ["RBD", "OBSERVATION", 93, 96], ["mostly", "OBSERVATION_MODIFIER", 100, 106]]], ["A lying-down conformation of the SARS-CoV-2 S protein may not be in favour of receptor binding but is helpful for immune evasion55.Receptor use and pathogenesisThe pathogenesis of SARS-CoV-2 infection in humans manifests itself as mild symptoms to severe respiratory failure.", [["respiratory", "ANATOMY", 255, 266], ["SARS-CoV-2 infection", "DISEASE", 180, 200], ["respiratory failure", "DISEASE", 255, 274], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 33, 45], ["SARS-CoV-2", "ORGANISM", 180, 190], ["humans", "ORGANISM", 204, 210], ["SARS-CoV-2 S protein", "PROTEIN", 33, 53], ["CoV-2", "SPECIES", 185, 190], ["humans", "SPECIES", 204, 210], ["SARS-CoV-2", "SPECIES", 180, 190], ["humans", "SPECIES", 204, 210], ["the SARS", "TEST", 29, 37], ["CoV-2 S protein", "TEST", 38, 53], ["receptor binding", "PROBLEM", 78, 94], ["immune evasion55", "TREATMENT", 114, 130], ["pathogenesis", "PROBLEM", 148, 160], ["SARS", "PROBLEM", 180, 184], ["CoV", "PROBLEM", 185, 188], ["2 infection in humans", "PROBLEM", 189, 210], ["mild symptoms", "PROBLEM", 231, 244], ["severe respiratory failure", "PROBLEM", 248, 274], ["SARS", "OBSERVATION", 180, 184], ["CoV", "OBSERVATION_MODIFIER", 185, 188], ["infection", "OBSERVATION", 191, 200], ["mild", "OBSERVATION_MODIFIER", 231, 235], ["severe", "OBSERVATION_MODIFIER", 248, 254], ["respiratory failure", "OBSERVATION", 255, 274]]], ["On binding to epithelial cells in the respiratory tract, SARS-CoV-2 starts replicating and migrating down to the airways and enters alveolar epithelial cells in the lungs.", [["epithelial cells", "ANATOMY", 14, 30], ["respiratory tract", "ANATOMY", 38, 55], ["airways", "ANATOMY", 113, 120], ["alveolar epithelial cells", "ANATOMY", 132, 157], ["lungs", "ANATOMY", 165, 170], ["epithelial cells", "CELL", 14, 30], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["airways", "ORGAN", 113, 120], ["alveolar epithelial cells", "CELL", 132, 157], ["lungs", "ORGAN", 165, 170], ["epithelial cells", "CELL_TYPE", 14, 30], ["alveolar epithelial cells", "CELL_TYPE", 132, 157], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["epithelial cells", "OBSERVATION", 14, 30], ["respiratory tract", "ANATOMY", 38, 55], ["airways", "ANATOMY", 113, 120], ["alveolar", "ANATOMY_MODIFIER", 132, 140], ["epithelial cells", "OBSERVATION", 141, 157], ["lungs", "ANATOMY", 165, 170]]], ["The rapid replication of SARS-CoV-2 in the lungs may trigger a strong immune response.", [["lungs", "ANATOMY", 43, 48], ["SARS", "DISEASE", 25, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["lungs", "ORGAN", 43, 48], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["CoV", "TEST", 30, 33], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["replication", "OBSERVATION_MODIFIER", 10, 21], ["SARS", "OBSERVATION", 25, 29], ["lungs", "ANATOMY", 43, 48]]], ["Cytokine storm syndrome causes acute respiratory distress syndrome and respiratory failure, which is considered the main cause of death in patients with COVID-19 (refs60,61).", [["respiratory", "ANATOMY", 37, 48], ["respiratory", "ANATOMY", 71, 82], ["acute respiratory distress syndrome", "DISEASE", 31, 66], ["respiratory failure", "DISEASE", 71, 90], ["death", "DISEASE", 130, 135], ["patients", "ORGANISM", 139, 147], ["Cytokine", "PROTEIN", 0, 8], ["patients", "SPECIES", 139, 147], ["Cytokine storm syndrome", "PROBLEM", 0, 23], ["acute respiratory distress syndrome", "PROBLEM", 31, 66], ["respiratory failure", "PROBLEM", 71, 90], ["death", "PROBLEM", 130, 135], ["COVID", "TEST", 153, 158], ["storm syndrome", "OBSERVATION", 9, 23], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["respiratory distress", "OBSERVATION", 37, 57], ["respiratory failure", "OBSERVATION", 71, 90]]], ["Patients of older age (>60 years) and with serious pre-existing diseases have a greater risk of developing acute respiratory distress syndrome and death62\u201364 (Fig. 4).", [["respiratory", "ANATOMY", 113, 124], ["acute respiratory distress syndrome", "DISEASE", 107, 142], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["serious pre-existing diseases", "PROBLEM", 43, 72], ["acute respiratory distress syndrome", "PROBLEM", 107, 142], ["diseases", "OBSERVATION", 64, 72], ["greater", "OBSERVATION_MODIFIER", 80, 87], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory distress syndrome", "OBSERVATION", 113, 142]]], ["Multiple organ failure has also been reported in some COVID-19 cases9,13,65.Receptor use and pathogenesisHistopathological changes in patients with COVID-19 occur mainly in the lungs.", [["organ", "ANATOMY", 9, 14], ["lungs", "ANATOMY", 177, 182], ["organ failure", "DISEASE", 9, 22], ["COVID-19", "CHEMICAL", 148, 156], ["COVID-19", "CHEMICAL", 148, 156], ["organ", "ORGAN", 9, 14], ["patients", "ORGANISM", 134, 142], ["lungs", "ORGAN", 177, 182], ["patients", "SPECIES", 134, 142], ["Multiple organ failure", "PROBLEM", 0, 22], ["some COVID", "TEST", 49, 59], ["pathogenesisHistopathological changes", "PROBLEM", 93, 130], ["COVID", "TEST", 148, 153], ["organ", "ANATOMY", 9, 14], ["failure", "OBSERVATION", 15, 22], ["lungs", "ANATOMY", 177, 182]]], ["Histopathology analyses showed bilateral diffused alveolar damage, hyaline membrane formation, desquamation of pneumocytes and fibrin deposits in lungs of patients with severe COVID-19.", [["alveolar", "ANATOMY", 50, 58], ["hyaline membrane", "ANATOMY", 67, 83], ["pneumocytes", "ANATOMY", 111, 122], ["lungs", "ANATOMY", 146, 151], ["alveolar damage", "DISEASE", 50, 65], ["alveolar", "TISSUE", 50, 58], ["hyaline membrane", "CELLULAR_COMPONENT", 67, 83], ["pneumocytes", "CELL", 111, 122], ["fibrin", "GENE_OR_GENE_PRODUCT", 127, 133], ["lungs", "ORGAN", 146, 151], ["patients", "ORGANISM", 155, 163], ["pneumocytes", "CELL_TYPE", 111, 122], ["patients", "SPECIES", 155, 163], ["Histopathology analyses", "TEST", 0, 23], ["bilateral diffused alveolar damage", "PROBLEM", 31, 65], ["hyaline membrane formation", "PROBLEM", 67, 93], ["desquamation", "PROBLEM", 95, 107], ["pneumocytes", "PROBLEM", 111, 122], ["fibrin deposits in lungs", "PROBLEM", 127, 151], ["severe COVID", "PROBLEM", 169, 181], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["diffused", "OBSERVATION_MODIFIER", 41, 49], ["alveolar damage", "OBSERVATION", 50, 65], ["hyaline membrane formation", "OBSERVATION", 67, 93], ["desquamation", "OBSERVATION_MODIFIER", 95, 107], ["pneumocytes", "OBSERVATION", 111, 122], ["fibrin deposits", "OBSERVATION", 127, 142], ["lungs", "ANATOMY", 146, 151], ["severe", "OBSERVATION_MODIFIER", 169, 175]]], ["Exudative inflammation was also shown in some cases.", [["inflammation", "DISEASE", 10, 22], ["Exudative inflammation", "PROBLEM", 0, 22], ["inflammation", "OBSERVATION", 10, 22]]], ["Immunohistochemistry assays detected SARS-CoV-2 antigen in the upper airway, bronchiolar epithelium and submucosal gland epithelium, as well as in type I and type II pneumocytes, alveolar macrophages and hyaline membranes in the lungs13,60,66,67.Receptor use and pathogenesisAnimal models used for studying SARS-CoV-2 infection pathogenesis include non-human primates (rhesus macaques, cynomolgus monkeys, marmosets and African green monkeys), mice (wild-type mice (with mouse-adapted virus) and human ACE2-transgenic or human ACE2-knock-in mice), ferrets and golden hamsters43,48,68\u201374.", [["upper airway", "ANATOMY", 63, 75], ["bronchiolar epithelium", "ANATOMY", 77, 99], ["submucosal gland epithelium", "ANATOMY", 104, 131], ["type II pneumocytes", "ANATOMY", 158, 177], ["alveolar macrophages", "ANATOMY", 179, 199], ["hyaline membranes", "ANATOMY", 204, 221], ["lungs", "ANATOMY", 229, 234], ["infection", "DISEASE", 318, 327], ["SARS-CoV-2 antigen", "GENE_OR_GENE_PRODUCT", 37, 55], ["upper airway", "TISSUE", 63, 75], ["bronchiolar epithelium", "TISSUE", 77, 99], ["submucosal gland epithelium", "TISSUE", 104, 131], ["type II pneumocytes", "CELL", 158, 177], ["alveolar macrophages", "CELL", 179, 199], ["hyaline membranes", "CELLULAR_COMPONENT", 204, 221], ["lungs", "ORGAN", 229, 234], ["SARS-CoV-2", "ORGANISM", 307, 317], ["non-human primates", "ORGANISM", 349, 367], ["rhesus macaques", "ORGANISM", 369, 384], ["cynomolgus monkeys", "ORGANISM", 386, 404], ["marmosets", "ORGANISM", 406, 415], ["African green monkeys", "ORGANISM", 420, 441], ["mice", "ORGANISM", 444, 448], ["wild-type mice", "ORGANISM", 450, 464], ["mouse-adapted virus", "ORGANISM", 471, 490], ["human", "ORGANISM", 496, 501], ["ACE2", "GENE_OR_GENE_PRODUCT", 502, 506], ["human", "ORGANISM", 521, 526], ["ACE2", "GENE_OR_GENE_PRODUCT", 527, 531], ["mice", "ORGANISM", 541, 545], ["ferrets", "ORGANISM", 548, 555], ["golden hamsters", "ORGANISM", 560, 575], ["SARS-CoV-2 antigen", "PROTEIN", 37, 55], ["type I and type II pneumocytes", "CELL_TYPE", 147, 177], ["alveolar macrophages", "CELL_TYPE", 179, 199], ["ACE2", "PROTEIN", 502, 506], ["ACE2", "PROTEIN", 527, 531], ["CoV-", "SPECIES", 312, 316], ["rhesus macaques", "SPECIES", 369, 384], ["cynomolgus monkeys", "SPECIES", 386, 404], ["marmosets", "SPECIES", 406, 415], ["green monkeys", "SPECIES", 428, 441], ["mice", "SPECIES", 444, 448], ["mice", "SPECIES", 460, 464], ["mouse", "SPECIES", 471, 476], ["human", "SPECIES", 496, 501], ["human", "SPECIES", 521, 526], ["mice", "SPECIES", 541, 545], ["ferrets", "SPECIES", 548, 555], ["hamsters", "SPECIES", 567, 575], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 307, 315], ["rhesus macaques", "SPECIES", 369, 384], ["cynomolgus monkeys", "SPECIES", 386, 404], ["African green monkeys", "SPECIES", 420, 441], ["mice", "SPECIES", 444, 448], ["mice", "SPECIES", 460, 464], ["mouse", "SPECIES", 471, 476], ["human", "SPECIES", 496, 501], ["human", "SPECIES", 521, 526], ["mice", "SPECIES", 541, 545], ["golden hamsters43,48,68\u201374", "SPECIES", 560, 586], ["Immunohistochemistry assays", "TEST", 0, 27], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["bronchiolar epithelium and submucosal gland epithelium", "PROBLEM", 77, 131], ["type I and type II pneumocytes, alveolar macrophages and hyaline membranes in the lungs", "PROBLEM", 147, 234], ["pathogenesis", "PROBLEM", 263, 275], ["Animal models", "TEST", 275, 288], ["studying SARS", "TEST", 298, 311], ["CoV-2 infection pathogenesis", "PROBLEM", 312, 340], ["non-human primates (rhesus macaques, cynomolgus monkeys", "TREATMENT", 349, 404], ["mouse-adapted virus", "TREATMENT", 471, 490], ["human ACE2", "TREATMENT", 496, 506], ["human ACE2", "TEST", 521, 531], ["upper", "ANATOMY_MODIFIER", 63, 68], ["airway", "ANATOMY", 69, 75], ["bronchiolar", "ANATOMY_MODIFIER", 77, 88], ["epithelium", "ANATOMY_MODIFIER", 89, 99], ["submucosal gland", "ANATOMY", 104, 120], ["pneumocytes", "OBSERVATION", 166, 177], ["alveolar macrophages", "OBSERVATION", 179, 199], ["hyaline membranes", "OBSERVATION", 204, 221], ["lungs", "ANATOMY", 229, 234]]], ["In non-human primate animal models, most species display clinical features similar to those of patients with COVID-19, including virus shedding, virus replication and host responses to SARS-CoV-2 infection69,72,73.", [["SARS", "DISEASE", 185, 189], ["infection", "DISEASE", 196, 205], ["patients", "ORGANISM", 95, 103], ["SARS-CoV-2", "ORGANISM", 185, 195], ["patients", "SPECIES", 95, 103], ["SARS-CoV-2", "SPECIES", 185, 195], ["clinical features", "PROBLEM", 57, 74], ["COVID", "TEST", 109, 114], ["virus shedding", "PROBLEM", 129, 143], ["virus replication", "TREATMENT", 145, 162], ["SARS", "PROBLEM", 185, 189], ["CoV", "TEST", 190, 193], ["infection", "PROBLEM", 196, 205]]], ["For example, in the rhesus macaque model, high viral loads were detected in the upper and lower respiratory tracts.", [["upper", "ANATOMY", 80, 85], ["lower respiratory tracts", "ANATOMY", 90, 114], ["rhesus", "ORGANISM", 20, 26], ["macaque", "ORGANISM", 27, 34], ["upper", "ORGANISM_SUBDIVISION", 80, 85], ["rhesus macaque", "SPECIES", 20, 34], ["rhesus macaque", "SPECIES", 20, 34], ["high viral loads", "PROBLEM", 42, 58], ["high", "OBSERVATION_MODIFIER", 42, 46], ["viral loads", "OBSERVATION", 47, 58], ["upper", "ANATOMY_MODIFIER", 80, 85], ["lower", "ANATOMY_MODIFIER", 90, 95], ["respiratory tracts", "ANATOMY", 96, 114]]], ["Acute viral interstitial pneumonia and humoral and cellular immune responses were observed48,75.", [["interstitial", "ANATOMY", 12, 24], ["cellular", "ANATOMY", 51, 59], ["pneumonia", "DISEASE", 25, 34], ["cellular", "CELL", 51, 59], ["Acute viral interstitial pneumonia", "PROBLEM", 0, 34], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["interstitial", "ANATOMY_MODIFIER", 12, 24], ["pneumonia", "OBSERVATION", 25, 34], ["humoral", "ANATOMY", 39, 46], ["cellular immune", "OBSERVATION", 51, 66]]], ["Moreover, prolonged virus shedding peaked early in the course of infection in asymptomatic macaques69, and old monkeys showed severer interstitial pneumonia than young monkeys76, which is similar to what is seen in patients with COVID-19.", [["interstitial", "ANATOMY", 134, 146], ["infection", "DISEASE", 65, 74], ["interstitial pneumonia", "DISEASE", 134, 156], ["monkeys", "ORGANISM", 111, 118], ["monkeys", "ORGANISM", 168, 175], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["prolonged virus shedding", "PROBLEM", 10, 34], ["infection", "PROBLEM", 65, 74], ["severer interstitial pneumonia", "PROBLEM", 126, 156], ["COVID", "TEST", 229, 234], ["prolonged", "OBSERVATION_MODIFIER", 10, 19], ["virus", "OBSERVATION", 20, 25], ["infection", "OBSERVATION", 65, 74], ["severer", "OBSERVATION_MODIFIER", 126, 133], ["interstitial", "ANATOMY_MODIFIER", 134, 146], ["pneumonia", "OBSERVATION", 147, 156]]], ["In human ACE2-transgenic mice infected with SARS-CoV-2, typical interstitial pneumonia was present, and viral antigens were observed mainly in the bronchial epithelial cells, macrophages and alveolar epithelia.", [["interstitial", "ANATOMY", 64, 76], ["bronchial epithelial cells", "ANATOMY", 147, 173], ["macrophages", "ANATOMY", 175, 186], ["alveolar epithelia", "ANATOMY", 191, 209], ["interstitial pneumonia", "DISEASE", 64, 86], ["human", "ORGANISM", 3, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["mice", "ORGANISM", 25, 29], ["SARS-CoV-2", "ORGANISM", 44, 54], ["interstitial pneumonia", "PATHOLOGICAL_FORMATION", 64, 86], ["bronchial epithelial cells", "CELL", 147, 173], ["macrophages", "CELL", 175, 186], ["alveolar epithelia", "TISSUE", 191, 209], ["ACE2", "PROTEIN", 9, 13], ["viral antigens", "PROTEIN", 104, 118], ["bronchial epithelial cells", "CELL_TYPE", 147, 173], ["macrophages", "CELL_TYPE", 175, 186], ["human", "SPECIES", 3, 8], ["mice", "SPECIES", 25, 29], ["human", "SPECIES", 3, 8], ["mice", "SPECIES", 25, 29], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["typical interstitial pneumonia", "PROBLEM", 56, 86], ["viral antigens", "TEST", 104, 118], ["alveolar epithelia", "PROBLEM", 191, 209], ["interstitial", "ANATOMY_MODIFIER", 64, 76], ["pneumonia", "OBSERVATION", 77, 86], ["bronchial epithelial cells", "ANATOMY", 147, 173], ["macrophages", "OBSERVATION", 175, 186], ["alveolar", "ANATOMY_MODIFIER", 191, 199], ["epithelia", "ANATOMY_MODIFIER", 200, 209]]], ["Some human ACE2-transgenic mice even died after infection70,71.", [["infection", "DISEASE", 48, 57], ["human", "ORGANISM", 5, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["mice", "ORGANISM", 27, 31], ["ACE2", "PROTEIN", 11, 15], ["human", "SPECIES", 5, 10], ["mice", "SPECIES", 27, 31], ["human", "SPECIES", 5, 10], ["mice", "SPECIES", 27, 31], ["infection", "PROBLEM", 48, 57]]], ["In wide-type mice, a SARS-CoV-2 mouse-adapted strain with the N501Y alteration in the RBD of the S protein was generated at passage 6.", [["SARS", "DISEASE", 21, 25], ["mice", "ORGANISM", 13, 17], ["SARS-CoV-2 mouse", "ORGANISM", 21, 37], ["RBD", "PROTEIN", 86, 89], ["S protein", "PROTEIN", 97, 106], ["mice", "SPECIES", 13, 17], ["mouse", "SPECIES", 32, 37], ["mice", "SPECIES", 13, 17], ["mouse", "SPECIES", 32, 37], ["a SARS", "TEST", 19, 25], ["adapted strain", "PROBLEM", 38, 52], ["the N501Y alteration", "PROBLEM", 58, 78], ["wide", "OBSERVATION_MODIFIER", 3, 7], ["-type", "OBSERVATION_MODIFIER", 7, 12], ["RBD", "OBSERVATION", 86, 89]]], ["Interstitial pneumonia and inflammatory responses were found in both young and aged mice after infection with the mouse-adapted strain74.", [["Interstitial", "ANATOMY", 0, 12], ["pneumonia", "DISEASE", 13, 22], ["infection", "DISEASE", 95, 104], ["mice", "ORGANISM", 84, 88], ["mouse", "ORGANISM", 114, 119], ["strain74", "CELL", 128, 136], ["mice", "SPECIES", 84, 88], ["mouse", "SPECIES", 114, 119], ["mice", "SPECIES", 84, 88], ["mouse", "SPECIES", 114, 119], ["Interstitial pneumonia", "PROBLEM", 0, 22], ["inflammatory responses", "PROBLEM", 27, 49], ["infection", "PROBLEM", 95, 104], ["pneumonia", "OBSERVATION", 13, 22], ["inflammatory", "OBSERVATION_MODIFIER", 27, 39]]], ["Golden hamsters also showed typical symptoms after being infected with SARS-CoV-2 (ref.77).", [["Golden hamsters", "ORGANISM", 0, 15], ["SARS-CoV-2", "ORGANISM", 71, 81], ["hamsters", "SPECIES", 7, 15], ["Golden hamsters", "SPECIES", 0, 15], ["SARS-CoV", "SPECIES", 71, 79], ["typical symptoms", "PROBLEM", 28, 44], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["infected", "OBSERVATION", 57, 65]]], ["In other animal models, including cats and ferrets, SARS-CoV-2 could efficiently replicate in the upper respiratory tract but did not induce severe clinical symptoms43,78.", [["upper respiratory tract", "ANATOMY", 98, 121], ["cats", "ORGANISM", 34, 38], ["ferrets", "ORGANISM", 43, 50], ["SARS-CoV-2", "ORGANISM", 52, 62], ["upper respiratory", "ORGANISM_SUBDIVISION", 98, 115], ["tract", "ORGANISM_SUBDIVISION", 116, 121], ["cats", "SPECIES", 34, 38], ["ferrets", "SPECIES", 43, 50], ["ferrets", "SPECIES", 43, 50], ["SARS-CoV", "SPECIES", 52, 60], ["cats", "TEST", 34, 38], ["severe clinical symptoms", "PROBLEM", 141, 165], ["upper", "ANATOMY_MODIFIER", 98, 103], ["respiratory tract", "ANATOMY", 104, 121]]], ["As transmission by direct contact and air was observed in infected ferrets and hamsters, these animals could be used to model different transmission modes of COVID-19 (refs77\u201379).", [["ferrets", "ORGANISM", 67, 74], ["hamsters", "ORGANISM", 79, 87], ["ferrets", "SPECIES", 67, 74], ["hamsters", "SPECIES", 79, 87], ["ferrets", "SPECIES", 67, 74], ["hamsters", "SPECIES", 79, 87], ["COVID", "TEST", 158, 163]]], ["Animal models offer important information for understanding the pathogenesis of SARS-CoV-2 infection and the transmission dynamics of SARS-CoV-2, and are important to evaluate the efficacy of antiviral therapeutics and vaccines.Clinical and epidemiological featuresIt appears that all ages of the population are susceptible to SARS-CoV-2 infection, and the median age of infection is around 50 years9,13,60,80,81.", [["SARS", "DISEASE", 80, 84], ["infection", "DISEASE", 91, 100], ["SARS", "DISEASE", 134, 138], ["SARS-CoV-2 infection", "DISEASE", 327, 347], ["infection", "DISEASE", 371, 380], ["SARS-CoV-2", "ORGANISM", 80, 90], ["SARS-CoV-2", "ORGANISM", 134, 144], ["SARS-CoV-2", "ORGANISM", 327, 337], ["SARS-CoV-2", "SPECIES", 80, 90], ["SARS-CoV", "SPECIES", 134, 142], ["SARS-CoV-2", "SPECIES", 327, 337], ["SARS", "PROBLEM", 80, 84], ["CoV", "PROBLEM", 85, 88], ["2 infection", "PROBLEM", 89, 100], ["antiviral therapeutics", "TREATMENT", 192, 214], ["vaccines", "TREATMENT", 219, 227], ["Clinical and epidemiological features", "PROBLEM", 228, 265], ["SARS", "PROBLEM", 327, 331], ["CoV-2 infection", "PROBLEM", 332, 347], ["infection", "PROBLEM", 371, 380], ["infection", "OBSERVATION", 91, 100], ["infection", "OBSERVATION", 338, 347], ["infection", "OBSERVATION", 371, 380]]], ["In general, older men (>60 years old) with co-morbidities are more likely to develop severe respiratory disease that requires hospitalization or even die, whereas most young people and children have only mild diseases (non-pneumonia or mild pneumonia) or are asymptomatic9,81,82.", [["respiratory", "ANATOMY", 92, 103], ["respiratory disease", "DISEASE", 92, 111], ["non-pneumonia", "DISEASE", 219, 232], ["pneumonia", "DISEASE", 241, 250], ["men", "ORGANISM", 18, 21], ["people", "ORGANISM", 174, 180], ["children", "ORGANISM", 185, 193], ["men", "SPECIES", 18, 21], ["people", "SPECIES", 174, 180], ["children", "SPECIES", 185, 193], ["co-morbidities", "PROBLEM", 43, 57], ["severe respiratory disease", "PROBLEM", 85, 111], ["mild diseases (non-pneumonia", "PROBLEM", 204, 232], ["mild pneumonia", "PROBLEM", 236, 250], ["more likely", "UNCERTAINTY", 62, 73], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["respiratory disease", "OBSERVATION", 92, 111], ["mild", "OBSERVATION_MODIFIER", 204, 208], ["diseases", "OBSERVATION", 209, 217], ["mild", "OBSERVATION_MODIFIER", 236, 240], ["pneumonia", "OBSERVATION", 241, 250]]], ["Notably, the risk of disease was not higher for pregnant women.", [["women", "ORGANISM", 57, 62], ["women", "SPECIES", 57, 62], ["disease", "PROBLEM", 21, 28], ["disease", "OBSERVATION", 21, 28]]], ["However, evidence of transplacental transmission of SARS-CoV-2 from an infected mother to a neonate was reported, although it was an isolated case83,84.", [["SARS", "DISEASE", 52, 56], ["SARS-CoV-2", "ORGANISM", 52, 62], ["neonate", "ORGANISM", 92, 99], ["CoV-2", "SPECIES", 57, 62], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "PROBLEM", 52, 56], ["SARS", "OBSERVATION", 52, 56], ["infected", "OBSERVATION", 71, 79]]], ["On infection, the most common symptoms are fever, fatigue and dry cough13,60,80,81.", [["infection", "DISEASE", 3, 12], ["fever", "DISEASE", 43, 48], ["fatigue", "DISEASE", 50, 57], ["dry cough", "DISEASE", 62, 71], ["infection", "PROBLEM", 3, 12], ["the most common symptoms", "PROBLEM", 14, 38], ["fever", "PROBLEM", 43, 48], ["fatigue", "PROBLEM", 50, 57], ["dry cough", "PROBLEM", 62, 71], ["infection", "OBSERVATION", 3, 12], ["fever", "OBSERVATION", 43, 48]]], ["Less common symptoms include sputum production, headache, haemoptysis, diarrhoea, anorexia, sore throat, chest pain, chills and nausea and vomiting in studies of patients in China13,60,80,81.", [["sputum", "ANATOMY", 29, 35], ["chest", "ANATOMY", 105, 110], ["sputum production", "DISEASE", 29, 46], ["headache", "DISEASE", 48, 56], ["haemoptysis", "DISEASE", 58, 69], ["diarrhoea", "DISEASE", 71, 80], ["anorexia", "DISEASE", 82, 90], ["sore throat", "DISEASE", 92, 103], ["chest pain", "DISEASE", 105, 115], ["chills", "DISEASE", 117, 123], ["nausea", "DISEASE", 128, 134], ["vomiting", "DISEASE", 139, 147], ["sputum", "ORGANISM_SUBSTANCE", 29, 35], ["chest", "ORGANISM_SUBDIVISION", 105, 110], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["Less common symptoms", "PROBLEM", 0, 20], ["sputum production", "PROBLEM", 29, 46], ["headache", "PROBLEM", 48, 56], ["haemoptysis", "PROBLEM", 58, 69], ["diarrhoea", "PROBLEM", 71, 80], ["anorexia", "PROBLEM", 82, 90], ["sore throat", "PROBLEM", 92, 103], ["chest pain", "PROBLEM", 105, 115], ["chills", "PROBLEM", 117, 123], ["nausea", "PROBLEM", 128, 134], ["vomiting", "PROBLEM", 139, 147], ["haemoptysis", "OBSERVATION", 58, 69], ["anorexia", "OBSERVATION", 82, 90], ["sore throat", "ANATOMY", 92, 103], ["chest", "ANATOMY", 105, 110], ["chills", "OBSERVATION", 117, 123]]], ["Self-reported olfactory and taste disorders were also reported by patients in Italy85.", [["olfactory", "ANATOMY", 14, 23], ["olfactory and taste disorders", "DISEASE", 14, 43], ["olfactory", "MULTI-TISSUE_STRUCTURE", 14, 23], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["taste disorders", "PROBLEM", 28, 43]]], ["Most people showed signs of diseases after an incubation period of 1\u201314 days (most commonly around 5 days), and dyspnoea and pneumonia developed within a median time of 8 days from illness onset9.Clinical and epidemiological featuresIn a report of 72,314 cases in China, 81% of the cases were classified as mild, 14% were severe cases that required ventilation in an intensive care unit (ICU) and a 5% were critical (that is, the patients had respiratory failure, septic shock and/or multiple organ dysfunction or failure)9,86.", [["respiratory", "ANATOMY", 443, 454], ["organ", "ANATOMY", 493, 498], ["dyspnoea", "DISEASE", 112, 120], ["pneumonia", "DISEASE", 125, 134], ["illness", "DISEASE", 181, 188], ["respiratory failure", "DISEASE", 443, 462], ["septic shock", "DISEASE", 464, 476], ["organ dysfunction", "DISEASE", 493, 510], ["people", "ORGANISM", 5, 11], ["patients", "ORGANISM", 430, 438], ["organ", "ORGAN", 493, 498], ["people", "SPECIES", 5, 11], ["patients", "SPECIES", 430, 438], ["diseases", "PROBLEM", 28, 36], ["dyspnoea", "PROBLEM", 112, 120], ["pneumonia", "PROBLEM", 125, 134], ["illness onset9", "PROBLEM", 181, 195], ["Clinical and epidemiological features", "PROBLEM", 196, 233], ["severe cases", "PROBLEM", 322, 334], ["ventilation", "TREATMENT", 349, 360], ["respiratory failure", "PROBLEM", 443, 462], ["septic shock", "PROBLEM", 464, 476], ["multiple organ dysfunction", "PROBLEM", 484, 510], ["failure)", "PROBLEM", 514, 522], ["diseases", "OBSERVATION", 28, 36], ["dyspnoea", "OBSERVATION", 112, 120], ["pneumonia", "OBSERVATION", 125, 134], ["mild", "OBSERVATION_MODIFIER", 307, 311], ["respiratory failure", "OBSERVATION", 443, 462], ["septic shock", "OBSERVATION", 464, 476], ["organ", "ANATOMY", 493, 498], ["dysfunction", "OBSERVATION", 499, 510], ["failure", "OBSERVATION", 514, 521]]], ["On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT)13,60,80,81.", [["ground-glass opacity", "PROBLEM", 14, 34], ["chest computed tomography", "TEST", 77, 102], ["CT", "TEST", 104, 106], ["ground", "OBSERVATION_MODIFIER", 14, 20], ["glass opacity", "OBSERVATION", 21, 34], ["most common", "OBSERVATION_MODIFIER", 43, 54], ["chest", "ANATOMY", 77, 82]]], ["Most patients also developed marked lymphopenia, similar to what was observed in patients with SARS and MERS, and non-survivors developed severer lymphopenia over time13,60,80,81.", [["lymphopenia", "DISEASE", 36, 47], ["SARS", "DISEASE", 95, 99], ["lymphopenia", "DISEASE", 146, 157], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 81, 89], ["marked lymphopenia", "PROBLEM", 29, 47], ["SARS", "PROBLEM", 95, 99], ["severer lymphopenia", "PROBLEM", 138, 157], ["marked", "OBSERVATION_MODIFIER", 29, 35], ["lymphopenia", "OBSERVATION", 36, 47], ["severer", "OBSERVATION_MODIFIER", 138, 145], ["lymphopenia", "OBSERVATION", 146, 157]]], ["Compared with non-ICU patients, ICU patients had higher levels of plasma cytokines, which suggests an immunopathological process caused by a cytokine storm60,86,87.", [["plasma", "ANATOMY", 66, 72], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 36, 44], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["plasma cytokines", "PROTEIN", 66, 82], ["cytokine", "PROTEIN", 141, 149], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 36, 44], ["plasma cytokines", "TEST", 66, 82], ["an immunopathological process", "PROBLEM", 99, 128], ["a cytokine storm", "TEST", 139, 155], ["immunopathological", "OBSERVATION", 102, 120], ["cytokine storm", "OBSERVATION", 141, 155]]], ["In this cohort of patient, around 2.3% people died within a median time of 16 days from disease onset9,86.", [["patient", "ORGANISM", 18, 25], ["people", "ORGANISM", 39, 45], ["patient", "SPECIES", 18, 25], ["people", "SPECIES", 39, 45]]], ["Men older than 68 years had a higher risk of respiratory failure, acute cardiac injury and heart failure that led to death, regardless of a history of cardiovascular disease86 (Fig. 4).", [["respiratory", "ANATOMY", 45, 56], ["cardiac", "ANATOMY", 72, 79], ["heart", "ANATOMY", 91, 96], ["cardiovascular", "ANATOMY", 151, 165], ["respiratory failure", "DISEASE", 45, 64], ["cardiac injury", "DISEASE", 72, 86], ["heart failure", "DISEASE", 91, 104], ["death", "DISEASE", 117, 122], ["cardiovascular disease86", "DISEASE", 151, 175], ["cardiac", "ORGAN", 72, 79], ["heart", "ORGAN", 91, 96], ["Men", "SPECIES", 0, 3], ["respiratory failure", "PROBLEM", 45, 64], ["acute cardiac injury", "PROBLEM", 66, 86], ["heart failure", "PROBLEM", 91, 104], ["death", "PROBLEM", 117, 122], ["cardiovascular disease86", "PROBLEM", 151, 175], ["respiratory", "ANATOMY", 45, 56], ["failure", "OBSERVATION", 57, 64], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["cardiac", "ANATOMY", 72, 79], ["injury", "OBSERVATION", 80, 86], ["heart", "ANATOMY", 91, 96], ["failure", "OBSERVATION", 97, 104], ["cardiovascular", "ANATOMY", 151, 165]]], ["Most patients recovered enough to be released from hospital in 2 weeks9,80 (Fig. 4).Clinical and epidemiological featuresEarly transmission of SARS-CoV-2 in Wuhan in December 2019 was initially linked to the Huanan Seafood Wholesale Market, and it was suggested as the source of the outbreak9,22,60.", [["SARS", "DISEASE", 143, 147], ["patients", "ORGANISM", 5, 13], ["SARS-CoV-2", "ORGANISM", 143, 153], ["patients", "SPECIES", 5, 13], ["SARS-CoV", "SPECIES", 143, 151], ["Clinical and epidemiological features", "PROBLEM", 84, 121], ["SARS", "PROBLEM", 143, 147]]], ["Later, ongoing human-to-human transmission propagated the outbreak9.", [["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 24, 29], ["outbreak9", "DNA", 58, 67], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 24, 29]]], ["It is generally accepted that SARS-CoV-2 is more transmissible than SARS-CoV and MERS-CoV; however, determination of an accurate reproduction number (R0) for COVID-19 is not possible yet, as many asymptomatic infections cannot be accurately accounted for at this stage89.", [["SARS", "DISEASE", 30, 34], ["SARS", "DISEASE", 68, 72], ["infections", "DISEASE", 209, 219], ["SARS-CoV-2", "ORGANISM", 30, 40], ["SARS-CoV", "ORGANISM", 68, 76], ["MERS-CoV", "ORGANISM", 81, 89], ["SARS-CoV", "SPECIES", 30, 38], ["SARS-CoV", "SPECIES", 68, 76], ["MERS-CoV", "SPECIES", 81, 89], ["CoV", "TEST", 35, 38], ["COVID", "TEST", 158, 163], ["many asymptomatic infections", "PROBLEM", 191, 219], ["not possible", "UNCERTAINTY", 170, 182], ["infections", "OBSERVATION", 209, 219]]], ["An estimated R0 of 2.5 (ranging from 1.8 to 3.6) has been proposed for SARS-CoV-2 recently, compared with 2.0\u20133.0 for SARS-CoV90.", [["SARS", "DISEASE", 71, 75], ["SARS", "DISEASE", 118, 122], ["SARS-CoV90", "SIMPLE_CHEMICAL", 118, 128], ["SARS-CoV", "SPECIES", 71, 79], ["An estimated R0", "TEST", 0, 15], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["R0", "OBSERVATION_MODIFIER", 13, 15]]], ["Notably, most of the SARS-CoV-2 human-to-human transmission early in China occurred in family clusters, and in other countries large outbreaks also happened in other settings, such as migrant worker communities, slaughterhouses and meat packing plants, indicating the necessity of isolating infected people9,12,91\u201393.", [["SARS", "DISEASE", 21, 25], ["SARS-CoV-2", "ORGANISM", 21, 31], ["human", "ORGANISM", 32, 37], ["human", "ORGANISM", 41, 46], ["meat", "ORGANISM_SUBDIVISION", 232, 236], ["people9", "ORGANISM", 300, 307], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["SARS-CoV", "SPECIES", 21, 29], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["the SARS", "TEST", 17, 25], ["meat packing plants", "TREATMENT", 232, 251], ["outbreaks", "OBSERVATION", 133, 142], ["infected", "OBSERVATION", 291, 299]]], ["Nosocomial transmission was not the main source of transmission in China because of the implementation of infection control measures in clinical settings9.", [["infection", "DISEASE", 106, 115], ["Nosocomial transmission", "PROBLEM", 0, 23], ["infection control measures", "TREATMENT", 106, 132], ["infection", "OBSERVATION", 106, 115]]], ["By contrast, a high risk of nosocomial transmission was reported in some other areas.", [["nosocomial transmission", "PROBLEM", 28, 51], ["nosocomial", "OBSERVATION", 28, 38]]], ["For example, a cohort study in London revealed 44% of the frontline health-care workers from a hospital were infected with SARS-CoV-2 (ref.94).Clinical and epidemiological featuresThe high transmissibility of SARS-CoV-2 may be attributed to the unique virological features of SARS-CoV-2.", [["SARS", "DISEASE", 123, 127], ["SARS", "DISEASE", 209, 213], ["SARS", "DISEASE", 276, 280], ["SARS-CoV-2", "ORGANISM", 123, 133], ["SARS-CoV-2", "ORGANISM", 209, 219], ["SARS-CoV-2", "ORGANISM", 276, 286], ["SARS-CoV", "SPECIES", 123, 131], ["SARS-CoV", "SPECIES", 209, 217], ["SARS-CoV", "SPECIES", 276, 284], ["a cohort study", "TEST", 13, 27], ["SARS", "TEST", 123, 127], ["CoV", "TEST", 128, 131], ["Clinical and epidemiological features", "PROBLEM", 143, 180], ["SARS", "PROBLEM", 209, 213], ["SARS", "PROBLEM", 276, 280], ["CoV", "TEST", 281, 284], ["high", "OBSERVATION_MODIFIER", 184, 188]]], ["Transmission of SARS-CoV occurred mainly after illness onset and peaked following disease severity95.", [["SARS", "DISEASE", 16, 20], ["illness", "DISEASE", 47, 54], ["SARS-CoV", "ORGANISM", 16, 24], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "PROBLEM", 21, 24], ["illness onset", "PROBLEM", 47, 60], ["disease severity95", "PROBLEM", 82, 100], ["SARS", "OBSERVATION", 16, 20], ["CoV", "OBSERVATION_MODIFIER", 21, 24]]], ["However, the SARS-CoV-2 viral load in upper respiratory tract samples was already highest during the first week of symptoms, and thus the risk of pharyngeal virus shedding was very high at the beginning of infection96,97.", [["upper respiratory tract samples", "ANATOMY", 38, 69], ["pharyngeal", "ANATOMY", 146, 156], ["SARS", "DISEASE", 13, 17], ["infection", "DISEASE", 206, 215], ["SARS-CoV-2 viral", "ORGANISM", 13, 29], ["upper respiratory", "ORGANISM_SUBDIVISION", 38, 55], ["tract", "ORGANISM_SUBDIVISION", 56, 61], ["pharyngeal virus", "ORGANISM", 146, 162], ["SARS-CoV", "SPECIES", 13, 21], ["the SARS", "TEST", 9, 17], ["CoV", "TEST", 18, 21], ["viral load in upper respiratory tract samples", "PROBLEM", 24, 69], ["symptoms", "PROBLEM", 115, 123], ["pharyngeal virus shedding", "PROBLEM", 146, 171], ["infection", "PROBLEM", 206, 215], ["upper", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61], ["pharyngeal virus", "ANATOMY", 146, 162], ["infection", "OBSERVATION", 206, 215]]], ["It was postulated that undocumented infections might account for 79% of documented cases owing to the high transmissibility of the virus during mild disease or the asymptomatic period89.", [["infections", "DISEASE", 36, 46], ["undocumented infections", "PROBLEM", 23, 46], ["the virus", "PROBLEM", 127, 136], ["mild disease", "PROBLEM", 144, 156], ["the asymptomatic period89", "PROBLEM", 160, 185], ["infections", "OBSERVATION", 36, 46], ["mild", "OBSERVATION_MODIFIER", 144, 148], ["disease", "OBSERVATION", 149, 156]]], ["A patient with COVID-19 spreads viruses in liquid droplets during speech.", [["patient", "ORGANISM", 2, 9], ["COVID-19", "DNA", 15, 23], ["patient", "SPECIES", 2, 9], ["COVID", "TEST", 15, 20], ["viruses in liquid droplets", "TREATMENT", 32, 58], ["liquid droplets", "OBSERVATION", 43, 58]]], ["However, smaller and much more numerous particles known as aerosol particles can also be visualized, which could linger in the air for a long time and then penetrate deep into the lungs when inhaled by someone else98\u2013100.", [["lungs", "ANATOMY", 180, 185], ["lungs", "ORGAN", 180, 185], ["aerosol particles", "TREATMENT", 59, 76], ["smaller", "OBSERVATION_MODIFIER", 9, 16], ["much more", "OBSERVATION_MODIFIER", 21, 30], ["numerous", "OBSERVATION_MODIFIER", 31, 39], ["particles", "OBSERVATION", 40, 49], ["aerosol particles", "OBSERVATION", 59, 76], ["air", "OBSERVATION", 127, 130], ["lungs", "ANATOMY", 180, 185]]], ["Airborne transmission was also observed in the ferret experiments mentioned above.", [["ferret", "ORGANISM", 47, 53], ["ferret", "SPECIES", 47, 53]]], ["SARS-CoV-2-infected ferrets shed viruses in nasal washes, saliva, urine and faeces for up to 8 days after infection, and a few naive ferrets with only indirect contact were positive for viral RNA, suggesting airborne transmission78.", [["nasal", "ANATOMY", 44, 49], ["saliva", "ANATOMY", 58, 64], ["urine", "ANATOMY", 66, 71], ["faeces", "ANATOMY", 76, 82], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 106, 115], ["SARS-CoV-2", "ORGANISM", 0, 10], ["ferrets", "ORGANISM", 20, 27], ["nasal", "ORGANISM_SUBDIVISION", 44, 49], ["saliva", "ORGANISM_SUBSTANCE", 58, 64], ["urine", "ORGANISM_SUBSTANCE", 66, 71], ["faeces", "ORGANISM_SUBSTANCE", 76, 82], ["ferrets", "ORGANISM", 133, 140], ["viral RNA", "RNA", 186, 195], ["ferrets", "SPECIES", 20, 27], ["ferrets", "SPECIES", 133, 140], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["infected ferrets", "PROBLEM", 11, 27], ["nasal washes", "TREATMENT", 44, 56], ["saliva, urine and faeces", "TEST", 58, 82], ["infection", "PROBLEM", 106, 115], ["viral RNA", "PROBLEM", 186, 195], ["nasal washes", "ANATOMY", 44, 56], ["infection", "OBSERVATION", 106, 115], ["viral RNA", "OBSERVATION", 186, 195], ["airborne transmission78", "OBSERVATION", 208, 231]]], ["In addition, transmission of the virus through the ocular surface and prolonged presence of SARS-CoV-2 viral RNA in faecal samples were also documented101,102.", [["ocular surface", "ANATOMY", 51, 65], ["faecal samples", "ANATOMY", 116, 130], ["SARS", "DISEASE", 92, 96], ["SARS-CoV-2", "ORGANISM", 92, 102], ["faecal samples", "ORGANISM_SUBSTANCE", 116, 130], ["SARS-CoV-2 viral RNA", "RNA", 92, 112], ["CoV-2", "SPECIES", 97, 102], ["SARS-CoV", "SPECIES", 92, 100], ["the virus", "PROBLEM", 29, 38], ["SARS", "PROBLEM", 92, 96], ["CoV", "TEST", 97, 100], ["viral RNA in faecal samples", "TEST", 103, 130], ["virus", "OBSERVATION", 33, 38], ["ocular", "ANATOMY", 51, 57], ["SARS", "OBSERVATION", 92, 96]]], ["Coronaviruses can persist on inanimate surfaces for days, which could also be the case for SARS-CoV-2 and could pose a prolonged risk of infection103.", [["SARS", "DISEASE", 91, 95], ["infection", "DISEASE", 137, 146], ["SARS-CoV-2", "ORGANISM", 91, 101], ["SARS-CoV", "SPECIES", 91, 99], ["Coronaviruses", "PROBLEM", 0, 13], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["infection", "PROBLEM", 137, 146], ["infection", "OBSERVATION", 137, 146]]], ["These findings explain the rapid geographic spread of COVID-19, and public health interventions to reduce transmission will provide benefit to mitigate the epidemic, as has proved successful in China and several other countries, such as South Korea89,104,105.DiagnosisEarly diagnosis is crucial for controlling the spread of COVID-19.", [["COVID-19", "CHEMICAL", 325, 333], ["COVID-19", "DNA", 325, 333], ["COVID", "TEST", 54, 59], ["public health interventions", "TREATMENT", 68, 95], ["COVID", "TEST", 325, 330], ["rapid", "OBSERVATION_MODIFIER", 27, 32]]], ["Molecular detection of SARS-CoV-2 nucleic acid is the gold standard.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 23, 46], ["SARS-CoV", "SPECIES", 23, 31], ["Molecular detection", "TEST", 0, 19], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["nucleic acid", "TEST", 34, 46]]], ["Many viral nucleic acid detection kits targeting ORF1b (including RdRp), N, E or S genes are commercially available11,106\u2013109.", [["nucleic acid", "CHEMICAL", 11, 23], ["ORF1b", "GENE_OR_GENE_PRODUCT", 49, 54], ["N, E", "GENE_OR_GENE_PRODUCT", 73, 77], ["ORF1b", "DNA", 49, 54], ["RdRp", "PROTEIN", 66, 70], ["N, E or S genes", "DNA", 73, 88], ["Many viral nucleic acid detection kits", "TEST", 0, 38], ["ORF1b", "TEST", 49, 54], ["RdRp", "TEST", 66, 70], ["N, E or S genes", "TEST", 73, 88], ["nucleic acid", "OBSERVATION", 11, 23]]], ["The detection time ranges from several minutes to hours depending on the technology106,107,109\u2013111.", [["the technology", "TEST", 69, 83]]], ["Although SARS-CoV-2 has been detected from a variety of respiratory sources, including throat swabs, posterior oropharyngeal saliva, nasopharyngeal swabs, sputum and bronchial fluid, the viral load is higher in lower respiratory tract samples11,96,112\u2013115.", [["throat swabs", "ANATOMY", 87, 99], ["oropharyngeal saliva", "ANATOMY", 111, 131], ["nasopharyngeal swabs", "ANATOMY", 133, 153], ["sputum", "ANATOMY", 155, 161], ["bronchial fluid", "ANATOMY", 166, 181], ["lower respiratory tract sample", "ANATOMY", 211, 241], ["SARS", "DISEASE", 9, 13], ["SARS-CoV-2", "ORGANISM", 9, 19], ["throat", "ORGANISM_SUBDIVISION", 87, 93], ["swabs", "ORGANISM_SUBSTANCE", 94, 99], ["oropharyngeal saliva", "ORGANISM_SUBSTANCE", 111, 131], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 133, 153], ["sputum", "ORGANISM_SUBSTANCE", 155, 161], ["bronchial fluid", "MULTI-TISSUE_STRUCTURE", 166, 181], ["SARS-CoV", "SPECIES", 9, 17], ["SARS", "PROBLEM", 9, 13], ["CoV", "TEST", 14, 17], ["throat swabs", "TEST", 87, 99], ["posterior oropharyngeal saliva", "TEST", 101, 131], ["nasopharyngeal swabs", "TEST", 133, 153], ["sputum and bronchial fluid", "PROBLEM", 155, 181], ["the viral load", "TEST", 183, 197], ["posterior", "ANATOMY_MODIFIER", 101, 110], ["oropharyngeal saliva", "ANATOMY", 111, 131], ["nasopharyngeal", "ANATOMY", 133, 147], ["bronchial", "ANATOMY", 166, 175], ["fluid", "OBSERVATION", 176, 181], ["viral load", "OBSERVATION", 187, 197], ["higher", "OBSERVATION_MODIFIER", 201, 207], ["lower", "ANATOMY_MODIFIER", 211, 216], ["respiratory tract", "ANATOMY", 217, 234]]], ["In addition, viral nucleic acid was also found in samples from the intestinal tract or blood even when respiratory samples were negative116.", [["samples", "ANATOMY", 50, 57], ["intestinal tract", "ANATOMY", 67, 83], ["blood", "ANATOMY", 87, 92], ["respiratory samples", "ANATOMY", 103, 122], ["nucleic acid", "CHEMICAL", 19, 31], ["samples", "CANCER", 50, 57], ["intestinal tract", "ORGAN", 67, 83], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["viral nucleic acid", "TEST", 13, 31], ["respiratory samples", "TEST", 103, 122], ["viral", "OBSERVATION", 13, 18], ["nucleic acid", "OBSERVATION", 19, 31], ["intestinal tract", "ANATOMY", 67, 83]]], ["Lastly, viral load may already drop from its peak level on disease onset96,97.", [["viral load", "TEST", 8, 18], ["viral load", "OBSERVATION", 8, 18]]], ["Accordingly, false negatives can be common when oral swabs and used, and so multiple detection methods should be adopted to confirm a COVID-19 diagnosis117,118.", [["oral swabs", "ANATOMY", 48, 58], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["swabs", "ORGANISM_SUBSTANCE", 53, 58], ["false negatives", "TEST", 13, 28], ["oral swabs", "TEST", 48, 58], ["multiple detection methods", "TEST", 76, 102], ["a COVID", "TEST", 132, 139]]], ["Other detection methods were therefore used to overcome this problem.", [["Other detection methods", "TEST", 0, 23]]], ["Chest CT was used to quickly identify a patient when the capacity of molecular detection was overloaded in Wuhan.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["Chest CT", "TEST", 0, 8], ["overloaded", "PROBLEM", 93, 103], ["overloaded", "OBSERVATION", 93, 103]]], ["Patients with COVID-19 showed typical features on initial CT, including bilateral multilobar ground-glass opacities with a peripheral or posterior distribution118,119.", [["Patients", "ORGANISM", 0, 8], ["COVID-19", "DNA", 14, 22], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19], ["typical features", "PROBLEM", 30, 46], ["initial CT", "TEST", 50, 60], ["bilateral multilobar ground-glass opacities", "PROBLEM", 72, 115], ["a peripheral or posterior distribution", "PROBLEM", 121, 159], ["bilateral", "ANATOMY_MODIFIER", 72, 81], ["multilobar", "OBSERVATION_MODIFIER", 82, 92], ["ground-glass opacities", "OBSERVATION", 93, 115], ["peripheral", "ANATOMY_MODIFIER", 123, 133], ["posterior", "ANATOMY_MODIFIER", 137, 146], ["distribution", "OBSERVATION_MODIFIER", 147, 159]]], ["Thus, it has been suggested that CT scanning combined with repeated swab tests should be used for individuals with high clinical suspicion of COVID-19 but who test negative in initial nucleic acid screening118.", [["nucleic acid", "CHEMICAL", 184, 196], ["CT scanning", "TEST", 33, 44], ["repeated swab tests", "TEST", 59, 78], ["COVID", "TEST", 142, 147], ["initial nucleic acid screening", "TEST", 176, 206]]], ["Finally, SARS-CoV-2 serological tests detecting antibodies to N or S protein could complement molecular diagnosis, particularly in late phases after disease onset or for retrospective studies116,120,121.", [["antibodies to N or S protein", "GENE_OR_GENE_PRODUCT", 48, 76], ["antibodies", "PROTEIN", 48, 58], ["N or S protein", "PROTEIN", 62, 76], ["SARS", "TEST", 9, 13], ["CoV", "TEST", 14, 17], ["serological tests", "TEST", 20, 37], ["S protein", "TEST", 67, 76], ["retrospective studies", "TEST", 170, 191]]], ["However, the extent and duration of immune responses are still unclear, and available serological tests differ in their sensitivity and specificity, all of which need to be taken into account when one is deciding on serological tests and interpreting their results or potentially in the future test for T cell responses.Inhibition of virus entry ::: TherapeuticsSARS-CoV-2 uses ACE2 as the receptor and human proteases as entry activators; subsequently it fuses the viral membrane with the cell membrane and achieves invasion.", [["T cell", "ANATOMY", 303, 309], ["membrane", "ANATOMY", 472, 480], ["cell membrane", "ANATOMY", 490, 503], ["T cell", "CELL", 303, 309], ["-CoV-2", "GENE_OR_GENE_PRODUCT", 366, 372], ["ACE2", "GENE_OR_GENE_PRODUCT", 378, 382], ["human", "ORGANISM", 403, 408], ["membrane", "CELLULAR_COMPONENT", 472, 480], ["cell membrane", "CELLULAR_COMPONENT", 490, 503], ["ACE2", "PROTEIN", 378, 382], ["human proteases", "PROTEIN", 403, 418], ["human", "SPECIES", 403, 408], ["human", "SPECIES", 403, 408], ["serological tests", "TEST", 86, 103], ["serological tests", "TEST", 216, 233], ["the future test", "TEST", 283, 298], ["TherapeuticsSARS-CoV", "TREATMENT", 350, 370], ["ACE2", "TREATMENT", 378, 382], ["the receptor", "TREATMENT", 386, 398], ["human proteases", "TREATMENT", 403, 418], ["entry activators", "TREATMENT", 422, 438], ["the cell membrane", "TREATMENT", 486, 503], ["invasion", "PROBLEM", 517, 525], ["extent", "OBSERVATION_MODIFIER", 13, 19], ["virus", "OBSERVATION", 334, 339], ["viral membrane", "OBSERVATION", 466, 480], ["cell membrane", "OBSERVATION", 490, 503], ["invasion", "OBSERVATION", 517, 525]]], ["Thus, drugs that interfere with entry may be a potential treatment for COVID-19.", [["COVID-19", "CHEMICAL", 71, 79], ["drugs", "TREATMENT", 6, 11], ["a potential treatment", "TREATMENT", 45, 66], ["COVID", "TEST", 71, 76]]], ["Umifenovir (Arbidol) is a drug approved in Russia and China for the treatment of influenza and other respiratory viral infections.", [["Umifenovir", "CHEMICAL", 0, 10], ["Arbidol", "CHEMICAL", 12, 19], ["influenza", "DISEASE", 81, 90], ["respiratory viral infections", "DISEASE", 101, 129], ["Umifenovir", "CHEMICAL", 0, 10], ["Arbidol", "CHEMICAL", 12, 19], ["Umifenovir", "SIMPLE_CHEMICAL", 0, 10], ["Arbidol", "SIMPLE_CHEMICAL", 12, 19], ["Umifenovir (Arbidol)", "TREATMENT", 0, 20], ["a drug", "TREATMENT", 24, 30], ["the treatment", "TREATMENT", 64, 77], ["influenza", "PROBLEM", 81, 90], ["other respiratory viral infections", "PROBLEM", 95, 129], ["influenza", "OBSERVATION", 81, 90], ["respiratory", "ANATOMY", 101, 112], ["viral infections", "OBSERVATION", 113, 129]]], ["It can target the interaction between the S protein and ACE2 and inhibit membrane fusion (Fig. 5).", [["membrane", "ANATOMY", 73, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["S protein", "PROTEIN", 42, 51], ["ACE2", "PROTEIN", 56, 60], ["the S protein and ACE2 and inhibit membrane fusion", "TREATMENT", 38, 88], ["membrane fusion", "OBSERVATION", 73, 88]]], ["In vitro experiments showed that it has activity against SARS-CoV-2, and current clinical data revealed it may be more effective than lopinavir and ritonavir in treating COVID-19 (refs122,123).", [["lopinavir", "CHEMICAL", 134, 143], ["ritonavir", "CHEMICAL", 148, 157], ["COVID-19", "CHEMICAL", 170, 178], ["lopinavir", "CHEMICAL", 134, 143], ["ritonavir", "CHEMICAL", 148, 157], ["SARS-CoV-2", "ORGANISM", 57, 67], ["lopinavir", "SIMPLE_CHEMICAL", 134, 143], ["ritonavir", "SIMPLE_CHEMICAL", 148, 157], ["SARS-CoV", "SPECIES", 57, 65], ["vitro experiments", "TEST", 3, 20], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["lopinavir", "TREATMENT", 134, 143], ["ritonavir", "TREATMENT", 148, 157], ["COVID", "TEST", 170, 175]]], ["However, other clinical studies showed umifenovir might not improve the prognosis of or accelerate SARS-CoV-2 clearance in patients with mild to moderate COVID-19 (refs124,125).", [["umifenovir", "CHEMICAL", 39, 49], ["SARS", "DISEASE", 99, 103], ["umifenovir", "CHEMICAL", 39, 49], ["umifenovir", "SIMPLE_CHEMICAL", 39, 49], ["CoV-2", "ORGANISM", 104, 109], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["other clinical studies", "TEST", 9, 31], ["umifenovir", "TREATMENT", 39, 49], ["accelerate SARS", "PROBLEM", 88, 103], ["CoV", "TEST", 104, 107], ["mild to moderate COVID", "PROBLEM", 137, 159], ["moderate", "OBSERVATION_MODIFIER", 145, 153]]], ["Yet some ongoing clinical trials are evaluating its efficacy for COVID-19 treatment.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "SIMPLE_CHEMICAL", 65, 73], ["COVID-19 treatment", "TREATMENT", 65, 83]]], ["Camostat mesylate is approved in Japan for the treatment of pancreatitis and postoperative reflux oesophagitis.", [["Camostat mesylate", "CHEMICAL", 0, 17], ["pancreatitis", "DISEASE", 60, 72], ["postoperative reflux oesophagitis", "DISEASE", 77, 110], ["Camostat mesylate", "CHEMICAL", 0, 17], ["Camostat mesylate", "SIMPLE_CHEMICAL", 0, 17], ["Camostat mesylate", "TREATMENT", 0, 17], ["pancreatitis", "PROBLEM", 60, 72], ["postoperative reflux oesophagitis", "PROBLEM", 77, 110], ["pancreatitis", "OBSERVATION", 60, 72], ["postoperative", "OBSERVATION", 77, 90], ["reflux oesophagitis", "OBSERVATION", 91, 110]]], ["Previous studies showed that it can prevent SARS-CoV from entering cells by blocking TMPRSS2 activity and protect mice from lethal infection with SARS-CoV in a pathogenic mouse model (wild-type mice infected with a mouse-adapted SARS-CoV strain)126,127.", [["cells", "ANATOMY", 67, 72], ["SARS", "DISEASE", 44, 48], ["infection", "DISEASE", 131, 140], ["SARS", "DISEASE", 146, 150], ["SARS", "DISEASE", 229, 233], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["cells", "CELL", 67, 72], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 85, 92], ["mice", "ORGANISM", 114, 118], ["SARS-CoV", "ORGANISM", 146, 154], ["mouse", "ORGANISM", 171, 176], ["mice", "ORGANISM", 194, 198], ["mouse", "ORGANISM", 215, 220], ["SARS-CoV strain", "ORGANISM", 229, 244], ["TMPRSS2", "PROTEIN", 85, 92], ["mice", "SPECIES", 114, 118], ["mouse", "SPECIES", 171, 176], ["mice", "SPECIES", 194, 198], ["mouse", "SPECIES", 215, 220], ["SARS-CoV", "SPECIES", 44, 52], ["mice", "SPECIES", 114, 118], ["SARS-CoV", "SPECIES", 146, 154], ["mouse", "SPECIES", 171, 176], ["mice", "SPECIES", 194, 198], ["mouse", "SPECIES", 215, 220], ["SARS-CoV", "SPECIES", 229, 237], ["Previous studies", "TEST", 0, 16], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["blocking TMPRSS2 activity", "TREATMENT", 76, 101], ["lethal infection", "PROBLEM", 124, 140], ["SARS", "PROBLEM", 146, 150], ["CoV", "PROBLEM", 151, 154], ["a pathogenic mouse model", "PROBLEM", 158, 182], ["lethal", "OBSERVATION_MODIFIER", 124, 130], ["infection", "OBSERVATION", 131, 140]]], ["Recently, a study revealed that camostat mesylate blocks the entry of SARS-CoV-2 into human lung cells47.", [["lung cells", "ANATOMY", 92, 102], ["camostat mesylate", "CHEMICAL", 32, 49], ["camostat mesylate", "CHEMICAL", 32, 49], ["camostat mesylate", "SIMPLE_CHEMICAL", 32, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 70, 80], ["human", "ORGANISM", 86, 91], ["lung cells", "CELL", 92, 102], ["human lung cells", "CELL_TYPE", 86, 102], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["a study", "TEST", 10, 17], ["camostat mesylate blocks", "TREATMENT", 32, 56], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["human lung cells", "TEST", 86, 102], ["lung", "ANATOMY", 92, 96]]], ["Thus, it can be a potential antiviral drug against SARS-CoV-2 infection, although so far there are not sufficient clinical data to support its efficacy.Inhibition of virus entry ::: TherapeuticsChloroquine and hydroxychloroquine are other potential but controversial drugs that interfere with the entry of SARS-CoV-2.", [["SARS-CoV-2 infection", "DISEASE", 51, 71], ["Chloroquine", "CHEMICAL", 194, 205], ["hydroxychloroquine", "CHEMICAL", 210, 228], ["SARS", "DISEASE", 306, 310], ["Chloroquine", "CHEMICAL", 194, 205], ["hydroxychloroquine", "CHEMICAL", 210, 228], ["SARS-CoV-2", "ORGANISM", 51, 61], ["Chloroquine", "SIMPLE_CHEMICAL", 194, 205], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 210, 228], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 306, 316], ["SARS-CoV-2", "SPECIES", 51, 61], ["SARS-CoV", "SPECIES", 306, 314], ["SARS", "PROBLEM", 51, 55], ["CoV-2 infection", "PROBLEM", 56, 71], ["TherapeuticsChloroquine", "TREATMENT", 182, 205], ["hydroxychloroquine", "TREATMENT", 210, 228], ["controversial drugs", "TREATMENT", 253, 272], ["infection", "OBSERVATION", 62, 71], ["virus", "OBSERVATION", 166, 171]]], ["They have been used in the prevention and treatment of malaria and autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.", [["malaria", "DISEASE", 55, 62], ["autoimmune diseases", "DISEASE", 67, 86], ["systemic lupus erythematosus", "DISEASE", 98, 126], ["rheumatoid arthritis", "DISEASE", 131, 151], ["treatment", "TREATMENT", 42, 51], ["malaria", "PROBLEM", 55, 62], ["autoimmune diseases", "PROBLEM", 67, 86], ["systemic lupus erythematosus", "PROBLEM", 98, 126], ["rheumatoid arthritis", "PROBLEM", 131, 151], ["malaria", "OBSERVATION", 55, 62], ["autoimmune diseases", "OBSERVATION", 67, 86], ["systemic", "OBSERVATION_MODIFIER", 98, 106], ["lupus erythematosus", "OBSERVATION", 107, 126], ["rheumatoid arthritis", "OBSERVATION", 131, 151]]], ["They can inhibit the glycosylation of cellular receptors and interfere with virus\u2013host receptor binding, as well as increase the endosomal pH and inhibit membrane fusion.", [["cellular", "ANATOMY", 38, 46], ["endosomal", "ANATOMY", 129, 138], ["membrane", "ANATOMY", 154, 162], ["cellular", "CELL", 38, 46], ["virus\u2013host receptor", "GENE_OR_GENE_PRODUCT", 76, 95], ["endosomal", "CELLULAR_COMPONENT", 129, 138], ["membrane", "CELLULAR_COMPONENT", 154, 162], ["cellular receptors", "PROTEIN", 38, 56], ["virus\u2013host receptor", "PROTEIN", 76, 95], ["cellular receptors", "TREATMENT", 38, 56], ["virus\u2013host receptor binding", "TREATMENT", 76, 103], ["the endosomal pH", "TREATMENT", 125, 141], ["inhibit membrane fusion", "TREATMENT", 146, 169], ["endosomal pH", "OBSERVATION", 129, 141], ["membrane fusion", "OBSERVATION", 154, 169]]], ["Currently, no scientific consensus has been reached for their efficacy in the treatment of COVID-19.", [["COVID-19", "CHEMICAL", 91, 99], ["COVID", "TEST", 91, 96], ["no", "UNCERTAINTY", 11, 13]]], ["Some studies showed they can inhibit SARS-CoV-2 infection in vitro, but the clinical data are insufficient128,129.", [["infection", "DISEASE", 48, 57], ["SARS-CoV-2", "ORGANISM", 37, 47], ["SARS-CoV-2", "SPECIES", 37, 47], ["Some studies", "TEST", 0, 12], ["SARS", "PROBLEM", 37, 41], ["CoV", "PROBLEM", 42, 45], ["2 infection in vitro", "PROBLEM", 46, 66], ["the clinical data", "TEST", 72, 89], ["infection", "OBSERVATION", 48, 57]]], ["Two clinical studies indicated no association with death rates in patients receiving chloroquine or hydroxychloroquine compared with those not receiving the drug and even suggest it may increase the risk of dying as a higher risk of cardiac arrest was found in the treated patients130,131.", [["cardiac", "ANATOMY", 233, 240], ["death", "DISEASE", 51, 56], ["chloroquine", "CHEMICAL", 85, 96], ["hydroxychloroquine", "CHEMICAL", 100, 118], ["cardiac arrest", "DISEASE", 233, 247], ["chloroquine", "CHEMICAL", 85, 96], ["hydroxychloroquine", "CHEMICAL", 100, 118], ["patients", "ORGANISM", 66, 74], ["chloroquine", "SIMPLE_CHEMICAL", 85, 96], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 100, 118], ["cardiac", "ORGAN", 233, 240], ["patient", "ORGANISM", 273, 280], ["patients", "SPECIES", 66, 74], ["patient", "SPECIES", 273, 280], ["Two clinical studies", "TEST", 0, 20], ["death rates", "PROBLEM", 51, 62], ["chloroquine", "TREATMENT", 85, 96], ["hydroxychloroquine", "TREATMENT", 100, 118], ["the drug", "TREATMENT", 153, 161], ["cardiac arrest", "PROBLEM", 233, 247], ["no association with", "UNCERTAINTY", 31, 50], ["cardiac", "ANATOMY", 233, 240], ["arrest", "OBSERVATION", 241, 247]]], ["On 15 June 2020, owing to the side effects observed in clinical trials, the US Food and Drug Administration (FDA) revoked the emergency use authorization for chloroquine and hydroxychloroquine for the treatment of COVID-19.", [["chloroquine", "CHEMICAL", 158, 169], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["COVID-19", "CHEMICAL", 214, 222], ["chloroquine", "CHEMICAL", 158, 169], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["COVID-19", "CHEMICAL", 214, 222], ["chloroquine", "SIMPLE_CHEMICAL", 158, 169], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 174, 192], ["chloroquine", "TREATMENT", 158, 169], ["hydroxychloroquine", "TREATMENT", 174, 192], ["COVID", "TEST", 214, 219]]], ["Another potential therapeutic strategy is to block binding of the S protein to ACE2 through soluble recombinant hACE2, specific monoclonal antibodies or fusion inhibitors that target the SARS-CoV-2 S protein132\u2013134 (Fig. 5).", [["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["hACE2", "GENE_OR_GENE_PRODUCT", 112, 117], ["S protein", "PROTEIN", 66, 75], ["ACE2", "PROTEIN", 79, 83], ["hACE2", "PROTEIN", 112, 117], ["monoclonal antibodies", "PROTEIN", 128, 149], ["SARS-CoV-2 S protein132\u2013134", "DNA", 187, 214], ["the S protein", "TREATMENT", 62, 75], ["soluble recombinant hACE2", "TREATMENT", 92, 117], ["specific monoclonal antibodies", "TREATMENT", 119, 149], ["fusion inhibitors", "TREATMENT", 153, 170], ["the SARS", "TEST", 183, 191], ["CoV", "TEST", 192, 195], ["S protein132", "TEST", 198, 210]]], ["The safety and efficacy of these strategies need to be assessed in future clinical trials.Inhibition of virus replication ::: TherapeuticsReplication inhibitors include remdesivir (GS-5734), favilavir (T-705), ribavirin, lopinavir and ritonavir.", [["remdesivir", "CHEMICAL", 169, 179], ["GS-5734", "CHEMICAL", 181, 188], ["favilavir", "CHEMICAL", 191, 200], ["T-705", "CHEMICAL", 202, 207], ["ribavirin", "CHEMICAL", 210, 219], ["lopinavir", "CHEMICAL", 221, 230], ["ritonavir", "CHEMICAL", 235, 244], ["remdesivir", "CHEMICAL", 169, 179], ["GS-5734", "CHEMICAL", 181, 188], ["favilavir", "CHEMICAL", 191, 200], ["T-705", "CHEMICAL", 202, 207], ["ribavirin", "CHEMICAL", 210, 219], ["lopinavir", "CHEMICAL", 221, 230], ["ritonavir", "CHEMICAL", 235, 244], ["remdesivir", "SIMPLE_CHEMICAL", 169, 179], ["GS-5734", "SIMPLE_CHEMICAL", 181, 188], ["favilavir", "SIMPLE_CHEMICAL", 191, 200], ["T-705", "SIMPLE_CHEMICAL", 202, 207], ["ribavirin", "SIMPLE_CHEMICAL", 210, 219], ["lopinavir", "SIMPLE_CHEMICAL", 221, 230], ["ritonavir", "SIMPLE_CHEMICAL", 235, 244], ["these strategies", "TREATMENT", 27, 43], ["TherapeuticsReplication inhibitors", "TREATMENT", 126, 160], ["remdesivir (GS", "TREATMENT", 169, 183], ["favilavir (T", "TREATMENT", 191, 203], ["ribavirin", "TREATMENT", 210, 219], ["lopinavir", "TREATMENT", 221, 230], ["ritonavir", "TREATMENT", 235, 244], ["virus replication", "OBSERVATION", 104, 121]]], ["Except for lopinavir and ritonavir, which inhibit 3CLpro, the other three all target RdRp128,135 (Fig. 5).", [["lopinavir", "CHEMICAL", 11, 20], ["ritonavir", "CHEMICAL", 25, 34], ["lopinavir", "CHEMICAL", 11, 20], ["ritonavir", "CHEMICAL", 25, 34], ["lopinavir", "SIMPLE_CHEMICAL", 11, 20], ["ritonavir", "SIMPLE_CHEMICAL", 25, 34], ["3CLpro", "SIMPLE_CHEMICAL", 50, 56], ["lopinavir", "TREATMENT", 11, 20], ["ritonavir", "TREATMENT", 25, 34], ["3CLpro", "TREATMENT", 50, 56]]], ["Remdesivir has shown activity against SARS-CoV-2 in vitro and in vivo128,136.", [["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV-2", "ORGANISM", 38, 48], ["SARS-CoV", "SPECIES", 38, 46], ["Remdesivir", "TREATMENT", 0, 10], ["SARS", "PROBLEM", 38, 42], ["CoV", "TEST", 43, 46], ["activity", "OBSERVATION_MODIFIER", 21, 29]]], ["A clinical study revealed a lower need for oxygen support in patients with COVID-19 (ref.137).", [["oxygen", "CHEMICAL", 43, 49], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["A clinical study", "TEST", 0, 16], ["oxygen support", "TREATMENT", 43, 57], ["COVID", "TEST", 75, 80], ["lower", "OBSERVATION_MODIFIER", 28, 33], ["oxygen support", "OBSERVATION", 43, 57]]], ["Preliminary results of the Adaptive COVID-19 Treatment Trial (ACTT) clinical trial by the National Institute of Allergy and Infectious Diseases (NIAID) reported that remdesivir can shorten the recovery time in hospitalized adults with COVID-19 by a couple days compared with placebo, but the difference in mortality was not statistically significant138.", [["Allergy and Infectious Diseases", "DISEASE", 112, 143], ["remdesivir", "CHEMICAL", 166, 176], ["remdesivir", "CHEMICAL", 166, 176], ["remdesivir", "SIMPLE_CHEMICAL", 166, 176], ["the Adaptive COVID", "TREATMENT", 23, 41], ["COVID", "TREATMENT", 235, 240], ["placebo", "TREATMENT", 275, 282]]], ["The FDA has issued an emergency use authorization for remdesivir for the treatment of hospitalized patients with severe COVID-19.", [["remdesivir", "CHEMICAL", 54, 64], ["remdesivir", "CHEMICAL", 54, 64], ["COVID-19", "CHEMICAL", 120, 128], ["remdesivir", "SIMPLE_CHEMICAL", 54, 64], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["remdesivir", "TREATMENT", 54, 64], ["severe COVID", "PROBLEM", 113, 125]]], ["It is also the first approved option by the European Union for treatment of adults and adolescents with pneumonia requiring supplemental oxygen.", [["pneumonia", "DISEASE", 104, 113], ["oxygen", "CHEMICAL", 137, 143], ["oxygen", "CHEMICAL", 137, 143], ["adults", "ORGANISM", 76, 82], ["oxygen", "SIMPLE_CHEMICAL", 137, 143], ["adolescents", "SPECIES", 87, 98], ["pneumonia", "PROBLEM", 104, 113], ["supplemental oxygen", "TREATMENT", 124, 143], ["pneumonia", "OBSERVATION", 104, 113]]], ["Several international phase III clinical trials are continuing to evaluate the safety and efficacy of remdesivir for the treatment of COVID-19.Inhibition of virus replication ::: TherapeuticsFavilavir (T-705), which is an antiviral drug developed in Japan to treat influenza, has been approved in China, Russia and India for the treatment of COVID-19.", [["remdesivir", "CHEMICAL", 102, 112], ["TherapeuticsFavilavir", "CHEMICAL", 179, 200], ["T-705", "CHEMICAL", 202, 207], ["influenza", "DISEASE", 265, 274], ["COVID-19", "CHEMICAL", 342, 350], ["remdesivir", "CHEMICAL", 102, 112], ["TherapeuticsFavilavir", "CHEMICAL", 179, 200], ["T-705", "CHEMICAL", 202, 207], ["remdesivir", "SIMPLE_CHEMICAL", 102, 112], ["TherapeuticsFavilavir", "SIMPLE_CHEMICAL", 179, 200], ["T-705", "SIMPLE_CHEMICAL", 202, 207], ["remdesivir", "TREATMENT", 102, 112], ["COVID", "TEST", 134, 139], ["TherapeuticsFavilavir", "TEST", 179, 200], ["an antiviral drug", "TREATMENT", 219, 236], ["influenza", "PROBLEM", 265, 274], ["COVID", "TEST", 342, 347], ["virus replication", "OBSERVATION", 157, 174], ["influenza", "OBSERVATION", 265, 274]]], ["A clinical study in China showed that favilavir significantly reduced the signs of improved disease signs on chest imaging and shortened the time to viral clearance139.", [["chest", "ANATOMY", 109, 114], ["favilavir", "CHEMICAL", 38, 47], ["favilavir", "CHEMICAL", 38, 47], ["favilavir", "SIMPLE_CHEMICAL", 38, 47], ["chest", "ORGANISM_SUBDIVISION", 109, 114], ["A clinical study", "TEST", 0, 16], ["improved disease signs", "PROBLEM", 83, 105], ["chest imaging", "TEST", 109, 122], ["viral clearance", "TEST", 149, 164], ["improved", "OBSERVATION_MODIFIER", 83, 91], ["disease", "OBSERVATION", 92, 99], ["chest", "ANATOMY", 109, 114]]], ["A preliminary report in Japan showed rates of clinical improvement of 73.8% and 87.8% from the start of favilavir therapy in patients with mild COVID-19 at 7 and 14 days, respectively, and 40.1% and 60.3% in patients with severe COVID-19 at 7 and 14 days, respectively140.", [["favilavir", "CHEMICAL", 104, 113], ["favilavir", "CHEMICAL", 104, 113], ["favilavir", "SIMPLE_CHEMICAL", 104, 113], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 208, 216], ["favilavir therapy", "TREATMENT", 104, 121], ["mild COVID", "PROBLEM", 139, 149], ["severe COVID", "PROBLEM", 222, 234], ["mild", "OBSERVATION_MODIFIER", 139, 143], ["severe", "OBSERVATION_MODIFIER", 222, 228]]], ["However, this study did not include a control arm, and most of the trials of favilavir were based on a small sample size.", [["favilavir", "CHEMICAL", 77, 86], ["favilavir", "CHEMICAL", 77, 86], ["favilavir", "SIMPLE_CHEMICAL", 77, 86], ["this study", "TEST", 9, 19], ["favilavir", "TREATMENT", 77, 86], ["small", "OBSERVATION_MODIFIER", 103, 108], ["sample", "OBSERVATION_MODIFIER", 109, 115], ["size", "OBSERVATION_MODIFIER", 116, 120]]], ["For more reliable assessment of the effectiveness of favilavir for treating COVID-19, large-scale randomized controlled trials should be conducted.Inhibition of virus replication ::: TherapeuticsLopinavir and ritonavir were reported to have in vitro inhibitory activity against SARS-CoV and MERS-CoV141,142.", [["favilavir", "CHEMICAL", 53, 62], ["TherapeuticsLopinavir", "CHEMICAL", 183, 204], ["ritonavir", "CHEMICAL", 209, 218], ["favilavir", "CHEMICAL", 53, 62], ["TherapeuticsLopinavir", "CHEMICAL", 183, 204], ["ritonavir", "CHEMICAL", 209, 218], ["favilavir", "SIMPLE_CHEMICAL", 53, 62], ["TherapeuticsLopinavir", "SIMPLE_CHEMICAL", 183, 204], ["ritonavir", "SIMPLE_CHEMICAL", 209, 218], ["SARS-CoV", "ORGANISM", 278, 286], ["MERS-CoV141,142", "ORGANISM", 291, 306], ["SARS-CoV", "SPECIES", 278, 286], ["favilavir", "TREATMENT", 53, 62], ["COVID", "TEST", 76, 81], ["large-scale randomized controlled trials", "TREATMENT", 86, 126], ["TherapeuticsLopinavir", "TREATMENT", 183, 204], ["ritonavir", "TREATMENT", 209, 218], ["SARS", "PROBLEM", 278, 282], ["virus replication", "OBSERVATION", 161, 178]]], ["Alone, the combination of lopinavir and ritonavir had little therapeutic benefit in patients with COVID-19, but appeared more effective when used in combination with other drugs, including ribavirin and interferon beta-1b143,144.", [["lopinavir", "CHEMICAL", 26, 35], ["ritonavir", "CHEMICAL", 40, 49], ["COVID-19", "CHEMICAL", 98, 106], ["ribavirin", "CHEMICAL", 189, 198], ["interferon beta-1b143,144", "CHEMICAL", 203, 228], ["lopinavir", "CHEMICAL", 26, 35], ["ritonavir", "CHEMICAL", 40, 49], ["COVID-19", "CHEMICAL", 98, 106], ["ribavirin", "CHEMICAL", 189, 198], ["lopinavir", "SIMPLE_CHEMICAL", 26, 35], ["ritonavir", "SIMPLE_CHEMICAL", 40, 49], ["patients", "ORGANISM", 84, 92], ["ribavirin", "SIMPLE_CHEMICAL", 189, 198], ["interferon beta-1b143,144", "GENE_OR_GENE_PRODUCT", 203, 228], ["interferon beta-1b143,144", "PROTEIN", 203, 228], ["patients", "SPECIES", 84, 92], ["lopinavir", "TREATMENT", 26, 35], ["ritonavir", "TREATMENT", 40, 49], ["COVID", "TEST", 98, 103], ["other drugs", "TREATMENT", 166, 177], ["ribavirin", "TREATMENT", 189, 198], ["interferon beta", "TREATMENT", 203, 218]]], ["The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, a national clinical trial programme in the UK, has stopped treatment with lopinavir and ritonavir as no significant beneficial effect was observed in a randomized trial established in March 2020 with a total of 1,596 patients145.", [["lopinavir", "CHEMICAL", 138, 147], ["ritonavir", "CHEMICAL", 152, 161], ["COVID-19", "CHEMICAL", 29, 37], ["lopinavir", "CHEMICAL", 138, 147], ["ritonavir", "CHEMICAL", 152, 161], ["lopinavir", "SIMPLE_CHEMICAL", 138, 147], ["ritonavir", "SIMPLE_CHEMICAL", 152, 161], ["patient", "ORGANISM", 281, 288], ["patient", "SPECIES", 281, 288], ["The Randomized Evaluation", "TEST", 0, 25], ["COVID", "TEST", 29, 34], ["treatment", "TREATMENT", 123, 132], ["lopinavir", "TREATMENT", 138, 147], ["ritonavir", "TREATMENT", 152, 161]]], ["Nevertheless, other clinical trials in different phases are still ongoing elsewhere.Immunomodulatory agents ::: TherapeuticsSARS-CoV-2 triggers a strong immune response which may cause cytokine storm syndrome60,61.", [["TherapeuticsSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 134], ["cytokine", "PROTEIN", 185, 193], ["Immunomodulatory agents", "TREATMENT", 84, 107], ["TherapeuticsSARS", "TEST", 112, 128], ["cytokine storm syndrome", "PROBLEM", 185, 208]]], ["Thus, immunomodulatory agents that inhibit the excessive inflammatory response may be a potential adjunctive therapy for COVID-19.", [["immunomodulatory agents", "TREATMENT", 6, 29], ["the excessive inflammatory response", "PROBLEM", 43, 78], ["a potential adjunctive therapy", "TREATMENT", 86, 116], ["COVID", "TEST", 121, 126]]], ["Dexamethasone is a corticosteroid often used in a wide range of conditions to relieve inflammation through its anti-inflammatory and immunosuppressant effects.", [["Dexamethasone", "CHEMICAL", 0, 13], ["inflammation", "DISEASE", 86, 98], ["Dexamethasone", "CHEMICAL", 0, 13], ["Dexamethasone", "SIMPLE_CHEMICAL", 0, 13], ["Dexamethasone", "TREATMENT", 0, 13], ["a corticosteroid", "TREATMENT", 17, 33], ["a wide range of conditions", "TREATMENT", 48, 74], ["inflammation", "PROBLEM", 86, 98], ["its anti-inflammatory", "TREATMENT", 107, 128], ["immunosuppressant effects", "TREATMENT", 133, 158], ["inflammation", "OBSERVATION", 86, 98], ["anti-inflammatory", "OBSERVATION_MODIFIER", 111, 128]]], ["Recently, the RECOVERY trial found dexamethasone reduced mortality by about one third in hospitalized patients with COVID-19 who received invasive mechanical ventilation and by one fifth in patients receiving oxygen.", [["dexamethasone", "CHEMICAL", 35, 48], ["oxygen", "CHEMICAL", 209, 215], ["dexamethasone", "CHEMICAL", 35, 48], ["oxygen", "CHEMICAL", 209, 215], ["dexamethasone", "SIMPLE_CHEMICAL", 35, 48], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 190, 198], ["oxygen", "SIMPLE_CHEMICAL", 209, 215], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 190, 198], ["dexamethasone", "TREATMENT", 35, 48], ["COVID", "TREATMENT", 116, 121], ["invasive mechanical ventilation", "TREATMENT", 138, 169], ["oxygen", "TREATMENT", 209, 215], ["mechanical ventilation", "OBSERVATION", 147, 169]]], ["By contrast, no benefit was found in patients without respiratory support146.Immunomodulatory agents ::: TherapeuticsTocilizumab and sarilumab, two types of interleukin-6 (IL-6) receptor-specific antibodies previously used to treat various types of arthritis, including rheumatoid arthritis, and cytokine release syndrome, showed effectiveness in the treatment of severe COVID-19 by attenuating the cytokine storm in a small uncontrolled trial147.", [["respiratory", "ANATOMY", 54, 65], ["Tocilizumab", "CHEMICAL", 117, 128], ["sarilumab", "CHEMICAL", 133, 142], ["arthritis", "DISEASE", 249, 258], ["rheumatoid arthritis", "DISEASE", 270, 290], ["COVID-19", "CHEMICAL", 371, 379], ["Tocilizumab", "CHEMICAL", 117, 128], ["sarilumab", "CHEMICAL", 133, 142], ["COVID-19", "CHEMICAL", 371, 379], ["patients", "ORGANISM", 37, 45], ["Tocilizumab", "SIMPLE_CHEMICAL", 117, 128], ["sarilumab", "SIMPLE_CHEMICAL", 133, 142], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 157, 170], ["IL-6", "GENE_OR_GENE_PRODUCT", 172, 176], ["interleukin-6 (IL-6) receptor", "PROTEIN", 157, 186], ["specific antibodies", "PROTEIN", 187, 206], ["cytokine", "PROTEIN", 296, 304], ["cytokine", "PROTEIN", 399, 407], ["patients", "SPECIES", 37, 45], ["respiratory support", "TREATMENT", 54, 73], ["Immunomodulatory agents", "TREATMENT", 77, 100], ["TherapeuticsTocilizumab", "TREATMENT", 105, 128], ["sarilumab", "TREATMENT", 133, 142], ["interleukin-6 (IL", "TREATMENT", 157, 174], ["receptor-specific antibodies", "TREATMENT", 178, 206], ["arthritis", "PROBLEM", 249, 258], ["rheumatoid arthritis", "PROBLEM", 270, 290], ["cytokine release syndrome", "PROBLEM", 296, 321], ["severe COVID", "PROBLEM", 364, 376], ["arthritis", "OBSERVATION", 249, 258], ["rheumatoid arthritis", "OBSERVATION", 270, 290], ["cytokine storm", "OBSERVATION", 399, 413], ["small", "OBSERVATION_MODIFIER", 419, 424]]], ["Bevacizumab is an anti-vascular endothelial growth factor (VEGF) medication that could potentially reduce pulmonary oedema in patients with severe COVID-19.", [["pulmonary", "ANATOMY", 106, 115], ["Bevacizumab", "CHEMICAL", 0, 11], ["pulmonary oedema", "DISEASE", 106, 122], ["Bevacizumab", "CHEMICAL", 0, 11], ["COVID-19", "CHEMICAL", 147, 155], ["Bevacizumab", "SIMPLE_CHEMICAL", 0, 11], ["anti-vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 18, 57], ["VEGF", "GENE_OR_GENE_PRODUCT", 59, 63], ["pulmonary", "ORGAN", 106, 115], ["patients", "ORGANISM", 126, 134], ["anti-vascular endothelial growth factor", "PROTEIN", 18, 57], ["VEGF", "PROTEIN", 59, 63], ["patients", "SPECIES", 126, 134], ["Bevacizumab", "TREATMENT", 0, 11], ["an anti-vascular endothelial growth factor (VEGF) medication", "TREATMENT", 15, 75], ["pulmonary oedema", "PROBLEM", 106, 122], ["severe COVID", "PROBLEM", 140, 152], ["pulmonary", "ANATOMY", 106, 115], ["oedema", "OBSERVATION", 116, 122]]], ["Eculizumab is a specific monoclonal antibody that inhibits the proinflammatory complement protein C5.", [["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "CHEMICAL", 0, 10], ["Eculizumab", "SIMPLE_CHEMICAL", 0, 10], ["complement protein C5", "GENE_OR_GENE_PRODUCT", 79, 100], ["monoclonal antibody", "PROTEIN", 25, 44], ["proinflammatory complement protein C5", "PROTEIN", 63, 100], ["Eculizumab", "TREATMENT", 0, 10], ["a specific monoclonal antibody", "PROBLEM", 14, 44], ["the proinflammatory complement protein C5", "PROBLEM", 59, 100], ["monoclonal antibody", "OBSERVATION", 25, 44]]], ["Preliminary results showed that it induced a drop of inflammatory markers and C-reactive protein levels, suggesting its potential to be an option for the treatment of severe COVID-19 (ref.148).Immunomodulatory agents ::: TherapeuticsThe interferon response is one of the major innate immunity defences against virus invasion.", [["COVID", "DISEASE", 174, 179], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 78, 96], ["inflammatory markers", "PROTEIN", 53, 73], ["C-reactive protein", "PROTEIN", 78, 96], ["interferon", "PROTEIN", 237, 247], ["a drop of inflammatory markers", "PROBLEM", 43, 73], ["C-reactive protein levels", "PROBLEM", 78, 103], ["severe COVID", "PROBLEM", 167, 179], ["Immunomodulatory agents", "TREATMENT", 193, 216], ["virus invasion", "PROBLEM", 310, 324], ["drop", "OBSERVATION_MODIFIER", 45, 49], ["inflammatory", "OBSERVATION_MODIFIER", 53, 65], ["reactive protein levels", "OBSERVATION", 80, 103], ["interferon", "OBSERVATION", 237, 247]]], ["Interferons induce the expression of diverse interferon-stimulated genes, which can interfere with every step of virus replication.", [["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 45, 72], ["Interferons", "PROTEIN", 0, 11], ["interferon-stimulated genes", "DNA", 45, 72], ["Interferons", "TREATMENT", 0, 11], ["diverse interferon-stimulated genes", "TREATMENT", 37, 72], ["virus replication", "TREATMENT", 113, 130], ["diverse", "OBSERVATION_MODIFIER", 37, 44], ["interferon", "OBSERVATION", 45, 55]]], ["Previous studies identified type I interferons as a promising therapeutic candidate for SARS149.", [["SARS149", "CHEMICAL", 88, 95], ["type I interferons", "GENE_OR_GENE_PRODUCT", 28, 46], ["SARS149", "SIMPLE_CHEMICAL", 88, 95], ["type I interferons", "PROTEIN", 28, 46], ["Previous studies", "TEST", 0, 16], ["type I interferons", "PROBLEM", 28, 46]]], ["In vitro data showed SARS-CoV-2 is even more sensitive to type I interferons than SARS-CoV, suggesting the potential effectiveness of type I interferons in the early treatment of COVID-19 (ref.150).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["type I interferons", "GENE_OR_GENE_PRODUCT", 58, 76], ["SARS-CoV", "ORGANISM", 82, 90], ["type I interferons", "GENE_OR_GENE_PRODUCT", 134, 152], ["type I interferons", "PROTEIN", 58, 76], ["type I interferons", "PROTEIN", 134, 152], ["SARS-CoV", "SPECIES", 21, 29], ["SARS-CoV", "SPECIES", 82, 90], ["vitro data", "TEST", 3, 13], ["SARS", "PROBLEM", 21, 25], ["CoV", "TEST", 26, 29], ["SARS", "PROBLEM", 82, 86], ["CoV", "PROBLEM", 87, 90], ["type I interferons", "TREATMENT", 134, 152], ["COVID", "TEST", 179, 184]]], ["In China, vapor inhalation of interferon-\u03b1 is included in the COVID-19 treatment guideline151.", [["interferon-\u03b1", "CHEMICAL", 30, 42], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 30, 42], ["interferon", "PROTEIN", 30, 40], ["vapor inhalation of interferon", "TREATMENT", 10, 40]]], ["Clinical trials are ongoing across the world to evaluate the efficacy of different therapies involving interferons, either alone or in combination with other agents152.Immunoglobulin therapy ::: TherapeuticsConvalescent plasma treatment is another potential adjunctive therapy for COVID-19.", [["plasma", "ANATOMY", 220, 226], ["interferons", "GENE_OR_GENE_PRODUCT", 103, 114], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 168, 182], ["plasma", "ORGANISM_SUBSTANCE", 220, 226], ["interferons", "PROTEIN", 103, 114], ["different therapies", "TREATMENT", 73, 92], ["interferons", "TREATMENT", 103, 114], ["Immunoglobulin therapy", "TREATMENT", 168, 190], ["TherapeuticsConvalescent plasma treatment", "TREATMENT", 195, 236], ["adjunctive therapy", "TREATMENT", 258, 276], ["COVID", "TEST", 281, 286]]], ["Preliminary findings have suggested improved clinical status after the treatment153,154.", [["the treatment", "TREATMENT", 67, 80], ["improved", "OBSERVATION_MODIFIER", 36, 44]]], ["The FDA has provided guidance for the use of COVID-19 convalescent plasma under an emergency investigational new drug application.", [["plasma", "ANATOMY", 67, 73], ["convalescent", "ORGANISM", 54, 66], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["COVID", "TREATMENT", 45, 50], ["an emergency investigational new drug application", "TREATMENT", 80, 129]]], ["However, this treatment may have adverse effects by causing antibody-mediated enhancement of infection, transfusion-associated acute lung injury and allergic transfusion reactions.Immunoglobulin therapy ::: TherapeuticsMonoclonal antibody therapy is an effective immunotherapy for the treatment of some viral infections in select patients.", [["lung", "ANATOMY", 133, 137], ["infection", "DISEASE", 93, 102], ["acute lung injury", "DISEASE", 127, 144], ["allergic transfusion reactions", "DISEASE", 149, 179], ["viral infections", "DISEASE", 303, 319], ["lung", "ORGAN", 133, 137], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 180, 194], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["this treatment", "TREATMENT", 9, 23], ["antibody-mediated enhancement of infection", "PROBLEM", 60, 102], ["transfusion", "TREATMENT", 104, 115], ["acute lung injury", "PROBLEM", 127, 144], ["allergic transfusion reactions", "PROBLEM", 149, 179], ["Immunoglobulin therapy", "TREATMENT", 180, 202], ["TherapeuticsMonoclonal antibody therapy", "TREATMENT", 207, 246], ["an effective immunotherapy", "TREATMENT", 250, 276], ["the treatment", "TREATMENT", 281, 294], ["some viral infections", "PROBLEM", 298, 319], ["infection", "OBSERVATION", 93, 102], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["lung", "ANATOMY", 133, 137], ["injury", "OBSERVATION", 138, 144], ["allergic transfusion", "OBSERVATION", 149, 169], ["viral", "OBSERVATION_MODIFIER", 303, 308], ["infections", "OBSERVATION", 309, 319]]], ["Recent studies reported specific monoclonal antibodies neutralizing SARS-CoV-2 infection in vitro and in vivo155\u2013158.", [["infection", "DISEASE", 79, 88], ["SARS-CoV-2", "ORGANISM", 68, 78], ["monoclonal antibodies", "PROTEIN", 33, 54], ["SARS-CoV-2", "SPECIES", 68, 78], ["Recent studies", "TEST", 0, 14], ["specific monoclonal antibodies neutralizing SARS", "PROBLEM", 24, 72], ["CoV", "TEST", 73, 76], ["2 infection", "PROBLEM", 77, 88]]], ["Compared with convalescent plasma, which has limited availability and cannot be amplified, monoclonal antibodies can be developed in larger quantities to meet clinical requirements.", [["plasma", "ANATOMY", 27, 33], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["monoclonal antibodies", "PROTEIN", 91, 112], ["convalescent plasma", "TEST", 14, 33], ["monoclonal antibodies", "TEST", 91, 112]]], ["Hence, they provide the possibility for the treatment and prevention of COVID-19.", [["COVID-19", "CHEMICAL", 72, 80], ["the treatment", "TREATMENT", 40, 53], ["COVID", "TEST", 72, 77]]], ["The neutralizing epitopes of these monoclonal antibodies also offer important information for vaccine design.", [["neutralizing epitopes", "PROTEIN", 4, 25], ["monoclonal antibodies", "PROTEIN", 35, 56], ["The neutralizing epitopes", "TREATMENT", 0, 25], ["these monoclonal antibodies", "TREATMENT", 29, 56], ["vaccine design", "TREATMENT", 94, 108], ["neutralizing", "OBSERVATION_MODIFIER", 4, 16]]], ["However, the high cost and limited capacity of manufacturing, as well as the problem of bioavailability, may restrict the wide application of monoclonal antibody therapy.VaccinesVaccination is the most effective method for a long-term strategy for prevention and control of COVID-19 in the future.", [["COVID-19", "CHEMICAL", 274, 282], ["monoclonal antibody", "PROTEIN", 142, 161], ["the high cost", "PROBLEM", 9, 22], ["manufacturing", "TREATMENT", 47, 60], ["monoclonal antibody therapy", "TREATMENT", 142, 169], ["VaccinesVaccination", "TREATMENT", 170, 189], ["a long-term strategy", "TREATMENT", 223, 243], ["COVID", "TEST", 274, 279], ["high", "OBSERVATION_MODIFIER", 13, 17], ["monoclonal antibody therapy", "OBSERVATION", 142, 169], ["most effective", "OBSERVATION_MODIFIER", 197, 211]]], ["Many different vaccine platforms against SARS-CoV-2 are in development, the strategies of which include recombinant vectors, DNA, mRNA in lipid nanoparticles, inactivated viruses, live attenuated viruses and protein subunits159\u2013161.", [["SARS", "DISEASE", 41, 45], ["SARS-CoV-2", "ORGANISM", 41, 51], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["lipid nanoparticles", "SIMPLE_CHEMICAL", 138, 157], ["recombinant vectors", "DNA", 104, 123], ["mRNA", "RNA", 130, 134], ["protein subunits159\u2013161", "PROTEIN", 208, 231], ["SARS-CoV", "SPECIES", 41, 49], ["Many different vaccine platforms", "TREATMENT", 0, 32], ["SARS", "PROBLEM", 41, 45], ["recombinant vectors", "TREATMENT", 104, 123], ["DNA", "PROBLEM", 125, 128], ["mRNA in lipid nanoparticles", "TREATMENT", 130, 157], ["inactivated viruses", "PROBLEM", 159, 178], ["live attenuated viruses", "PROBLEM", 180, 203], ["protein subunits", "TEST", 208, 224]]], ["As of 2 October 2020, ~174 vaccine candidates for COVID-19 had been reported and 51 were in human clinical trials (COVID-19 vaccine and therapeutics tracker).", [["COVID-19", "CHEMICAL", 50, 58], ["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["COVID", "TEST", 50, 55], ["COVID-19 vaccine", "TREATMENT", 115, 131], ["therapeutics tracker", "TREATMENT", 136, 156]]], ["Many of these vaccine candidates are in phase II testing, and some have already advanced to phase III trials.", [["these vaccine candidates", "TREATMENT", 8, 32], ["phase II testing", "TEST", 40, 56], ["phase III trials", "TREATMENT", 92, 108]]], ["A randomized double-blinded phase II trial of an adenovirus type 5-vectored vaccine expressing the SARS-CoV-2 S protein, developed by CanSino Biologicals and the Academy of Military Medical Sciences of China, was conducted in 603 adult volunteers in Wuhan.", [["adenovirus type 5", "ORGANISM", 49, 66], ["volunteers", "ORGANISM", 236, 246], ["SARS-CoV-2 S protein", "PROTEIN", 99, 119], ["A randomized double-blinded phase II trial", "TREATMENT", 0, 42], ["an adenovirus type 5-vectored vaccine", "TREATMENT", 46, 83], ["the SARS", "TEST", 95, 103], ["CoV", "TEST", 104, 107]]], ["The vaccine has proved to be safe and induced considerable humoral and cellular immune response in most recipients after a single immunization162.", [["cellular", "ANATOMY", 71, 79], ["cellular", "CELL", 71, 79], ["recipients", "ORGANISM", 104, 114], ["The vaccine", "TREATMENT", 0, 11], ["a single immunization", "TREATMENT", 121, 142], ["cellular immune response", "OBSERVATION", 71, 95]]], ["Another vectored vaccine, ChAdOx1, was developed on the basis of chimpanzee adenovirus by the University of Oxford.", [["ChAdOx1", "CHEMICAL", 26, 33], ["ChAdOx1", "SIMPLE_CHEMICAL", 26, 33], ["chimpanzee", "ORGANISM", 65, 75], ["adenovirus", "ORGANISM", 76, 86], ["chimpanzee adenovirus", "SPECIES", 65, 86], ["Another vectored vaccine", "TREATMENT", 0, 24], ["ChAdOx1", "TREATMENT", 26, 33], ["chimpanzee adenovirus", "TREATMENT", 65, 86]]], ["In a randomized controlled phase I/II trial, it induced neutralizing antibodies against SARS-CoV-2 in all 1,077 participants after a second vaccine dose, while its safety profile was acceptable as well163.", [["SARS-CoV-2", "ORGANISM", 88, 98], ["participants", "ORGANISM", 112, 124], ["neutralizing antibodies", "PROTEIN", 56, 79], ["participants", "SPECIES", 112, 124], ["SARS-CoV", "SPECIES", 88, 96], ["a randomized controlled phase I/II trial", "TREATMENT", 3, 43], ["neutralizing antibodies", "TEST", 56, 79], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["a second vaccine dose", "TREATMENT", 131, 152]]], ["The NIAID and Moderna co-manufactured mRNA-1273, a lipid nanoparticle-formulated mRNA vaccine candidate that encodes the stabilized prefusion SARS-CoV-2 S protein.", [["mRNA-1273", "CHEMICAL", 38, 47], ["CoV-2 S", "GENE_OR_GENE_PRODUCT", 147, 154], ["NIAID and Moderna co-manufactured mRNA-1273", "DNA", 4, 47], ["prefusion SARS-CoV-2 S protein", "PROTEIN", 132, 162], ["The NIAID", "TEST", 0, 9], ["Moderna co-manufactured mRNA", "TEST", 14, 42], ["a lipid nanoparticle", "TREATMENT", 49, 69], ["mRNA vaccine", "TREATMENT", 81, 93], ["the stabilized prefusion SARS", "PROBLEM", 117, 146], ["CoV", "TEST", 147, 150]]], ["Its immunogenicity has been confirmed by a phase I trial in which robust neutralizing antibody responses were induced in a dose-dependent manner and increased after a second dose164.", [["a phase I trial", "TREATMENT", 41, 56]]], ["Regarding inactivated vaccines, a successful phase I/II trial involving 320 participants has been reported in China.", [["participants", "SPECIES", 76, 88], ["inactivated vaccines", "TREATMENT", 10, 30], ["a successful phase I/II trial", "TREATMENT", 32, 61]]], ["The whole-virus COVID-19 vaccine had a low rate of adverse reactions and effectively induced neutralizing antibody production165.", [["The whole-virus COVID", "TEST", 0, 21], ["adverse reactions", "PROBLEM", 51, 68], ["effectively induced neutralizing antibody production", "PROBLEM", 73, 125]]], ["The verified safety and immunogenicity support advancement of these vaccine candidates to phase III clinical trials, which will evaluate their efficacy in protecting healthy populations from SARS-CoV-2 infection.Future perspectivesCOVID-19 is the third highly pathogenic human coronavirus disease to date.", [["SARS-CoV-2 infection", "DISEASE", 191, 211], ["coronavirus disease", "DISEASE", 277, 296], ["SARS-CoV-2", "ORGANISM", 191, 201], ["human", "ORGANISM", 271, 276], ["human", "SPECIES", 271, 276], ["SARS-CoV-2", "SPECIES", 191, 201], ["human coronavirus", "SPECIES", 271, 288], ["these vaccine", "TREATMENT", 62, 75], ["SARS", "PROBLEM", 191, 195], ["CoV-2 infection", "PROBLEM", 196, 211], ["Future perspectivesCOVID", "TEST", 212, 236], ["the third highly pathogenic human coronavirus disease", "PROBLEM", 243, 296], ["infection", "OBSERVATION", 202, 211], ["pathogenic human coronavirus disease", "OBSERVATION", 260, 296]]], ["Although less deadly than SARS and MERS, the rapid spreading of this highly contagious disease has posed the severest threat to global health in this century.", [["SARS", "DISEASE", 26, 30], ["MERS", "DISEASE", 35, 39], ["SARS", "PROBLEM", 26, 30], ["this highly contagious disease", "PROBLEM", 64, 94], ["less", "OBSERVATION_MODIFIER", 9, 13], ["deadly", "OBSERVATION_MODIFIER", 14, 20]]], ["The SARS-CoV-2 outbreak has lasted for more than half a year now, and it is likely that this emerging virus will establish a niche in humans and coexist with us for a long time166.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["humans", "ORGANISM", 134, 140], ["humans", "SPECIES", 134, 140], ["SARS-CoV", "SPECIES", 4, 12], ["humans", "SPECIES", 134, 140], ["The SARS", "TEST", 0, 8], ["this emerging virus", "PROBLEM", 88, 107]]], ["Before clinically approved vaccines are widely available, there is no better way to protect us from SARS-CoV-2 than personal preventive behaviours such as social distancing and wearing masks, and public health measures, including active testing, case tracing and restrictions on social gatherings.", [["SARS", "DISEASE", 100, 104], ["vaccines", "TREATMENT", 27, 35], ["active testing", "TEST", 230, 244]]], ["Despite a flood of SARS-CoV-2 research published every week, current knowledge of this novel coronavirus is just the tip of the iceberg.", [["SARS", "DISEASE", 19, 23], ["coronavirus", "DISEASE", 93, 104], ["coronavirus", "ORGANISM", 93, 104], ["SARS", "PROBLEM", 19, 23], ["this novel coronavirus", "PROBLEM", 82, 104], ["coronavirus", "OBSERVATION", 93, 104], ["tip", "OBSERVATION_MODIFIER", 117, 120], ["iceberg", "OBSERVATION", 128, 135]]], ["The animal origin and cross-species infection route of SARS-CoV-2 are yet to be uncovered.", [["infection", "DISEASE", 36, 45], ["SARS", "DISEASE", 55, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["cross-species infection", "PROBLEM", 22, 45], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["origin", "OBSERVATION_MODIFIER", 11, 17], ["cross-species", "OBSERVATION_MODIFIER", 22, 35], ["infection", "OBSERVATION", 36, 45]]], ["The molecular mechanisms of SARS-CoV-2 infection pathogenesis and virus\u2013host interactions remain largely unclear.", [["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 39, 48], ["SARS-CoV-2", "ORGANISM", 28, 38], ["SARS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36], ["2 infection pathogenesis", "PROBLEM", 37, 61], ["virus\u2013host interactions", "PROBLEM", 66, 89], ["SARS", "OBSERVATION", 28, 32], ["CoV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 39, 48]]], ["Intensive studies on these virological profiles of SARS-CoV-2 will provide the basis for the development of preventive and therapeutic strategies against COVID-19.", [["SARS", "DISEASE", 51, 55], ["SARS-CoV-2", "ORGANISM", 51, 61], ["SARS-CoV", "SPECIES", 51, 59], ["Intensive studies", "TEST", 0, 17], ["these virological profiles", "TEST", 21, 47], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["COVID", "TEST", 154, 159]]], ["Moreover, continued genomic monitoring of SARS-CoV-2 in new cases is needed worldwide, as it is important to promptly identify any mutation that may result in phenotypic changes of the virus.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "ORGANISM", 42, 52], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["any mutation", "PROBLEM", 127, 139], ["phenotypic changes of the virus", "PROBLEM", 159, 190]]], ["Finally, COVID-19 is challenging all human beings.", [["human", "ORGANISM", 37, 42], ["COVID-19", "DNA", 9, 17], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["COVID", "TEST", 9, 14]]]], "PMC7475731": [], "6cab26f503af61365106a1be2eaeba79f1096381": [["INTRODUCTIONAmid the global pandemic on coronavirus disease 2019 (COVID- 19) , epidemiologists promote containment strategies to prevent community transmission.(1) Contact tracing of susceptible persons and extensive testing in South Korea demonstrated as an example of successful containment.(1) South Korea reported the first confirmed cases on January 20, 2020, and the instances spiked from February 20 to 29, 2020.(2,3) As of mid-March, 2020, such containment strategies helped flatten the curve of new confirmed cases.", [["coronavirus disease", "DISEASE", 40, 59], ["coronavirus", "ORGANISM", 40, 51], ["persons", "ORGANISM", 195, 202], ["coronavirus", "SPECIES", 40, 51], ["persons", "SPECIES", 195, 202], ["coronavirus disease", "PROBLEM", 40, 59], ["COVID", "TEST", 66, 71], ["containment strategies", "TREATMENT", 103, 125], ["extensive testing", "TEST", 207, 224], ["such containment strategies", "TREATMENT", 448, 475], ["global", "OBSERVATION_MODIFIER", 21, 27], ["pandemic", "OBSERVATION_MODIFIER", 28, 36], ["coronavirus disease", "OBSERVATION", 40, 59], ["successful", "OBSERVATION_MODIFIER", 270, 280], ["containment", "OBSERVATION", 281, 292]]], ["(2) The contact tracing and testing allow us to investigate different transmission dynamics into various local communities.", [["The contact tracing", "TEST", 4, 23]]], ["Person-to-person transmissions can be represented as a transmission network, and this network facilitates investigation of topological dynamics in disease transmission and detection of super-spreaders.", [["person", "SPECIES", 10, 16], ["super-spreaders", "PROBLEM", 185, 200]]], ["(4, 5) Also, the transmission network can be divided into individual infection clusters that have different characteristics in terms of demographics and network topology.", [["infection", "DISEASE", 69, 78], ["(4, 5)", "CHEMICAL", 0, 6], ["individual infection clusters", "PROBLEM", 58, 87], ["infection", "OBSERVATION", 69, 78]]], ["The network analysis has been widely studied in various infectious diseases such as Middle East Respiratory Syndrome (MERS), (4, 5) Several Acute Respiratory Syndrome (SARS),(6)(6,7) tuberculosis, (8, 9) and cholera.(10) Some COVID-19 studies have revealed evolving person-to-person transmission dynamics in China in a longitudinal view.", [["infectious diseases", "DISEASE", 56, 75], ["Middle East Respiratory Syndrome", "DISEASE", 84, 116], ["MERS", "DISEASE", 118, 122], ["Acute Respiratory Syndrome", "DISEASE", 140, 166], ["SARS", "DISEASE", 168, 172], ["tuberculosis", "DISEASE", 183, 195], ["cholera", "DISEASE", 208, 215], ["person", "SPECIES", 266, 272], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 84, 123], ["The network analysis", "TEST", 0, 20], ["various infectious diseases", "PROBLEM", 48, 75], ["Middle East Respiratory Syndrome", "PROBLEM", 84, 116], ["Several Acute Respiratory Syndrome (SARS),(6)(6,7) tuberculosis", "PROBLEM", 132, 195], ["cholera", "PROBLEM", 208, 215], ["Some COVID-19 studies", "TEST", 221, 242], ["infectious", "OBSERVATION", 56, 66], ["Middle", "ANATOMY_MODIFIER", 84, 90], ["Respiratory Syndrome", "OBSERVATION", 96, 116], ["Acute", "OBSERVATION_MODIFIER", 140, 145], ["Respiratory Syndrome", "OBSERVATION", 146, 166], ["tuberculosis", "OBSERVATION", 183, 195]]], ["(11, 12) A genomic mutation study has investigated country-to-country transmission dynamics on a global scale.", [["A genomic mutation study", "TEST", 9, 33], ["a global scale", "TREATMENT", 95, 109]]], ["(13) A piece of critical missing knowledge is how person-to-person transmission differs across different demographics and also different super-spreading environments in cluster infections.INTRODUCTIONThus, the objective of our study was to investigate network characteristics of person-to-person transmission in the different granularity: entire country and individual cluster infections.", [["infections", "DISEASE", 177, 187], ["infections", "DISEASE", 377, 387], ["person", "SPECIES", 50, 56], ["person", "SPECIES", 279, 285], ["person", "SPECIES", 289, 295], ["cluster infections", "PROBLEM", 169, 187], ["our study", "TEST", 223, 232], ["individual cluster infections", "PROBLEM", 358, 387], ["infections", "OBSERVATION", 177, 187], ["cluster", "OBSERVATION_MODIFIER", 369, 376], ["infections", "OBSERVATION", 377, 387]]], ["We provided interactive visualization in the code repository (https://github.com/yejinjkim/covid19-transmission-network) for an intuitive understanding of the evolving transmission network.", [["interactive visualization", "TEST", 12, 37]]], ["To the best of our knowledge, our work is first to compare transmission dynamics in cluster-wise.Data collectionWe conducted a retrospective observational study with contact tracing data from the Center for Disease Controls and Prevention (CDC) of South Korea.", [["a retrospective observational study", "TEST", 125, 160], ["contact tracing data", "TEST", 166, 186], ["Disease Controls", "PROBLEM", 207, 223]]], ["The South Korea CDC actively performed testing, monitoring, and tracing contacts and disseminated the information to the public.", [["testing", "TEST", 39, 46], ["monitoring", "TEST", 48, 58]]], ["We collected the contact tracing data prepared in the Data Science for COVID-19 Project in South Korea,(14) which enables researchers to access the data publicly.", [["COVID", "TEST", 71, 76]]], ["This data contains demographics, exposure type or travel history, confirmed/release date, underlying disease, deceased status.", [["underlying disease", "PROBLEM", 90, 108], ["disease", "OBSERVATION", 101, 108]]], ["This study used 3,127 patient's transmission data from January 20, 2020 to April 7, 2020, retrieved on April 8, 2020.Statistical AnalysisThe evolving transmission network.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["This study", "TEST", 0, 10], ["Statistical Analysis", "TEST", 117, 137]]], ["We built a longitudinal transmission network using the transmission data.", [["the transmission data", "TEST", 51, 72]]], ["The transmission network consisted of nodes for the infected persons and directed edges from infectious nodes (infector) to infected nodes (infectee).", [["nodes", "ANATOMY", 38, 43], ["nodes", "ANATOMY", 104, 109], ["infector", "ANATOMY", 111, 119], ["nodes", "ANATOMY", 133, 138], ["nodes", "MULTI-TISSUE_STRUCTURE", 38, 43], ["persons", "ORGANISM", 61, 68], ["infectious nodes", "MULTI-TISSUE_STRUCTURE", 93, 109], ["nodes", "MULTI-TISSUE_STRUCTURE", 133, 138], ["persons", "SPECIES", 61, 68], ["nodes", "PROBLEM", 38, 43], ["the infected persons", "PROBLEM", 48, 68], ["infectious nodes", "PROBLEM", 93, 109], ["infected nodes", "PROBLEM", 124, 138], ["nodes", "OBSERVATION", 38, 43], ["infected", "OBSERVATION_MODIFIER", 52, 60], ["edges", "OBSERVATION_MODIFIER", 82, 87], ["infectious", "OBSERVATION_MODIFIER", 93, 103], ["nodes", "OBSERVATION", 104, 109], ["infected", "OBSERVATION_MODIFIER", 124, 132], ["nodes", "OBSERVATION", 133, 138]]], ["The nodes and edges had timestamps at which the infectee's infections are confirmed.", [["nodes", "ANATOMY", 4, 9], ["infections", "DISEASE", 59, 69], ["nodes", "MULTI-TISSUE_STRUCTURE", 4, 9], ["timestamps", "TREATMENT", 24, 34], ["the infectee's infections", "PROBLEM", 44, 69], ["nodes", "OBSERVATION", 4, 9], ["edges", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 59, 69]]], ["This longitudinal network evolved over time as accumulating all previous nodes and edges.Statistical AnalysisTransmission network characteristics.", [["nodes", "ANATOMY", 73, 78], ["longitudinal network", "MULTI-TISSUE_STRUCTURE", 5, 25], ["all", "OBSERVATION_MODIFIER", 60, 63], ["nodes", "OBSERVATION", 73, 78], ["edges", "OBSERVATION_MODIFIER", 83, 88]]], ["We presented network characteristics in terms of centrality and path lengths:Statistical Analysis-Centrality is a useful measure to investigate individual patients who shed the virus most (i.e., superspreaders) over time.", [["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["Statistical Analysis", "TEST", 77, 97], ["the virus", "PROBLEM", 173, 182]]], ["Node degree is the number of edges linked to the node in the network.", [["node", "ANATOMY", 49, 53], ["node", "MULTI-TISSUE_STRUCTURE", 49, 53], ["degree", "OBSERVATION_MODIFIER", 5, 11], ["node", "OBSERVATION", 49, 53]]], ["Betweenness is the extent to which a node lies on the shortest paths between other nodes.(15) Nodes with high betweenness may have high control over transmission passing between nodes.", [["node", "ANATOMY", 37, 41], ["nodes", "ANATOMY", 83, 88], ["nodes", "ANATOMY", 178, 183], ["nodes", "MULTI-TISSUE_STRUCTURE", 83, 88], ["nodes", "MULTI-TISSUE_STRUCTURE", 178, 183], ["a node", "PROBLEM", 35, 41], ["Nodes with high betweenness", "PROBLEM", 94, 121], ["high control over transmission passing between nodes", "PROBLEM", 131, 183], ["extent", "OBSERVATION_MODIFIER", 19, 25], ["node", "OBSERVATION", 37, 41], ["nodes", "OBSERVATION", 83, 88], ["Nodes", "OBSERVATION", 94, 99], ["high", "OBSERVATION_MODIFIER", 131, 135], ["nodes", "OBSERVATION", 178, 183]]], ["We used betweenness to measure how much a patient contributed to the transmission as intermediate hosts.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49]]], ["We defined a super-spreading person as a person with a degree > 3.5 for degree or top 5% betweenness values.(16) Note that the node degree was calculated based on all accumulated transmissions (whereas the reproduction number is generally calculated within the observation period). -Path length can measure how far the transmission chain of successive cases can go.", [["node", "ANATOMY", 127, 131], ["node", "MULTI-TISSUE_STRUCTURE", 127, 131], ["person", "SPECIES", 29, 35], ["person", "SPECIES", 41, 47], ["the node degree", "TEST", 123, 138], ["node", "OBSERVATION", 127, 131], ["accumulated", "OBSERVATION_MODIFIER", 167, 178], ["transmissions", "OBSERVATION_MODIFIER", 179, 192]]], ["The path length is the number of nodes or steps in the shortest path from a source node to a target node.", [["node", "ANATOMY", 83, 87], ["node", "ANATOMY", 100, 104], ["node", "MULTI-TISSUE_STRUCTURE", 100, 104], ["path", "OBSERVATION_MODIFIER", 4, 8], ["length", "OBSERVATION_MODIFIER", 9, 15], ["number", "OBSERVATION_MODIFIER", 23, 29], ["nodes", "OBSERVATION", 33, 38], ["source node", "OBSERVATION", 76, 87], ["target", "OBSERVATION_MODIFIER", 93, 99], ["node", "OBSERVATION", 100, 104]]], ["The average path length is the average value of the shortest path lengths between all pairs of nodes in the network.", [["average", "OBSERVATION_MODIFIER", 4, 11], ["path", "OBSERVATION_MODIFIER", 12, 16], ["length", "OBSERVATION_MODIFIER", 17, 23], ["nodes", "OBSERVATION", 95, 100]]], ["The longest path length (also known as diameter) is the maximum amount of the shortest path length.Statistical AnalysisInfection clusters.", [["Statistical AnalysisInfection clusters", "PROBLEM", 99, 137], ["longest", "OBSERVATION_MODIFIER", 4, 11], ["path", "OBSERVATION_MODIFIER", 12, 16], ["length", "OBSERVATION_MODIFIER", 17, 23], ["diameter", "OBSERVATION_MODIFIER", 39, 47], ["maximum", "OBSERVATION_MODIFIER", 56, 63], ["amount", "OBSERVATION_MODIFIER", 64, 70], ["shortest", "OBSERVATION_MODIFIER", 78, 86]]], ["We divided the transmission network into subgraphs with connected nodes (i.e., the connected components).", [["nodes", "MULTI-TISSUE_STRUCTURE", 66, 71], ["connected nodes", "PROBLEM", 56, 71], ["nodes", "OBSERVATION", 66, 71]]], ["The connected components are an extended concept of infection cluster, as the connected components include all successive infected persons who are infected from the infection cluster.", [["infection", "DISEASE", 52, 61], ["infection", "DISEASE", 165, 174], ["persons", "ORGANISM", 131, 138], ["persons", "SPECIES", 131, 138], ["infection cluster", "PROBLEM", 52, 69], ["the infection cluster", "PROBLEM", 161, 182], ["infection", "OBSERVATION", 52, 61], ["all", "OBSERVATION_MODIFIER", 107, 110], ["successive", "OBSERVATION_MODIFIER", 111, 121], ["infected", "OBSERVATION_MODIFIER", 122, 130], ["infection", "OBSERVATION", 165, 174]]], ["For briefly, we denoted the connected components as the infection cluster.", [["infection", "DISEASE", 56, 65], ["the infection cluster", "PROBLEM", 52, 73], ["infection", "OBSERVATION", 56, 65]]], ["During the contact tracing, it is expected that the index patient was unidentifiable in each infection cluster.", [["infection", "DISEASE", 93, 102], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["the contact tracing", "TEST", 7, 26], ["each infection cluster", "PROBLEM", 88, 110], ["infection", "OBSERVATION", 93, 102]]], ["To represent links among the nodes in the same cluster with an unknown index patient, we set a virtual index patient and we made edges from the virtual index patient to infected patients for each infection cluster.RESULTSThe evolving transmission network.", [["nodes", "ANATOMY", 29, 34], ["infection", "DISEASE", 196, 205], ["patient", "ORGANISM", 77, 84], ["patient", "ORGANISM", 109, 116], ["patient", "ORGANISM", 158, 165], ["patients", "ORGANISM", 178, 186], ["patient", "SPECIES", 77, 84], ["patient", "SPECIES", 109, 116], ["patient", "SPECIES", 158, 165], ["patients", "SPECIES", 178, 186], ["the nodes", "PROBLEM", 25, 34], ["each infection cluster", "PROBLEM", 191, 213], ["nodes", "OBSERVATION", 29, 34], ["index", "OBSERVATION", 71, 76], ["infection", "OBSERVATION", 196, 205]]], ["From January 20, 2020 to April 7, 2020, we identified a total 1,611 transmission from 3,127 patients (727 person to person; 884 persons in infection clusters with unknown index patient).", [["infection", "DISEASE", 139, 148], ["patients", "ORGANISM", 92, 100], ["persons", "ORGANISM", 128, 135], ["patient", "ORGANISM", 177, 184], ["patients", "SPECIES", 92, 100], ["person", "SPECIES", 106, 112], ["person", "SPECIES", 116, 122], ["persons", "SPECIES", 128, 135], ["patient", "SPECIES", 177, 184]]], ["We presented demographic characteristics of patients and their transmission ( Fig.1 , Table 1 ) when newly confirmed cases rapidly increase (weeks 4, 5, 6) and after the recently confirmed cases decrease (after peak, week 10).", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Note that the mass cluster infection occurred at week 4 with an outbreak in religious gathering in Daegu.", [["infection", "DISEASE", 27, 36], ["the mass cluster infection", "PROBLEM", 10, 36], ["mass", "OBSERVATION", 14, 18], ["cluster", "OBSERVATION_MODIFIER", 19, 26], ["infection", "OBSERVATION", 27, 36]]], ["(17) The demographic characteristics of patients and their transmission varied in different observation periods.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["Also, female-to-female transmissions were more frequent than male-to-male transmissions (but there was no statistical power as chi-squared value of the contingency table=1.36, p-value=0.2430).RESULTSThroughout all observations, the largest age group was age 25-49.", [["chi-squared value", "TEST", 127, 144], ["the contingency table", "TEST", 148, 169], ["p-value", "TEST", 176, 183]]], ["Although there was no reported transmission among similar aged children and adolescents (presumably due to strict school closure), this young age group sometimes infected their middle-aged parents.", [["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71], ["adolescents", "SPECIES", 76, 87], ["strict school closure", "TREATMENT", 107, 128], ["no", "UNCERTAINTY", 19, 21]]], ["In week 6, South Korea reported an increased number of new confirmed cases from older adults, and the transmissions occurred mostly among the older adults.", [["increased", "OBSERVATION_MODIFIER", 35, 44]]], ["The centrality of individual patients.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["centrality", "OBSERVATION_MODIFIER", 4, 14]]], ["We further investigated the distribution of the network centrality concerning infected persons' sex and race (animated plot in Supplement 2).", [["persons", "ORGANISM", 87, 94], ["persons", "SPECIES", 87, 94]]], ["(18) As a result, we found that women have higher centrality scores than men as the confirmed cases exponentially increase around week 5 to 6 (Fig. 3) .", [["(18) As", "CHEMICAL", 0, 7], ["women", "ORGANISM", 32, 37], ["men", "ORGANISM", 73, 76], ["women", "SPECIES", 32, 37], ["men", "SPECIES", 73, 76], ["higher centrality scores", "PROBLEM", 43, 67]]], ["During the first four weeks after the first case, the number of instances slowly increased, and men tend to have higher degrees and betweenness.", [["men", "ORGANISM", 96, 99], ["men", "SPECIES", 96, 99], ["slowly", "OBSERVATION_MODIFIER", 74, 80], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["higher degrees", "OBSERVATION_MODIFIER", 113, 127]]], ["Women, however, started to have higher degrees and betweenness after week 5.", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5], ["higher degrees", "OBSERVATION_MODIFIER", 32, 46]]], ["We used the Mann-Whitney-U for hypothesis testing on whether super-spreading women have higher centrality values than super-spreading men.", [["women", "ORGANISM", 77, 82], ["men", "ORGANISM", 134, 137], ["women", "SPECIES", 77, 82], ["men", "SPECIES", 134, 137], ["hypothesis testing", "TEST", 31, 49], ["higher centrality values", "PROBLEM", 88, 112]]], ["The p-values were statistically significant after week 6 for degree (p-value=0.0156) and week 11 for betweenness (p-value=0.0402).RESULTSWe found that older adults have higher centrality than young/middle-aged adults after the peak has passed around week 9 (Fig. 3) .", [["adults", "ORGANISM", 210, 216], ["The p-values", "TEST", 0, 12], ["p-value", "TEST", 69, 76], ["p-value", "TEST", 114, 121]]], ["After week 9, more older adults had higher degree and betweenness values than young/middle-aged adults.", [["adults", "ORGANISM", 96, 102], ["higher degree and betweenness values", "PROBLEM", 36, 72]]], ["We used the Mann-Whitney-U for hypothesis testing on whether the super-spreading older adults have higher centrality than super-spreading young adults.", [["adults", "ORGANISM", 87, 93], ["adults", "ORGANISM", 144, 150], ["hypothesis testing", "TEST", 31, 49]]], ["The p-values were statistically significant after week 9 for degree (p-value=0.0413).", [["The p-values", "TEST", 0, 12], ["p-value", "TEST", 69, 76], ["significant", "OBSERVATION_MODIFIER", 32, 43]]], ["Note that there was a time lag between degree and betweenness as the betweenness increases after successive transmission occurs.Infection clustersThere were a total of 147 clusters (defined as connected components) and we selected 12 clusters that have at least 20 patients involved.", [["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["Infection clusters", "PROBLEM", 128, 146]]], ["The clusters' network visualization is available at Supplement1.Infection clustersOverall, the top four largest clusters were related to Guro customer call center, Shincheonji Church, River of Grace Community Church, and gym facilities in Cheonan.", [["network", "MULTI-TISSUE_STRUCTURE", 14, 21], ["Infection clusters", "PROBLEM", 64, 82], ["largest", "OBSERVATION_MODIFIER", 104, 111]]], ["A common characteristic of the four largest clusters was that they all had higher women rates (72%, 55%, 60%, and 72%, respectively).", [["women", "ORGANISM", 82, 87], ["women", "SPECIES", 82, 87], ["four", "OBSERVATION_MODIFIER", 31, 35], ["largest", "OBSERVATION_MODIFIER", 36, 43], ["higher", "OBSERVATION_MODIFIER", 75, 81]]], ["Clusters with the smallest path lengths were all related to nursing homes (Gunpo Nursing Home, Cheongdo Daenam Hospital Psychiatric Ward, and Bongwha Nursing Home).", [["smallest", "OBSERVATION_MODIFIER", 18, 26]]], ["No reuse allowed without permission.Infection clusters(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Infection clustersThe copyright holder for this preprint this version posted May 12, 2020. .DISCUSSIONThe objective of this study was to provide the evolving transmission dynamics of COVID-19 in South Korea.", [["Infection clusters", "PROBLEM", 36, 54], ["Infection clusters", "PROBLEM", 189, 207], ["The copyright holder", "TREATMENT", 207, 227], ["this study", "TEST", 308, 318], ["COVID", "TEST", 372, 377], ["med", "ANATOMY", 133, 136]]], ["We investigated network property and demographic features from the whole transmission network and also clustered level.DISCUSSIONThe demographics of newly confirmed patients and their transmission provided an overview of how various demographic groups contribute to transmission.", [["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["the whole transmission network", "TEST", 63, 93]]], ["The main observation includes: i) In early days until week four most confirmed positives were imported cases who were male in their 40s; ii) women were more than 50% of newly confirmed cases after week 4; iii) there were more female-to-female transmissions than male-to-male transmissions; iv) children and adolescents infected their parents; and v) older adults infected other older adults.", [["women", "ORGANISM", 141, 146], ["children", "ORGANISM", 294, 302], ["women", "SPECIES", 141, 146], ["children", "SPECIES", 294, 302], ["adolescents", "SPECIES", 307, 318], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Further investigation is needed to obtain statistical power.", [["Further investigation", "TEST", 0, 21]]], ["We expect these observations can provide situational awareness to future contact tracing efforts.DISCUSSIONThe network characteristics of the entire system found the transmission network's density and successive transmission lengths evolved over time.", [["successive transmission lengths", "PROBLEM", 201, 232]]], ["The transmission network was getting sparse as the number of newly confirmed cases rapidly increased.", [["rapidly", "OBSERVATION_MODIFIER", 83, 90], ["increased", "OBSERVATION_MODIFIER", 91, 100]]], ["The sparsity limitation was inherited from the contact tracing containing the increasing number of unknown transmission paths in local communities.", [["the contact tracing", "TEST", 43, 62], ["increasing", "OBSERVATION_MODIFIER", 78, 88], ["number", "OBSERVATION_MODIFIER", 89, 95]]], ["Thus our estimate on network property (degree, betweenness, diameter, and path length) should be interpreted as a lower bound.DISCUSSIONThe main finding from network centrality analysis was that women had higher centrality (in both degree and betweenness) than men had as the instances rapidly increased.", [["women", "ORGANISM", 195, 200], ["men", "ORGANISM", 261, 264], ["women", "SPECIES", 195, 200], ["men", "SPECIES", 261, 264], ["a lower bound", "PROBLEM", 112, 125], ["main", "OBSERVATION_MODIFIER", 140, 144], ["higher", "OBSERVATION_MODIFIER", 205, 211], ["centrality", "OBSERVATION_MODIFIER", 212, 222], ["both degree", "OBSERVATION_MODIFIER", 227, 238], ["rapidly", "OBSERVATION_MODIFIER", 286, 293], ["increased", "OBSERVATION_MODIFIER", 294, 303]]], ["This implies not only that women's reproduction number was larger than men's, but also that some women bridged the long successive transmissions.", [["women", "ORGANISM", 27, 32], ["men", "ORGANISM", 71, 74], ["women", "ORGANISM", 97, 102], ["women", "SPECIES", 27, 32], ["men", "SPECIES", 71, 74], ["women", "SPECIES", 97, 102], ["not only", "UNCERTAINTY", 13, 21]]], ["A possible explanation might be that men are more likely to die or critically ill than women, and consequently men have less opportunity to shed the virus.", [["critically ill", "DISEASE", 67, 81], ["men", "ORGANISM", 37, 40], ["women", "ORGANISM", 87, 92], ["men", "ORGANISM", 111, 114], ["men", "SPECIES", 37, 40], ["women", "SPECIES", 87, 92], ["men", "SPECIES", 111, 114], ["the virus", "PROBLEM", 145, 154], ["possible explanation might", "UNCERTAINTY", 2, 28]]], ["(19) Note that the higher portion of confirmed cases does not necessarily cause higher centrality.DISCUSSIONThe second finding is that older adults had high centrality after the peak has passed around week 9.", [["adults", "ORGANISM", 141, 147], ["does not necessarily cause", "UNCERTAINTY", 53, 79], ["higher", "OBSERVATION_MODIFIER", 80, 86], ["centrality", "OBSERVATION", 87, 97]]], ["Note that these older adults with high reproduction numbers were not related to nursing homes.", [["high reproduction numbers", "PROBLEM", 34, 59]]], ["Older adults are more vulnerable to critical illness.(20) Based on our findings, they were not active super-spreaders in the early days.", [["adults", "ORGANISM", 6, 12], ["illness", "OBSERVATION", 45, 52]]], ["Still, after the virus propagated into local communities, the older adults were more likely to be infected by the virus and be superspreaders.DISCUSSIONA breakdown into smaller infection clusters allowed us to find common network characteristics within similar activities.", [["infection", "DISEASE", 177, 186], ["adults", "ORGANISM", 68, 74], ["the virus", "PROBLEM", 13, 22], ["the virus", "PROBLEM", 110, 119], ["DISCUSSIONA breakdown into smaller infection clusters", "PROBLEM", 142, 195], ["more likely to be", "UNCERTAINTY", 80, 97], ["infected", "OBSERVATION", 98, 106], ["virus", "OBSERVATION", 114, 119], ["smaller", "OBSERVATION_MODIFIER", 169, 176], ["infection", "OBSERVATION", 177, 186]]], ["The religious gathering and gym facilities clusters had high path length and diameter.", [["high", "OBSERVATION_MODIFIER", 56, 60], ["path", "OBSERVATION_MODIFIER", 61, 65], ["length", "OBSERVATION_MODIFIER", 66, 72], ["diameter", "OBSERVATION_MODIFIER", 77, 85]]], ["These clusters mainly consisted of young/middle-aged adults.", [["adults", "ORGANISM", 53, 59]]], ["This observation may imply that the active behavior (e.g., physically close gatherings in church, active group workout in closed facilities) of young/middle-aged adults can spread further away to other communities.", [["adults", "ORGANISM", 162, 168], ["active", "OBSERVATION_MODIFIER", 36, 42]]], ["Thus, restricting trips to other cities would be an adequate policy to prevent the spread effectively.DISCUSSIONIn contrast, the nursing home type clusters consist of older adults with low path lengths and low diameter.", [["low diameter", "OBSERVATION_MODIFIER", 206, 218]]], ["Each nursing home cluster grew fast with relatively short path length, implying that the clusters might have a small-world property that spread the virus rapidly as the majority of nodes were reachable in a small number of steps.", [["nodes", "ANATOMY", 181, 186], ["nodes", "MULTI-TISSUE_STRUCTURE", 181, 186], ["the virus", "PROBLEM", 144, 153], ["small", "OBSERVATION_MODIFIER", 111, 116], ["virus", "OBSERVATION", 148, 153], ["nodes", "OBSERVATION", 181, 186], ["small", "OBSERVATION_MODIFIER", 207, 212]]], ["This closed psychiatric ward has many long-term patients with underlying diseases.", [["psychiatric", "DISEASE", 12, 23], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["underlying diseases", "PROBLEM", 62, 81], ["long-term", "OBSERVATION_MODIFIER", 38, 47], ["diseases", "OBSERVATION", 73, 81]]], ["(17) Apart from the above local community infections, imported cases were also consistently increasing during all observation periods.", [["infections", "DISEASE", 42, 52], ["the above local community infections", "PROBLEM", 16, 52], ["local", "OBSERVATION_MODIFIER", 26, 31], ["community", "OBSERVATION_MODIFIER", 32, 41], ["infections", "OBSERVATION", 42, 52]]], ["The mean age of the imported patients was 42 years old at week two and consistently decreased to 35.6 years old until week 11.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Men took more than 50% of the imported cases for all observation periods (from 71% to 59% at week two and week 11).DISCUSSIONThis study's limitation mainly comes from the sample bias in contact tracing data.", [["the sample bias", "TEST", 167, 182], ["contact tracing data", "TEST", 186, 206]]], ["The contact tracing of the rapidly evolving infectious disease inevitably contains case ascertainment biases, non-homogenous sampling over time and location, and uncontrolled correlation.(11) A substantial number of cases were missing (officially confirmed cases from Korea CDC was more than 8,000 as of April).", [["infectious disease", "DISEASE", 44, 62], ["The contact tracing", "TEST", 0, 19], ["the rapidly evolving infectious disease", "PROBLEM", 23, 62], ["Korea CDC", "TEST", 268, 277], ["rapidly", "OBSERVATION_MODIFIER", 27, 34], ["evolving", "OBSERVATION_MODIFIER", 35, 43], ["infectious", "OBSERVATION", 44, 54], ["substantial", "OBSERVATION_MODIFIER", 194, 205]]], ["Each local province government performs and reports the contact tracing, but the difficulty of the instances or granularity of reporting varies from each local government.", [["the contact tracing", "TEST", 52, 71]]], ["For example, the import cases were more likely to be tracked well, but the mass infection cluster in ShinCheonji Church has not been carefully investigated.DISCUSSIONDespite the limitations, our descriptive study can provide an overview of evolving transmission dynamics in the country and infection clusters for the rapidly emerging infectious disease.", [["infection", "DISEASE", 80, 89], ["infection", "DISEASE", 290, 299], ["infectious disease", "DISEASE", 334, 352], ["the mass infection", "PROBLEM", 71, 89], ["our descriptive study", "TEST", 191, 212], ["infection clusters", "PROBLEM", 290, 308], ["the rapidly emerging infectious disease", "PROBLEM", 313, 352], ["mass", "OBSERVATION_MODIFIER", 75, 79], ["infection", "OBSERVATION", 80, 89], ["infectious", "OBSERVATION", 334, 344]]], ["Our findings suggest a different level of reproduction and successive transmission chain over sex, age, and cluster activities.", [["different", "OBSERVATION_MODIFIER", 23, 32]]], ["No reuse allowed without permission.DISCUSSION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10.1101/2020.05.07.20091769 doi: medRxiv preprint", [["The copyright holder", "TREATMENT", 191, 211], ["medRxiv", "TREATMENT", 315, 322], ["med", "ANATOMY", 125, 128]]]], "00a00d0edc750db4a0c299dd1ec0c6871f5a4f24": [["EditorialThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.\u24d2 2015 The Korean Society of Medical InformaticsThe Middle East Respiratory Syndrome (MERS) crisis in Korea is coming to an end, but that's not the end of the story.", [["Middle East Respiratory Syndrome", "DISEASE", 365, 397], ["MERS", "DISEASE", 399, 403], ["The Middle East Respiratory Syndrome", "PROBLEM", 361, 397], ["crisis", "PROBLEM", 405, 411], ["Open", "OBSERVATION_MODIFIER", 20, 24], ["Access", "OBSERVATION", 25, 31], ["Non-Commercial License", "OBSERVATION", 104, 126], ["Middle", "ANATOMY_MODIFIER", 365, 371], ["Respiratory Syndrome", "OBSERVATION", 377, 397]]], ["The World Health Organization (WHO) has warned that the MERS crisis was a 'wakeup call. '", [["the MERS crisis", "PROBLEM", 52, 67]]], ["Like Severe Acute Respiratory Syndrome (SARS) in 2003 and swine flu in 2009, epidemic outbreaks will continue to happen anywhere.", [["Acute Respiratory Syndrome", "DISEASE", 12, 38], ["SARS", "DISEASE", 40, 44], ["swine", "SPECIES", 58, 63], ["Severe Acute Respiratory Syndrome", "PROBLEM", 5, 38], ["SARS", "PROBLEM", 40, 44], ["Severe", "OBSERVATION_MODIFIER", 5, 11], ["Acute", "OBSERVATION_MODIFIER", 12, 17], ["Respiratory Syndrome", "OBSERVATION", 18, 38]]], ["Scholars and colleagues in the medical informatics field should take a moment and think hard about how we can work to fight against another epidemic invasion in the future.\u24d2 2015 The Korean Society of Medical InformaticsThe Ebola epidemic of 2013 is the largest such outbreak on record, influencing many nations in Africa as well as other countries [1] .", [["Ebola", "DISEASE", 224, 229], ["Ebola", "OBSERVATION_MODIFIER", 224, 229], ["largest", "OBSERVATION_MODIFIER", 254, 261]]], ["The WHO expert panel has pointed out the inadequate emergency care response and has recommended more effective mechanisms for research and development.", [["The WHO expert panel", "TEST", 0, 20]]], ["Others have strongly recommended WHO to innovate because recent Ebola outbreaks have been radically different from previous events, and they have tended to be simultaneous and parallel: \"Highly mobile populations, the spread of Ebola into densely populated cities ... made this epidemic of many outbreaks difficult to control [2] . \"\u24d2 2015 The Korean Society of Medical InformaticsOther criticisms also include outdated therapeutic protocols, irrelevant information, untimely communication, delays in decision-making due to uncoordinated leadership, unreasonable social behavior, and so on.", [["Ebola", "DISEASE", 64, 69], ["Ebola", "DISEASE", 228, 233], ["Ebola", "ORGANISM", 64, 69], ["Ebola", "ORGANISM", 228, 233], ["recent Ebola outbreaks", "PROBLEM", 57, 79], ["Highly mobile populations", "PROBLEM", 187, 212], ["outdated therapeutic protocols", "TREATMENT", 411, 441], ["Ebola", "OBSERVATION", 64, 69], ["mobile", "OBSERVATION_MODIFIER", 194, 200]]], ["The recom- tems.", [["recom- tems", "DNA", 4, 15]]], ["The NEDSS can be called a medical informatics leader, which provides a standardized information infrastructure with HL7, LOINC, and SNOMED-CT.", [["NEDSS", "DNA", 4, 9], ["CT", "TEST", 139, 141]]], ["All we need is to find a conduit for connection.", [["a conduit", "TREATMENT", 23, 32], ["conduit", "OBSERVATION", 25, 32]]], ["For example, the task of disease surveillance for MERS is relatively small compared to NEDSS.", [["MERS", "DISEASE", 50, 54], ["disease surveillance", "TEST", 25, 45], ["MERS", "PROBLEM", 50, 54], ["disease", "OBSERVATION", 25, 32], ["relatively", "OBSERVATION_MODIFIER", 58, 68], ["small", "OBSERVATION_MODIFIER", 69, 74]]], ["Using the cell phone data network, we can instantly establish a real-time patient tracking system to monitor 3-tuple data (time, location, temperature) in the country.", [["cell", "ANATOMY", 10, 14], ["cell", "CELL", 10, 14], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81]]], ["Cell phone rental can help track down suspicious foreign visitors from arrival to departure.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4]]], ["With the support of ISO standards, global healthcare networking is not a hard nut to crack.What Digital Systems Should Do for MedicineWhen the MERS epidemic outbreak was on the headline news, many attempts were made to compare MERS with tuberculosis.", [["tuberculosis", "DISEASE", 237, 249], ["ISO standards", "TREATMENT", 20, 33], ["tuberculosis", "PROBLEM", 237, 249], ["tuberculosis", "OBSERVATION", 237, 249]]], ["That is, the mortality rate of MERS is far below that of tuberculosis, so it was argued that there was no need to worry about it.", [["MERS", "DISEASE", 31, 35], ["tuberculosis", "DISEASE", 57, 69], ["tuberculosis", "PROBLEM", 57, 69], ["tuberculosis", "OBSERVATION", 57, 69]]], ["The point was clear, but the timing was not right.", [["clear", "OBSERVATION", 14, 19], ["right", "ANATOMY_MODIFIER", 44, 49]]], ["Saying that \"It's OK you're not bleeding\" or \"You won't die from it\" would not comfort anybody at all.", [["bleeding", "DISEASE", 32, 40], ["bleeding", "PROBLEM", 32, 40]]], ["I would venture to say that it is surely mistaken to compare the pain at present with a probable outcome yet to happen.What Digital Systems Should Do for MedicineWhen hospital visitors became MERS patients, a typical example of nosocomial infection was demonstrated.", [["pain", "DISEASE", 65, 69], ["nosocomial infection", "DISEASE", 228, 248], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["the pain", "PROBLEM", 61, 69], ["nosocomial infection", "PROBLEM", 228, 248], ["nosocomial", "OBSERVATION_MODIFIER", 228, 238], ["infection", "OBSERVATION", 239, 248]]], ["The WHO experts reminded us that hospital shopping greatly contributed to the rapid spread of MERS in Korea.", [["MERS", "DISEASE", 94, 98]]], ["We have to understand why patients pursue hospital shopping.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["The death of professionalism may be an unexpected result of the fashionable social network services (SNS).", [["death", "DISEASE", 4, 9], ["social network", "MULTI-TISSUE_STRUCTURE", 76, 90], ["SNS", "ANATOMICAL_SYSTEM", 101, 104]]], ["Patients use SNSs to data-mine their own diagnosis and prescription and then seek medical advice to compare with their own ideas about their personal health.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SNSs", "TREATMENT", 13, 17]]], ["However, such patients suggesting their own diagnoses and treatments can be described as \"Jack of all trades, master of none\".", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["treatments", "TREATMENT", 58, 68]]], ["When the MERS epidemic turned fatal, SNS was the only rescue.", [["SNS", "TREATMENT", 37, 40]]], ["The other side of the river is not the land of promise.", [["river", "ANATOMY", 22, 27]]], ["Because the river of medicine eventu-ally runs into the ocean of the human race, why don't we go with the river instead?", [["human", "ORGANISM", 69, 74], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74]]], ["There is no doubt that doctors and nurses were the final frontiers in the MERS battle.", [["no doubt", "UNCERTAINTY", 9, 17]]], ["Despite all the wonderful scientific accomplishments, the MERS crisis reminds us that clinical expertise is the most important value as clearly as ever.", [["the MERS crisis", "PROBLEM", 54, 69]]], ["Similarly, medical informatics should be able to balance between analog medicine and digital technology to create a new value.", [["analog medicine", "TREATMENT", 65, 80]]], ["Digital technology should help clinicians restore the humanistic flavor of medicine by eliminating managerial overload in healthcare settings.", [["managerial overload", "PROBLEM", 99, 118]]], ["Neither Cyclops (the single-eyed monster in Homer's Odyssey) nor Argus (the 100-eyed giant in Greek mythology) is ideal to find the right path.", [["right", "ANATOMY_MODIFIER", 132, 137]]], ["Two-eyed medical informaticians must walk through the path on the mountain ridge, carefully looking at both sides of IT and medicine for balance.What Digital Systems Should Do for MedicineIn 1347, the first biological warfare took place in the siege of Caffa (now Feodosia in Ukraine) on the Black Sea coast.", [["MedicineIn 1347", "CHEMICAL", 180, 195], ["Caffa", "CHEMICAL", 253, 258], ["the mountain ridge", "TREATMENT", 62, 80]]], ["The Mongol army with bubonic plague catapulted corpse of those who had died from the Black Death over the city walls.", [["Death", "DISEASE", 91, 96], ["the Black Death", "PROBLEM", 81, 96], ["bubonic", "OBSERVATION_MODIFIER", 21, 28], ["plague", "OBSERVATION_MODIFIER", 29, 35], ["Black Death", "OBSERVATION", 85, 96]]], ["Fleeing from central trading ports along the coast, infected inhabitants and rats may have carried the disease throughout Europe [7] (The plague might have killed more than 25 million people).", [["rats", "ORGANISM", 77, 81], ["people", "ORGANISM", 184, 190], ["rats", "SPECIES", 77, 81], ["people", "SPECIES", 184, 190], ["central trading ports", "TREATMENT", 13, 34], ["the disease", "PROBLEM", 99, 110], ["central", "ANATOMY_MODIFIER", 13, 20], ["infected", "OBSERVATION", 52, 60]]], ["A few regions survived.", [["few", "OBSERVATION_MODIFIER", 2, 5], ["regions", "OBSERVATION_MODIFIER", 6, 13], ["survived", "OBSERVATION", 14, 22]]], ["They simply closed their ports of entry and isolated patients in remote places.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["ports", "OBSERVATION_MODIFIER", 25, 30]]], ["When in doubt, isolate an infection until it's clear.", [["infection", "DISEASE", 26, 35], ["an infection", "PROBLEM", 23, 35], ["infection", "OBSERVATION", 26, 35]]], ["Medicine should stay analog with a little hint of digital.", [["analog", "TREATMENT", 21, 27]]], ["That's all it takes to fight against any epidemic or pandemic attack in the future.", [["pandemic", "DISEASE", 53, 61]]]], "166a5dcb5ebab32f5213ea770e4f1b4e26faa4b6": [["\u2022 Le renforcement des directives concernant la manutention des substances contr\u00f4l\u00e9es et la minimisation de leur d\u00e9tournement \u00e0 l'aide de directives plus sp\u00e9cifiques; \u2022 une mise \u00e0 jour des recommandations concernant le je\u00fb ne et des recommandations plus claires, notamment les directives concernant les liquides clairs chez les patients p\u00e9diatriques, les patientes en travail actif et la pr\u00e9m\u00e9dication en cas d'accouchement par c\u00e9sarienne; \u2022 une toute nouvelle section 5.2 Prise en charge des voies a\u00e9riennes afin de souligner l'importance de la prise en charge des voies a\u00e9riennes difficiles ou de l'\u00e9chec de la prise en charge en ce qui touche \u00e0 la s\u00e9curit\u00e9 des patients.", [["patients", "ORGANISM", 327, 335], ["patients", "ORGANISM", 663, 671], ["patients", "SPECIES", 327, 335], ["patients", "SPECIES", 663, 671], ["Le renforcement des directives", "TREATMENT", 2, 32], ["la manutention des substances", "TREATMENT", 44, 73], ["le je\u00fb ne et des", "TREATMENT", 215, 231]]], ["Les moniteurs de bloc neuromusculaire sont d\u00e9sormais consid\u00e9r\u00e9s comme du mat\u00e9riel \u00ab requis \u00bb, alors qu'avant ils \u00e9taient cat\u00e9goris\u00e9s comme \u00ab accessibles en exclusivit\u00e9 \u00bb lors du recours \u00e0 des bloqueurs neuromusculaires; \u2022 les directives sous la section 5.7 Dossiers sont dor\u00e9navant plus sp\u00e9cifiques; elles recommandent notamment la documentation de la capnographie chez les patients chez lesquels un dispositif supraglottique est utilis\u00e9, de tout \u00e9v\u00e9nement impr\u00e9vu ou ind\u00e9sirable, et elles encouragent d'envisager l'utilisation de syst\u00e8mes \u00e9lectroniques de gestion de l'information en anesth\u00e9sie (SGIA) l\u00e0 o\u00f9 les ressources le permettent; \u2022 une mise \u00e0 jour de la section 7.2 porte sur l'administration de perfusions p\u00e9ridurales continues, de bolus p\u00e9riduraux intermittents programm\u00e9s et sur l'analg\u00e9sie p\u00e9ridurale contr\u00f4l\u00e9e par la patiente pour le maintien de l'anesth\u00e9sie r\u00e9gionale pendant le travail obst\u00e9trical. \u2022 L'Annexe 1: Association canadienne de normalisation -Normes concernant le mat\u00e9riel a \u00e9t\u00e9 mise \u00e0 jour en coop\u00e9ration avec le Groupe de la CSA. \u2022 L'Annexe 4: Lignes directrices, normes et autres \u00e9nonc\u00e9s officiels disponibles sur l'internet a \u00e9galement \u00e9t\u00e9 am\u00e9lior\u00e9e et r\u00e9organis\u00e9e de fa\u00e7on plus conviviale, et inclut d\u00e9sormais des liens hypertexte afin de pouvoir acc\u00e9der directement aux ressources sur le web.", [["patients", "ORGANISM", 374, 382], ["patients", "SPECIES", 374, 382], ["des bloqueurs neuromusculaires", "PROBLEM", 188, 218], ["la section", "TREATMENT", 242, 252], ["la documentation", "TEST", 329, 345], ["jour de la section", "TREATMENT", 652, 670], ["r\u00e9gionale pendant le travail obst\u00e9trical", "TREATMENT", 873, 913]]], ["Overview The Guidelines to the Practice of Anesthesia Revised Edition 2020 (the Guidelines) were prepared by the Canadian Anesthesiologists' Society (CAS), which reserves the right to determine their publication and distribution.", [["right", "ANATOMY_MODIFIER", 175, 180], ["publication", "OBSERVATION", 200, 211]]], ["The Guidelines are subject to revision and updated versions are published annually.", [["revision", "TREATMENT", 30, 38]]], ["Although the CAS encourages Canadian anesthesiologists to adhere to its practice guidelines to ensure high-quality patient care, the CAS cannot guarantee any specific patient outcome.", [["patient", "ORGANISM", 115, 122], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 115, 122], ["patient", "SPECIES", 167, 174], ["its practice guidelines", "TREATMENT", 68, 91]]], ["Anesthesiologists should exercise their own professional judgement in determining the proper course of action for any patient's circumstances.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125]]], ["The CAS assumes no responsibility or liability for any error or omission arising from the use of any information contained in its Guidelines to the Practice of Anesthesia.PreambleAnesthesiology is a dynamic specialty of medicine that fosters continuous improvements in anesthetic care for patients undergoing surgical and obstetric procedures in Canada.", [["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["any error", "PROBLEM", 51, 60], ["Anesthesia", "TREATMENT", 160, 170], ["anesthetic care", "TREATMENT", 269, 284], ["surgical and obstetric procedures", "TREATMENT", 309, 342], ["no", "UNCERTAINTY", 16, 18]]], ["This document is reviewed annually and revised periodically.PreambleThe following recommendations are aimed at providing basic guidelines to anesthetic practice.", [["anesthetic practice", "TREATMENT", 141, 160]]], ["They are intended as a framework for reasonable and acceptable patient care and should be interpreted as such to allow for some degree of flexibility in different circumstances.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70]]], ["Each section of the Guidelines is subject to revision as warranted by the evolution of technology and practice.Basic PrinciplesIn this document, the term anesthesiologist is used to designate all licensed medical practitioners with privileges to administer anesthetics.", [["revision", "TREATMENT", 45, 53], ["anesthetics", "TREATMENT", 257, 268]]], ["An anesthetic is the deliberate performance of any procedure to render a patient temporarily insensitive to pain or to the external environment so that a diagnostic or therapeutic procedure can be performed.Basic PrinciplesThese Guidelines are intended to apply to all anesthesiologists in Canada.", [["pain", "DISEASE", 108, 112], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["An anesthetic", "TREATMENT", 0, 13], ["any procedure", "TREATMENT", 47, 60], ["insensitive to pain", "PROBLEM", 93, 112], ["therapeutic procedure", "TREATMENT", 168, 189]]], ["The independent practice of anesthesia is a specialized field of medicine, and as such, it should be practiced by physicians with appropriate training in anesthesia.", [["anesthesia", "TREATMENT", 28, 38], ["anesthesia", "TREATMENT", 154, 164]]], ["The only route to specialist recognition in anesthesia in Canada is through the certification process of the Royal College of Physicians and Surgeons of Canada.Basic PrinciplesThe Canadian Anesthesiologists' Society (CAS) acknowledges the fact that remote communities often lack the population base to support a specialist Text approved by CAS Board for 2020 Edition.Basic PrinciplesTexte approuv\u00e9 par le Conseil CA pour l'\u00e9dition 2020.Basic PrinciplesElectronic supplementary material The online version of this article (https://doi.org/10.1007/s12630-019-01507-4) contains supplementary material, which is available to authorized users. anesthesiology practice.Basic PrinciplesIn these communities, appropriately trained family physicians may be required to provide anesthesia services.", [["Electronic supplementary material", "TREATMENT", 452, 485], ["anesthesiology practice", "TREATMENT", 639, 662], ["anesthesia services", "TREATMENT", 768, 787]]], ["All anesthesiologists must continue their education in the practice of anesthesia, pain management, perioperative care, and resuscitation and participate in a structured maintenance of competence program (e.g., Royal College MOC).Organization of Anesthetic ServicesThe department of anesthesia should be properly organized, directed, and integrated with other departments in the organization or facility, and it should include all facility staff members who provide anesthetic services to patients for surgical, obstetric, diagnostic, and therapeutic purposes.Organization of Anesthetic ServicesThe department should be staffed appropriately, bearing in mind the scope and nature of the services it provides, and it should strive to ensure that these services are available as required by the healthcare facility.Organization of Anesthetic ServicesThe chief of the department should be a physician who has obtained certification or appropriate training in anesthesia.", [["pain", "DISEASE", 83, 87], ["patients", "ORGANISM", 489, 497], ["patients", "SPECIES", 489, 497], ["anesthesia", "TREATMENT", 71, 81], ["pain management", "TREATMENT", 83, 98], ["perioperative care", "TREATMENT", 100, 118], ["resuscitation", "TREATMENT", 124, 137], ["anesthesia", "TREATMENT", 283, 293], ["therapeutic purposes", "TEST", 539, 559], ["anesthesia", "TREATMENT", 956, 966]]], ["To be aware of the current CAS Guidelines to the Practice of Anesthesia, the requirements of the Canadian Council on Health Services Accreditation, and the requirements of the provincial licensing authority as they relate to anesthesia;Organization of Anesthetic Services2.", [["Anesthesia", "TREATMENT", 61, 71], ["anesthesia", "TREATMENT", 225, 235], ["Anesthetic Services2", "TREATMENT", 252, 272]]], ["To ensure that written policies with respect to the practice of anesthesia are established and enforced; 3.", [["anesthesia", "TREATMENT", 64, 74]]], ["To evaluate the qualifications and abilities of the physicians providing anesthetic care as well as other health professionals providing ancillary care-this includes, but is not restricted to, recommending clinical privileges for physicians with anesthetic responsibilities and annually reviewing these privileges; 4.", [["anesthetic care", "TREATMENT", 73, 88], ["ancillary care", "TREATMENT", 137, 151]]], ["To employ a systematic approach for monitoring the quality of anesthetic care provided by members of the department of anesthesia throughout the healthcare facility; Monitoring quality of care may include, but need not be restricted to, the use of chart audits, clinical indicator and outcome monitoring, adverse event reporting systems, morbidity and mortality conferences, and critical incident case reviews.", [["a systematic approach", "TREATMENT", 10, 31], ["anesthetic care", "TREATMENT", 62, 77], ["anesthesia", "TREATMENT", 119, 129], ["clinical indicator", "TEST", 262, 280], ["outcome monitoring", "TEST", 285, 303]]], ["The extent of quality improvement activities will vary depending on the departmental and health facility resources available to the chief.", [["extent", "OBSERVATION_MODIFIER", 4, 10], ["quality", "OBSERVATION_MODIFIER", 14, 21], ["improvement", "OBSERVATION", 22, 33]]], ["To ensure that records are kept for all anesthetic procedures-these records should allow for evaluation of all anesthetic care in the facility; 6.", [["all anesthetic procedures", "TREATMENT", 36, 61], ["evaluation", "TEST", 93, 103], ["all anesthetic care", "TREATMENT", 107, 126]]], ["To carry out such other duties as the governing body of the facility may delegate to ensure safe anesthetic care; 7.", [["body", "ORGANISM_SUBDIVISION", 48, 52], ["safe anesthetic care", "TREATMENT", 92, 112]]], ["To promote institutional compliance with applicable Canadian Standards Association (CSA) Standards (Appendix 1); and 8.", [["applicable Canadian Standards Association (CSA)", "TREATMENT", 41, 88]]], ["To coordinate liaison between the departments of anesthesiology, biomedical engineering, and information management services.Privileges in AnesthesiaAll physicians applying for privileges in anesthesia should demonstrate satisfactory completion of specialist postgraduate training in anesthesia or family practice anesthesia training.", [["privileges in anesthesia", "TREATMENT", 177, 201], ["specialist postgraduate training", "TREATMENT", 248, 280], ["anesthesia training", "TREATMENT", 314, 333]]], ["Family physicians practicing anesthesia should demonstrate satisfactory completion of an accredited postgraduate program with at least one year of training.Privileges in AnesthesiaSpecial areas of anesthetic care may have specific concerns.", [["practicing anesthesia", "TREATMENT", 18, 39], ["an accredited postgraduate program", "TREATMENT", 86, 120], ["anesthetic care", "TREATMENT", 197, 212]]], ["The department of anesthesia in each institution may determine privileges in pediatric anesthesia according to the pediatric population it serves, the child's age, the presence of comorbidities, the physician's specific training and experience in pediatric anesthesia, and the complexity of the procedure involved.Privileges in AnesthesiaPhysicians with anesthetic privileges should possess the knowledge and technical and non-technical skills necessary for the practice of anesthesia.Privileges in AnesthesiaKnowledge and technical skills include the ability:Privileges in Anesthesia\u2022 To provide preanesthetic evaluation of the patient and determine the appropriate anesthetic management; \u2022 To render the patient insensible to pain for the performance of diagnostic and therapeutic procedures, surgical operations, and obstetric procedures; \u2022 To monitor and support the vital organ systems during the perioperative period;Privileges in Anesthesia\u2022 To provide immediate postanesthetic management of the patient; \u2022 To provide resuscitation and intensive care when indicated; and \u2022 To provide relief from acute and chronic pain.Privileges in AnesthesiaNon-technical skills include:Privileges in Anesthesia\u2022 Task management: planning and preparing, prioritizing, providing and maintaining standards, and identifying and utilizing resources; \u2022 Teamwork: coordinating activities with team members, exchanging information, using authority and assertiveness, assessing capabilities, supporting others, and supporting the World Health Organization Surgical Safety Checklist; \u2022 Situational awareness: anticipating, gathering information, recognizing, and understanding, and;Privileges in Anesthesia\u2022 Decision-making: identifying options, balancing risks and selecting options, and re-evaluating.Fitness to PracticeThe provision of anesthesia care requires anesthesiologists to have a high level of expertise, sound judgment, and the ability to recognize and respond to changing clinical situations despite sometimes adverse personal physical circumstances.", [["organ", "ANATOMY", 877, 882], ["pain", "DISEASE", 728, 732], ["pain", "DISEASE", 1121, 1125], ["patient", "ORGANISM", 629, 636], ["patient", "ORGANISM", 706, 713], ["organ", "ORGAN", 877, 882], ["patient", "ORGANISM", 1003, 1010], ["patient", "SPECIES", 629, 636], ["patient", "SPECIES", 706, 713], ["patient", "SPECIES", 1003, 1010], ["anesthesia", "TREATMENT", 18, 28], ["pediatric anesthesia", "TREATMENT", 77, 97], ["pediatric anesthesia", "TREATMENT", 247, 267], ["the procedure", "TREATMENT", 291, 304], ["anesthetic privileges", "TREATMENT", 354, 375], ["anesthesia", "TREATMENT", 474, 484], ["preanesthetic evaluation", "TEST", 597, 621], ["the appropriate anesthetic management", "TREATMENT", 651, 688], ["insensible to pain", "PROBLEM", 714, 732], ["therapeutic procedures", "TREATMENT", 771, 793], ["surgical operations", "TREATMENT", 795, 814], ["obstetric procedures", "TEST", 820, 840], ["the vital organ systems", "TEST", 867, 890], ["immediate postanesthetic management", "TREATMENT", 960, 995], ["resuscitation", "TREATMENT", 1025, 1038], ["intensive care", "TREATMENT", 1043, 1057], ["acute and chronic pain", "PROBLEM", 1103, 1125], ["anesthesia care", "TREATMENT", 1822, 1837], ["anesthesiologists", "TREATMENT", 1847, 1864], ["changing clinical situations", "PROBLEM", 1960, 1988], ["acute", "OBSERVATION_MODIFIER", 1103, 1108], ["chronic", "OBSERVATION_MODIFIER", 1113, 1120], ["pain", "OBSERVATION", 1121, 1125]]], ["Anesthesia departments must recognize that fit anesthesia practitioners provide optimal patient care.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["anesthesia practitioners", "TREATMENT", 47, 71], ["optimal patient care", "TREATMENT", 80, 100]]], ["A variety of factors impair health and fitness for duty, including adverse physical conditions, mental impairment, and fatigue.", [["mental impairment", "DISEASE", 96, 113], ["fatigue", "DISEASE", 119, 126], ["adverse physical conditions", "PROBLEM", 67, 94], ["mental impairment", "PROBLEM", 96, 113], ["fatigue", "PROBLEM", 119, 126]]], ["Many studies have shown that fatigue impairs judgement and psychomotor performance in a manner similar to drugs or alcohol.", [["fatigue", "DISEASE", 29, 36], ["alcohol", "CHEMICAL", 115, 122], ["alcohol", "CHEMICAL", 115, 122], ["alcohol", "SIMPLE_CHEMICAL", 115, 122], ["Many studies", "TEST", 0, 12], ["fatigue impairs judgement", "PROBLEM", 29, 54], ["psychomotor performance", "PROBLEM", 59, 82]]], ["Shifting circadian rhythms, aging, and lack of sleep reinforce such problems; a fatigue-induced lack of recognition of these problems can compound the potential for errors in such circumstances.", [["fatigue", "DISEASE", 80, 87], ["Shifting circadian rhythms", "PROBLEM", 0, 26], ["such problems", "PROBLEM", 63, 76], ["a fatigue", "PROBLEM", 78, 87], ["these problems", "PROBLEM", 119, 133], ["errors in such circumstances", "PROBLEM", 165, 193]]], ["Physical impairment, illness, and severe stress can have similar detrimental effects on performance.Fitness to PracticeAnesthesia departments and individual anesthesiologists have a responsibility to organize their working duties such that illness and fatigue do not regularly affect clinical duties.", [["Physical impairment", "DISEASE", 0, 19], ["illness", "DISEASE", 21, 28], ["illness", "DISEASE", 240, 247], ["fatigue", "DISEASE", 252, 259], ["Physical impairment", "PROBLEM", 0, 19], ["illness", "PROBLEM", 21, 28], ["severe stress", "PROBLEM", 34, 47], ["fatigue", "PROBLEM", 252, 259], ["impairment", "OBSERVATION", 9, 19]]], ["Individual rosters must allow adequate rest between working shifts, and daily rosters should allow appropriate breaks for physiological needs, nutrition, and mental fitness.", [["daily rosters", "TREATMENT", 72, 85]]], ["Operating room scheduling should avoid requiring anesthesiologists to undertake non-emergency procedures during unfavourable hours.Fitness to PracticeNo specific prescription for working shifts and daily rosters can be appropriate for every working situation.", [["PracticeNo", "CHEMICAL", 142, 152], ["non-emergency procedures", "TREATMENT", 80, 104]]], ["Nevertheless, this important area of professional practice must receive ongoing consideration and attention.ResidentsResidents in anesthesia are registered medical practitioners who participate in the provision of anesthesia services both inside and outside the operating room as part of their training.", [["professional practice", "TREATMENT", 37, 58], ["anesthesia services", "TREATMENT", 214, 233]]], ["The degree of this supervision must consider the condition of each patient, the nature of the anesthetic service, and the experience and capabilities of the resident (increasing professional responsibility).", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74]]], ["At the discretion of the supervising staff anesthesiologist, residents may provide a range of anesthetic care with minimal supervision.", [["a range of anesthetic care", "TREATMENT", 83, 109]]], ["In all cases, the supervising attending anesthesiologist must remain readily available to give advice or assist the resident with urgent or routine patient care.", [["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 148, 155], ["routine patient care", "TREATMENT", 140, 160]]], ["Whether supervision is direct or indirect, close communication between the resident and the responsible supervising staff anesthesiologist is essential for safe patient care.", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["safe patient care", "TREATMENT", 156, 173]]], ["Ancillary personnel should have the competencies to meet the specific needs of subspecialty areas of anesthesia, reflecting on the need for specific skills in areas such as specialty pediatric anesthesia.Ancillary PersonnelIt is recommended that facilities have a formally designated anesthesia assistant with specific training in anesthesia assistance.", [["anesthesia", "TREATMENT", 101, 111], ["specialty pediatric anesthesia", "TREATMENT", 173, 203], ["anesthesia assistance", "TREATMENT", 331, 352]]], ["The department of anesthesia and the appropriate administrative bodies must approve the scope of practice for anesthesia assistants working in a specific institution.", [["anesthesia", "TREATMENT", 18, 28], ["anesthesia assistants", "TREATMENT", 110, 131]]], ["Duties and tasks delegated to anesthesia assistants must be consistent with existing governmental regulations, the policies and guidelines established by professional regulatory agencies, and the policies of the local facility.Ancillary PersonnelAn institution without formal anesthesia assistants must provide other paramedical personnel to assist the anesthesiologist.", [["formal anesthesia", "TREATMENT", 269, 286]]], ["An anesthesiologist must only delegate or assign those tasks for which such personnel have approval or accreditation.Anesthetic Equipment and Anesthetizing LocationAn anesthetic must be administered in an appropriate facility.", [["Anesthetic Equipment", "TREATMENT", 117, 137], ["Anesthetizing LocationAn anesthetic", "TREATMENT", 142, 177]]], ["All necessary equipment, including emergency equipment, life support systems, medications, and supplies must be readily available.", [["emergency equipment", "TREATMENT", 35, 54], ["life support systems", "TREATMENT", 56, 76], ["medications", "TREATMENT", 78, 89]]], ["It is strongly recommended that a cognitive aid manual be made available at all anesthetizing locations in support of the management of critical perioperative emergencies.", [["the management", "TREATMENT", 118, 132]]], ["The contents of the manual should be regularly reviewed, updated as required, and periodically practiced as a team.Anesthetic Equipment and Anesthetizing LocationThe healthcare facility, in consultation with the department of anesthesia, is responsible for the design and maintenance of preoperative, postoperative, and anesthetizing locations, as well as the purchase, maintenance, and disposal of anesthetic and ancillary equipment and supplies.", [["anesthesia", "TREATMENT", 226, 236], ["anesthetic", "TREATMENT", 399, 409], ["ancillary equipment", "TREATMENT", 414, 433]]], ["The Canadian Standards Association (CSA) and other standards development organizations have published standards and guidance documents for the design, construction, and renovation of healthcare facilities and for the risk management, basic safety, and essential performance of medical equipment (Appendix 1).Responsibilities of the Healthcare FacilityThe healthcare facility must ensure that:Responsibilities of the Healthcare Facility1.", [["the risk management", "TREATMENT", 213, 232]]], ["The operating rooms, anesthetizing locations, and perioperative care locations comply with at least the minimum design and construction requirements of the national, provincial, and local building, plumbing, electrical, HVAC (heating, ventilation, and air conditioning), fire, and security codes at the time of construction or renovation.", [["electrical, HVAC (heating", "TREATMENT", 208, 233], ["ventilation", "TREATMENT", 235, 246], ["air conditioning", "TREATMENT", 252, 268]]], ["Medical gas and vacuum systems, waste anesthetic gas scavenging systems, terminal units, head walls, low pressure connecting assemblies, and pressure regulators meet the requirements of the CSA and are certified by a CSA-approved testing agency.", [["head walls", "ANATOMY", 89, 99], ["head", "ORGANISM_SUBDIVISION", 89, 93], ["Medical gas and vacuum systems", "TEST", 0, 30], ["waste anesthetic", "TREATMENT", 32, 48], ["terminal units", "TREATMENT", 73, 87], ["head walls", "TREATMENT", 89, 99], ["low pressure connecting assemblies", "TREATMENT", 101, 135], ["pressure regulators", "TREATMENT", 141, 160], ["the CSA", "TREATMENT", 186, 193], ["a CSA", "TEST", 215, 220], ["vacuum systems", "OBSERVATION", 16, 30], ["head", "ANATOMY", 89, 93], ["walls", "ANATOMY_MODIFIER", 94, 99], ["low pressure", "OBSERVATION", 101, 113]]], ["Oxygen concentrators that comply with CSA requirements are an acceptable substitute for bulk oxygen supply systems.", [["oxygen", "CHEMICAL", 93, 99], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 93, 99], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 93, 99], ["Oxygen concentrators", "TREATMENT", 0, 20], ["CSA requirements", "TREATMENT", 38, 54], ["bulk oxygen supply systems", "TREATMENT", 88, 114]]], ["The facility medical oxygen supply may deliver a fraction of inspired oxygen (FiO 2 ) that varies from 0.93 to 0.99; b.", [["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 70, 76], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 70, 76], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["The facility medical oxygen supply", "TREATMENT", 0, 34], ["inspired oxygen (FiO", "TREATMENT", 61, 81]]], ["Oxygen analyzers must be calibrated against 100% O 2 (FiO 2 0.99) and room air or equivalent (FiO 2 0.21); c.", [["Oxygen", "CHEMICAL", 0, 6], ["O 2", "CHEMICAL", 49, 52], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen analyzers", "TEST", 0, 16], ["FiO", "TEST", 54, 57], ["FiO", "TEST", 94, 97]]], ["The use of low-flow (less than one litre total fresh gas flow) anesthetic techniques may result in the accumulation of inert gas (argon) and the dilution of nitrous oxide and oxygen in the circuit.Responsibilities of the Healthcare Facility4.", [["nitrous oxide", "CHEMICAL", 157, 170], ["oxygen", "CHEMICAL", 175, 181], ["nitrous oxide", "CHEMICAL", 157, 170], ["oxygen", "CHEMICAL", 175, 181], ["nitrous oxide", "SIMPLE_CHEMICAL", 157, 170], ["oxygen", "SIMPLE_CHEMICAL", 175, 181], ["low-flow", "TREATMENT", 11, 19], ["one litre total fresh gas flow)", "TREATMENT", 31, 62], ["anesthetic techniques", "TREATMENT", 63, 84], ["inert gas (argon)", "TREATMENT", 119, 136], ["the dilution of nitrous oxide", "TREATMENT", 141, 170], ["oxygen in the circuit", "TREATMENT", 175, 196], ["low", "OBSERVATION_MODIFIER", 11, 14], ["flow", "OBSERVATION_MODIFIER", 15, 19], ["inert gas", "OBSERVATION", 119, 128], ["nitrous oxide", "OBSERVATION", 157, 170]]], ["There is compliance with all safety regulations with respect to the storage, preparation, identification, labelling, disposal, and use of medical gases, medications, and related materials.", [["medical gases", "TREATMENT", 138, 151], ["medications", "TREATMENT", 153, 164]]], ["Through cooperation between the departments of anesthesia and pharmacy, there are policies developed and enforced for the safe handling, storage, and disposal of controlled medications (e.g., opioids) in the operating rooms and postanesthesia care unit (PACU) that are consistent with the law, with any regulatory authority requirements, and established best practice principles.", [["anesthesia", "TREATMENT", 47, 57], ["storage", "TREATMENT", 137, 144], ["disposal of controlled medications", "TREATMENT", 150, 184], ["opioids", "TREATMENT", 192, 199]]], ["The goals of such policies should be to limit access of unauthorized personnel to controlled medications to minimize the risk of controlled medication diversion, and to establish robust documentation procedures that can be audited, while also protecting patient safety by still permitting anesthesia providers immediate access to any medications required for patient care.Responsibilities of the Healthcare FacilityBest practice principles support a variety of specific strategies to achieve these goals.", [["patient", "ORGANISM", 254, 261], ["patient", "ORGANISM", 359, 366], ["patient", "SPECIES", 254, 261], ["patient", "SPECIES", 359, 366], ["such policies", "TREATMENT", 13, 26], ["unauthorized personnel", "TREATMENT", 56, 78], ["medications", "TREATMENT", 93, 104], ["controlled medication diversion", "TREATMENT", 129, 160], ["anesthesia providers", "TREATMENT", 289, 309], ["any medications", "TREATMENT", 330, 345], ["patient care", "TREATMENT", 359, 371], ["specific strategies", "TREATMENT", 461, 480]]], ["Robust systems and procedures must be implemented.", [["procedures", "TREATMENT", 19, 29]]], ["Due consideration should be given to any limitation in resources available to implement specific security systems and procedures within a facility, particularly for smaller facilities.Responsibilities of the Healthcare FacilityRecommendations include, but need not be restricted to:Responsibilities of the Healthcare Facility\u2022 storing controlled substances in a secure lockable safe or locked drawer when the OR is unattended by anesthesia personnel (e.g., between cases) \u2022 never leaving controlled substances (including those drawn up into syringes or bags) unattended in any location \u2022 emptying the contents of syringes and bags containing controlled substances before disposalResponsibilities of the Healthcare Facility\u2022 adopting disposal and/or destruction systems to dispose of controlled substance waste \u2022 consideration of a requirement that controlled substance waste be returned to the pharmacy and be subjected to random analysis \u2022 periodic audits of a healthcare provider's controlled substance utilization records and their anesthesia records \u2022 consideration of the implementation of automated anesthesia cabinets or automated medication dispensing cabinets (e.g. Pyxis TM )Responsibilities of the Healthcare FacilityThe operating room, labour and delivery, postanesthesia care unit (PACU), and regional block areas, for example, should all be recognized as high risk areas for controlled medication diversion and therefore must be subject to heightened security, surveillance, and auditing.Responsibilities of the Healthcare Facility5.", [["a secure lockable safe", "TREATMENT", 360, 382], ["syringes", "TREATMENT", 613, 621], ["bags", "TREATMENT", 626, 630], ["destruction systems", "PROBLEM", 749, 768], ["automated anesthesia cabinets", "TREATMENT", 1095, 1124], ["automated medication dispensing cabinets", "TREATMENT", 1128, 1168], ["regional block areas", "TREATMENT", 1306, 1326], ["high risk areas", "PROBLEM", 1369, 1384], ["controlled medication diversion", "TREATMENT", 1389, 1420], ["surveillance", "TEST", 1475, 1487]]], ["If general anesthesia is provided using an electronic anesthetic system (gas machine), it must comply with CAN/CSA-C22.2 No. 60601-2-13.", [["general anesthesia", "TREATMENT", 3, 21], ["an electronic anesthetic system", "TREATMENT", 40, 71]]], ["An alternate means of ventilation (e.g., manual bag and mask resuscitator) must be immediately available with each anesthesia system.", [["ventilation", "TREATMENT", 22, 33], ["manual bag and mask resuscitator", "TREATMENT", 41, 73], ["each anesthesia system", "TREATMENT", 110, 132]]], ["The workstations must be equipped with at least an oxygen analyzer, an airway pressure monitor, a waste anesthetic gas scavenging system, and a high vacuum tracheal suction system with a backup means of suction.", [["airway", "ANATOMY", 71, 77], ["tracheal", "ANATOMY", 156, 164], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["airway", "MULTI-TISSUE_STRUCTURE", 71, 77], ["an oxygen analyzer", "TEST", 48, 66], ["an airway pressure monitor", "TEST", 68, 94], ["a waste anesthetic gas scavenging system", "TREATMENT", 96, 136], ["a high vacuum tracheal suction system", "TREATMENT", 142, 179], ["a backup means of suction", "TREATMENT", 185, 210], ["airway", "ANATOMY", 71, 77], ["tracheal", "ANATOMY", 156, 164], ["suction", "OBSERVATION", 165, 172]]], ["If vaporizers are used, they must use an agent-specific filling system to ensure filling with the correct agent.", [["vaporizers", "TREATMENT", 3, 13], ["an agent", "TREATMENT", 38, 46], ["the correct agent", "TREATMENT", 94, 111]]], ["If a ventilator is provided, it must have a low-pressure or disconnect alarm.", [["a ventilator", "TREATMENT", 3, 15], ["disconnect alarm", "PROBLEM", 60, 76]]], ["Whenever possible, the use of low total gas flow anesthesia is recommended to facilitate the efficient use of inhalational anesthesia agents and to minimize the environmental impact of waste anesthesia agents.", [["low total gas flow anesthesia", "TREATMENT", 30, 59], ["inhalational anesthesia agents", "TREATMENT", 110, 140], ["waste anesthesia agents", "TREATMENT", 185, 208]]], ["Appropriate minimum total gas flows will vary, taking into account the specific inhalational agent and the clinical situation.", [["minimum", "OBSERVATION_MODIFIER", 12, 19], ["total", "OBSERVATION_MODIFIER", 20, 25], ["gas flows", "OBSERVATION", 26, 35]]], ["Wherever obstetric anesthesia is performed, a separate area for newborn assessment and resuscitation must be provided.", [["obstetric anesthesia", "TREATMENT", 9, 29], ["newborn assessment", "TEST", 64, 82], ["resuscitation", "TREATMENT", 87, 100]]], ["This area must include designated oxygen, suction apparatus, electrical outlets, a source of radiant heat, and equipment for neonatal airway management and resuscitation.", [["airway", "ANATOMY", 134, 140], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["airway", "MULTI-TISSUE_STRUCTURE", 134, 140], ["suction apparatus", "TREATMENT", 42, 59], ["radiant heat", "TREATMENT", 93, 105], ["neonatal airway management", "TREATMENT", 125, 151], ["resuscitation", "TREATMENT", 156, 169], ["oxygen", "OBSERVATION_MODIFIER", 34, 40], ["airway", "ANATOMY", 134, 140]]], ["Personal protection devices, including N95 masks, face masks, and means of disposal of hazardous and infectious wastes and sharps are provided.", [["Personal protection devices", "TREATMENT", 0, 27], ["N95 masks", "TREATMENT", 39, 48], ["face masks", "TREATMENT", 50, 60], ["infectious wastes", "TREATMENT", 101, 118], ["infectious", "OBSERVATION", 101, 111]]], ["Surgical, diagnostic, therapeutic, and esthetic settings must have plume scavenging systems complying with CSA Z305.13-09.", [["CSA Z305.13-09", "CHEMICAL", 107, 121], ["Z305.13-09", "CHEMICAL", 111, 121], ["esthetic settings", "TREATMENT", 39, 56], ["CSA", "TEST", 107, 110]]], ["Infusion pump systems with a drug library, appropriate soft and hard limits for each medication, and enabled alarms for the delivery of medications by continuous intravenous infusion are available as required.", [["intravenous", "ANATOMY", 162, 173], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 162, 173], ["Infusion pump systems", "TREATMENT", 0, 21], ["a drug library", "TREATMENT", 27, 41], ["each medication", "TREATMENT", 80, 95], ["the delivery of medications", "TREATMENT", 120, 147], ["continuous intravenous infusion", "TREATMENT", 151, 182]]], ["Oxygen supplies for transport of perioperative patients must be provided.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Oxygen supplies", "TREATMENT", 0, 15]]], ["The use of transport oxygen cylinders capable of providing an audible low-pressure alarm is strongly recommended.", [["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["transport oxygen cylinders", "TREATMENT", 11, 37], ["an audible low-pressure alarm", "TEST", 59, 88]]], ["Qualified personnel conduct regular inspections and maintenance of all anesthetic and ancillary equipment.", [["all anesthetic", "TREATMENT", 67, 81], ["ancillary equipment", "TREATMENT", 86, 105]]], ["The facility administration and the department of anesthesia must retain records indicating conformity to regulations and inspection and maintenance.Responsibilities of the Healthcare FacilityAnesthesia providers must ensure that potentially infectious materials or agents are not transferred from one patient to another.", [["patient", "ORGANISM", 302, 309], ["patient", "SPECIES", 302, 309], ["anesthesia", "TREATMENT", 50, 60], ["inspection", "TEST", 122, 132], ["potentially infectious materials", "PROBLEM", 230, 262]]], ["Special attention in this regard should be given to syringes, infusion pump administration sets, and multi-dose drug vials.Responsibilities of the Healthcare FacilityTraining on the safe use of all anesthesia equipment should be provided to all anesthesia department members prior to use.", [["syringes", "TREATMENT", 52, 60], ["infusion pump administration sets", "TREATMENT", 62, 95], ["multi-dose drug vials", "TREATMENT", 101, 122], ["all anesthesia equipment", "TREATMENT", 194, 218]]], ["These training sessions should be repeated as necessary for new or established department members.Waste GasesRecommendations for reducing occupational exposure to waste anesthetic gases:Waste Gases1.", [["These training sessions", "TREATMENT", 0, 23]]], ["Dilution ventilation at the rate of 20 exchanges per hour must be provided in all anesthetizing locations where volatile anesthetic gases or nitrous oxide (N 2 O) are used.", [["nitrous oxide", "CHEMICAL", 141, 154], ["N 2 O", "CHEMICAL", 156, 161], ["nitrous oxide", "CHEMICAL", 141, 154], ["N 2 O", "CHEMICAL", 156, 161], ["nitrous oxide", "SIMPLE_CHEMICAL", 141, 154], ["N 2 O", "SIMPLE_CHEMICAL", 156, 161], ["Dilution ventilation", "TREATMENT", 0, 20], ["volatile anesthetic gases", "TREATMENT", 112, 137], ["nitrous oxide (N 2 O)", "TREATMENT", 141, 162]]], ["Recirculation of exhaust air must not be permitted during the hours when operations may be in progress, and it is not recommended at any other time.", [["exhaust air", "PROBLEM", 17, 28], ["operations", "TREATMENT", 73, 83], ["exhaust air", "OBSERVATION", 17, 28]]], ["Wherever an anesthetic delivery system is used, a scavenger must be provided to capture anesthetic gases that might be released from the anesthetic circuit or ventilator.", [["an anesthetic delivery system", "TREATMENT", 9, 38], ["a scavenger", "TREATMENT", 48, 59], ["anesthetic gases", "TREATMENT", 88, 104], ["the anesthetic circuit", "TREATMENT", 133, 155], ["ventilator", "TREATMENT", 159, 169]]], ["A maintenance program must be established in each healthcare facility to detect and repair leakage from the anesthetic delivery system and to maintain the effectiveness of the waste anesthetic scavenging unit.", [["A maintenance program", "TREATMENT", 0, 21], ["repair leakage", "TREATMENT", 84, 98], ["the anesthetic delivery system", "TREATMENT", 104, 134], ["the waste anesthetic scavenging unit", "TREATMENT", 172, 208], ["leakage", "OBSERVATION", 91, 98]]], ["The healthcare facility must be responsible for conducting regular monitoring of exposure to waste anesthetic gases.", [["waste anesthetic gases", "TREATMENT", 93, 115]]], ["The monitoring protocol should include individuals and the air flow patterns of the rooms being assessed.", [["The monitoring protocol", "TEST", 0, 23], ["the air flow patterns", "TEST", 55, 76], ["air flow", "OBSERVATION", 59, 67]]], ["When N 2 O is used in the operating room, N 2 O monitoring is a suitable representation for the assessment of adequacy of scavenging.The Preanesthetic PeriodThe department of anesthesia should establish policies regarding preanesthetic assessment.", [["N 2 O", "CHEMICAL", 5, 10], ["N 2 O", "CHEMICAL", 5, 10], ["N 2 O", "CHEMICAL", 42, 47], ["N 2 O", "SIMPLE_CHEMICAL", 5, 10], ["the assessment", "TEST", 92, 106], ["anesthesia", "TREATMENT", 175, 185], ["preanesthetic assessment", "TEST", 222, 246]]], ["The primary goal of preanesthetic assessment is to obtain the information required to plan anesthetic management.", [["preanesthetic assessment", "TEST", 20, 44], ["anesthetic management", "TREATMENT", 91, 112]]], ["Accordingly, a physician who is knowledgeable about anesthetic management for the proposed diagnostic or therapeutic procedure should document all aspects of the patient's medical and surgical history, findings on physical examination, and laboratory investigations that are relevant to anesthetic management.", [["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["anesthetic management", "TREATMENT", 52, 73], ["therapeutic procedure", "TREATMENT", 105, 126], ["physical examination", "TEST", 214, 234], ["laboratory investigations", "TEST", 240, 265], ["anesthetic management", "TREATMENT", 287, 308]]], ["The patient's history should include past and current medical problems, current and recent drug therapy, unusual reactions or responses to drugs, and any problems or complications associated with previous anesthetics.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["current medical problems", "PROBLEM", 46, 70], ["recent drug therapy", "TREATMENT", 84, 103], ["unusual reactions", "PROBLEM", 105, 122], ["drugs", "TREATMENT", 139, 144], ["any problems", "PROBLEM", 150, 162], ["complications", "PROBLEM", 166, 179], ["previous anesthetics", "TREATMENT", 196, 216]]], ["A family history of adverse reactions associated with anesthesia should also be obtained.", [["adverse reactions", "PROBLEM", 20, 37], ["anesthesia", "TREATMENT", 54, 64]]], ["Information about the anesthetic that the patient considers relevant should also be documented.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["the anesthetic", "TREATMENT", 18, 32]]], ["An American Society of Anesthesiologists physical status classification (Appendix 2) should be recorded for each patient.The Preanesthetic PeriodIn appropriate cases, the availability of an ''Advance Care Plan'' (representation agreement, advanced directive, ''living will'', ''do not resuscitate'' directive, etc.) should be ascertained, and its applicability to the proposed intervention should be determined and documented on the anesthetic assessment record.The Preanesthetic PeriodThe surgeon may request consultation with an anesthesiologist.", [["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["the anesthetic assessment", "TEST", 429, 454]]], ["Medical consultations should be obtained when indicated.The Preanesthetic PeriodPreoperative anesthetic assessment or consultation may take place in an outpatient clinic before admission for the operative procedure.", [["The Preanesthetic PeriodPreoperative anesthetic assessment", "TEST", 56, 114], ["the operative procedure", "TREATMENT", 191, 214]]], ["Indications for pre-admission assessment include the presence of significant medical problems (comorbidities), the nature of the proposed diagnostic or therapeutic procedure, and patient request.", [["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 179, 186], ["pre-admission assessment", "TEST", 16, 40], ["significant medical problems", "PROBLEM", 65, 93], ["therapeutic procedure", "TREATMENT", 152, 173]]], ["A parent/guardian must be present if the patient is a child or not competent to provide informed consent.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48]]], ["All patients should be informed that arrangements will be made to meet with an anesthesiologist if they wish to discuss anesthetic management before admission to the facility.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["anesthetic management", "TREATMENT", 120, 141]]], ["The preoperative assessment clinic should also allow nursing and other healthcare personnel to assess the patient.", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["The preoperative assessment", "TEST", 0, 27]]], ["The attending anesthesiologist is responsible for performing a final preanesthetic assessment in the immediate preoperative period.Preoperative TestingLaboratory testing should not be performed on a routine basis but should be obtained only when results will change perioperative management.", [["a final preanesthetic assessment", "TEST", 61, 93], ["Preoperative TestingLaboratory testing", "TEST", 131, 169], ["a routine basis", "TEST", 197, 212], ["perioperative management", "TREATMENT", 266, 290]]], ["Laboratory investigations should be performed when indicated by the patient's medical status, drug therapy, and the nature of the proposed procedure.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["Laboratory investigations", "TEST", 0, 25], ["drug therapy", "TREATMENT", 94, 106], ["the proposed procedure", "TREATMENT", 126, 148]]], ["Routine laboratory blood testing, electrocardiograms, and chest radiographs are not recommended for asymptomatic patients having low-risk surgery.", [["blood", "ANATOMY", 19, 24], ["chest", "ANATOMY", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Routine laboratory blood testing", "TEST", 0, 32], ["electrocardiograms", "TEST", 34, 52], ["chest radiographs", "TEST", 58, 75], ["low-risk surgery", "TREATMENT", 129, 145], ["chest", "ANATOMY", 58, 63]]], ["Examples of low-risk surgery include, but are not restricted to, cataract surgery, minor breast surgery, superficial procedures, and many minor ambulatory procedures.", [["breast", "ANATOMY", 89, 95], ["cataract", "DISEASE", 65, 73], ["low-risk surgery", "TREATMENT", 12, 28], ["cataract surgery", "TREATMENT", 65, 81], ["minor breast surgery", "TREATMENT", 83, 103], ["superficial procedures", "TREATMENT", 105, 127], ["many minor ambulatory procedures", "TREATMENT", 133, 165], ["low", "OBSERVATION_MODIFIER", 12, 15], ["cataract", "OBSERVATION", 65, 73], ["breast", "ANATOMY", 89, 95], ["surgery", "OBSERVATION", 96, 103], ["superficial", "OBSERVATION_MODIFIER", 105, 116], ["procedures", "OBSERVATION", 117, 127]]], ["For more detailed definitions of low-risk surgery and for other recommendations related to preoperative testing, visit Choosing Wisely on the CAS website and the associated Internet links.Fasting GuidelinesFasting policies should vary to account for age and preexisting medical conditions and should apply to all forms of anesthesia, including procedural sedation (see Appendix 6).", [["Fasting", "ORGANISM_SUBSTANCE", 188, 195], ["low-risk surgery", "TREATMENT", 33, 49], ["preoperative testing", "TEST", 91, 111], ["Fasting GuidelinesFasting policies", "TREATMENT", 188, 222], ["preexisting medical conditions", "PROBLEM", 258, 288], ["anesthesia", "TREATMENT", 322, 332], ["procedural sedation", "TREATMENT", 344, 363]]], ["1 Emergent or urgent procedures should be undertaken after considering the risk of delaying surgery vs the risk of aspiration of gastric contents.", [["gastric", "ANATOMY", 129, 136], ["gastric", "ORGAN", 129, 136], ["urgent procedures", "TREATMENT", 14, 31], ["delaying surgery", "TREATMENT", 83, 99], ["aspiration of gastric contents", "PROBLEM", 115, 145], ["aspiration", "OBSERVATION", 115, 125], ["gastric", "ANATOMY", 129, 136]]], ["The type and amount of food ingested should be considered in determining the duration of fasting.", [["amount", "OBSERVATION_MODIFIER", 13, 19]]], ["Before elective procedures, the minimum duration of fasting should be:Fasting Guidelines\u2022 Eight hours after a large meal of solids particularly containing protein (e.g., meat) or fatty foods \u2022 Six hours after a light meal (e.g., non-fatty meal such as toast) \u2022 Six hours after ingestion of infant formula, nonhuman milk, or expressed breast milk fortified with additions \u2022 Four hours after ingestion of breast milk \u2022 Two hours after ingestion of clear fluids for adults \u2022 One hour after ingestion of clear fluids for infants and childrenFasting GuidelinesUnless contraindicated, adults and children should be encouraged to drink clear fluids (including water, pulp-free juice, complex carbohydrate beverages, and tea or coffee without milk) up to two hours before elective surgery.", [["meat", "ANATOMY", 170, 174], ["milk", "ANATOMY", 315, 319], ["breast milk", "ANATOMY", 334, 345], ["breast milk", "ANATOMY", 403, 414], ["pulp", "ANATOMY", 660, 664], ["juice", "ANATOMY", 670, 675], ["tea", "ANATOMY", 713, 716], ["milk", "ANATOMY", 735, 739], ["carbohydrate", "CHEMICAL", 685, 697], ["meat", "ORGANISM_SUBDIVISION", 170, 174], ["nonhuman", "ORGANISM", 306, 314], ["milk", "ORGANISM_SUBSTANCE", 315, 319], ["breast milk", "ORGANISM_SUBSTANCE", 334, 345], ["breast", "ORGANISM_SUBDIVISION", 403, 409], ["milk", "ORGANISM_SUBSTANCE", 410, 414], ["adults", "ORGANISM", 579, 585], ["children", "ORGANISM", 590, 598], ["pulp", "TISSUE", 660, 664], ["juice", "ORGANISM_SUBSTANCE", 670, 675], ["tea", "ORGANISM_SUBDIVISION", 713, 716], ["milk", "ORGANISM_SUBDIVISION", 735, 739], ["infant", "SPECIES", 290, 296], ["milk", "SPECIES", 315, 319], ["infants", "SPECIES", 517, 524], ["children", "SPECIES", 590, 598], ["elective procedures", "TREATMENT", 7, 26], ["Fasting Guidelines", "TREATMENT", 70, 88], ["a large meal of solids", "TREATMENT", 108, 130], ["a light meal (e.g., non-fatty meal", "TREATMENT", 209, 243], ["breast milk", "TREATMENT", 403, 414], ["clear fluids", "TREATMENT", 500, 512], ["infants and childrenFasting Guidelines", "TREATMENT", 517, 555], ["elective surgery", "TREATMENT", 764, 780], ["breast", "ANATOMY", 334, 340]]], ["Pediatric patients should also be encouraged to consume clear fluids, as defined, up to one hour before elective procedures.Fasting GuidelinesConditions that delay gastric emptying require individual patient assessment.", [["gastric", "ANATOMY", 164, 171], ["patients", "ORGANISM", 10, 18], ["gastric", "ORGAN", 164, 171], ["patient", "ORGANISM", 200, 207], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 200, 207], ["elective procedures", "TREATMENT", 104, 123], ["Fasting Guidelines", "TREATMENT", 124, 142], ["delay gastric emptying", "PROBLEM", 158, 180], ["individual patient assessment", "TEST", 189, 218], ["gastric", "ANATOMY", 164, 171]]], ["These guidelines may be modified at the discretion of the physician.Fasting GuidelinesPremedication, when indicated, should be ordered by the anesthesiologist.", [["Fasting", "ORGANISM_SUBSTANCE", 68, 75], ["Fasting GuidelinesPremedication", "TREATMENT", 68, 99]]], ["Orders should be specific as to dose, time, and route of administration.Fasting GuidelinesAn oral H2 receptor antagonist is recommended the night before and on the morning of an elective Cesarean delivery.Fasting GuidelinesAn intravenous H2 receptor antagonist and 30 ml of oral 0.3 molar sodium citrate are recommended prior to an emergent Cesarean delivery if general anesthesia is planned.", [["oral", "ANATOMY", 93, 97], ["intravenous", "ANATOMY", 226, 237], ["oral", "ANATOMY", 274, 278], ["sodium citrate", "CHEMICAL", 289, 303], ["sodium citrate", "CHEMICAL", 289, 303], ["Fasting", "ORGANISM_SUBSTANCE", 72, 79], ["oral H2 receptor antagonist", "GENE_OR_GENE_PRODUCT", 93, 120], ["Fasting", "ORGANISM_SUBSTANCE", 205, 212], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 226, 237], ["H2 receptor antagonist", "GENE_OR_GENE_PRODUCT", 238, 260], ["oral", "ORGANISM_SUBDIVISION", 274, 278], ["sodium citrate", "SIMPLE_CHEMICAL", 289, 303], ["Fasting GuidelinesAn oral H2 receptor antagonist", "TREATMENT", 72, 120], ["an elective Cesarean delivery", "TREATMENT", 175, 204], ["Fasting GuidelinesAn intravenous H2 receptor antagonist", "TREATMENT", 205, 260], ["oral 0.3 molar sodium citrate", "TREATMENT", 274, 303], ["an emergent Cesarean delivery", "TREATMENT", 329, 358], ["general anesthesia", "TREATMENT", 362, 380]]], ["See Section 7.3 for fasting guidelines specific to patients in active labour.Additional RegulationsProvincial legislation or facility bylaws may dictate additional regulations governing the conduct of anesthesia.Preparation for AnesthesiaBefore beginning anesthesia, the anesthesiologist must ensure thatPreparation for Anesthesia1.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["fasting guidelines", "TREATMENT", 20, 38], ["anesthesia", "TREATMENT", 201, 211], ["AnesthesiaBefore beginning anesthesia", "TREATMENT", 228, 265], ["Anesthesia1", "TREATMENT", 320, 331], ["active", "OBSERVATION_MODIFIER", 63, 69], ["labour", "OBSERVATION", 70, 76]]], ["An explanation of the planned anesthetic procedure, including recognized risks and alternative techniques, has been provided and documented;Preparation for Anesthesia2.", [["the planned anesthetic procedure", "TREATMENT", 18, 50], ["alternative techniques", "TREATMENT", 83, 105], ["Anesthesia2", "TREATMENT", 156, 167]]], ["An adequate review of the patient's condition has been performed; 3.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["adequate", "OBSERVATION_MODIFIER", 3, 11]]], ["All equipment that is expected to be required is available and in working order, including the equipment required for supporting core temperature management (patient core temperature 36-37\u00b0C); 4.", [["patient", "ORGANISM", 158, 165], ["patient", "SPECIES", 158, 165], ["All equipment", "TREATMENT", 0, 13], ["supporting core temperature management", "TREATMENT", 118, 156], ["patient core temperature", "TEST", 158, 182]]], ["A reserve source of oxygen under pressure is available; 5.", [["oxygen", "CHEMICAL", 20, 26], ["oxygen", "CHEMICAL", 20, 26], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["oxygen under pressure", "TREATMENT", 20, 41]]], ["All drugs and agents that are expected to be required are correctly identified-user-applied drug labels should conform to the CSA Standard CAN/CSA-Z264.3-98 (R2005) (Appendix 1); 6.", [["All drugs", "TREATMENT", 0, 9], ["agents", "TREATMENT", 14, 20], ["CSA", "TEST", 143, 146]]], ["If Luer neuraxial connectors are used, both sides of all Luer connections must be labelled.", [["Luer neuraxial connectors", "TREATMENT", 3, 28], ["all Luer connections", "TREATMENT", 53, 73], ["neuraxial connectors", "OBSERVATION", 8, 28]]], ["Consideration should be given to the use of neuraxial connectors complying with ISO 80369-6:2016-small bore connectors for neuraxial application (e.g., NRFit\u00d2 connectors) subject to availability from equipment suppliers; and 7.", [["neuraxial", "ANATOMY", 123, 132], ["ISO 80369-6:2016", "CHEMICAL", 80, 96], ["ISO 80369-6:2016", "CHEMICAL", 80, 96], ["neuraxial connectors", "TREATMENT", 44, 64], ["ISO", "TEST", 80, 83], ["small bore connectors", "TREATMENT", 97, 118], ["neuraxial application (e.g., NRFit\u00d2 connectors", "TREATMENT", 123, 169]]], ["The manufacturers' recommendations concerning the use, handling, and disposal of anesthetic equipment and supplies have been considered.Airway ManagementAirway management, particularly of the difficult airway, contributes to a significant proportion of anesthesia related morbidity and mortality.", [["Airway", "ANATOMY", 136, 142], ["airway", "ANATOMY", 202, 208], ["Airway", "MULTI-TISSUE_STRUCTURE", 136, 142], ["airway", "MULTI-TISSUE_STRUCTURE", 202, 208], ["anesthetic equipment", "TREATMENT", 81, 101], ["Airway ManagementAirway management", "TREATMENT", 136, 170], ["the difficult airway", "PROBLEM", 188, 208], ["anesthesia related morbidity", "PROBLEM", 253, 281]]], ["The appropriate management of those patients who have a predicted, or an unanticipated difficult intubation, a failed airway, where bag-mask ventilation or supraglottic device placement may be difficult, or who require a surgical airway is critical for patient safety.", [["airway", "ANATOMY", 118, 124], ["supraglottic", "ANATOMY", 156, 168], ["airway", "ANATOMY", 230, 236], ["patients", "ORGANISM", 36, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 118, 124], ["airway", "MULTI-TISSUE_STRUCTURE", 230, 236], ["patient", "ORGANISM", 253, 260], ["patients", "SPECIES", 36, 44], ["patient", "SPECIES", 253, 260], ["an unanticipated difficult intubation", "PROBLEM", 70, 107], ["bag-mask ventilation", "TREATMENT", 132, 152], ["supraglottic device placement", "TREATMENT", 156, 185], ["a surgical airway", "TREATMENT", 219, 236], ["airway", "ANATOMY", 118, 124], ["airway", "ANATOMY", 230, 236]]], ["This includes, but need not be restricted to, adequate airway assessment, equipment (e.g., difficult airway carts, videolaryngoscopes, bronchoscopes), training and simulation, support personnel and the use of protocols and cognitive aids to optimize difficult airway management.", [["airway", "ANATOMY", 55, 61], ["airway", "ANATOMY", 101, 107], ["airway", "ANATOMY", 260, 266], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["airway", "MULTI-TISSUE_STRUCTURE", 101, 107], ["airway", "MULTI-TISSUE_STRUCTURE", 260, 266], ["adequate airway assessment", "TEST", 46, 72], ["difficult airway carts", "TREATMENT", 91, 113], ["videolaryngoscopes", "TREATMENT", 115, 133], ["bronchoscopes", "TREATMENT", 135, 148], ["protocols", "TREATMENT", 209, 218], ["cognitive aids", "TREATMENT", 223, 237], ["difficult airway management", "TREATMENT", 250, 277], ["airway", "ANATOMY", 55, 61]]], ["The CAS does not endorse any one specific protocol, algorithm, or cognitive aid for difficult and failed airway management but strongly recommends that readers refer to Appendix 4 for up to date publications related to this topic.Delegation of Patient CareThe anesthesiologist's primary responsibility is to the patient receiving care.", [["airway", "ANATOMY", 105, 111], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["patient", "ORGANISM", 312, 319], ["Patient", "SPECIES", 244, 251], ["patient", "SPECIES", 312, 319], ["algorithm", "TEST", 52, 61], ["airway management", "TREATMENT", 105, 122]]], ["The anesthesiologist or an anesthesia assistant supervised by the anesthesiologist must remain with the patient at all times throughout the conduct of all general and major regional, anesthetics and for procedural sedation until the patient is transferred to the care of personnel in an appropriate care unit.Delegation of Patient CareIf the attending anesthesiologist leaves the operating room temporarily, he/she must delegate care of the patient to another anesthesiologist, a resident in anesthesia, or an anesthesia assistant.", [["patient", "ORGANISM", 104, 111], ["patient", "ORGANISM", 233, 240], ["patient", "ORGANISM", 441, 448], ["patient", "SPECIES", 104, 111], ["patient", "SPECIES", 233, 240], ["Patient", "SPECIES", 323, 330], ["patient", "SPECIES", 441, 448], ["anesthetics", "TREATMENT", 183, 194], ["procedural sedation", "TREATMENT", 203, 222]]], ["When the attending anesthesiologist delegates care to a resident in anesthesia or an anesthesia assistant, the attending anesthesiologist remains responsible for the anesthetic management of the patient.", [["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202], ["the anesthetic management", "TREATMENT", 162, 187]]], ["Before delegating care of the patient to an anesthesia assistant, the anesthesiologist must ensure that the patient's condition is stable and that the anesthesia assistant is familiar with the operative procedure and the operating room environment and equipment.", [["patient", "ORGANISM", 30, 37], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 108, 115], ["the patient's condition", "PROBLEM", 104, 127], ["the operative procedure", "TREATMENT", 189, 212]]], ["The attending anesthesiologist must remain immediately available when care is delegated to an anesthesia assistant.Delegation of Patient CareAn anesthesiologist may briefly delegate routine care of a stable patient to a competent person who is not an anesthesia assistant only under the most exceptional circumstances, e.g., to provide life-saving emergency care to another patient.", [["patient", "ORGANISM", 207, 214], ["patient", "ORGANISM", 374, 381], ["Patient", "SPECIES", 129, 136], ["patient", "SPECIES", 207, 214], ["person", "SPECIES", 230, 236], ["patient", "SPECIES", 374, 381]]], ["That person's only responsibility would be to monitor the patient during the anesthesiologist's absence and to keep the anesthesiologist informed until he/ she returns.", [["patient", "ORGANISM", 58, 65], ["person", "SPECIES", 5, 11], ["patient", "SPECIES", 58, 65]]], ["In this situation, the anesthesiologist remains responsible for the care of the patient and must inform the operating room team.Delegation of Patient CareAn intraoperative handover of care between two anesthesiologists should be documented in the anesthesia record and follow a structured protocol.Delegation of Patient CareIt is unacceptable for one anesthesiologist to simultaneously administer general anesthesia, major regional anesthesia (spinal, epidural, or other), or deep procedural sedation (see Appendix 6) 1 for concurrent diagnostic or therapeutic procedures on more than one patient.", [["spinal", "ANATOMY", 444, 450], ["epidural", "ANATOMY", 452, 460], ["patient", "ORGANISM", 80, 87], ["spinal", "ORGANISM_SUBDIVISION", 444, 450], ["patient", "ORGANISM", 589, 596], ["patient", "SPECIES", 80, 87], ["Patient", "SPECIES", 142, 149], ["Patient", "SPECIES", 312, 319], ["patient", "SPECIES", 589, 596], ["a structured protocol", "TEST", 276, 297], ["general anesthesia", "TREATMENT", 397, 415], ["major regional anesthesia", "TREATMENT", 417, 442], ["spinal, epidural", "TREATMENT", 444, 460], ["deep procedural sedation", "TREATMENT", 476, 500], ["therapeutic procedures", "TREATMENT", 549, 571], ["spinal", "ANATOMY", 444, 450], ["epidural", "ANATOMY", 452, 460]]], ["Nevertheless, it may be appropriate in specific circumstances for one anesthesiologist to supervise more than one patient where only minimal to moderate sedation is administered, provided an appropriately trained, qualified, and accredited individual approved by the department of anesthesiology, and the healthcare institution is in constant attendance with each patient receiving care.", [["patient", "ORGANISM", 114, 121], ["patient", "ORGANISM", 364, 371], ["patient", "SPECIES", 114, 121], ["patient", "SPECIES", 364, 371], ["moderate sedation", "TREATMENT", 144, 161]]], ["In an obstetric unit, however, it is acceptable to supervise more than one patient receiving regional analgesia for labour.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["regional analgesia", "TREATMENT", 93, 111], ["labour", "PROBLEM", 116, 122]]], ["Due care must be taken to ensure that a suitably trained person adequately observes each patient following an established protocol.", [["patient", "ORGANISM", 89, 96], ["person", "SPECIES", 57, 63], ["patient", "SPECIES", 89, 96], ["an established protocol", "TREATMENT", 107, 130]]], ["When an anesthesiologist is providing anesthetic care for an obstetric delivery, a second appropriately trained person should be available to provide neonatal resuscitation.Delegation of Patient CareIt is unacceptable for a single physician to administer an anesthetic, including deep procedural sedation, and simultaneously perform a diagnostic or therapeutic procedure, except for procedures done with only infiltration of local anesthetic and/or minimal sedation.Patient MonitoringThe only indispensable monitor is the presence, at all times, of a physician or an anesthesia assistant who is under the immediate supervision of an anesthesiologist and has appropriate training and experience.", [["person", "SPECIES", 112, 118], ["Patient", "SPECIES", 187, 194], ["Patient", "SPECIES", 466, 473], ["anesthetic care", "TREATMENT", 38, 53], ["an obstetric delivery", "TREATMENT", 58, 79], ["a second appropriately trained person", "TREATMENT", 81, 118], ["neonatal resuscitation", "TREATMENT", 150, 172], ["an anesthetic", "TREATMENT", 255, 268], ["deep procedural sedation", "TREATMENT", 280, 304], ["therapeutic procedure", "TREATMENT", 349, 370], ["procedures", "TREATMENT", 383, 393], ["local anesthetic", "TREATMENT", 425, 441], ["minimal sedation", "TREATMENT", 449, 465], ["Patient Monitoring", "TEST", 466, 484]]], ["Mechanical and electronic monitors are, at best, aids to vigilance.", [["Mechanical and electronic monitors", "TREATMENT", 0, 34]]], ["Such devices assist the anesthesiologist to ensure the integrity of the vital organs and, in particular, the adequacy of tissue perfusion and oxygenation.", [["organs", "ANATOMY", 78, 84], ["tissue", "ANATOMY", 121, 127], ["organs", "ORGAN", 78, 84], ["tissue", "TISSUE", 121, 127], ["Such devices", "TREATMENT", 0, 12], ["tissue perfusion", "TEST", 121, 137], ["oxygenation", "OBSERVATION_MODIFIER", 142, 153]]], ["Monitoring equipment must be used as intended by the manufacturer and approved by Health Canada for the specific application.Patient MonitoringThe healthcare facility is responsible for the provision and maintenance of monitoring equipment that meets current published equipment standards.Patient MonitoringThe chief of anesthesia is responsible for advising the healthcare facility regarding the procurement of monitoring equipment and for establishing policies for monitoring to help ensure patient safety.Patient MonitoringThe anesthesiologist is responsible for monitoring the patient receiving care and for ensuring that appropriate monitoring equipment is available and working correctly.", [["patient", "ORGANISM", 493, 500], ["patient", "ORGANISM", 581, 588], ["Patient", "SPECIES", 125, 132], ["Patient", "SPECIES", 289, 296], ["patient", "SPECIES", 493, 500], ["Patient", "SPECIES", 508, 515], ["patient", "SPECIES", 581, 588], ["Monitoring equipment", "TREATMENT", 0, 20], ["monitoring equipment", "TREATMENT", 219, 239], ["anesthesia", "TREATMENT", 320, 330], ["monitoring equipment", "TREATMENT", 412, 432], ["monitoring", "TEST", 467, 477], ["care", "TREATMENT", 599, 603]]], ["A preanesthetic checklist (Appendix 3 or equivalent) must be completed prior to initiation of anesthesia.Patient MonitoringCautious dosing, vigilant monitoring, and the appropriate reversal of neuromuscular blocking drugs are all essential for patient safety.", [["neuromuscular", "ANATOMY", 193, 206], ["patient", "ORGANISM", 244, 251], ["Patient", "SPECIES", 105, 112], ["patient", "SPECIES", 244, 251], ["A preanesthetic checklist", "TEST", 0, 25], ["anesthesia", "TREATMENT", 94, 104], ["Cautious dosing", "TREATMENT", 123, 138], ["vigilant monitoring", "TEST", 140, 159], ["neuromuscular blocking drugs", "TREATMENT", 193, 221]]], ["Neuromuscular monitoring must be utilized when neuromuscular blocking agents are administered.Patient MonitoringMonitoring guidelines for standard patient care apply to all patients receiving general anesthesia, regional anesthesia, or procedural sedation.Required Monitoring EquipmentMonitoring equipment is classified as follows:Required Monitoring Equipment\u2022 Required: These monitors must be in continuous use throughout the administration of all anesthetics. \u2022 Exclusively available for each patient: These monitors must be available at each anesthetic work station so that they can be used with no delay. \u2022 Immediately available: These monitors must be available to facilitate their use without undue delay.Required Monitoring EquipmentThe following monitoring equipment is required:Required Monitoring Equipment\u2022 Pulse oximeter;Required Monitoring Equipment\u2022 Apparatus to measure blood pressure, either directly or noninvasively; \u2022 Electrocardiography; \u2022 Neuromuscular blockade monitor when neuromuscular blocking drugs are used;Required Monitoring Equipment\u2022 Capnography for general anesthesia and to assess the adequacy of ventilation for moderate or deep procedural sedation; and \u2022 Agent-specific anesthetic gas monitor, when inhalational anesthetic agents are used.Required Monitoring EquipmentThe following monitoring equipment must be exclusively available for each patient:Required Monitoring Equipment\u2022 Apparatus to measure temperature; \u2022 Stethoscope; \u2022 Appropriate lighting to visualize an exposed portion of the patient.Required Monitoring EquipmentThe following monitoring equipment must be immediately available:Required Monitoring Equipment\u2022 Spirometer to measure tidal volume; \u2022 Manometer to measure endotracheal tube cuff pressure.Required Monitoring Equipment\u2022 Equipment for invasive hemodynamic monitoring if indicated (e.g., arterial, central venous).Required Monitoring EquipmentThe anesthesiologist must remain constantly vigilant, understanding that brief interruptions in continuous monitoring may be unavoidable and there are certain circumstances in which a monitor may fail.Required Monitoring EquipmentAudible and visual alarms for oximetry and capnography should not be indefinitely disabled during the conduct of an anesthetic except during unusual circumstances.", [["Neuromuscular", "ANATOMY", 0, 13], ["neuromuscular", "ANATOMY", 47, 60], ["blood", "ANATOMY", 886, 891], ["Neuromuscular", "ANATOMY", 961, 974], ["neuromuscular", "ANATOMY", 997, 1010], ["endotracheal tube", "ANATOMY", 1720, 1737], ["arterial", "ANATOMY", 1849, 1857], ["central venous", "ANATOMY", 1859, 1873], ["patient", "ORGANISM", 147, 154], ["patients", "ORGANISM", 173, 181], ["patient", "ORGANISM", 496, 503], ["blood", "ORGANISM_SUBSTANCE", 886, 891], ["patient", "ORGANISM", 1378, 1385], ["patient", "ORGANISM", 1528, 1535], ["arterial", "MULTI-TISSUE_STRUCTURE", 1849, 1857], ["central venous", "MULTI-TISSUE_STRUCTURE", 1859, 1873], ["Patient", "SPECIES", 94, 101], ["patient", "SPECIES", 147, 154], ["patients", "SPECIES", 173, 181], ["patient", "SPECIES", 496, 503], ["patient", "SPECIES", 1378, 1385], ["patient", "SPECIES", 1528, 1535], ["Neuromuscular monitoring", "TEST", 0, 24], ["neuromuscular blocking agents", "TREATMENT", 47, 76], ["standard patient care", "TREATMENT", 138, 159], ["general anesthesia", "TREATMENT", 192, 210], ["regional anesthesia", "TREATMENT", 212, 231], ["procedural sedation", "TREATMENT", 236, 255], ["These monitors", "TREATMENT", 372, 386], ["all anesthetics", "TREATMENT", 446, 461], ["These monitors", "TEST", 505, 519], ["undue delay", "PROBLEM", 700, 711], ["Monitoring Equipment", "TREATMENT", 721, 741], ["Pulse oximeter", "TREATMENT", 819, 833], ["blood pressure", "TEST", 886, 900], ["Electrocardiography", "TEST", 938, 957], ["Neuromuscular blockade", "TREATMENT", 961, 983], ["neuromuscular blocking drugs", "TREATMENT", 997, 1025], ["Capnography", "TEST", 1066, 1077], ["general anesthesia", "TREATMENT", 1082, 1100], ["ventilation", "TREATMENT", 1131, 1142], ["deep procedural sedation", "TREATMENT", 1159, 1183], ["Agent", "TREATMENT", 1191, 1196], ["specific anesthetic gas monitor", "TEST", 1197, 1228], ["inhalational anesthetic agents", "TREATMENT", 1235, 1265], ["Monitoring Equipment", "TREATMENT", 1284, 1304], ["Stethoscope", "TREATMENT", 1453, 1464], ["Monitoring Equipment", "TREATMENT", 1545, 1565], ["Spirometer", "TREATMENT", 1661, 1671], ["tidal volume", "TEST", 1683, 1695], ["\u2022 Manometer", "TREATMENT", 1697, 1708], ["endotracheal tube cuff pressure", "TEST", 1720, 1751], ["invasive hemodynamic monitoring", "TEST", 1797, 1828], ["Monitoring Equipment", "TREATMENT", 1884, 1904], ["continuous monitoring", "TEST", 2000, 2021], ["Monitoring EquipmentAudible", "TEST", 2114, 2141], ["visual alarms", "TEST", 2146, 2159], ["oximetry", "TEST", 2164, 2172], ["capnography", "TEST", 2177, 2188], ["an anesthetic", "TREATMENT", 2247, 2260], ["endotracheal", "OBSERVATION", 1720, 1732], ["tube cuff", "OBSERVATION", 1733, 1742], ["pressure", "OBSERVATION_MODIFIER", 1743, 1751], ["arterial", "ANATOMY", 1849, 1857], ["central venous", "ANATOMY", 1859, 1873]]], ["The variable pitch, pulse tone, and lowthreshold alarm of the pulse oximeter and the capnograph apnea alarm must give an audible and visual warning.Perioperative Temperature ManagementMonitoring patient core temperature is strongly recommended during cases of general and neuraxial regional anesthesia lasting 30 min or longer.", [["apnea", "DISEASE", 96, 101], ["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202], ["the pulse oximeter", "TEST", 58, 76], ["the capnograph apnea alarm", "PROBLEM", 81, 107], ["Perioperative Temperature Management", "TREATMENT", 148, 184], ["Monitoring patient core temperature", "TEST", 184, 219], ["general and neuraxial regional anesthesia", "TREATMENT", 260, 301], ["variable", "OBSERVATION_MODIFIER", 4, 12], ["pitch", "OBSERVATION_MODIFIER", 13, 18], ["pulse tone", "OBSERVATION", 20, 30]]], ["In the absence of surgical or patient indications for intraoperative hypothermia, active patient warming systems, control of the operating room ambient temperature, and other methods, should be used to target a central core temperature of 36-37\u00b0C.RecordsAll monitored physiologic variables should be charted at intervals appropriate to the clinical circumstances.", [["hypothermia", "DISEASE", 69, 80], ["patient", "ORGANISM", 30, 37], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 89, 96], ["intraoperative hypothermia", "PROBLEM", 54, 80], ["active patient warming systems", "TREATMENT", 82, 112], ["a central core temperature", "TEST", 209, 235], ["surgical", "OBSERVATION", 18, 26]]], ["Heart rate and blood pressure should be recorded at least every five minutes.", [["Heart", "ANATOMY", 0, 5], ["blood", "ANATOMY", 15, 20], ["Heart", "ORGAN", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["Heart rate", "TEST", 0, 10], ["blood pressure", "TEST", 15, 29], ["blood pressure", "OBSERVATION", 15, 29]]], ["Oxygen saturation must be monitored continuously and should be recorded at frequent intervals, at a minimum of every five minutes, for all patients.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Oxygen saturation", "TEST", 0, 17]]], ["End-tidal carbon dioxide concentration must be monitored continuously and recorded at frequent intervals if the trachea is intubated or a supraglottic device is in situ.", [["trachea", "ANATOMY", 112, 119], ["supraglottic", "ANATOMY", 138, 150], ["carbon dioxide", "CHEMICAL", 10, 24], ["carbon dioxide", "CHEMICAL", 10, 24], ["End-tidal carbon dioxide", "SIMPLE_CHEMICAL", 0, 24], ["trachea", "ORGAN", 112, 119], ["End-tidal carbon dioxide concentration", "TREATMENT", 0, 38], ["a supraglottic device", "TREATMENT", 136, 157], ["trachea", "ANATOMY", 112, 119], ["supraglottic", "ANATOMY", 138, 150]]], ["Reasons for deviation from these charting guidelines should be documented in the anesthetic record.", [["deviation", "PROBLEM", 12, 21]]], ["Monitors, equipment, and techniques, as well as time, dose, and route of all drugs and intravenous fluids should be recorded.", [["intravenous", "ANATOMY", 87, 98], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 98], ["all drugs", "TREATMENT", 73, 82], ["intravenous fluids", "TREATMENT", 87, 105]]], ["All other relevant intraoperative anesthesia care and events, including unexpected or adverse events, should also be recorded.RecordsThe anesthesia record should include the patient's level of consciousness, heart rate, blood pressure, oxygen saturation, and respiratory rate as first determined in the PACU.", [["heart", "ANATOMY", 208, 213], ["blood", "ANATOMY", 220, 225], ["respiratory", "ANATOMY", 259, 270], ["oxygen", "CHEMICAL", 236, 242], ["oxygen", "CHEMICAL", 236, 242], ["patient", "ORGANISM", 174, 181], ["heart", "ORGAN", 208, 213], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["oxygen", "SIMPLE_CHEMICAL", 236, 242], ["patient", "SPECIES", 174, 181], ["intraoperative anesthesia care", "TREATMENT", 19, 49], ["unexpected or adverse events", "PROBLEM", 72, 100], ["heart rate", "TEST", 208, 218], ["blood pressure", "TEST", 220, 234], ["oxygen saturation", "TEST", 236, 253], ["respiratory rate", "TEST", 259, 275], ["heart", "ANATOMY", 208, 213], ["oxygen saturation", "OBSERVATION", 236, 253]]], ["These recommendations apply to both manually created (handwritten) and electronic anesthesia information management system (AIMS) created anesthesia records.", [["electronic anesthesia", "TREATMENT", 71, 92]]], ["At present, there are no practice standards for what additional data (e.g., gas analysis, ventilator, and respiratory data) that can potentially be collected by an AIMS charting system should become part of a patient's permanent health record.RecordsAIMS have been shown to have potential benefits over handwritten records in several key areas, including improved legibility, precision and reliability of anesthesia records, providing searchable data for quality improvement, outcome and performance reporting and translational research, enhanced medication safety and tracking and real-time clinical decision support for users.", [["patient", "ORGANISM", 209, 216], ["patient", "SPECIES", 209, 216], ["gas analysis", "TEST", 76, 88], ["ventilator", "TREATMENT", 90, 100], ["enhanced medication safety", "TREATMENT", 538, 564]]], ["The anesthesia patient safety literature supports the use of AIMS.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["The anesthesia", "TREATMENT", 0, 14]]], ["Importantly, AIMS maintain a longitudinal patient database so historical patient encounters should be easily retrievable for review and this should be considered an important feature of any system.", [["patient", "ORGANISM", 42, 49], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 42, 49], ["patient", "SPECIES", 73, 80]]], ["Ideally it should be implemented and supported in cooperation with the facility information technology department including communication with other facility electronic patient databases wherever possible.Records6.0 The Postanesthetic PeriodRecovery FacilityA PACU must be available in any facility that provides anesthetic services.", [["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176]]], ["Administrative policies to coordinate medical and nursing care responsibilities must be enforced in accordance with facility bylaws.Recovery FacilityThe department of anesthesia should have overall medical administrative responsibility for the PACU.", [["anesthesia", "TREATMENT", 167, 177]]], ["There should be a PACU policy manual approved by appropriate medical, nursing, and administrative authorities.Recovery FacilityThe anesthesiologist should accompany the patient to the PACU, communicate necessary information to the PACU nurse(s) as part of a structured handover of care protocol, and write appropriate orders.", [["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["care protocol", "TREATMENT", 281, 294]]], ["Continuous monitoring of patients is recommended during the perioperative period appropriate to the clinical situation.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["Continuous monitoring", "TEST", 0, 21]]], ["If clinically indicated, supplemental oxygen, portable pulse oximetry, and other appropriate monitoring devices should be applied during transport to the PACU or intensive care unit.", [["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 38, 44], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["supplemental oxygen", "TREATMENT", 25, 44], ["portable pulse oximetry", "TEST", 46, 69], ["other appropriate monitoring devices", "TREATMENT", 75, 111]]], ["The anesthesiologist should delegate care to the PACU nurse only when assured that nursing staff may safely observe and care for the patient.", [["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140]]], ["Discharge from the PACU is the responsibility of the anesthesiologist; this responsibility may be delegated in accordance with facility policy.Recovery FacilitySupplemental oxygen and suction must be available for every patient in the PACU.", [["oxygen", "CHEMICAL", 173, 179], ["oxygen", "CHEMICAL", 173, 179], ["oxygen", "SIMPLE_CHEMICAL", 173, 179], ["patient", "ORGANISM", 220, 227], ["patient", "SPECIES", 220, 227], ["Recovery FacilitySupplemental oxygen", "TREATMENT", 143, 179], ["suction", "TREATMENT", 184, 191], ["oxygen", "OBSERVATION_MODIFIER", 173, 179]]], ["Emergency equipment for airway management, resuscitation, and life support must be available in the PACU.", [["airway", "ANATOMY", 24, 30], ["airway", "MULTI-TISSUE_STRUCTURE", 24, 30], ["Emergency equipment", "TREATMENT", 0, 19], ["airway management", "TREATMENT", 24, 41], ["resuscitation", "TREATMENT", 43, 56], ["life support", "TREATMENT", 62, 74], ["airway", "ANATOMY", 24, 30]]], ["Equipment for management of the difficult airway must be immediately available to the PACU.", [["airway", "ANATOMY", 42, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["management", "TREATMENT", 14, 24], ["the difficult airway", "PROBLEM", 28, 48]]], ["The monitoring used in the PACU should be appropriate to the patient's condition, and a full range of monitoring devices should be available.", [["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["The monitoring", "TEST", 0, 14], ["a full range of monitoring devices", "TREATMENT", 86, 120]]], ["Monitor alarms should be enabled with alarm settings appropriate to the condition and age of the patient.", [["patient", "ORGANISM", 97, 104], ["patient", "SPECIES", 97, 104], ["alarm settings", "TREATMENT", 38, 52]]], ["The use of continuous pulse oximetry is required in the initial phase of recovery.", [["continuous pulse oximetry", "TREATMENT", 11, 36]]], ["Capnography is required for intubated and deeply sedated patients and is recommended for unconscious patients with in situ supraglottic airway devices.", [["supraglottic airway", "ANATOMY", 123, 142], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 101, 109], ["supraglottic airway", "MULTI-TISSUE_STRUCTURE", 123, 142], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 101, 109], ["Capnography", "TEST", 0, 11], ["intubated", "TREATMENT", 28, 37], ["unconscious patients with in situ supraglottic airway devices", "TREATMENT", 89, 150], ["supraglottic airway", "ANATOMY", 123, 142]]], ["An apnea monitor is recommended for preterm infants with a gestational age of less than 50 weeks.Recovery FacilityAn accurate record of the immediate recovery period must be maintained.", [["apnea", "DISEASE", 3, 8], ["infants", "ORGANISM", 44, 51], ["infants", "SPECIES", 44, 51], ["An apnea monitor", "TEST", 0, 16]]], ["This must include a record of vital signs together with other aspects of treatment and observation.", [["vital signs", "TEST", 30, 41], ["treatment", "TREATMENT", 73, 82], ["observation", "TEST", 87, 98]]], ["Any complications that bear any relation to the anesthetic should be recorded either on the recovery record or on the progress notes on the patient's chart.Recovery FacilityIn some circumstances, it may be considered acceptable to transfer a patient directly to other care units or to bypass the PACU if the appropriate level of care is available in another unit in the facility and the suitability of the patient for this transfer is documented on the anesthetic record.Discharge of Patients After Day SurgeryDischarge of patients after day surgery must utilize a formal care plan approved by the institution and be documented in the patient care notes.", [["patient", "ORGANISM", 140, 147], ["patient", "ORGANISM", 242, 249], ["patient", "ORGANISM", 406, 413], ["Patients", "ORGANISM", 484, 492], ["patients", "ORGANISM", 523, 531], ["patient", "ORGANISM", 635, 642], ["patient", "SPECIES", 140, 147], ["patient", "SPECIES", 242, 249], ["patient", "SPECIES", 406, 413], ["Patients", "SPECIES", 484, 492], ["patients", "SPECIES", 523, 531], ["patient", "SPECIES", 635, 642], ["Any complications", "PROBLEM", 0, 17], ["the anesthetic", "TREATMENT", 44, 58], ["bypass", "TREATMENT", 285, 291], ["surgery", "TREATMENT", 542, 549], ["complications", "OBSERVATION", 4, 17]]], ["Patients should meet the facility discharge to home criteria using a validated assessment tool. (e.g., Post Anesthetic Discharge Scoring System).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["a validated assessment", "TEST", 67, 89]]], ["Specific written instructions should include management of pain and postoperative complications, and both routine and emergency follow-up.", [["pain", "DISEASE", 59, 63], ["pain", "PROBLEM", 59, 63], ["postoperative complications", "PROBLEM", 68, 95]]], ["The patient should be advised regarding the additive effects of alcohol and other sedative drugs, the danger of driving or operating other hazardous machinery during the postoperative period (most commonly 24 hr postoperatively), and the necessity for attention by a competent adult during the postoperative period (most commonly 24 hr postoperatively).Guidelines for Obstetric Regional AnalgesiaAnesthesia services for parturients include obstetric analgesia for labour-for both uncomplicated and complicated deliveries-or for operative deliveries.", [["alcohol", "CHEMICAL", 64, 71], ["alcohol", "CHEMICAL", 64, 71], ["patient", "ORGANISM", 4, 11], ["alcohol", "SIMPLE_CHEMICAL", 64, 71], ["parturients", "ORGANISM", 420, 431], ["patient", "SPECIES", 4, 11], ["alcohol", "TREATMENT", 64, 71], ["other sedative drugs", "TREATMENT", 76, 96], ["Obstetric Regional AnalgesiaAnesthesia services", "TREATMENT", 368, 415], ["parturients", "TREATMENT", 420, 431], ["obstetric analgesia", "TREATMENT", 440, 459], ["operative deliveries", "TREATMENT", 528, 548]]], ["All guidelines regarding provision of anesthesia for other diagnostic or therapeutic procedures also apply to the provision of obstetric anesthesia.", [["anesthesia", "TREATMENT", 38, 48], ["therapeutic procedures", "TREATMENT", 73, 95], ["obstetric anesthesia", "TREATMENT", 127, 147]]], ["The guidelines in this section pertain to epidural and spinal analgesia during labour.", [["epidural", "ANATOMY", 42, 50], ["spinal", "ANATOMY", 55, 61], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 50], ["spinal", "ORGANISM_SUBDIVISION", 55, 61], ["The guidelines", "TREATMENT", 0, 14], ["this section", "TREATMENT", 18, 30], ["epidural", "TREATMENT", 42, 50], ["spinal analgesia", "TREATMENT", 55, 71], ["epidural", "ANATOMY", 42, 50], ["spinal", "ANATOMY", 55, 61]]], ["The term ''regional analgesia'' includes epidural, spinal, and combined spinal-epidural analgesia.Guidelines for Obstetric Regional AnalgesiaThese guidelines are reviewed annually by the Obstetric Anesthesia Section of CAS and updated as indicated.", [["epidural", "ANATOMY", 41, 49], ["spinal", "ANATOMY", 51, 57], ["spinal", "ANATOMY", 72, 78], ["epidural", "ANATOMY", 79, 87], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 49], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 87], ["The term ''regional analgesia", "TREATMENT", 0, 29], ["epidural", "TREATMENT", 41, 49], ["spinal", "TREATMENT", 51, 57], ["combined spinal-epidural analgesia", "TREATMENT", 63, 97], ["epidural", "ANATOMY", 41, 49], ["spinal", "ANATOMY", 51, 57], ["spinal", "ANATOMY", 72, 78], ["epidural", "ANATOMY", 79, 87], ["analgesia", "OBSERVATION", 88, 97]]], ["Each facility may choose to develop additional guidelines or policies for specific situations in which obstetric regional analgesia is provided.Guidelines for Obstetric Regional AnalgesiaUnder the direction of an anesthesiologist, some aspects of monitoring and management of obstetric regional analgesia may be delegated to other healthcare personnel.", [["obstetric regional analgesia", "TREATMENT", 103, 131], ["an anesthesiologist", "TREATMENT", 210, 229], ["monitoring", "TEST", 247, 257], ["management", "TREATMENT", 262, 272], ["obstetric regional analgesia", "TREATMENT", 276, 304]]], ["Each facility should ensure that such other personnel receive the same training, certification, continuing education, and recertification in obstetric regional analgesia.Initiation of Obstetric Regional AnalgesiaBefore introducing obstetric regional analgesia, the facility should have appropriate monitoring protocols in place.", [["continuing education", "TREATMENT", 96, 116], ["obstetric regional analgesia", "TREATMENT", 141, 169], ["Obstetric Regional AnalgesiaBefore", "TREATMENT", 184, 218], ["obstetric regional analgesia", "TREATMENT", 231, 259], ["appropriate monitoring protocols", "TREATMENT", 286, 318]]], ["These protocols should outline the types of monitoring required and the frequency of monitoring.", [["These protocols", "TREATMENT", 0, 15], ["monitoring", "TEST", 85, 95]]], ["In addition, they should clearly state how to manage common problems and emergencies and indicate whom to contact if assistance is required.Initiation of Obstetric Regional Analgesia1.", [["Obstetric Regional Analgesia1", "TREATMENT", 154, 183], ["Regional Analgesia1", "OBSERVATION", 164, 183]]], ["Obstetric regional analgesia should be provided only by physicians with training, facility privileges, and licence to provide these services.", [["Obstetric regional analgesia", "TREATMENT", 0, 28]]], ["Regional analgesia should be initiated and maintained only in locations where appropriate resuscitation equipment and drugs are immediately available.", [["Regional analgesia", "TREATMENT", 0, 18], ["appropriate resuscitation equipment", "TREATMENT", 78, 113], ["drugs", "TREATMENT", 118, 123], ["analgesia", "OBSERVATION", 9, 18]]], ["Intravenous access must be established before initiating regional analgesia, and it should be maintained throughout the administration of regional analgesia.", [["Intravenous access", "TREATMENT", 0, 18], ["regional analgesia", "TREATMENT", 57, 75], ["regional analgesia", "TREATMENT", 138, 156]]], ["The anesthesiologist should be immediately available until analgesia is established and the patient's vital signs are stable.Maintenance of Regional Anesthesia During LabourContinuous Epidural Infusions (CEI), Programmed Intermittent Epidural Bolus (PIEB), and Patient-Controlled Epidural Analgesia (PCEA) of low dose diluted epidural local anesthetics (e.g., bupivacaine \u00a3 0.125% or ropivacaine \u00a3 0.16%) with or without adjuncts (e.g., opioids) are associated with a very low incidence of significant complications.", [["Epidural", "ANATOMY", 184, 192], ["Epidural", "ANATOMY", 280, 288], ["epidural", "ANATOMY", 326, 334], ["Bolus", "CHEMICAL", 243, 248], ["bupivacaine", "CHEMICAL", 360, 371], ["ropivacaine", "CHEMICAL", 384, 395], ["bupivacaine", "CHEMICAL", 360, 371], ["ropivacaine", "CHEMICAL", 384, 395], ["patient", "ORGANISM", 92, 99], ["bupivacaine", "SIMPLE_CHEMICAL", 360, 371], ["ropivacaine", "SIMPLE_CHEMICAL", 384, 395], ["patient", "SPECIES", 92, 99], ["Patient", "SPECIES", 261, 268], ["analgesia", "TREATMENT", 59, 68], ["the patient's vital signs", "TEST", 88, 113], ["Regional Anesthesia", "TREATMENT", 140, 159], ["LabourContinuous Epidural Infusions", "TREATMENT", 167, 202], ["CEI)", "TREATMENT", 204, 208], ["Programmed Intermittent Epidural Bolus (PIEB)", "TREATMENT", 210, 255], ["Epidural Analgesia (PCEA", "TREATMENT", 280, 304], ["low dose diluted epidural local anesthetics", "TREATMENT", 309, 352], ["bupivacaine \u00a3", "TREATMENT", 360, 373], ["ropivacaine", "TREATMENT", 384, 395], ["adjuncts", "TREATMENT", 421, 429], ["opioids", "TREATMENT", 437, 444], ["significant complications", "PROBLEM", 490, 515], ["stable", "OBSERVATION_MODIFIER", 118, 124], ["Regional Anesthesia", "OBSERVATION", 140, 159], ["Epidural", "ANATOMY", 234, 242], ["significant", "OBSERVATION_MODIFIER", 490, 501], ["complications", "OBSERVATION", 502, 515]]], ["Consequently, it is not necessary for an anesthesiologist to remain present or immediately available during maintenance of CEI or PIEB with or without PCEA provided that:Maintenance of Regional Anesthesia During Labour\u2022 there are appropriate protocols for management of patients receiving CEI, PIEB, and PCEA and; \u2022 the anesthesiologist can be contacted for the purpose of obtaining advice and direction.Maintenance of Regional Anesthesia During LabourWhen initial and top-up bolus epidural local anesthetics are administered, the anesthesiologist must be immediately available to intervene appropriately recognizing that these techniques can cause immediate life-threatening complications.Maintenance of Regional Anesthesia During LabourIndividual departments of anesthesiology should establish their own policies regarding the appropriate availability of an anesthesiologist to manage the potential complications of regional analgesia for labour and delivery.Maintenance of Regional Anesthesia During LabourSafety systems must be in place to secure epidural local anesthetic mixtures and supplies containing controlled substances (e.g., opioids) to minimize the risk of diversion.Oral Intake During LabourGastric emptying of solids is delayed during labour and opioid analgesics may further delay gastric emptying.", [["epidural", "ANATOMY", 482, 490], ["epidural", "ANATOMY", 1051, 1059], ["Oral", "ANATOMY", 1182, 1186], ["gastric", "ANATOMY", 1299, 1306], ["gastric emptying", "DISEASE", 1299, 1315], ["PCEA", "CHEMICAL", 151, 155], ["patients", "ORGANISM", 270, 278], ["Oral", "ORGANISM_SUBDIVISION", 1182, 1186], ["gastric", "ORGAN", 1299, 1306], ["patients", "SPECIES", 270, 278], ["CEI", "TREATMENT", 123, 126], ["PIEB", "TREATMENT", 130, 134], ["PCEA", "TREATMENT", 151, 155], ["Regional Anesthesia", "TREATMENT", 185, 204], ["appropriate protocols", "TREATMENT", 230, 251], ["management", "TREATMENT", 256, 266], ["CEI", "TREATMENT", 289, 292], ["PIEB", "TREATMENT", 294, 298], ["PCEA", "TREATMENT", 304, 308], ["Regional Anesthesia", "TREATMENT", 419, 438], ["top-up bolus epidural local anesthetics", "TREATMENT", 469, 508], ["these techniques", "TREATMENT", 622, 638], ["immediate life-threatening complications", "PROBLEM", 649, 689], ["Regional Anesthesia", "TREATMENT", 705, 724], ["an anesthesiologist", "TREATMENT", 857, 876], ["regional analgesia", "TREATMENT", 918, 936], ["labour", "PROBLEM", 941, 947], ["delivery", "TREATMENT", 952, 960], ["Regional Anesthesia", "TREATMENT", 976, 995], ["LabourSafety systems", "TREATMENT", 1003, 1023], ["epidural local anesthetic mixtures", "TREATMENT", 1051, 1085], ["opioids", "TREATMENT", 1139, 1146], ["diversion", "TREATMENT", 1172, 1181], ["LabourGastric emptying of solids", "TREATMENT", 1201, 1233], ["opioid analgesics", "TREATMENT", 1263, 1280], ["further delay gastric emptying", "PROBLEM", 1285, 1315], ["Regional", "OBSERVATION_MODIFIER", 419, 427], ["Anesthesia", "OBSERVATION", 428, 438], ["Regional", "OBSERVATION_MODIFIER", 976, 984], ["Anesthesia", "OBSERVATION", 985, 995], ["diversion", "OBSERVATION", 1172, 1181], ["gastric", "ANATOMY", 1299, 1306], ["emptying", "OBSERVATION", 1307, 1315]]], ["Therefore, parturients should generally be discouraged from ingesting solid foods when in active labour.", [["parturients", "ORGANISM", 11, 22]]], ["In contrast to solid food, clear fluids are emptied relatively rapidly from the stomach during labour.", [["fluids", "ANATOMY", 33, 39], ["stomach", "ANATOMY", 80, 87], ["stomach", "ORGAN", 80, 87], ["clear", "OBSERVATION_MODIFIER", 27, 32], ["fluids", "OBSERVATION", 33, 39], ["stomach", "ANATOMY", 80, 87]]], ["Therefore, in general, women should be permitted clear fluids as desired during active labour.", [["women", "ORGANISM", 23, 28], ["women", "SPECIES", 23, 28]]], ["Individual facilities should develop protocols regarding the intake of solids and clear fluids by women in active labour.Guidelines for Acute Pain Management Using Neuraxial AnalgesiaWhen neuraxial analgesia is managed by anesthesiologists, the incidence of side effects is no higher than when alternative techniques of pain management are used.", [["Pain", "DISEASE", 142, 146], ["pain", "DISEASE", 320, 324], ["women", "ORGANISM", 98, 103], ["women", "SPECIES", 98, 103], ["protocols", "TREATMENT", 37, 46], ["Acute Pain Management", "TREATMENT", 136, 157], ["Neuraxial AnalgesiaWhen neuraxial analgesia", "TREATMENT", 164, 207], ["side effects", "PROBLEM", 258, 270], ["pain management", "TREATMENT", 320, 335]]], ["Accordingly, when its use is appropriate, neuraxial analgesia should be managed by anesthesiologists.Guidelines for Acute Pain Management Using Neuraxial AnalgesiaFor the purposes of these guidelines, neuraxial analgesia is defined as intrathecal or epidural administration of opioids and/or local anesthetics for treatment of postoperative pain or other acute pain problems.", [["epidural", "ANATOMY", 250, 258], ["Pain", "DISEASE", 122, 126], ["postoperative pain", "DISEASE", 327, 345], ["pain", "DISEASE", 361, 365], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 258], ["neuraxial analgesia", "TREATMENT", 42, 61], ["Acute Pain Management", "TREATMENT", 116, 137], ["Neuraxial AnalgesiaFor", "TREATMENT", 144, 166], ["these guidelines", "TREATMENT", 183, 199], ["neuraxial analgesia", "TREATMENT", 201, 220], ["intrathecal or epidural administration", "TREATMENT", 235, 273], ["opioids", "TREATMENT", 277, 284], ["local anesthetics", "TREATMENT", 292, 309], ["treatment", "TREATMENT", 314, 323], ["postoperative pain", "PROBLEM", 327, 345], ["other acute pain problems", "PROBLEM", 349, 374], ["acute", "OBSERVATION_MODIFIER", 355, 360], ["pain", "OBSERVATION", 361, 365]]], ["These guidelines are to provide anesthesiologists with the principles of management to maximize the benefit-risk ratio of providing neuraxial analgesia.Administrative and Educational PoliciesThe department of anesthesia should establish an acute pain service that is responsible for 1.", [["neuraxial", "ANATOMY", 132, 141], ["pain", "DISEASE", 246, 250], ["management", "TREATMENT", 73, 83], ["neuraxial analgesia", "TREATMENT", 132, 151], ["anesthesia", "TREATMENT", 209, 219], ["an acute pain service", "TREATMENT", 237, 258]]], ["Developing policies and procedures for neuraxial analgesia.", [["neuraxial", "ANATOMY", 39, 48], ["procedures", "TREATMENT", 24, 34], ["neuraxial analgesia", "TREATMENT", 39, 58]]], ["Participation of other departments (e.g., nursing, pharmacy, surgery, and materials management) should be sought as needed. \u2022 Signs and symptoms of the rare but catastrophic complications of epidural hematoma or abscess.Policies for Drug AdministrationEach facility should use a limited number of standard solutions.", [["epidural", "ANATOMY", 191, 199], ["abscess", "ANATOMY", 212, 219], ["epidural hematoma", "DISEASE", 191, 208], ["abscess", "DISEASE", 212, 219], ["epidural hematoma", "PATHOLOGICAL_FORMATION", 191, 208], ["abscess", "PATHOLOGICAL_FORMATION", 212, 219], ["surgery", "TREATMENT", 61, 68], ["Signs and symptoms", "PROBLEM", 126, 144], ["catastrophic complications", "PROBLEM", 161, 187], ["epidural hematoma", "PROBLEM", 191, 208], ["abscess", "PROBLEM", 212, 219], ["Drug AdministrationEach facility", "TREATMENT", 233, 265], ["catastrophic", "OBSERVATION_MODIFIER", 161, 173], ["complications", "OBSERVATION", 174, 187], ["epidural", "ANATOMY", 191, 199], ["hematoma", "OBSERVATION", 200, 208], ["abscess", "OBSERVATION", 212, 219]]], ["Before any solution that is not standard in the facility is dispensed, the anesthesiologist should verify the order with nursing and pharmacy personnel and discuss its indications and all concerns relating to its use with the nurses responsible for administering the drug and monitoring the patient.", [["patient", "ORGANISM", 291, 298], ["patient", "SPECIES", 291, 298], ["the drug", "TREATMENT", 263, 271]]], ["The risk of errors due to incorrect route of drug injection must be minimized.", [["drug injection", "TREATMENT", 45, 59]]], ["For continuous infusions or PCEA, the use of unique tamper-proof pumps that are distinct from the pumps used for intravenous fluid or drug administration is strongly recommended.", [["intravenous", "ANATOMY", 113, 124], ["PCEA", "CHEMICAL", 28, 32], ["PCEA", "CHEMICAL", 28, 32], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["continuous infusions", "TREATMENT", 4, 24], ["PCEA", "TREATMENT", 28, 32], ["unique tamper-proof pumps", "TREATMENT", 45, 70], ["the pumps", "TREATMENT", 94, 103], ["intravenous fluid", "TREATMENT", 113, 130], ["drug administration", "TREATMENT", 134, 153]]], ["The tubing between neuraxial analgesia infusion pumps and catheters should not have ports that could permit unintentional injection of intravenous drugs (see section 5.1-6).Policies for Drug AdministrationPreparation of solutions should follow a standardized procedure.", [["neuraxial", "ANATOMY", 19, 28], ["intravenous", "ANATOMY", 135, 146], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 146], ["The tubing between neuraxial analgesia infusion pumps", "TREATMENT", 0, 53], ["catheters", "TREATMENT", 58, 67], ["ports", "TREATMENT", 84, 89], ["intravenous drugs", "TREATMENT", 135, 152], ["Drug AdministrationPreparation of solutions", "TREATMENT", 186, 229], ["a standardized procedure", "TREATMENT", 244, 268], ["tubing", "OBSERVATION", 4, 10], ["catheters", "OBSERVATION", 58, 67]]], ["All analgesic drug solutions should be labeled with the composition of the solution (opioid, local anesthetic, or both) and its intended route of administration.", [["opioid", "SIMPLE_CHEMICAL", 85, 91], ["All analgesic drug solutions", "TREATMENT", 0, 28], ["the solution (opioid", "TREATMENT", 71, 91], ["local anesthetic", "TREATMENT", 93, 109]]], ["For epidural administration, this should include the date and time of preparation and the name of the individual who prepared it.Patient Monitoring and Management of Adverse EventsPatients receiving neuraxial analgesia should be in a room equipped with oxygen and suction.", [["epidural", "ANATOMY", 4, 12], ["oxygen", "CHEMICAL", 253, 259], ["oxygen", "CHEMICAL", 253, 259], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 12], ["Patients", "ORGANISM", 180, 188], ["oxygen", "SIMPLE_CHEMICAL", 253, 259], ["Patient", "SPECIES", 129, 136], ["Patients", "SPECIES", 180, 188], ["epidural administration", "TREATMENT", 4, 27], ["Patient Monitoring", "TEST", 129, 147], ["Management", "TREATMENT", 152, 162], ["Adverse Events", "PROBLEM", 166, 180], ["neuraxial analgesia", "TREATMENT", 199, 218], ["oxygen and suction", "TREATMENT", 253, 271]]], ["Resuscitation drugs and equipment must be immediately available.", [["Resuscitation drugs", "TREATMENT", 0, 19], ["equipment", "TREATMENT", 24, 33]]], ["Before initiating neuraxial analgesia, intravenous access must be secured, and after discontinuing neuraxial analgesia, intravenous access must be maintained for the expected duration of drug effects.Patient Monitoring and Management of Adverse EventsEpidural catheter dressings should permit examination for catheter movement and daily inspection of the catheter entry site for any signs of infection.Patient Monitoring and Management of Adverse EventsStandardized policies for patient management should be established.", [["neuraxial", "ANATOMY", 18, 27], ["intravenous", "ANATOMY", 39, 50], ["neuraxial", "ANATOMY", 99, 108], ["intravenous", "ANATOMY", 120, 131], ["catheter", "ANATOMY", 309, 317], ["infection", "DISEASE", 392, 401], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 131], ["patient", "ORGANISM", 479, 486], ["Patient", "SPECIES", 200, 207], ["Patient", "SPECIES", 402, 409], ["patient", "SPECIES", 479, 486], ["neuraxial analgesia", "TREATMENT", 18, 37], ["intravenous access", "TREATMENT", 39, 57], ["neuraxial analgesia", "TREATMENT", 99, 118], ["intravenous access", "TREATMENT", 120, 138], ["drug effects", "TREATMENT", 187, 199], ["Patient Monitoring", "TEST", 200, 218], ["Management", "TREATMENT", 223, 233], ["Adverse Events", "PROBLEM", 237, 251], ["Epidural catheter dressings", "TREATMENT", 251, 278], ["examination", "TEST", 293, 304], ["catheter movement", "TREATMENT", 309, 326], ["daily inspection", "TEST", 331, 347], ["the catheter entry site", "TREATMENT", 351, 374], ["infection", "PROBLEM", 392, 401], ["Patient Monitoring", "TEST", 402, 420], ["Management", "TREATMENT", 425, 435], ["Adverse Events", "PROBLEM", 439, 453], ["patient management", "TREATMENT", 479, 497], ["catheter", "OBSERVATION", 260, 268], ["catheter", "OBSERVATION", 355, 363], ["infection", "OBSERVATION", 392, 401]]], ["The parameters to be assessed, frequency of assessments, documentation, and procedures for management of complications should be specified.", [["assessments", "TEST", 44, 55], ["documentation", "TEST", 57, 70], ["procedures", "TREATMENT", 76, 86], ["management", "TREATMENT", 91, 101], ["complications", "PROBLEM", 105, 118]]], ["Adequate nursing personnel must be available to assess and manage patients receiving neuraxial analgesia.", [["neuraxial", "ANATOMY", 85, 94], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["neuraxial analgesia", "TREATMENT", 85, 104]]], ["Monitoring should continue after discontinuation of neuraxial analgesia until its effects have dissipated.Patient Monitoring and Management of Adverse EventsAn anesthesiologist must be readily available to advise nursing personnel on such issues as dose titration and management of adverse effects.", [["neuraxial", "ANATOMY", 52, 61], ["Patient", "SPECIES", 106, 113], ["neuraxial analgesia", "TREATMENT", 52, 71], ["Patient Monitoring", "TEST", 106, 124], ["Adverse Events", "PROBLEM", 143, 157], ["such issues", "TREATMENT", 234, 245], ["dose titration", "TREATMENT", 249, 263], ["management", "TREATMENT", 268, 278], ["adverse effects", "PROBLEM", 282, 297]]], ["Each facility with an acute pain service should ensure that an anesthesiologist is available to attend directly to patients receiving neuraxial analgesia within an appropriate time depending on the clinical situation.", [["neuraxial", "ANATOMY", 134, 143], ["pain", "DISEASE", 28, 32], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["an acute pain service", "TREATMENT", 19, 40], ["neuraxial analgesia", "TREATMENT", 134, 153]]], ["Each facility should also specify procedures for emergent management of any lifethreatening complications.Patient Monitoring and Management of Adverse EventsOther drugs, particularly benzodiazepines or parenteral opioids, may cause severe respiratory depression in patients receiving neuraxial analgesia.", [["respiratory", "ANATOMY", 239, 250], ["neuraxial", "ANATOMY", 284, 293], ["benzodiazepines", "CHEMICAL", 183, 198], ["respiratory depression", "DISEASE", 239, 261], ["benzodiazepines", "CHEMICAL", 183, 198], ["patients", "ORGANISM", 265, 273], ["Patient", "SPECIES", 106, 113], ["patients", "SPECIES", 265, 273], ["emergent management", "TREATMENT", 49, 68], ["any lifethreatening complications", "PROBLEM", 72, 105], ["Patient Monitoring", "TEST", 106, 124], ["Management", "TREATMENT", 129, 139], ["Adverse Events", "PROBLEM", 143, 157], ["Other drugs", "TREATMENT", 157, 168], ["benzodiazepines", "TREATMENT", 183, 198], ["parenteral opioids", "TREATMENT", 202, 220], ["severe respiratory depression", "PROBLEM", 232, 261], ["neuraxial analgesia", "TREATMENT", 284, 303], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["respiratory depression", "OBSERVATION", 239, 261]]], ["For this reason, other physicians should not order sedatives or analgesics for any patient receiving neuraxial analgesia.", [["neuraxial", "ANATOMY", 101, 110], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["sedatives", "TREATMENT", 51, 60], ["analgesics", "TREATMENT", 64, 74], ["neuraxial analgesia", "TREATMENT", 101, 120]]], ["The acute pain service should direct analgesic and sedative therapy until the effects of neuraxial analgesia have dissipated.Epidurals and AnticoagulationPatients with epidural catheters may receive prophylactic low-dose anticoagulant therapy if appropriate precautions are taken:Epidurals and Anticoagulation\u2022 To minimize the risk of epidural hematoma, catheter insertion and removal and the timing of anticoagulant administration must be coordinated so that no clinically significant anticoagulant effect is present at these times. \u2022 Use of nonsteroidal anti-inflammatory drugs in patients receiving neuraxial analgesia is appropriate, but concurrent administration of these drugs or other antiplatelet medication and an anticoagulant may increase the risk of epidural hematoma. \u2022 Where neuraxial analgesia is used for prolonged postoperative pain management, every effort should be made to avoid lower extremity motor blockade. \u2022 Nursing staff should be aware of the signs and symptoms of epidural hematoma.", [["neuraxial", "ANATOMY", 89, 98], ["epidural", "ANATOMY", 168, 176], ["epidural", "ANATOMY", 335, 343], ["catheter", "ANATOMY", 354, 362], ["nonsteroidal", "ANATOMY", 543, 555], ["neuraxial", "ANATOMY", 602, 611], ["epidural", "ANATOMY", 762, 770], ["lower extremity", "ANATOMY", 899, 914], ["epidural", "ANATOMY", 992, 1000], ["pain", "DISEASE", 10, 14], ["hematoma", "DISEASE", 344, 352], ["epidural hematoma", "DISEASE", 762, 779], ["postoperative pain", "DISEASE", 831, 849], ["epidural hematoma", "DISEASE", 992, 1009], ["epidural hematoma", "PATHOLOGICAL_FORMATION", 335, 352], ["patients", "ORGANISM", 583, 591], ["epidural hematoma", "PATHOLOGICAL_FORMATION", 762, 779], ["epidural hematoma", "PATHOLOGICAL_FORMATION", 992, 1009], ["patients", "SPECIES", 583, 591], ["The acute pain service", "TREATMENT", 0, 22], ["direct analgesic", "TREATMENT", 30, 46], ["sedative therapy", "TREATMENT", 51, 67], ["neuraxial analgesia", "TREATMENT", 89, 108], ["Epidurals", "TREATMENT", 125, 134], ["epidural catheters", "TREATMENT", 168, 186], ["prophylactic low-dose anticoagulant therapy", "TREATMENT", 199, 242], ["appropriate precautions", "TREATMENT", 246, 269], ["Epidurals", "TREATMENT", 280, 289], ["Anticoagulation", "TREATMENT", 294, 309], ["epidural hematoma", "PROBLEM", 335, 352], ["catheter insertion", "TREATMENT", 354, 372], ["removal", "TREATMENT", 377, 384], ["anticoagulant administration", "TREATMENT", 403, 431], ["clinically significant anticoagulant effect", "PROBLEM", 463, 506], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 543, 579], ["neuraxial analgesia", "TREATMENT", 602, 621], ["these drugs", "TREATMENT", 671, 682], ["other antiplatelet medication", "TREATMENT", 686, 715], ["an anticoagulant", "TREATMENT", 720, 736], ["epidural hematoma", "PROBLEM", 762, 779], ["neuraxial analgesia", "TREATMENT", 789, 808], ["prolonged postoperative pain management", "TREATMENT", 821, 860], ["lower extremity motor blockade", "TREATMENT", 899, 929], ["the signs and symptoms", "PROBLEM", 966, 988], ["epidural hematoma", "PROBLEM", 992, 1009], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["epidural", "ANATOMY", 168, 176], ["catheters", "OBSERVATION", 177, 186], ["epidural", "ANATOMY", 335, 343], ["hematoma", "OBSERVATION", 344, 352], ["catheter", "OBSERVATION", 354, 362], ["significant", "OBSERVATION_MODIFIER", 474, 485], ["anticoagulant", "OBSERVATION", 486, 499], ["epidural", "ANATOMY", 762, 770], ["hematoma", "OBSERVATION", 771, 779], ["lower extremity", "ANATOMY", 899, 914], ["motor blockade", "OBSERVATION", 915, 929], ["epidural", "ANATOMY", 992, 1000], ["hematoma", "OBSERVATION", 1001, 1009]]], ["Any change in neurologic status or new-onset back pain must be investigated immediately.Epidurals and AnticoagulationIf full anticoagulation is indicated in a patient with an epidural catheter, the anesthesiologist should be consulted so that catheter removal and initiation of alternative analgesic management are accomplished before anticoagulation.Guidelines for the Practice of Anesthesia Outside a Hospital FacilityThe basic principles, training requirements, techniques, equipment, and drugs used for the practice of anesthesia are noted in other sections of these guidelines.", [["neurologic", "ANATOMY", 14, 24], ["back", "ANATOMY", 45, 49], ["epidural", "ANATOMY", 175, 183], ["catheter", "ANATOMY", 243, 251], ["back pain", "DISEASE", 45, 54], ["back", "ORGANISM_SUBDIVISION", 45, 49], ["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["Any change in neurologic status", "PROBLEM", 0, 31], ["new-onset back pain", "PROBLEM", 35, 54], ["Epidurals", "TREATMENT", 88, 97], ["Anticoagulation", "TREATMENT", 102, 117], ["full anticoagulation", "TREATMENT", 120, 140], ["an epidural catheter", "TREATMENT", 172, 192], ["catheter removal", "TREATMENT", 243, 259], ["alternative analgesic management", "TREATMENT", 278, 310], ["anticoagulation", "TREATMENT", 335, 350], ["training requirements", "TREATMENT", 442, 463], ["equipment", "TREATMENT", 477, 486], ["drugs", "TREATMENT", 492, 497], ["anesthesia", "TREATMENT", 523, 533], ["change", "OBSERVATION_MODIFIER", 4, 10], ["epidural", "ANATOMY", 175, 183], ["catheter", "OBSERVATION", 184, 192], ["catheter", "OBSERVATION", 243, 251]]], ["The following are guidelines for certain aspects particular to anesthetic practice outside a hospital facility.Patient SelectionThe physical status of patients should be classified in a manner similar to that in use by the American Society of Anesthesiologists (ASA) (Appendix 2).", [["patients", "ORGANISM", 151, 159], ["Patient", "SPECIES", 111, 118], ["patients", "SPECIES", 151, 159], ["Anesthesiologists (ASA)", "TREATMENT", 243, 266]]], ["Usually, only patients in ASA classifications I and II should be considered for anesthesia outside a hospital facility.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Patients in ASA classification III may be accepted under certain circumstances.Preoperative ConsiderationsThe patient must have had a recent recorded history, physical examination, and appropriate laboratory investigations.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 110, 117], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 110, 117], ["ASA classification III", "TREATMENT", 12, 34], ["physical examination", "TEST", 159, 179], ["appropriate laboratory investigations", "TEST", 185, 222]]], ["The duration of fasting before anesthesia should conform to the previously stated guidelines.", [["fasting before anesthesia", "TREATMENT", 16, 41]]], ["The patient should be given an information sheet with instructions for both the preanesthetic and postanesthetic periods.Conduct of AnesthesiaThe anesthetic and recovery facilities must conform to facility standards published by the CSA as defined in other sections.", [["sections", "ANATOMY", 257, 265], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Anesthesia", "TREATMENT", 132, 142], ["The anesthetic", "TREATMENT", 142, 156], ["Anesthesia", "OBSERVATION", 132, 142]]], ["The standards of care and monitoring must be the same in all anesthetizing locations.Conduct of AnesthesiaAcknowledgements Contributions to earlier versions of the Guidelines from former members of the Committee on Standards to the Practice of Anesthesia are gratefully acknowledged.", [["monitoring", "TREATMENT", 26, 36], ["Anesthesia", "TREATMENT", 244, 254]]], ["None of the authors have any financial or commercial interest relating to the companies or manufacturers of medical devices referenced either in this article or in the related appendices.", [["medical devices", "TREATMENT", 108, 123]]], ["The CAS is not responsible for the accuracy, currency, or reliability of the content.", [["CAS", "OBSERVATION", 4, 7], ["not responsible for", "UNCERTAINTY", 11, 30]]], ["It is not responsible for the information found through these links and does not necessarily endorse the sites or their content.", [["not responsible", "UNCERTAINTY", 6, 21]]], ["Guide d'exercice de l'anesth\u00e9sie de la SCA -\u00c9 dition r\u00e9vis\u00e9e 2020Conduct of AnesthesiaR\u00e9sum\u00e9 Le Guide d'exercice de l'anesth\u00e9sie, version r\u00e9vis\u00e9e 2020 (le Guide), a \u00e9t\u00e9 pr\u00e9par\u00e9 par la Soci\u00e9t\u00e9 canadienne des anesth\u00e9siologistes (SCA), qui se r\u00e9serve le droit de d\u00e9cider des termes de sa publication et de sa diffusion.", [["a \u00e9t\u00e9 pr\u00e9par\u00e9 par la Soci\u00e9t\u00e9 canadienne des", "TREATMENT", 163, 206], ["qui se r\u00e9serve le droit de d\u00e9cider des", "TREATMENT", 233, 271]]], ["Bien que la SCA incite les anesth\u00e9siologistes du Canada \u00e0 se conformer \u00e0 son guide d'exercice pour assurer une grande qualit\u00e9 des soins dispens\u00e9s aux patients, elle ne peut garantir les r\u00e9sultats d'une intervention sp\u00e9cifique.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158]]], ["Les anesth\u00e9siologistes doivent exercer leur jugement professionnel pour d\u00e9terminer la m\u00e9thode d'intervention la mieux adapt\u00e9e \u00e0 l'\u00e9tat de leur patient.", [["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150]]], ["La SCA n'accepte aucune responsabilit\u00e9 ou imputabilit\u00e9 de quelque nature que ce soit d\u00e9coulant d'erreurs ou d'omissions ou de l'utilisation des renseignements contenus dans son Guide d'exercice de l'anesth\u00e9sie.Conduct of AnesthesiaPr\u00e9ambule L'anesth\u00e9siologie est une sp\u00e9cialit\u00e9 dynamique de la m\u00e9decine qui encourage les progr\u00e8s constants en mati\u00e8re de soins anesth\u00e9siques pour les patients subissant des interventions chirurgicales et obst\u00e9tricales au Canada.", [["patients", "ORGANISM", 382, 390], ["patients", "SPECIES", 382, 390], ["AnesthesiaPr\u00e9ambule", "TEST", 221, 240], ["en mati\u00e8re de soins anesth\u00e9siques pour les patients subissant des interventions", "TREATMENT", 339, 418]]], ["Le pr\u00e9sent guide est revu annuellement et r\u00e9vis\u00e9 de fa\u00e7on p\u00e9riodique.Conduct of AnesthesiaLes recommandations suivantes ont pour objectif de proposer des lignes directrices de base touchant l'exercice de l'anesth\u00e9sie.", [["AnesthesiaLes recommandations", "TREATMENT", 80, 109], ["ont pour objectif de proposer des", "TREATMENT", 120, 153]]], ["Leur but est de constituer un cadre pour la prestation de soins aux patients qui soient raisonnables et acceptables, et c'est ainsi qu'elles devraient \u00eatre interpr\u00e9t\u00e9es, ce qui permet une certaine flexibilit\u00e9 selon les circonstances.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76]]], ["Chaque partie du Guide peut faire l'objet de r\u00e9vision au besoin, selon l'\u00e9volution de la technologie et de la pratique.Principes de baseDans le pr\u00e9sent document, le mot anesth\u00e9siologiste est utilis\u00e9 pour d\u00e9signer toute personne qui a un permis d'exercer la m\u00e9decine avec privil\u00e8ge d'administrer l'anesth\u00e9sie.", [["selon l'\u00e9volution", "TREATMENT", 65, 82]]], ["L'anesth\u00e9sie est la r\u00e9alisation d\u00e9lib\u00e9r\u00e9e de toute intervention visant \u00e0 rendre un patient temporairement insensible \u00e0 la douleur ou \u00e0 l'environnement externe dans le but d'ex\u00e9cuter une intervention diagnostique ou th\u00e9rapeutique.Principes de baseLe pr\u00e9sent Guide s'adresse \u00e0 tous les anesth\u00e9siologistes du Canada.", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["L'anesth\u00e9sie est la r\u00e9alisation", "TREATMENT", 0, 31]]], ["Le processus de certification du Coll\u00e8ge royal des m\u00e9decins et chirurgiens du Canada constitue la seule voie de reconnaissance comme sp\u00e9cialiste en anesth\u00e9sie au Canada.Principes de baseLa Soci\u00e9t\u00e9 canadienne des anesth\u00e9siologistes (SCA) reconna\u00eet que la population dans les collectivit\u00e9s \u00e9loign\u00e9es n'est souvent pas suffisamment nombreuse pour justifier une pratique d'anesth\u00e9siologie sp\u00e9cialis\u00e9e.", [["processus", "OBSERVATION", 3, 12]]], ["Tous les anesth\u00e9siologistes doivent poursuivre une formation continue dans la pratique de l'anesth\u00e9sie, de la prise en charge de la douleur, des soins p\u00e9riop\u00e9ratoires et de la r\u00e9animation, et participer \u00e0 un programme structur\u00e9 de maintien des comp\u00e9tences (par ex., MDC du Coll\u00e8ge royal).Organisation des services d'anesth\u00e9sieLe d\u00e9partement d'anesth\u00e9sie devrait \u00eatre organis\u00e9, dirig\u00e9 et int\u00e9gr\u00e9 de fa\u00e7on appropri\u00e9e aux autres d\u00e9partements de l'organisme ou de l'\u00e9tablissement, et devrait regrouper tous les membres du personnel de l'\u00e9tablissement qui assurent des soins anesth\u00e9siques aux patients, aussi bien \u00e0 des fins chirurgicales, obst\u00e9tricales, diagnostiques ou th\u00e9rapeutiques.Organisation des services d'anesth\u00e9sieCompte tenu de l'ampleur et de la nature des services offerts, le d\u00e9partement devrait comporter le personnel n\u00e9cessaire et s'efforcer d'assurer que ces services soient disponibles comme l'\u00e9tablissement de soins de sant\u00e9 le requiert.Organisation des services d'anesth\u00e9sieLe chef du d\u00e9partement devrait \u00eatre un m\u00e9decin certifi\u00e9 en anesth\u00e9sie ou encore poss\u00e9dant une formation ad\u00e9quate en anesth\u00e9sie.", [["patients", "ORGANISM", 588, 596], ["patients", "SPECIES", 588, 596]]], ["Veiller \u00e0 ce que, en mati\u00e8re d'exercice de l'anesth\u00e9sie, des directives \u00e9crites soient \u00e9tablies et suivies.\u00c9 valuer la comp\u00e9tence et les capacit\u00e9s des m\u00e9decinsqui dispensent les soins anesth\u00e9siques ainsi que celles des autres professionnels de la sant\u00e9 qui assurent les services de soutien -ce qui comprend, sans cependant s'y limiter, les recommandations touchant les privil\u00e8ges cliniques accord\u00e9s aux m\u00e9decins qui exercent l'anesth\u00e9sie et la r\u00e9vision annuelle de tels privil\u00e8ges.", [["valuer", "TEST", 109, 115]]], ["La surveillance de la qualit\u00e9 des soins peut comprendre, sans cependant s'y limiter, le recours \u00e0 des v\u00e9rifications de dossiers, la surveillance d'indicateurs et de suivis cliniques, les syst\u00e8mes de surveillance des \u00e9v\u00e8nements ind\u00e9sirables, des conf\u00e9rences sur la morbidit\u00e9 et la mortalit\u00e9, et la r\u00e9vision des cas d'incidents critiques.", [["La surveillance", "TEST", 0, 15]]], ["L'\u00e9tendue des activit\u00e9s d'am\u00e9lioration de la qualit\u00e9 variera selon les ressources d\u00e9partementales et institutionnelles mises \u00e0 la disposition du chef de d\u00e9partement.", [["L'\u00e9tendue des", "TREATMENT", 0, 13]]], ["Pour une am\u00e9lioration efficace de la qualit\u00e9, tous les membres du d\u00e9partement sont fortement encourag\u00e9s \u00e0 prendre une part active \u00e0 de telles activit\u00e9s.", [["Pour une am\u00e9lioration", "TEST", 0, 21]]], ["Plusieurs facteurs peuvent affecter n\u00e9gativement la sant\u00e9 et l'aptitude au travail, notamment les maladies physiques, les troubles mentaux et la fatigue.", [["maladies physiques", "DISEASE", 98, 116], ["fatigue", "DISEASE", 145, 152], ["Plusieurs", "TEST", 0, 9], ["les troubles mentaux et la fatigue", "PROBLEM", 118, 152]]], ["Tous ces facteurs alt\u00e8rent la sant\u00e9 et l'aptitude \u00e0 reconna\u00eetre des circonstances cliniques \u00e9voluant souvent tr\u00e8s rapidement et \u00e0 y r\u00e9agir de fa\u00e7on adapt\u00e9e.", [["Tous ces", "TEST", 0, 8], ["reconna\u00eetre des circonstances", "TREATMENT", 52, 81]]], ["Des rythmes circadiens irr\u00e9guliers, le vieillissement et le manque de sommeil aggravent de tels probl\u00e8mes; une non-reconnaissance de ces probl\u00e8mes, caus\u00e9e par la fatigue, peut augmenter la probabilit\u00e9 de commettre des erreurs dans de telles circonstances.", [["par la fatigue", "PROBLEM", 155, 169]]], ["La planification des salles d'op\u00e9ration devrait \u00e9viter d'exiger que les anesth\u00e9siologistes entreprennent des interventions non urgentes pendant des heures d\u00e9favorables.Privil\u00e8ges d'exercice en anesth\u00e9sieAucune recommandation sp\u00e9cifique concernant les quarts de travail et la liste de garde quotidienne ne peut \u00eatre adapt\u00e9e \u00e0 toutes les situations de travail.", [["La planification des", "TREATMENT", 0, 20], ["entreprennent des interventions", "TREATMENT", 91, 122]]], ["Les grands d\u00e9partements disposent de la flexibilit\u00e9 n\u00e9cessaire \u00e0 int\u00e9grer des quarts de travail courts et des cong\u00e9s personnels, alors que les d\u00e9partements plus petits pourraient ne pas jouir de cette libert\u00e9.", [["petits pourraient", "TREATMENT", 161, 178]]], ["Toutefois, ce domaine important de l'exercice professionnel doit faire l'objet d'une attention et d'une consid\u00e9ration constantes.R\u00e9sidentsLes r\u00e9sidents en anesth\u00e9sie sont des m\u00e9decins autoris\u00e9s qui participent \u00e0 la prestation des soins anesth\u00e9siques tant en salle d'op\u00e9ration qu'\u00e0 l'ext\u00e9rieur de celle-ci dans le cadre de leur formation.", [["leur", "TISSUE", 322, 326]]], ["Le Coll\u00e8ge royal des m\u00e9decins et chirurgiens du Canada et les organismes de r\u00e8glementation provinciaux et locaux exigent qu'un anesth\u00e9siologiste responsable supervise toutes les activit\u00e9s des r\u00e9sidents.", [["Le Coll\u00e8ge royal des", "TREATMENT", 0, 20], ["Canada et les organismes", "TREATMENT", 48, 72]]], ["Le degr\u00e9 de supervision doit prendre en consid\u00e9ration l'\u00e9tat de chaque patient, la nature des soins anesth\u00e9siques, ainsi que l'exp\u00e9rience et les capacit\u00e9s du r\u00e9sident (responsabilit\u00e9 professionnelle croissante).", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["Que la supervision soit directe ou indirecte, une communication \u00e9troite entre le r\u00e9sident et l'anesth\u00e9siologiste superviseur est essentielle pour garantir des soins s\u00e9curitaires aux patients.", [["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190]]], ["Par cons\u00e9quent, un m\u00e9decin bien inform\u00e9 quant \u00e0 la prise en charge anesth\u00e9sique pour la proc\u00e9dure diagnostique ou th\u00e9rapeutique propos\u00e9e devrait documenter tous les aspects des ant\u00e9c\u00e9dents m\u00e9dicochirurgicaux du patient, le bilan de l'examen physique et les r\u00e9sultats des analyses de laboratoire pertinents \u00e0 la prise en charge anesth\u00e9sique.", [["patient", "ORGANISM", 211, 218], ["patient", "SPECIES", 211, 218], ["le bilan de l'examen physique et les r\u00e9sultats", "TREATMENT", 220, 266]]], ["Les ant\u00e9c\u00e9dents du patient devraient inclure les probl\u00e8mes m\u00e9dicaux pass\u00e9s et actuels, la prise de m\u00e9dicaments r\u00e9cente et actuelle, les r\u00e9actions ou r\u00e9ponses inhabituelles aux m\u00e9dicaments et tous les probl\u00e8mes et complications associ\u00e9s aux anesth\u00e9sies administr\u00e9es ant\u00e9rieurement.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["les", "PROBLEM", 45, 48], ["et complications", "PROBLEM", 210, 226]]], ["Tout renseignement concernant l'anesth\u00e9sie que le patient juge pertinent de signaler devrait \u00e9galement \u00eatre not\u00e9.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57]]], ["Il convient enfin d'inscrire au dossier m\u00e9dical de chaque patient le code de classification de l'American Society of Anesthesiologists (Annexe 2).La p\u00e9riode pr\u00e9anesth\u00e9siqueDans les cas adapt\u00e9s, la disponibilit\u00e9 d'un \u00ab Plan de soins avanc\u00e9s \u00bb (accord de repr\u00e9sentation, directive pr\u00e9alable, \u00ab testament biologique \u00bb, directive \u00ab ne pas r\u00e9animer \u00bb, etc.) doit \u00eatre v\u00e9rifi\u00e9e et son applicabilit\u00e9 \u00e0 l'intervention propos\u00e9e d\u00e9termin\u00e9e et document\u00e9e au dossier d'\u00e9valuation anesth\u00e9sique.La p\u00e9riode pr\u00e9anesth\u00e9siqueLe chirurgien peut solliciter une consultation avec un anesth\u00e9siologiste.", [["patient", "SPECIES", 58, 65]]], ["Les consultations m\u00e9dicales devraient \u00eatre obtenues lorsque cela est indiqu\u00e9.La p\u00e9riode pr\u00e9anesth\u00e9siqueGuidelines to the Practice of Anesthesia -Revised Edition 2020 89La p\u00e9riode pr\u00e9anesth\u00e9siqueLe bilan ou la consultation anesth\u00e9sique pr\u00e9op\u00e9ratoire peut avoir lieu en clinique externe avant l'admission pour l'op\u00e9ration.", [["Les consultations", "TEST", 0, 17], ["pour l'op\u00e9ration", "TREATMENT", 303, 319]]], ["Les indications concernant l'\u00e9valuation pr\u00e9alable \u00e0 l'admission comprennent l'existence de probl\u00e8mes m\u00e9dicaux importants (comorbidit\u00e9s), la nature de la proc\u00e9dure diagnostique ou th\u00e9rapeutique propos\u00e9e, et la demande du patient.", [["patient", "ORGANISM", 220, 227], ["patient", "SPECIES", 220, 227]]], ["La pr\u00e9sence d'un parent/tuteur l\u00e9gal est n\u00e9cessaire si le patient est un enfant ou n'est pas apte \u00e0 fournir un consentement \u00e9clair\u00e9.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["La pr\u00e9sence d'un parent/tuteur l\u00e9gal est n\u00e9cessaire si le patient est un enfant ou n'est pas apte \u00e0 fournir un consentement \u00e9clair\u00e9", "SPECIES", 0, 131]]], ["Tous les patients devraient \u00eatre inform\u00e9s que des dispositions seront prises pour rencontrer un anesth\u00e9siologiste s'ils souhaitent s'entretenir de leur prise en charge anesth\u00e9sique avant leur admission \u00e0 l'\u00e9tablissement.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["La clinique d'\u00e9valuation pr\u00e9op\u00e9ratoire devrait \u00e9galement permettre au personnel infirmier et aux autres membres du personnel de sant\u00e9 d'\u00e9valuer le patient.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["La clinique d'\u00e9valuation pr\u00e9op\u00e9ratoire", "TREATMENT", 0, 38]]], ["L'anesth\u00e9siologiste en charge du patient est responsable de l'\u00e9valuation pr\u00e9anesth\u00e9sique finale durant la p\u00e9riode pr\u00e9op\u00e9ratoire imm\u00e9diate.Examens pr\u00e9op\u00e9ratoiresLes examens de laboratoire ne devraient pas \u00eatre r\u00e9alis\u00e9s sur une base r\u00e9guli\u00e8re mais uniquement lorsque les r\u00e9sultats modifieront la prise en charge p\u00e9riop\u00e9ratoire.", [["patient", "SPECIES", 33, 40], ["Examens", "TEST", 138, 145]]], ["Les analyses de laboratoire devraient \u00eatre r\u00e9alis\u00e9es lorsque l'\u00e9tat du patient, le traitement m\u00e9dicamenteux et la nature de l'intervention propos\u00e9e les justifient.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["Les analyses", "TEST", 0, 12]]], ["Les tests sanguins de laboratoire, les \u00e9lectrocardiogrammes et les radiographies du poumon de routine ne sont pas recommand\u00e9s chez les patients asymptomatiques subissant une chirurgie \u00e0 faible risque.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["Les tests sanguins", "TEST", 0, 18]]], ["Pour obtenir une d\u00e9finition plus d\u00e9taill\u00e9e des chirurgies \u00e0 faible risque et d'autres recommandations concernant les examens pr\u00e9op\u00e9ratoires, consultez la section Choisir avec soin du site de la SCA et les liens internet associ\u00e9s.Examens pr\u00e9op\u00e9ratoiresVoici quelques indications raisonnables pour r\u00e9aliser des tests sp\u00e9cifiques :TEST INDICATIONSFormule sanguine compl\u00e8te \u2022 Peut \u00eatre envisag\u00e9e en fonction du risque de perte sanguine importante, des \u00e2ges extr\u00eames (c'est-\u00e0-dire \u00a0un an), d'une maladie h\u00e9patique ou h\u00e9matologique, d'un ant\u00e9c\u00e9dent d'an\u00e9mie ou de cancer.TEST INDICATIONSD\u00e9pistage d'h\u00e9maties falciformes \u2022 Devrait \u00eatre propos\u00e9 avec consultation aux patients pr\u00e9sentant un risque \u00e9lev\u00e9 en raison de leur origine ethnique.TEST INDICATIONSTemps de thromboplastine partielle/rapport international normalis\u00e9 Peut \u00eatre envisag\u00e9 :TEST INDICATIONS\u2022 Avec les affections ou m\u00e9dicaments associ\u00e9s \u00e0 une alt\u00e9ration de la coagulation (p. ex., maladies h\u00e9patiques, malnutrition), ant\u00e9c\u00e9dents de saignements excessifs, ou ant\u00e9c\u00e9dents familiaux de coagulopathies transmissibles.H\u00e9moglobine A1c\u2022 Peut \u00eatre envisag\u00e9 chez les diab\u00e9tiques connus, le plus t\u00f4t possible avant la chirurgie (de pr\u00e9f\u00e9rence, sit\u00f4t le patient adress\u00e9 au chirurgien) si les r\u00e9sultats sont susceptibles de modifier la prise en charge du patient.H\u00e9moglobine A1cTest de grossesse En fonction des lignes directrices propres \u00e0 l'\u00e9tablissement \u2022 Devrait \u00eatre propos\u00e9 aux femmes en \u00e2ge de procr\u00e9er en fonction de la probabilit\u00e9 raisonnable de grossesse, de la fiabilit\u00e9 de l'historique des menstruations et si le r\u00e9sultat est susceptible d'annuler ou modifier la proc\u00e9dure ou la prise en charge de l'anesth\u00e9sie. \u2022 La possibilit\u00e9 d'effectuer un test urinaire ou sanguin au point de service est l'id\u00e9al et donc recommand\u00e9e.H\u00e9moglobine A1c\u00c9 lectrocardiogramme \u2022 Peut \u00eatre envisag\u00e9 chez les patients avec une coronaropathie, une arythmie significative, une maladie vasculaire p\u00e9riph\u00e9rique ou toute autre cardiopathie importante connue ou soup\u00e7onn\u00e9e. \u2022 Peut \u00eatre envisag\u00e9 en l'absence de sympt\u00f4mes ou de maladie cardiovasculaire connue chez les patients devant subir une chirurgie \u00e0 risque interm\u00e9diaire ou \u00e9lev\u00e9e en pr\u00e9sence de facteurs de risque cliniques (par ex.", [["cancer", "ANATOMY", 558, 564], ["cancer", "DISEASE", 558, 564], ["la coagulation", "DISEASE", 915, 929], ["maladies h\u00e9patiques", "DISEASE", 939, 958], ["malnutrition", "DISEASE", 960, 972], ["coagulopathies transmissibles", "DISEASE", 1041, 1070], ["H\u00e9moglobine A1c\u2022", "CHEMICAL", 1071, 1087], ["H\u00e9moglobine", "CHEMICAL", 1309, 1320], ["H\u00e9moglobine", "CHEMICAL", 1779, 1790], ["H\u00e9moglobine A1c\u2022", "CHEMICAL", 1071, 1087], ["de cancer", "CANCER", 555, 564], ["patients", "ORGANISM", 659, 667], ["patient", "ORGANISM", 1301, 1308], ["H\u00e9moglobine", "SIMPLE_CHEMICAL", 1309, 1320], ["H\u00e9moglobine", "SIMPLE_CHEMICAL", 1779, 1790], ["patients", "ORGANISM", 1845, 1853], ["patients", "ORGANISM", 2098, 2106], ["patients", "SPECIES", 659, 667], ["patient", "SPECIES", 1201, 1208], ["patient", "SPECIES", 1301, 1308], ["patients", "SPECIES", 1845, 1853], ["patients", "SPECIES", 2098, 2106], ["Pour obtenir une d\u00e9finition plus d\u00e9taill\u00e9e des", "TREATMENT", 0, 46], ["la section", "TREATMENT", 151, 161], ["falciformes", "PROBLEM", 602, 613], ["TEST INDICATIONSTemps", "TEST", 730, 751], ["Avec les affections", "PROBLEM", 851, 870], ["malnutrition", "PROBLEM", 960, 972], ["coagulopathies transmissibles", "PROBLEM", 1041, 1070], ["H\u00e9moglobine", "TREATMENT", 1071, 1082], ["Peut", "TEST", 1088, 1092], ["En fonction des lignes directrices", "TREATMENT", 1342, 1376], ["La possibilit\u00e9 d'effectuer un test", "TEST", 1672, 1706], ["H\u00e9moglobine", "TEST", 1779, 1790], ["Peut \u00eatre envisag\u00e9 chez les", "TEST", 1817, 1844], ["cancer", "OBSERVATION", 558, 564], ["le", "ANATOMY", 1136, 1138]]], ["\u00c9 chocardiographie au reposH\u00e9moglobine A1c\u2022 Peut \u00eatre envisag\u00e9e si l'\u00e9valuation clinique sugg\u00e8re une anomalie intracardiaque obstructive s\u00e9v\u00e8re et non diagnostiqu\u00e9e, une cardiomyopathie ou une hypertension pulmonaire s\u00e9v\u00e8re.TEST INDICATIONSRadiographie pulmonaire \u2022 Non recommand\u00e9e chez les patients asymptomatiques dans le cadre de l'\u00e9valuation pr\u00e9op\u00e9ratoire de routine, \u00e0 moins que cet examen ne fasse partie d'un bilan chirurgical ou oncologique non li\u00e9 \u00e0 l'\u00e9valuation du risque p\u00e9riop\u00e9ratoire. \u2022 Peut \u00eatre envisag\u00e9e chez les patients souffrant de maladie cardiopulmonaire aigu\u00eb ou chronique en fonction de leurs ant\u00e9c\u00e9dents et de l'examen physique, si cela modifiera la prise en charge.Lignes directrices concernant le je\u00fbneLes r\u00e8gles concernant le je\u00fbne devraient varier en fonction de l'\u00e2ge du patient et de ses ant\u00e9c\u00e9dents m\u00e9dicaux et s'appliquer \u00e0 toutes les formes d'anesth\u00e9sie, incluant la s\u00e9dation proc\u00e9durale (voir Annexe 6).", [["H\u00e9moglobine A1c\u2022", "CHEMICAL", 27, 43], ["obstructive s\u00e9v\u00e8re et non diagnostiqu\u00e9e", "DISEASE", 125, 164], ["hypertension", "DISEASE", 193, 205], ["H\u00e9moglobine A1c\u2022", "CHEMICAL", 27, 43], ["patients", "ORGANISM", 291, 299], ["patients", "ORGANISM", 529, 537], ["patient", "ORGANISM", 800, 807], ["patients", "SPECIES", 291, 299], ["patients", "SPECIES", 529, 537], ["patient", "SPECIES", 800, 807], ["Non recommand\u00e9e chez les patients asymptomatiques dans le cadre de l'\u00e9valuation pr\u00e9op\u00e9ratoire de routine, \u00e0 moins que cet examen ne fasse partie d'un bilan chirurgical ou oncologique non li\u00e9 \u00e0 l'\u00e9valuation du risque p\u00e9riop\u00e9ratoire", "SPECIES", 266, 496], ["chocardiographie", "TEST", 2, 18], ["H\u00e9moglobine", "TEST", 27, 38], ["une anomalie intracardiaque obstructive s\u00e9v\u00e8re et non diagnostiqu\u00e9e", "PROBLEM", 97, 164], ["une cardiomyopathie", "PROBLEM", 166, 185], ["une hypertension pulmonaire s\u00e9v\u00e8re", "PROBLEM", 189, 223], ["Lignes", "TEST", 690, 696], ["obstructive", "OBSERVATION_MODIFIER", 125, 136], ["une hypertension", "OBSERVATION", 189, 205]]], ["1 Les interventions tr\u00e8s urgentes ou urgentes doivent \u00eatre r\u00e9alis\u00e9es apr\u00e8s avoir examin\u00e9 les risques qu'entra\u00eenerait leur report comparativement au risque d'aspiration du contenu de l'estomac.", [["Les interventions", "TREATMENT", 2, 19]]], ["Avant une intervention non urgente, la dur\u00e9e minimale du je\u00fbne devait \u00eatre de :Lignes directrices concernant le je\u00fbne\u2022 Huit heures apr\u00e8s un repas copieux comportant des aliments solides, particuli\u00e8rement s'il contenait des prot\u00e9ines (par ex. de la viande) ou des aliments gras; \u2022 Six heures apr\u00e8s un repas l\u00e9ger (par ex. repas faible en gras tel une tartine); \u2022 Six heures apr\u00e8s l'ingestion de lait maternis\u00e9, de lait non humain ou de lait maternel tir\u00e9 et fortifi\u00e9 avec des adjuvants; \u2022 Quatre heures apr\u00e8s l'ingestion de lait maternel; \u2022 Deux heures apr\u00e8s l'ingestion de liquides clairs pour un adulte; \u2022 Une heure apr\u00e8s l'ingestion de liquides clairs pour les nourrissons ou les enfants.Lignes directrices concernant le je\u00fbneSauf contre-indication, il convient d'encourager les adultes \u00e0 boire des liquides clairs (eau, jus sans pulpe, boissons \u00e0 base de sucres complexes, et th\u00e9 ou caf\u00e9 sans lait) jusqu'\u00e0 deux heures avant une chirurgie non urgente.Les patients p\u00e9diatriques devraient \u00e9galement \u00eatreGuidelines to the Practice of Anesthesia -Revised Edition 2020 91 encourag\u00e9s \u00e0 boire des liquides clairs, tels que d\u00e9finis, jusqu'\u00e0 une heure avant une chirurgie non urgente.", [["patients", "ORGANISM", 958, 966], ["patients", "SPECIES", 958, 966]]], ["Les conditions retardant la vidange gastrique n\u00e9cessitent une \u00e9valuation au cas par cas du patient.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98]]], ["Ces recommandations peuvent \u00eatre modifi\u00e9es \u00e0 la discr\u00e9tion du m\u00e9decin.Les patients p\u00e9diatriques devraient \u00e9galement \u00eatreUn antagoniste oral des r\u00e9cepteurs H2 de l'histamine est recommand\u00e9 la nuit pr\u00e9c\u00e9dant et le matin d'un accouchement par c\u00e9sarienne programm\u00e9.Les patients p\u00e9diatriques devraient \u00e9galement \u00eatreUn antagoniste intraveineux des r\u00e9cepteurs H2 de l'histamine et 30 mL de citrate de sodium molaire 0,3 oral sont recommand\u00e9s avant un accouchement par c\u00e9sarienne urgent si l'on planifie une anesth\u00e9sie g\u00e9n\u00e9rale.Les patients p\u00e9diatriques devraient \u00e9galement \u00eatreVoir la Section 7.3 pour les recommandations de je\u00fb ne sp\u00e9cifiques aux patientes en travail actif.R\u00e8glementations suppl\u00e9mentairesDes lois provinciales ou la r\u00e8glementation de l'\u00e9tablissement pourraient prescrire d'autres directives r\u00e9gissant l'administration de l'anesth\u00e9sie.Pr\u00e9paration \u00e0 l'anesth\u00e9sieAvant le d\u00e9but de l'anesth\u00e9sie, l'anesth\u00e9siologiste doit s'assurer que 1.", [["sodium", "CHEMICAL", 395, 401], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 265, 273], ["patients", "ORGANISM", 525, 533], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 265, 273], ["patients", "SPECIES", 525, 533], ["Les patients p\u00e9diatriques devraient \u00e9galement", "TREATMENT", 70, 115], ["oral des", "TREATMENT", 135, 143], ["Les patients p\u00e9diatriques devraient \u00e9galement", "TREATMENT", 261, 306], ["antagoniste intraveineux des r\u00e9cepteurs H2 de l'histamine et", "TREATMENT", 314, 374], ["citrate de sodium molaire", "TREATMENT", 384, 409]]], ["La proc\u00e9dure anesth\u00e9sique pr\u00e9vue a \u00e9t\u00e9 expliqu\u00e9e au patient, y compris les risques reconnus et les techniques alternatives, et on a document\u00e9 cette explication; 2.", [["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["y compris les risques", "TREATMENT", 61, 82], ["et les techniques", "TREATMENT", 92, 109], ["a document\u00e9 cette explication", "TREATMENT", 130, 159]]], ["Une \u00e9valuation adapt\u00e9e de l'\u00e9tat du patient a \u00e9t\u00e9 r\u00e9alis\u00e9e; 3.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43]]], ["Tout le mat\u00e9riel qu'on pr\u00e9voit n\u00e9cessaire est accessible et en bon \u00e9tat de fonctionnement, y compris le mat\u00e9riel n\u00e9cessaire au maintien de la temp\u00e9rature centrale (temp\u00e9rature centrale du patient 36-37\u00b0C); 4.", [["patient", "SPECIES", 188, 195], ["Tout le mat\u00e9riel qu'on pr\u00e9voit", "TREATMENT", 0, 30]]], ["Tous les m\u00e9dicaments et agents qu'on pr\u00e9voit n\u00e9cessaires sont correctement identifi\u00e9s -les \u00e9tiquettes de m\u00e9dicament appos\u00e9es par l'usager doivent \u00eatre conformes \u00e0 la norme de la CSA CAN/ CSA -Z264.3-98 (R2005) (Annexe 1); 6.", [["Tous les m\u00e9dicaments et agents", "TREATMENT", 0, 30], ["CSA", "TEST", 187, 190]]], ["Il faut envisager l'utilisation de connecteurs neuraxiaux conformes \u00e0 la norme ISO 80369-6:2016connecteurs de petit diam\u00e8tre interne pour application neuraxiale (raccords NRFit\u00d2) en fonction des disponibilit\u00e9s des fournisseurs de mat\u00e9riel; et 7.", [["en fonction des", "TREATMENT", 179, 194]]], ["On a tenu compte des indications du fabricant quant \u00e0 l'utilisation, \u00e0 la manipulation et \u00e0 la disposition de l'\u00e9quipement et du mat\u00e9riel d'anesth\u00e9sie.Prise en charge des voies a\u00e9riennesLa prise en charge des voies a\u00e9riennes, particuli\u00e8rement en cas de voies a\u00e9riennes difficiles, contribue significativement \u00e0 la morbidit\u00e9 et \u00e0 la mortalit\u00e9 li\u00e9es \u00e0 l'anesth\u00e9sie.", [["a tenu compte des indications", "TREATMENT", 3, 32]]], ["Une prise en charge adapt\u00e9e des patients dont l'intubation est difficile, de mani\u00e8re pr\u00e9vue ou impr\u00e9vue, chez lesquels l'intubation a \u00e9chou\u00e9, lorsqu'une ventilation au masque ou le positionnement d'un dispositif supraglottique pourrait \u00eatre difficile, ou qui n\u00e9cessitent des voies a\u00e9riennes chirurgicales, est essentielle \u00e0 la s\u00e9curit\u00e9 des patients.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 340, 348], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 340, 348], ["lorsqu'une ventilation au masque ou le positionnement d'un dispositif supraglottique pourrait \u00eatre difficile, ou qui n\u00e9cessitent des voies a\u00e9riennes chirurgicales", "SPECIES", 142, 304], ["lorsqu'une ventilation", "TREATMENT", 142, 164], ["difficile", "PROBLEM", 241, 250]]], ["Cette prise en charge comprend, sans n\u00e9cessairement s'y limiter, une \u00e9valuation adapt\u00e9e des voies a\u00e9riennes, du mat\u00e9riel (par ex. chariots pour les voies a\u00e9riennes difficiles, vid\u00e9olaryngoscopes, bronchoscopes), une formation et des exercices de simulation appropri\u00e9s, du personnel de soutien et le recours aux protocoles et listes de contr\u00f4le ad\u00e9quats afin de prendre en charge au mieux des voies a\u00e9riennes difficiles.", [["a\u00e9riennes difficiles", "DISEASE", 398, 418], ["chariots", "TEST", 130, 138], ["difficiles", "PROBLEM", 164, 174], ["vid\u00e9olaryngoscopes", "TEST", 176, 194], ["a\u00e9riennes difficiles", "PROBLEM", 398, 418]]], ["La SCA ne recommande pas un protocole, un algorithme ou une liste de contr\u00f4le en particulier pour la prise en charge des voies a\u00e9riennes difficiles ou lors d'un \u00e9chec d'intubation, mais elle encourage fortement les lecteurs \u00e0 se r\u00e9f\u00e9rer \u00e0 l'Annexe 4 pour acc\u00e9der aux publications les plus r\u00e9centes sur le sujet.D\u00e9l\u00e9gation des soins aux patientsL'anesth\u00e9siologiste est avant tout responsable du patient qu'il a sous ses soins.", [["patients", "ORGANISM", 336, 344], ["patient", "ORGANISM", 394, 401], ["patients", "SPECIES", 336, 344], ["patient", "SPECIES", 394, 401], ["D\u00e9l\u00e9gation des soins aux patientsL'anesth\u00e9siologiste est avant tout responsable du patient qu'il", "SPECIES", 311, 407], ["intubation", "TREATMENT", 169, 179], ["Annexe", "TEST", 241, 247]]], ["L'anesth\u00e9siologiste ou un assistant en anesth\u00e9sie supervis\u00e9 par l'anesth\u00e9siologiste doit demeurer constamment aux c\u00f4t\u00e9s du patient pour toute la dur\u00e9e d'une anesth\u00e9sie g\u00e9n\u00e9rale, r\u00e9gionale majeure et intraveineuse monitor\u00e9e, jusqu'\u00e0 ce que le patient ait \u00e9t\u00e9 confi\u00e9 aux soins du personnel de l'unit\u00e9 de soins comp\u00e9tente.D\u00e9l\u00e9gation des soins aux patientsSi l'anesth\u00e9siologiste traitant quitte temporairement la salle d'op\u00e9ration, il doit confier les soins du patient \u00e0 un autre anesth\u00e9siologiste, \u00e0 un r\u00e9sident en anesth\u00e9sie ou \u00e0 un assistant en anesth\u00e9sie.", [["Si", "CHEMICAL", 352, 354], ["patient", "ORGANISM", 123, 130], ["patient", "ORGANISM", 242, 249], ["patients", "ORGANISM", 344, 352], ["patient", "ORGANISM", 457, 464], ["patient", "SPECIES", 123, 130], ["patient", "SPECIES", 242, 249], ["patients", "SPECIES", 344, 352], ["patient", "SPECIES", 457, 464]]], ["Lorsque l'anesth\u00e9siologiste traitant d\u00e9l\u00e8gue les soins \u00e0 un r\u00e9sident en anesth\u00e9sie ou \u00e0 un assistant en anesth\u00e9sie, il demeure responsable de la prise en charge anesth\u00e9sique du patient.", [["patient", "ORGANISM", 177, 184], ["patient", "SPECIES", 177, 184]]], ["Avant de d\u00e9l\u00e9guer les soins du patient \u00e0 un assistant en anesth\u00e9sie, l'anesth\u00e9siologiste doit s'assurer que l'\u00e9tat du patient est stable et que l'assistant en anesth\u00e9sie est familier avec l'intervention chirurgicale ainsi qu'avec l'environnement et le mat\u00e9riel de la salle d'op\u00e9ration.", [["patient", "ORGANISM", 31, 38], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 31, 38], ["patient", "SPECIES", 118, 125], ["Avant de d\u00e9l\u00e9guer les soins du patient \u00e0 un assistant en anesth\u00e9sie, l'anesth\u00e9siologiste doit s'assurer que l'\u00e9tat du patient est stable et que l'assistant en anesth\u00e9sie est familier avec l'intervention chirurgicale ainsi qu'avec l'environnement et le mat\u00e9riel de la salle d'op\u00e9ration", "SPECIES", 0, 284]]], ["L'anesth\u00e9siologiste traitant doit demeurer imm\u00e9diatement disponible lorsque les soins sont d\u00e9l\u00e9gu\u00e9s \u00e0 un assistant en anesth\u00e9sie.D\u00e9l\u00e9gation des soins aux patientsUn anesth\u00e9siologiste peut bri\u00e8vement confier les soins courants d'un patient dont l'\u00e9tat est stable \u00e0 une personne comp\u00e9tente qui n'est pas un assistant en anesth\u00e9sie qu'en cas de circonstances particuli\u00e8rement exceptionnelles, pour se porter par exemple au secours d'un autre patient dont la vie est en danger.", [["patients", "ORGANISM", 154, 162], ["patient", "ORGANISM", 231, 238], ["patient", "ORGANISM", 439, 446], ["patients", "SPECIES", 154, 162], ["patient", "SPECIES", 231, 238], ["patient", "SPECIES", 439, 446]]], ["L'unique responsabilit\u00e9 de cette personne devrait \u00eatre de surveiller le patient en l'absence de l'anesth\u00e9siologiste et de tenir l'anesth\u00e9siologiste inform\u00e9 jusqu'\u00e0 son retour.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79]]], ["Dans de telles circonstances, l'anesth\u00e9siologiste demeure responsable des soins prodigu\u00e9s au patient et se doit de tenir l'\u00e9quipe de la salle d'op\u00e9ration au courant.D\u00e9l\u00e9gation des soins aux patientsLe transfert perop\u00e9ratoire des soins entre deux anesth\u00e9siologistes doit \u00eatre not\u00e9 au dossier d'anesth\u00e9sie et se conformer \u00e0 un protocole structur\u00e9.D\u00e9l\u00e9gation des soins aux patientsIl est inacceptable qu'un anesth\u00e9siologiste administre simultan\u00e9ment une anesth\u00e9sie g\u00e9n\u00e9rale, une anesth\u00e9sie r\u00e9gionale majeure (rachidienne, p\u00e9ridurale ou autre) ou une s\u00e9dation proc\u00e9durale profonde (voir Annexe 6) 1 pour des interventions diagnostiques ou th\u00e9rapeutiques concomitantes pratiqu\u00e9es sur plus d'un patient \u00e0 la fois.", [["patient", "ORGANISM", 93, 100], ["patients", "ORGANISM", 190, 198], ["patients", "ORGANISM", 370, 378], ["patient", "ORGANISM", 689, 696], ["patient", "SPECIES", 93, 100], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 370, 378], ["patient", "SPECIES", 689, 696], ["pour des interventions", "TREATMENT", 595, 617]]], ["Toutefois, il peut \u00eatre admis, dans des circonstances particuli\u00e8res, qu'un anesth\u00e9siologiste supervise plus d'un patient chez lequel une s\u00e9dation minime \u00e0 mod\u00e9r\u00e9e est administr\u00e9e, \u00e0 condition qu'un individu ayant re\u00e7u une formation ad\u00e9quate, qualifi\u00e9, accr\u00e9dit\u00e9 et approuv\u00e9 par le service d'anesth\u00e9siologie et l'\u00e9tablissement de sant\u00e9, soit constamment pr\u00e9sent aupr\u00e8s de chaque patient recevant des soins.", [["patient", "ORGANISM", 378, 385], ["patient", "SPECIES", 113, 120], ["patient", "SPECIES", 378, 385]]], ["Il sera par contre admis, dans un service d'obst\u00e9trique, de surveiller simultan\u00e9ment plus d'une patiente \u00e0 laquelle est administr\u00e9e une analg\u00e9sie r\u00e9gionale pour le travail.", [["pour le travail", "TREATMENT", 156, 171]]], ["Lorsqu'un anesth\u00e9siologiste dispense des soins anesth\u00e9siques en vue d'un accouchement, une deuxi\u00e8me personne d\u00fbment form\u00e9e doit se tenir pr\u00eate \u00e0 intervenir pour pratiquer la r\u00e9animation n\u00e9onatale.D\u00e9l\u00e9gation des soins aux patientsIl est inacceptable qu'un seul m\u00e9decin administre une anesth\u00e9sie y compris la s\u00e9dation proc\u00e9durale profonde simultan\u00e9ment \u00e0 la r\u00e9alisation d'une proc\u00e9dure diagnostique ou th\u00e9rapeutique, exception faite des interventions r\u00e9alis\u00e9es par seule infiltration d'anesth\u00e9siques locaux et/ou une s\u00e9dation minimale.Monitorage du patientLe seul moniteur indispensable est la pr\u00e9sence, \u00e0 tous les instants, d'un m\u00e9decin ou d'un assistant en anesth\u00e9sie plac\u00e9 sous la supervision imm\u00e9diate d'un anesth\u00e9siologiste et d\u00e9tenant la formation et l'exp\u00e9rience appropri\u00e9es.", [["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["des interventions", "TREATMENT", 431, 448], ["infiltration", "PROBLEM", 469, 481]]], ["Ces appareils aident l'anesth\u00e9siologiste \u00e0 s'assurer de l'int\u00e9grit\u00e9 des organes vitaux et, en particulier, de la perfusion et de l'oxyg\u00e9nation satisfaisantes des tissus.", [["Ces", "TEST", 0, 3]]], ["Le mat\u00e9riel de monitorage doit \u00eatre utilis\u00e9 comme pr\u00e9vu par le fabricant et approuv\u00e9 par Sant\u00e9 Canada pour l'application sp\u00e9cifique.Monitorage du patientIl incombe \u00e0 l'\u00e9tablissement de soins de sant\u00e9 de fournir et d'entretenir un \u00e9quipement de monitorage qui respecte les normes en vigueur.Monitorage du patientIl incombe au chef du d\u00e9partement d'anesth\u00e9sie de conseiller l'\u00e9tablissement de soins de sant\u00e9 au sujet de l'acquisition de l'\u00e9quipement de monitorage et d'\u00e9tablir les normes de monitorage qui aideront \u00e0 assurer la s\u00e9curit\u00e9 du patient.Monitorage du patientIl incombe \u00e0 l'anesth\u00e9siologiste de monitorer le patient qui est sous ses soins et de s'assurer que l'\u00e9quipement de monitorage appropri\u00e9 soit disponible et fonctionne correctement.", [["patient", "ORGANISM", 304, 311], ["patient", "ORGANISM", 538, 545], ["patient", "ORGANISM", 616, 623], ["patient", "SPECIES", 304, 311], ["patient", "SPECIES", 538, 545], ["patient", "SPECIES", 616, 623]]], ["Une feuille de v\u00e9rification pr\u00e9anesth\u00e9sique (Annexe 3 ou \u00e9quivalent) doit \u00eatre remplie avant l'amorce de l'anesth\u00e9sie.Monitorage du patientUne posologie prudente, un monitorage vigilant et la neutralisation ad\u00e9quate des bloqueurs neuromusculaires sont des \u00e9l\u00e9ments essentiels \u00e0 la s\u00e9curit\u00e9 des patients.", [["patient", "ORGANISM", 132, 139], ["patients", "ORGANISM", 294, 302], ["patient", "SPECIES", 132, 139], ["patients", "SPECIES", 294, 302]]], ["Les directives de monitorage pour les soins standard aux patients s'appliquent \u00e0 tous les patients recevant une anesth\u00e9sie g\u00e9n\u00e9rale, une anesth\u00e9sie r\u00e9gionale ou une s\u00e9dation intraveineuse.Mat\u00e9riel de monitorage requisLe mat\u00e9riel de monitorage est cat\u00e9goris\u00e9 comme suit :Mat\u00e9riel de monitorage requis\u2022 Requis : Ces moniteurs doivent \u00eatre utilis\u00e9s sans interruption pendant toute la dur\u00e9e de l'administration de toute anesth\u00e9sie. \u2022 Accessible en exclusivit\u00e9 pour chaque patient : Ces moniteurs doivent \u00eatre accessibles \u00e0 chaque poste de travail d'anesth\u00e9sie, de sorte qu'ils puissent \u00eatre utilis\u00e9s sans d\u00e9lai. \u2022 \u00c0 port\u00e9e imm\u00e9diate : Ces moniteurs doivent \u00eatre accessibles afin de faciliter leur utilisation sans d\u00e9lai indu.Mat\u00e9riel de monitorage requisLe mat\u00e9riel de monitorage suivant est requis :Mat\u00e9riel de monitorage requisGuidelines to the Practice of Anesthesia -Revised Edition 2020 93Mat\u00e9riel de monitorage requis\u2022 Un saturom\u00e8tre;Mat\u00e9riel de monitorage requis\u2022 Un appareil permettant de mesurer la tension art\u00e9rielle, directement ou sans effraction; \u2022 Un \u00e9lectrocardiographe; \u2022 Un moniteur de bloc neuromusculaire lors de l'utilisation de bloqueurs neuromusculaires; \u2022 Un capnographe, pour l'anesth\u00e9sie g\u00e9n\u00e9rale et pour \u00e9valuer le caract\u00e8re ad\u00e9quat de la ventilation pour une s\u00e9dation mod\u00e9r\u00e9e ou une s\u00e9dation proc\u00e9durale profonde; et \u2022 Un moniteur de gaz anesth\u00e9siques sp\u00e9cifique \u00e0 l'agent, lorsque des agents anesth\u00e9siques par inhalation sont utilis\u00e9s.Mat\u00e9riel de monitorage requisLe mat\u00e9riel de monitorage suivant doit \u00eatre accessible en exclusivit\u00e9 pour chaque patient :Mat\u00e9riel de monitorage requis\u2022 Un appareil pour mesurer la temp\u00e9rature;Mat\u00e9riel de monitorage requis\u2022 Un stimulateur des nerfs p\u00e9riph\u00e9riques, lors de l'utilisation de bloqueurs neuromusculaires; \u2022 Un st\u00e9thoscope -pr\u00e9cordial, oesophagien ou paratrach\u00e9al; et \u2022 Un \u00e9clairage suffisant pour visualiser une partie expos\u00e9e du patient.Mat\u00e9riel de monitorage requisLe mat\u00e9riel de monitorage suivant sera \u00e0 port\u00e9e imm\u00e9diate :Mat\u00e9riel de monitorage requis\u2022 Un spirom\u00e8tre pour mesurer le volume respiratoire;Mat\u00e9riel de monitorage requis\u2022 Un manom\u00e8tre pour mesurer la pression du ballonnet du tube endotrach\u00e9al.", [["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 90, 98], ["patient", "ORGANISM", 468, 475], ["patient", "ORGANISM", 1570, 1577], ["patient", "ORGANISM", 1899, 1906], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 90, 98], ["patient", "SPECIES", 468, 475], ["patient", "SPECIES", 1570, 1577], ["patient", "SPECIES", 1899, 1906], ["Ces", "TEST", 310, 313], ["Ces", "TEST", 478, 481], ["lorsque des agents", "TREATMENT", 1397, 1415], ["st\u00e9thoscope", "TEST", 1779, 1790], ["Un manom\u00e8tre pour mesurer la pression du ballonnet du tube endotrach\u00e9al", "TREATMENT", 2107, 2178], ["pour chaque", "OBSERVATION", 456, 467], ["du tube", "OBSERVATION", 2158, 2165], ["endotrach\u00e9al", "OBSERVATION", 2166, 2178]]], ["Le dossier anesth\u00e9sique doit inclure le niveau de conscience du patient, sa fr\u00e9quence cardiaque, sa tension art\u00e9rielle, sa saturation en oxyg\u00e8ne et sa fr\u00e9quence respiratoire tels que mesur\u00e9s \u00e0 l'arriv\u00e9e en salle de r\u00e9veil.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["sa saturation en oxyg\u00e8ne", "TREATMENT", 120, 144]]], ["\u00c0 l'heure actuelle, il n'existe aucune norme de pratique indiquant quelles donn\u00e9es suppl\u00e9mentaires (par ex. donn\u00e9es d'analyse de gaz, de ventilation et respiratoires) potentiellement r\u00e9colt\u00e9es par un syst\u00e8me de dossier de SGIA devraient faire partie du dossier de sant\u00e9 permanent d'un patient.Mat\u00e9riel de monitorage requisIl a \u00e9t\u00e9 d\u00e9montr\u00e9 que les SGIA pouvaient avoir des avantages potentiels par rapport aux dossiers r\u00e9dig\u00e9s \u00e0 la main dans plusieurs domaines cl\u00e9s, notamment en augmentant la lisibilit\u00e9, la pr\u00e9cision et la fiabilit\u00e9 des dossiers anesth\u00e9siques, en cr\u00e9ant des donn\u00e9es interrogeables favorisant l'am\u00e9lioration de la qualit\u00e9, la communication des r\u00e9sultats et de la performance, la recherche translationnelle, une meilleure innocuit\u00e9 et un meilleur suivi des m\u00e9dicaments, ainsi qu'un suivi et un soutien \u00e0 la d\u00e9cision clinique en temps r\u00e9el pour les utilisateurs.", [["patient", "ORGANISM", 285, 292], ["patient", "SPECIES", 285, 292], ["cl\u00e9s", "PROBLEM", 461, 465], ["la pr\u00e9cision et la fiabilit\u00e9 des", "TREATMENT", 506, 538], ["la recherche translationnelle", "TEST", 694, 723]]], ["La litt\u00e9rature sur la s\u00e9curit\u00e9 des patients en anesth\u00e9sie appuie l'utilisation des SGIA.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["Il est important de mentionner que les SGIA permettent de cr\u00e9er une base de donn\u00e9es de patients longitudinale, de telle mani\u00e8re que les ant\u00e9c\u00e9dents anesth\u00e9siques importants des patients soient facilement trouvables si l'on veut les passer en revue, ce qui devrait \u00eatre consid\u00e9r\u00e9 comme une propri\u00e9t\u00e9 importante pour tout syst\u00e8me.", [["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 177, 185]]], ["Dans l'id\u00e9al, ce syst\u00e8me devrait \u00eatre mis en oeuvre et g\u00e9r\u00e9 en coop\u00e9ration avec le d\u00e9partement des technologies de l'information de l'\u00e9tablissement, et devrait permettre la communication avec les autres bases de donn\u00e9es \u00e9lectroniques de patients de l'\u00e9tablissement dans la mesure du possible.Mat\u00e9riel de monitorage requis6.0 La p\u00e9riode postanesth\u00e9sique 6.1 La salle de r\u00e9veil Une salle de r\u00e9veil doit \u00eatre disponible dans tout \u00e9tablissement offrant des services anesth\u00e9siques.", [["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245]]], ["Il devrait exister un manuel des politiques de la salle de r\u00e9veil approuv\u00e9 par les autorit\u00e9s m\u00e9dicales, infirmi\u00e8res et administratives comp\u00e9tentes.Mat\u00e9riel de monitorage requisL'anesth\u00e9siologiste devrait accompagner le patient en salle de r\u00e9veil, transmettre les renseignements n\u00e9cessaires au personnel infirmier de la salle de r\u00e9veil dans le cadre d'un transfert structur\u00e9 du protocole de soins, et r\u00e9diger les ordonnances n\u00e9cessaires.", [["patient", "ORGANISM", 219, 226], ["patient", "SPECIES", 219, 226]]], ["Le monitorage continu des patients est recommand\u00e9 pendant la phase p\u00e9riop\u00e9ratoire en fonction de la situation clinique.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Si cliniquement indiqu\u00e9, de l'oxyg\u00e8ne suppl\u00e9mentaire, une oxym\u00e9trie de pouls portable et d'autres dispositifs de monitorage adapt\u00e9s doivent \u00eatre utilis\u00e9s pendant le transfert vers la salle de r\u00e9veil ou l'USI.", [["Si", "CHEMICAL", 0, 2]]], ["Si indiqu\u00e9 cliniquement, une source d'oxyg\u00e8ne d'appoint et des appareils de monitorage appropri\u00e9s tels que, entre autres, un saturom\u00e8tre portable, devraient \u00eatre appliqu\u00e9s durant le transport \u00e0 la salle de r\u00e9veil.", [["Si", "CHEMICAL", 0, 2]]], ["L'anesth\u00e9siologiste ne devrait d\u00e9l\u00e9guer les soins du patient \u00e0 l'infirmier ou l'infirmi\u00e8re de la salle de r\u00e9veil que lorsqu'il est assur\u00e9 que le personnel infirmier pourra ad\u00e9quatement observer et prendre soin du patient.", [["patient", "ORGANISM", 53, 60], ["patient", "ORGANISM", 213, 220], ["patient", "SPECIES", 53, 60], ["patient", "SPECIES", 213, 220]]], ["Le cong\u00e9 de la salle de r\u00e9veil est sous la responsabilit\u00e9 de l'anesth\u00e9siologiste; cette responsabilit\u00e9 peut \u00eatre d\u00e9l\u00e9gu\u00e9e en accord avec les politiques de l'\u00e9tablissement.Mat\u00e9riel de monitorage requisUne source d'oxyg\u00e8ne d'appoint et une succion doivent \u00eatre disponibles pour chaque patient en salle de r\u00e9veil.", [["patient", "ORGANISM", 283, 290], ["patient", "SPECIES", 283, 290]]], ["Le monitorage utilis\u00e9 en salle de r\u00e9veil doit \u00eatre adapt\u00e9 \u00e0 l'\u00e9tat du patient et un \u00e9ventail complet d'appareils de monitorage doit \u00eatre disponible.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77]]], ["Les alarmes des moniteurs doivent \u00eatre en fonction, avec des param\u00e8tres d'alarme adapt\u00e9s \u00e0 l'\u00e9tat et \u00e0 l'\u00e2ge du patient.", [["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119]]], ["Un capnographe est requis pour les patients intub\u00e9s ou sous s\u00e9dation profonde et est recommand\u00e9 pour les patients inconscients ayant des dispositifs supraglottiques in situ dans les voies a\u00e9riennes.", [["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 105, 113]]], ["Celui-ci doit inclure un enregistrement des signes vitaux ainsi que des autres aspects du traitement et de l'observation.", [["Celui", "TEST", 0, 5], ["un enregistrement des", "TREATMENT", 22, 43]]], ["Toute complication ayant un lien avec l'anesth\u00e9sie doit \u00eatre not\u00e9e sur la feuille de la salle de r\u00e9veil ou dans les notes d'\u00e9volution du dossier du patient.Mat\u00e9riel de monitorage requisDans certaines situations, il peut \u00eatre acceptable de transf\u00e9rer un patient directement vers d'autres unit\u00e9s de soins ou de passer outre la salle de r\u00e9veil si un niveau de soins adapt\u00e9 est disponible dans une autre unit\u00e9 de l'\u00e9tablissement et s'il est not\u00e9 au dossier anesth\u00e9sique que le patient est jug\u00e9 apte \u00e0 ce transfert.Cong\u00e9 des patients apr\u00e8s chirurgie d'un jourLe cong\u00e9 des patients apr\u00e8s une chirurgie ambulatoire doit se faire en utilisant un plan formel de soins approuv\u00e9 par l'institution et document\u00e9 dans les notes de soins prodigu\u00e9s aux patients.", [["patient", "ORGANISM", 148, 155], ["patient", "ORGANISM", 253, 260], ["patient", "ORGANISM", 473, 480], ["patients", "ORGANISM", 520, 528], ["patients", "ORGANISM", 567, 575], ["patients", "ORGANISM", 737, 745], ["patient", "SPECIES", 148, 155], ["patient", "SPECIES", 253, 260], ["patient", "SPECIES", 473, 480], ["patients", "SPECIES", 520, 528], ["patients", "SPECIES", 567, 575], ["patients", "SPECIES", 737, 745], ["r\u00e9veil si un niveau de soins adapt\u00e9 est disponible dans une autre unit\u00e9 de l'\u00e9tablissement et s'il est not\u00e9 au dossier anesth\u00e9sique que le patient est jug\u00e9 apte \u00e0 ce transfert", "SPECIES", 334, 509], ["Toute complication", "PROBLEM", 0, 18]]], ["Les patients doivent satisfaire les crit\u00e8res de cong\u00e9 au domicile en utilisant un outil d'\u00e9valuation valid\u00e9 (p. ex., le syst\u00e8me de cotation de cong\u00e9 post-anesth\u00e9sie [PADSS]).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["La prise en charge de la douleur et des complications postop\u00e9ratoires, ainsi que le suivi de routine et d'urgence, doivent tous faire l'objet d'instructions \u00e9crites sp\u00e9cifiques.", [["La prise en charge de la douleur et des complications", "TREATMENT", 0, 53]]], ["Le patient doit \u00eatre averti au sujet des synergies additives qu'il existe entre l'alcool et d'autres s\u00e9datifs, du danger de conduire ou d'utiliser des machines dangereuses dans la p\u00e9riode postop\u00e9ratoire (dans la plupart des cas durant les 24 heures suivant l'op\u00e9ration), et de la n\u00e9cessit\u00e9 d'attention de la part d'un adulte comp\u00e9tent dans la p\u00e9riode postop\u00e9ratoire (dans la plupart des cas durant les 24 heures suivant l'op\u00e9ration).Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9triqueLes services d'anesth\u00e9sie destin\u00e9s aux parturientes comprennent l'analg\u00e9sie obst\u00e9tricale pour le travailpour l'accouchement avec ou sans complication -ou pour les c\u00e9sariennes.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["conduire ou d'utiliser des machines dangereuses dans la p\u00e9riode postop\u00e9ratoire (dans la plupart des cas durant les 24 heures suivant l'op\u00e9ration), et de la n\u00e9cessit\u00e9 d'attention de la part d'un adulte comp\u00e9tent dans la p\u00e9riode postop\u00e9ratoire (dans la plupart des cas durant les 24 heures suivant l'op\u00e9ration", "SPECIES", 124, 431], ["d'anesth\u00e9sie destin\u00e9s aux parturientes comprennent l'analg\u00e9sie obst\u00e9tricale pour le travailpour l'accouchement avec ou sans complication -ou pour les c\u00e9sariennes", "SPECIES", 506, 667], ["dans la plupart des cas durant les", "TREATMENT", 204, 238], ["dans la plupart des cas durant les", "TREATMENT", 367, 401]]], ["Les directives de la pr\u00e9sente section portent sur l'analg\u00e9sie p\u00e9ridurale et la rachianesth\u00e9sie pendant le travail.", [["et la rachianesth\u00e9sie pendant le travail", "TREATMENT", 73, 113]]], ["L'expression \u00ab analg\u00e9sie r\u00e9gionale \u00bb d\u00e9signe l'analg\u00e9sie p\u00e9ridurale, la rachianesth\u00e9sie et la combinaison des deux.Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9triqueCes directives sont pass\u00e9es en revue chaque ann\u00e9e par la Section d'anesth\u00e9sie obst\u00e9tricale de la SCA et mises \u00e0 jour au besoin.", [["analg\u00e9sie", "TEST", 15, 24]]], ["Chaque \u00e9tablissement peut d\u00e9cider d'\u00e9laborer des directives ou politiques suppl\u00e9mentaires pour des situations sp\u00e9cifiques dans lesquelles une analg\u00e9sie r\u00e9gionale obst\u00e9tricale est dispens\u00e9e.Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9triqueSous la direction d'un anesth\u00e9siologiste, certains aspects du monitorage et de la prise en charge de l'analg\u00e9sie r\u00e9gionale obst\u00e9tricale peuvent \u00eatre d\u00e9l\u00e9gu\u00e9s \u00e0 d'autres membres du personnel de sant\u00e9.", [["Chaque \u00e9tablissement peut d\u00e9cider d'\u00e9laborer des directives ou politiques suppl\u00e9mentaires pour des situations sp\u00e9cifiques dans lesquelles une analg\u00e9sie r\u00e9gionale obst\u00e9tricale est dispens\u00e9e", "SPECIES", 0, 188]]], ["Chaque \u00e9tablissement doit s'assurer que ces personnes re\u00e7oivent les m\u00eames formation, certification, formation continue et recertification en analg\u00e9sie r\u00e9gionale en obst\u00e9trique.", [["et recertification", "TREATMENT", 119, 137]]], ["7.2 Maintien de l'anesth\u00e9sie r\u00e9gionale pendant le travail L'analg\u00e9sie p\u00e9ridurale par perfusion continue (APPC), l'administration programm\u00e9e de bolus p\u00e9riduraux (PIEB) et l'analg\u00e9sie p\u00e9ridurale contr\u00f4l\u00e9e par la patiente (APCP) d'anesth\u00e9siques locaux p\u00e9riduraux dilu\u00e9s \u00e0 faible dose (par ex., bupivaca\u00efne \u00a3 0,125 % ou ropivaca\u00efne \u00a3 0,16 %) avec ou sans adjuvants (par ex., opio\u00efdes) sont associ\u00e9es \u00e0 une tr\u00e8s faible incidence de complications majeures.", [["ropivaca\u00efne", "CHEMICAL", 316, 327], ["Maintien de l'anesth\u00e9sie r\u00e9gionale pendant le travail", "TREATMENT", 4, 57], ["p\u00e9ridurale par perfusion", "TREATMENT", 70, 94], ["l'administration programm\u00e9e de bolus p\u00e9riduraux (PIEB)", "TREATMENT", 112, 166], ["locaux p\u00e9riduraux dilu\u00e9s", "TREATMENT", 242, 266], ["bupivaca\u00efne", "TREATMENT", 291, 302], ["ropivaca\u00efne", "TREATMENT", 316, 327], ["ou sans adjuvants", "TREATMENT", 343, 360], ["complications majeures", "PROBLEM", 427, 449]]], ["Par cons\u00e9quent, il n'est pas n\u00e9cessaire que l'anesth\u00e9siologiste reste pr\u00e9sent ou soit imm\u00e9diatement disponible pendant le maintien d'une APPC ou d'une PIEB, avec ou sans APCP, \u00e0 condition :Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9trique\u2022 qu'il existe des protocoles adapt\u00e9s pour la prise en charge des patientes recevant une APPC, une PIEB et une APCP; et \u2022 que l'on puisse joindre l'anesth\u00e9siologiste pour obtenir conseils et instructions.Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9triqueLors de l'administration du bolus initial et de bolus p\u00e9riduraux suppl\u00e9mentaires d'anesth\u00e9sique local, l'anesth\u00e9siologiste doit \u00eatre imm\u00e9diatement disponible pour intervenir ad\u00e9quatement, \u00e9tant conscient que ces techniques peuvent provoquer des complications imm\u00e9diates potentiellement fatales.Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9triqueChaque d\u00e9partement d'anesth\u00e9siologie devrait \u00e9tablir ses propres politiques concernant la disponibilit\u00e9 jug\u00e9e adapt\u00e9e d'un anesth\u00e9siologiste pour prendre en charge les complications potentielles li\u00e9es \u00e0 l'analg\u00e9sie r\u00e9gionale pour le travail obst\u00e9trical et l'accouchement.Lignes directrices pour l'analg\u00e9sie r\u00e9gionale en obst\u00e9triqueDes syst\u00e8mes de s\u00e9curit\u00e9 doivent exister pour prot\u00e9ger les m\u00e9langes d'anesth\u00e9siques locaux p\u00e9riduraux contenant des substances contr\u00f4l\u00e9es (par ex. des opio\u00efdes) de fa\u00e7on \u00e0 minimiser les risques de d\u00e9tournement.Absorption orale pendant le travailLa vidange gastrique des aliments solides est retard\u00e9e pendant le travail, et les analg\u00e9siques opio\u00efdes peuvent la retarder encore davantage.", [["des opio\u00efdes", "CHEMICAL", 1345, 1357], ["Lignes directrices", "TREATMENT", 189, 207], ["en obst\u00e9trique\u2022 qu'il existe des", "TREATMENT", 235, 267], ["pour la prise en charge des", "TREATMENT", 287, 314], ["une APPC", "PROBLEM", 334, 342], ["Lignes directrices", "TREATMENT", 453, 471], ["du bolus", "TREATMENT", 538, 546], ["initial et de bolus p\u00e9riduraux", "TREATMENT", 547, 577], ["potentiellement fatales", "PROBLEM", 783, 806], ["pour le travail obst\u00e9trical et l'accouchement", "TREATMENT", 1092, 1137], ["Lignes", "TEST", 1138, 1144], ["locaux p\u00e9riduraux contenant des substances", "TREATMENT", 1282, 1324], ["Absorption orale pendant le travailLa vidange gastrique des", "TREATMENT", 1408, 1467], ["est retard\u00e9e pendant le travail", "TREATMENT", 1485, 1516]]], ["Par cons\u00e9quent, on devrait g\u00e9n\u00e9ralement d\u00e9courager les parturientes d'ing\u00e9rer des aliments solides pendant le travail actif.", [["pendant le travail actif", "TREATMENT", 99, 123]]], ["Contrairement aux aliments solides, les liquides clairs sont \u00e9limin\u00e9s relativement rapidement de l'estomac pendant le travail.", [["l'estomac pendant le travail", "TREATMENT", 97, 125]]], ["Chaque \u00e9tablissement devrait \u00e9laborer des protocoles concernant l'absorption d'aliments solides et de liquides clairs par les femmes en travail actif.Absorption orale pendant le travail8.0 Lignes directrices pour la prise en charge de la douleur aigu\u00eb \u00e0 l'aide de l'analg\u00e9sie neuraxiale Lorsque l'analg\u00e9sie neuraxiale est prise en charge par des anesth\u00e9siologistes, l'incidence d'effets secondaires n'est pas plus \u00e9lev\u00e9e que lorsque des techniques alternatives de prise en charge de la douleur sont utilis\u00e9es.", [["Absorption orale pendant le travail", "TREATMENT", 150, 185], ["Lignes directrices pour la", "TREATMENT", 189, 215]]], ["En cons\u00e9quence, lorsque son utilisation est indiqu\u00e9e, l'analg\u00e9sie neuraxiale devrait \u00eatre prise en charge par les anesth\u00e9siologistes.Absorption orale pendant le travailAux fins de ce guide, l'analg\u00e9sie neuraxiale se d\u00e9finit comme l'administration intrath\u00e9cale ou p\u00e9ridurale d'opio\u00efdes et/ou d'anesth\u00e9siques locaux en vue du traitement de la douleur postop\u00e9ratoire ou d'autres probl\u00e8mes de douleur aigu\u00eb.", [["d\u00e9finit comme l'administration intrath\u00e9cale ou p\u00e9ridurale d'opio\u00efdes et/ou d'anesth\u00e9siques locaux en vue du traitement de la douleur postop\u00e9ratoire ou d'autres probl\u00e8mes de douleur aigu\u00eb", "SPECIES", 216, 402], ["Absorption orale pendant le travail", "TREATMENT", 133, 168]]], ["Ce guide vise \u00e0 fournir aux anesth\u00e9siologistes les principes de prise en charge afin que l'analg\u00e9sie neuraxiale soit pratiqu\u00e9e de mani\u00e8re \u00e0 en maximiser les avantages et en minimiser les risques.", [["Ce", "CHEMICAL", 0, 2]]], ["Pour des perfusions continues ou une APCP, l'emploi de pompes inviolables distinctes de celles utilis\u00e9es pour l'administration de solut\u00e9s ou de m\u00e9dicaments est vivement recommand\u00e9.", [["Pour des perfusions", "PROBLEM", 0, 19]]], ["La tubulure entre les pompes de perfusion de l'analg\u00e9sie neuraxiale et les cath\u00e9ters ne devrait comporter aucun orifice susceptible de permettre une injection non intentionnelle de m\u00e9dicaments intraveineux.Absorption orale pendant le travailLa pr\u00e9paration des solutions devrait suivre une proc\u00e9dure standardis\u00e9e.", [["Absorption orale pendant le travailLa pr\u00e9paration des solutions", "TREATMENT", 206, 269]]], ["Dans le cas d'une administration p\u00e9ridurale, cela doit inclure la date et l'heure de la pr\u00e9paration ainsi que le nom de la personne l'ayant pr\u00e9par\u00e9e.Monitorage des patients et prise en charge des \u00e9v\u00e8nements ind\u00e9sirablesLes patients auxquels est administr\u00e9e une analg\u00e9sie neuraxiale devraient \u00eatre plac\u00e9s dans une chambre \u00e9quip\u00e9e d'oxyg\u00e8ne et de succion.", [["Dans le cas d'une", "CHEMICAL", 0, 17], ["patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 223, 231]]], ["L'acc\u00e8s intraveineux doit \u00eatre \u00e9tabli avant d'amorcer l'analg\u00e9sie neuraxiale et, apr\u00e8s cessation de l'analg\u00e9sie neuraxiale, maintenu pendant toute la dur\u00e9e pr\u00e9vue des effets m\u00e9dicamenteux.Monitorage des patients et prise en charge des \u00e9v\u00e8nements ind\u00e9sirablesLe pansement qui maintient en place le cath\u00e9ter p\u00e9ridural doit permettre l'examen du cath\u00e9ter pour d\u00e9tecter tout mouvement et permettre l'inspection quotidienne du point d'entr\u00e9e afin de d\u00e9celer tout signe d'infection.Monitorage des patients et prise en charge des \u00e9v\u00e8nements ind\u00e9sirablesL'adoption de politiques standardis\u00e9es au chapitre de la prise en charge des patients est pr\u00e9conis\u00e9e.", [["patients", "ORGANISM", 203, 211], ["patients", "ORGANISM", 491, 499], ["patients", "ORGANISM", 623, 631], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 491, 499], ["patients", "SPECIES", 623, 631], ["Le pansement qui maintient en place le cath\u00e9ter p\u00e9ridural doit", "TREATMENT", 258, 320], ["du cath\u00e9ter pour d\u00e9tecter", "TREATMENT", 340, 365], ["Monitorage des patients et prise en charge des \u00e9v\u00e8nements", "TREATMENT", 476, 533], ["L'adoption de politiques standardis\u00e9es au chapitre de la prise en charge des", "TREATMENT", 546, 622]]], ["Un personnel de soins infirmiers en nombre suffisant doit \u00eatre pr\u00e9sent pour \u00e9valuer et prendre en charge les patients recevant une analg\u00e9sie neuraxiale.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117]]], ["Le monitorage devrait se poursuivre apr\u00e8s cessation de l'analg\u00e9sie neuraxiale jusqu'\u00e0 ce que ses effets se soient dissip\u00e9s.Monitorage des patients et prise en charge des \u00e9v\u00e8nements ind\u00e9sirablesUn anesth\u00e9siologiste doit \u00eatre imm\u00e9diatement disponible afin de conseiller le personnel infirmier sur des aspects tels que le titrage de la dose et la prise en charge des effets ind\u00e9sirables.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["que le titrage de la dose et la prise en charge des", "TREATMENT", 312, 363]]], ["Chaque \u00e9tablissement dot\u00e9 d'un service de traitement de la douleur aigu\u00eb doit veiller \u00e0 ce qu'un anesth\u00e9siologiste soit disponible pour s'occuper directement des patients recevant une analg\u00e9sie neuraxiale dans un d\u00e9lai appropri\u00e9 en fonction de la situation clinique.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170]]], ["Chaque \u00e9tablissement devrait \u00e9galement d\u00e9terminer les proc\u00e9dures en vue d'une prise en charge urgente de toute complication mena\u00e7ant le pronostic vital.Monitorage des patients et prise en charge des \u00e9v\u00e8nements ind\u00e9sirablesD'autres m\u00e9dicaments, notamment les benzodiaz\u00e9pines ou les opio\u00efdes parent\u00e9raux, peuvent causer une d\u00e9pression respiratoire majeure chez les patients recevant une analg\u00e9sie neuraxiale.", [["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 363, 371], ["Chaque \u00e9tablissement", "TREATMENT", 0, 20], ["Monitorage des patients et prise en charge des", "TREATMENT", 152, 198]]], ["Pour cette raison, les autres m\u00e9decins ne devraient pas prescrire de s\u00e9datifs ou d'analg\u00e9siques \u00e0 tout patient recevant une analg\u00e9sie neuraxiale.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110]]], ["Le service de traitement de la douleur aigu\u00eb devrait demeurer en charge de la th\u00e9rapeutique analg\u00e9sique et s\u00e9dative jusqu'\u00e0 dissipation des effets de l'analg\u00e9sie neuraxiale.P\u00e9ridurales et anticoagulationLes patients porteurs d'un cath\u00e9ter p\u00e9ridural peuvent recevoir un traitement prophylactique d'anticoagulants \u00e0 faible dose, si les pr\u00e9cautions appropri\u00e9es sont prises :P\u00e9ridurales et anticoagulation\u2022 Afin de minimiser le risque d'h\u00e9matome p\u00e9ridural, l'installation et le retrait du cath\u00e9ter ainsi que l'horaire d'administration de l'anticoagulant doivent \u00eatre coordonn\u00e9s de telle sorte qu'aucun effet anticoagulant significatif d'un point de vue clinique ne soit pr\u00e9sent \u00e0 ces moments.P\u00e9ridurales et anticoagulation\u2022 L'emploi d'agents anti-inflammatoires non st\u00e9ro\u00efdiens chez des patients recevant une analg\u00e9sie neuraxiale est appropri\u00e9, mais l'administration concomitante de ces m\u00e9dicaments ou d'autres antiagr\u00e9gants plaquettaires et d'un anticoagulant peut augmenter le risque d'un h\u00e9matome p\u00e9ridural. \u2022 Lorsque l'analg\u00e9sie neuraxiale est utilis\u00e9e pour une prise en charge prolong\u00e9e de la douleur postop\u00e9ratoire, il convient de d\u00e9ployer tous les efforts n\u00e9cessaires afin d'\u00e9viter un bloc moteur des membres inf\u00e9rieurs. \u2022 Le personnel infirmier doit conna\u00eetre les signes et sympt\u00f4mes de l'h\u00e9matome p\u00e9ridural.", [["patients", "ORGANISM", 207, 215], ["patients", "ORGANISM", 783, 791], ["patients", "SPECIES", 207, 215], ["patients", "SPECIES", 783, 791], ["p\u00e9ridural peuvent recevoir un traitement prophylactique", "TREATMENT", 239, 294], ["anticoagulants", "TREATMENT", 297, 311], ["si les pr\u00e9cautions", "TREATMENT", 327, 345], ["P\u00e9ridurales et anticoagulation", "TREATMENT", 371, 401], ["P\u00e9ridurales et anticoagulation", "TREATMENT", 688, 718], ["L'emploi d'agents", "TREATMENT", 720, 737], ["anti-inflammatoires", "TREATMENT", 738, 757], ["et d'un anticoagulant", "TREATMENT", 935, 956]]], ["Toute alt\u00e9ration de l'\u00e9tat neurologique ou toute apparition soudaine d'une douleur dorsale doit \u00eatre imm\u00e9diatement examin\u00e9e.P\u00e9ridurales et anticoagulationSi une anticoaguloth\u00e9rapie compl\u00e8te est indiqu\u00e9e chez un patient porteur d'un cath\u00e9ter p\u00e9ridural, l'anesth\u00e9siologiste devrait \u00eatre consult\u00e9 afin que le retrait du cath\u00e9ter et l'amorce d'un traitement analg\u00e9sique de substitution puissent \u00eatre effectu\u00e9s avant le d\u00e9but de l'anticoaguloth\u00e9rapie.P\u00e9ridurales et anticoagulation9.0 Lignes directrices pour l'exercice de l'anesth\u00e9sie hors du milieu hospitalier Les principes fondamentaux, les exigences de formation, les techniques, le mat\u00e9riel et les m\u00e9dicaments utilis\u00e9s pour la pratique de l'anesth\u00e9sie ont \u00e9t\u00e9 document\u00e9s dans d'autres sections de ce guide.", [["Si", "CHEMICAL", 154, 156], ["patient", "ORGANISM", 211, 218], ["patient", "SPECIES", 211, 218], ["P\u00e9ridurales et anticoagulation", "TREATMENT", 124, 154], ["P\u00e9ridurales et anticoagulation", "TREATMENT", 446, 476], ["Lignes directrices", "TREATMENT", 480, 498], ["les techniques", "TEST", 614, 628]]], ["Les lignes directrices suivantes concernent certains aspects propres \u00e0 l'exercice de l'anesth\u00e9sie \u00e0 l'ext\u00e9rieur d'un \u00e9tablissement hospitalier.S\u00e9lection des patientsLe statut physique des patients devrait \u00eatre cat\u00e9goris\u00e9 d'une fa\u00e7on similaire \u00e0 celle utilis\u00e9e par l'American Society of Anesthesiologists (ASA) (Annexe 2).", [["patients", "ORGANISM", 157, 165], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 188, 196], ["Anesthesiologists (ASA)", "TREATMENT", 286, 309]]], ["D'une mani\u00e8re g\u00e9n\u00e9rale, seuls les patients des classes ASA I et II devraient \u00eatre retenus pour subir une anesth\u00e9sie hors d'un \u00e9tablissement hospitalier.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Les patients de statut ASA III pourraient \u00eatre accept\u00e9s sous certaines conditions.Consid\u00e9rations pr\u00e9op\u00e9ratoiresUne histoire de cas et un examen physique r\u00e9cent devraient para\u00eetre au dossier du patient, ainsi que les r\u00e9sultats des examens de laboratoire appropri\u00e9s.", [["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 193, 200], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 193, 200], ["ASA III", "TREATMENT", 23, 30]]], ["Le patient devrait recevoir un feuillet d'information \u00e9num\u00e9rant les directives relatives aux p\u00e9riodes pr\u00e9-et postanesth\u00e9siques.Conduite de l'anesth\u00e9sieLes installations des salles d'anesth\u00e9sie et de r\u00e9veil doivent r\u00e9pondre aux normes hospitali\u00e8res de la CSA telles que d\u00e9finies dans les autres sections du pr\u00e9sent guide.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10]]], ["Le Comit\u00e9 tient \u00e0 remercier sinc\u00e8rement le Dr David McKnight pour son aide majeure \u00e0 la r\u00e9daction de ce manuscrit.Conduite de l'anesth\u00e9sieConflits d'int\u00e9r\u00eats Tous les auteurs de cet article font partie du Comit\u00e9 des normes de la Soci\u00e9t\u00e9 canadienne des anesth\u00e9siologistes (SCA).", [["SCA", "DISEASE", 272, 275]]], ["Aucun des auteurs n'a un quelconque int\u00e9r\u00eat financier ou commercial li\u00e9 aux soci\u00e9t\u00e9s ou fabricants d'appareils m\u00e9dicaux dont il est fait mention dans cet article ou dans les annexes associ\u00e9es.", [["Aucun des auteurs n'a un quelconque int\u00e9r\u00eat financier ou commercial li\u00e9 aux soci\u00e9t\u00e9s ou fabricants d'appareils m\u00e9dicaux dont il est fait mention dans cet article ou dans les annexes associ\u00e9es", "SPECIES", 0, 191]]], ["Dr Gregory Dobson est pr\u00e9sident du Comit\u00e9 des normes de la SCA.Annexe 1: Association canadienne de normalisation -Normes concernant le mat\u00e9rielDisponible en mat\u00e9riel \u00e9lectronique suppl\u00e9mentaire.Annexe 1: Association canadienne de normalisation -Normes concernant le mat\u00e9rielAnnexe 2: Classification de l'\u00e9tat de sant\u00e9 des patients, selon l'American Society of Anesthesiologists Disponible en mat\u00e9riel \u00e9lectronique suppl\u00e9mentaire.Annexe 3: Liste de v\u00e9rification pr\u00e9anesth\u00e9siqueDisponible en mat\u00e9riel \u00e9lectronique suppl\u00e9mentaire.Annexe 3: Liste de v\u00e9rification pr\u00e9anesth\u00e9siqueAnnexe 4: Lignes directrices, normes et autres \u00e9nonc\u00e9s officiels disponibles sur l'internet L'Annexe 4 (disponible au : http://www.cas.ca/Francais/ Guide-d-exercice) offre une liste non exhaustive de sites contenant des d\u00e9clarations officielles promulgu\u00e9es par d'autres associations m\u00e9dicales au Canada et ailleurs dans le monde.", [["SCA", "DISEASE", 59, 62], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 322, 330], ["Disponible en mat\u00e9riel \u00e9lectronique suppl\u00e9mentaire", "TREATMENT", 143, 193], ["la SCA", "ANATOMY", 56, 62]]], ["La SCA n'est pas responsable de l'exactitude, de la mise \u00e0 jour ou de la fiabilit\u00e9 du contenu de ces sites.", [["La SCA", "TEST", 0, 6]]], ["La SCA n'offre aucune garantie \u00e0 cet effet.", [["La SCA", "TEST", 0, 6]]]], "PMC7122881": [["IntroductionRapid development of microelectronics in recent decades has been proven based on miniaturization and integration of electronic parts and according to the predictions of the ITRS1 institute, this fast development will also continue in the next decade.", [["microelectronics", "OBSERVATION_MODIFIER", 33, 49]]], ["In this regard, MOS field effect transistors or MOSFET2 is the main and basic component of most of the electronic systems nowadays.", [["MOSFET2", "CHEMICAL", 48, 55], ["MOSFET2", "SIMPLE_CHEMICAL", 48, 55], ["MOS field effect transistors", "PROBLEM", 16, 44], ["main", "OBSERVATION_MODIFIER", 63, 67], ["component", "OBSERVATION_MODIFIER", 78, 87]]], ["The predicted process of decrement of the gate length by ITRS, has been shown in the Figs.", [["ITRS", "PROTEIN", 57, 61], ["ITRS", "TEST", 57, 61], ["decrement", "OBSERVATION_MODIFIER", 25, 34], ["gate length", "OBSERVATION_MODIFIER", 42, 53]]], ["The reasons for the dimensions decrease are as follow: improvement of the part\u2019s quality and performance, improvement of reliability, decreasing the power loss, improving the output efficiency, and decreasing its price.", [["the power loss", "PROBLEM", 145, 159], ["decreasing", "OBSERVATION_MODIFIER", 134, 144], ["power loss", "OBSERVATION", 149, 159], ["output efficiency", "OBSERVATION", 175, 192]]]]}